{"version":3,"sources":["webpack:///webpack/bootstrap","webpack:///./src/assets/m1-11.png","webpack:///./src/components/inclusivity.vue?526e","webpack:///./src/assets/edu1-1.png","webpack:///./src/assets/com2-2.png","webpack:///./src/assets/in1-1.png","webpack:///./src/components/model.vue?553c","webpack:///./src/assets/2-1.gif","webpack:///./src/components/imple.vue?af37","webpack:///./src/assets/m1-3.png","webpack:///./src/assets/m1-1.png","webpack:///./src/assets/en2-2.png","webpack:///./src/assets/des1-2.png","webpack:///./src/components/proof.vue?08c8","webpack:///./src/assets/en3-2.png","webpack:///./src/assets/com2-1.png","webpack:///./src/assets/in1-3.png","webpack:///./src/assets/2-3.gif","webpack:///./src/assets/3.gif","webpack:///./src/assets/des2-2.png","webpack:///./src/assets/homeTop.png","webpack:///./src/assets/ha2.png","webpack:///./src/components/entre.vue?f3f5","webpack:///./src/assets/2-2.gif","webpack:///./src/components/sustain.vue?7170","webpack:///./src/assets/en1-2.png","webpack:///./src/components/description.vue?93ea","webpack:///./src/assets/sus2.png","webpack:///./src/assets/down.png","webpack:///./src/components/design.vue?6b32","webpack:///./src/components/software.vue","webpack:///./src/App.vue?5fd7","webpack:///src/App.vue","webpack:///./src/App.vue?4c4f","webpack:///./src/App.vue","webpack:///./src/components/myHome.vue?4e88","webpack:///src/components/myHome.vue","webpack:///./src/components/myHome.vue?d585","webpack:///./src/components/myHome.vue","webpack:///./src/components/description.vue?1602","webpack:///src/components/description.vue","webpack:///./src/components/description.vue?e8dc","webpack:///./src/components/description.vue","webpack:///./src/components/design.vue?59a9","webpack:///src/components/design.vue","webpack:///./src/components/design.vue?5670","webpack:///./src/components/design.vue","webpack:///./src/components/proof.vue?9997","webpack:///src/components/proof.vue","webpack:///./src/components/proof.vue?e8f0","webpack:///./src/components/proof.vue","webpack:///./src/components/experiment.vue?7190","webpack:///src/components/experiment.vue","webpack:///./src/components/experiment.vue?7055","webpack:///./src/components/experiment.vue","webpack:///./src/components/safety.vue?439f","webpack:///src/components/safety.vue","webpack:///./src/components/safety.vue?e7dd","webpack:///./src/components/safety.vue","webpack:///./src/components/imple.vue?d6e3","webpack:///src/components/imple.vue","webpack:///./src/components/imple.vue?5a58","webpack:///./src/components/imple.vue","webpack:///./src/components/Integrated.vue?f640","webpack:///src/components/Integrated.vue","webpack:///./src/components/Integrated.vue?4369","webpack:///./src/components/Integrated.vue","webpack:///./src/components/communication.vue?8822","webpack:///src/components/communication.vue","webpack:///./src/components/communication.vue?e6fb","webpack:///./src/components/communication.vue","webpack:///./src/components/education.vue?a02f","webpack:///src/components/education.vue","webpack:///./src/components/education.vue?e2d9","webpack:///./src/components/education.vue","webpack:///./src/components/inclusivity.vue?dea6","webpack:///src/components/inclusivity.vue","webpack:///./src/components/inclusivity.vue?41f9","webpack:///./src/components/inclusivity.vue","webpack:///./src/components/entre.vue?d96b","webpack:///src/components/entre.vue","webpack:///./src/components/entre.vue?7ddd","webpack:///./src/components/entre.vue","webpack:///./src/components/sustain.vue?6170","webpack:///src/components/sustain.vue","webpack:///./src/components/sustain.vue?4bbc","webpack:///./src/components/sustain.vue","webpack:///./src/components/model.vue?d045","webpack:///src/components/model.vue","webpack:///./src/components/model.vue?c4ce","webpack:///./src/components/model.vue","webpack:///./src/components/hardware.vue?7d01","webpack:///src/components/hardware.vue","webpack:///./src/components/hardware.vue?1535","webpack:///./src/components/hardware.vue","webpack:///./src/components/part.vue?8728","webpack:///src/components/part.vue","webpack:///./src/components/part.vue?4f98","webpack:///./src/components/part.vue","webpack:///./src/router/index.js","webpack:///./src/main.js","webpack:///./src/assets/m2-4.gif","webpack:///./src/components/hardware.vue?65ae","webpack:///./src/assets/ha4.png","webpack:///./src/assets/ha1.png","webpack:///./src/assets/m2-3.gif","webpack:///./src/assets/top.png","webpack:///./src/components/Integrated.vue?7068","webpack:///./src/assets/en4-5.png","webpack:///./src/App.vue?9b10","webpack:///./src/assets/en4-6.png","webpack:///./src/assets/m1-13.png","webpack:///./src/assets/edu2-1.png","webpack:///./src/assets/en4-4.png","webpack:///./src/assets/in1-4-1.png","webpack:///./src/assets/m1-6.png","webpack:///./src/assets/com2-3.png","webpack:///./src/assets/des1-2-2.png","webpack:///./src/assets/in1-2.png","webpack:///./src/assets/sus1.png","webpack:///./src/assets/ha3.png","webpack:///./src/assets/en3-1.png","webpack:///./src/assets/des2-1.jpg","webpack:///./src/assets/in1-3-1.png","webpack:///./src/assets/sa2-3.png","webpack:///./src/assets/sa2-1.png","webpack:///./src/assets/m2-5.gif","webpack:///./src/assets/en1-3.png","webpack:///./src/assets/com2-4.png","webpack:///./src/assets/des1-1.png","webpack:///./src/assets/in1-2-1.png","webpack:///./src/assets/sa2-2.png","webpack:///./src/assets/1.gif","webpack:///./src/assets/m1-10.gif","webpack:///./src/assets/m1-12.png","webpack:///./src/assets/m2-2.gif","webpack:///./src/assets/com1-3.png","webpack:///./src/assets/com1-2.png","webpack:///./src/components/myHome.vue?d84f","webpack:///./src/assets/in1-4-2.png","webpack:///./src/components/education.vue?4e89","webpack:///./src/components/part.vue?1389","webpack:///./src/assets/en4-7.png","webpack:///./src/assets/en2-1.png","webpack:///./src/assets/com1-1.png","webpack:///./src/assets/logo.png","webpack:///./src/assets/m1-9.gif","webpack:///./src/assets/des2-3-1.png","webpack:///./src/assets/m2-1.png","webpack:///./src/assets/en1-1.png","webpack:///./src/assets/des1-3.png","webpack:///./src/components/experiment.vue?bfc4","webpack:///./src/assets/des2-3-2.png","webpack:///./src/assets/edu3-1.png","webpack:///./src/assets/part.png","webpack:///./src/assets/m1-7.gif","webpack:///./src/assets/m1-2.png","webpack:///./src/components/communication.vue?7e4e","webpack:///./src/assets/m2-6.png","webpack:///./src/assets/m1-4.png","webpack:///./src/assets/m1-8.gif","webpack:///./src/components/safety.vue?1b26","webpack:///./src/assets/sa3-1.png","webpack:///./src/assets/m1-5.png","webpack:///./src/assets/en3-3.png"],"names":["webpackJsonpCallback","data","moduleId","chunkId","chunkIds","moreModules","executeModules","i","resolves","length","Object","prototype","hasOwnProperty","call","installedChunks","push","modules","parentJsonpFunction","shift","deferredModules","apply","checkDeferredModules","result","deferredModule","fulfilled","j","depId","splice","__webpack_require__","s","installedModules","exports","module","l","m","c","d","name","getter","o","defineProperty","enumerable","get","r","Symbol","toStringTag","value","t","mode","__esModule","ns","create","key","bind","n","object","property","p","jsonpArray","window","oldJsonpFunction","slice","_vm","this","_h","$createElement","_c","_self","attrs","_m","staticRenderFns","staticClass","_v","return","mounted","addEvent","obj","type","fn","attachEvent","addEventListener","navbar","classList","add","remove","component","pageYOffset","lef","on","$event","ch1","ch2","ch3","methods","p1","p2","p3","ch4","p4","script","Vue","use","VueRouter","router","routes","path","myHome","description","design","proof","experiment","safety","imple","Integrated","communication","education","inclusivity","entre","sustain","model","software","hardware","part","config","productionTip","render","h","App","$mount","directive","el","binding","style","color"],"mappings":"aACE,SAASA,EAAqBC,GAQ7B,IAPA,IAMIC,EAAUC,EANVC,EAAWH,EAAK,GAChBI,EAAcJ,EAAK,GACnBK,EAAiBL,EAAK,GAIHM,EAAI,EAAGC,EAAW,GACpCD,EAAIH,EAASK,OAAQF,IACzBJ,EAAUC,EAASG,GAChBG,OAAOC,UAAUC,eAAeC,KAAKC,EAAiBX,IAAYW,EAAgBX,IACpFK,EAASO,KAAKD,EAAgBX,GAAS,IAExCW,EAAgBX,GAAW,EAE5B,IAAID,KAAYG,EACZK,OAAOC,UAAUC,eAAeC,KAAKR,EAAaH,KACpDc,EAAQd,GAAYG,EAAYH,IAG/Be,GAAqBA,EAAoBhB,GAE5C,MAAMO,EAASC,OACdD,EAASU,OAATV,GAOD,OAHAW,EAAgBJ,KAAKK,MAAMD,EAAiBb,GAAkB,IAGvDe,IAER,SAASA,IAER,IADA,IAAIC,EACIf,EAAI,EAAGA,EAAIY,EAAgBV,OAAQF,IAAK,CAG/C,IAFA,IAAIgB,EAAiBJ,EAAgBZ,GACjCiB,GAAY,EACRC,EAAI,EAAGA,EAAIF,EAAed,OAAQgB,IAAK,CAC9C,IAAIC,EAAQH,EAAeE,GACG,IAA3BX,EAAgBY,KAAcF,GAAY,GAE3CA,IACFL,EAAgBQ,OAAOpB,IAAK,GAC5Be,EAASM,EAAoBA,EAAoBC,EAAIN,EAAe,KAItE,OAAOD,EAIR,IAAIQ,EAAmB,GAKnBhB,EAAkB,CACrB,IAAO,GAGJK,EAAkB,GAGtB,SAASS,EAAoB1B,GAG5B,GAAG4B,EAAiB5B,GACnB,OAAO4B,EAAiB5B,GAAU6B,QAGnC,IAAIC,EAASF,EAAiB5B,GAAY,CACzCK,EAAGL,EACH+B,GAAG,EACHF,QAAS,IAUV,OANAf,EAAQd,GAAUW,KAAKmB,EAAOD,QAASC,EAAQA,EAAOD,QAASH,GAG/DI,EAAOC,GAAI,EAGJD,EAAOD,QAKfH,EAAoBM,EAAIlB,EAGxBY,EAAoBO,EAAIL,EAGxBF,EAAoBQ,EAAI,SAASL,EAASM,EAAMC,GAC3CV,EAAoBW,EAAER,EAASM,IAClC3B,OAAO8B,eAAeT,EAASM,EAAM,CAAEI,YAAY,EAAMC,IAAKJ,KAKhEV,EAAoBe,EAAI,SAASZ,GACX,qBAAXa,QAA0BA,OAAOC,aAC1CnC,OAAO8B,eAAeT,EAASa,OAAOC,YAAa,CAAEC,MAAO,WAE7DpC,OAAO8B,eAAeT,EAAS,aAAc,CAAEe,OAAO,KAQvDlB,EAAoBmB,EAAI,SAASD,EAAOE,GAEvC,GADU,EAAPA,IAAUF,EAAQlB,EAAoBkB,IAC/B,EAAPE,EAAU,OAAOF,EACpB,GAAW,EAAPE,GAA8B,kBAAVF,GAAsBA,GAASA,EAAMG,WAAY,OAAOH,EAChF,IAAII,EAAKxC,OAAOyC,OAAO,MAGvB,GAFAvB,EAAoBe,EAAEO,GACtBxC,OAAO8B,eAAeU,EAAI,UAAW,CAAET,YAAY,EAAMK,MAAOA,IACtD,EAAPE,GAA4B,iBAATF,EAAmB,IAAI,IAAIM,KAAON,EAAOlB,EAAoBQ,EAAEc,EAAIE,EAAK,SAASA,GAAO,OAAON,EAAMM,IAAQC,KAAK,KAAMD,IAC9I,OAAOF,GAIRtB,EAAoB0B,EAAI,SAAStB,GAChC,IAAIM,EAASN,GAAUA,EAAOiB,WAC7B,WAAwB,OAAOjB,EAAO,YACtC,WAA8B,OAAOA,GAEtC,OADAJ,EAAoBQ,EAAEE,EAAQ,IAAKA,GAC5BA,GAIRV,EAAoBW,EAAI,SAASgB,EAAQC,GAAY,OAAO9C,OAAOC,UAAUC,eAAeC,KAAK0C,EAAQC,IAGzG5B,EAAoB6B,EAAI,IAExB,IAAIC,EAAaC,OAAO,gBAAkBA,OAAO,iBAAmB,GAChEC,EAAmBF,EAAW3C,KAAKsC,KAAKK,GAC5CA,EAAW3C,KAAOf,EAClB0D,EAAaA,EAAWG,QACxB,IAAI,IAAItD,EAAI,EAAGA,EAAImD,EAAWjD,OAAQF,IAAKP,EAAqB0D,EAAWnD,IAC3E,IAAIU,EAAsB2C,EAI1BzC,EAAgBJ,KAAK,CAAC,EAAE,kBAEjBM,K,gECvJTW,EAAOD,QAAU,IAA0B,0B,oCCA3C,W,uBCAAC,EAAOD,QAAU,IAA0B,2B,uBCA3CC,EAAOD,QAAU,IAA0B,2B,uBCA3CC,EAAOD,QAAU,IAA0B,0B,oCCA3C,W,uBCAAC,EAAOD,QAAU,IAA0B,wB,kCCA3C,W,qBCAAC,EAAOD,QAAU,0wF,gDCAjBC,EAAOD,QAAU,IAA0B,yB,qBCA3CC,EAAOD,QAAU,IAA0B,0B,qBCA3CC,EAAOD,QAAU,IAA0B,2B,oCCA3C,W,uBCAAC,EAAOD,QAAU,IAA0B,0B,uBCA3CC,EAAOD,QAAU,IAA0B,2B,qBCA3CC,EAAOD,QAAU,IAA0B,0B,uBCA3CC,EAAOD,QAAU,IAA0B,wB,uBCA3CC,EAAOD,QAAU,IAA0B,sB,uECA3CC,EAAOD,QAAU,IAA0B,2B,qBCA3CC,EAAOD,QAAU,kzF,uBCAjBC,EAAOD,QAAU,IAA0B,wB,oCCA3C,W,uBCAAC,EAAOD,QAAU,IAA0B,wB,oCCA3C,W,uBCAAC,EAAOD,QAAU,IAA0B,0B,oCCA3C,W,uBCAAC,EAAOD,QAAU,IAA0B,yB,qBCA3CC,EAAOD,QAAU,kzI,kCCAjB,W,8GCAI,EAAQ,E,YCAR,EAAS,WAAa,IAAI+B,EAAIC,KAASC,EAAGF,EAAIG,eAAmBC,EAAGJ,EAAIK,MAAMD,IAAIF,EAAG,OAAOE,EAAG,MAAM,CAACE,MAAM,CAAC,GAAK,QAAQ,CAACN,EAAIO,GAAG,GAAGH,EAAG,gBAAgB,IACxJI,EAAkB,CAAC,WAAa,IAAIR,EAAIC,KAASC,EAAGF,EAAIG,eAAmBC,EAAGJ,EAAIK,MAAMD,IAAIF,EAAG,OAAOE,EAAG,MAAM,CAACK,YAAY,UAAU,CAACL,EAAG,MAAM,CAACK,YAAY,MAAMH,MAAM,CAAC,GAAK,WAAW,CAACF,EAAG,MAAM,CAACK,YAAY,OAAOH,MAAM,CAAC,IAAM,EAAQ,QAAqB,IAAM,UAAUF,EAAG,KAAK,CAACK,YAAY,QAAQH,MAAM,CAAC,GAAK,SAAS,CAACF,EAAG,KAAK,CAACK,YAAY,yBAAyB,CAACL,EAAG,IAAI,CAACK,YAAY,OAAOH,MAAM,CAAC,KAAO,aAAa,CAACF,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,cAAcN,EAAG,KAAK,CAACK,YAAY,UAAU,CAACL,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,aAAaN,EAAG,KAAK,CAACA,EAAG,KAAK,CAACA,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,kBAAkB,CAACN,EAAIU,GAAG,mBAAmBN,EAAG,KAAK,CAACA,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,aAAa,CAACN,EAAIU,GAAG,cAAcN,EAAG,KAAK,CAACA,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,YAAY,CAACN,EAAIU,GAAG,aAAaN,EAAG,KAAK,CAACA,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,iBAAiB,CAACN,EAAIU,GAAG,kBAAkBN,EAAG,KAAK,CAACA,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,aAAa,CAACN,EAAIU,GAAG,kBAAkBN,EAAG,KAAK,CAACK,YAAY,UAAU,CAACL,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,WAAW,CAACF,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,cAAcN,EAAG,KAAK,CAACK,YAAY,UAAU,CAACL,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,YAAYN,EAAG,KAAK,CAACA,EAAG,KAAK,CAACA,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,YAAY,CAACN,EAAIU,GAAG,aAAaN,EAAG,KAAK,CAACA,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,eAAe,CAACN,EAAIU,GAAG,oBAAoBN,EAAG,KAAK,CAACK,YAAY,UAAU,CAACL,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,mBAAmBN,EAAG,KAAK,CAACA,EAAG,KAAK,CAACA,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,iBAAiB,CAACN,EAAIU,GAAG,qBAAqBN,EAAG,KAAK,CAACA,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,oBAAoB,CAACN,EAAIU,GAAG,oBAAoBN,EAAG,KAAK,CAACA,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,gBAAgB,CAACN,EAAIU,GAAG,iBAAiBN,EAAG,KAAK,CAACA,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,kBAAkB,CAACN,EAAIU,GAAG,mBAAmBN,EAAG,KAAK,CAACA,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,YAAY,CAACN,EAAIU,GAAG,wBAAwBN,EAAG,KAAK,CAACA,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,cAAc,CAACN,EAAIU,GAAG,uBAAuBN,EAAG,KAAK,CAACK,YAAY,UAAU,CAACL,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,UAAUN,EAAG,KAAK,CAACA,EAAG,KAAK,CAACA,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,YAAY,CAACN,EAAIU,GAAG,YAAYN,EAAG,KAAK,CAACA,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,YAAY,CAACN,EAAIU,GAAG,+BC6Ml/D,GACEC,OADF,aAEEC,QAFF,WAGI,IAAJ,oCACI,SAASC,EAASC,EAAKC,EAAMC,GAEvBF,EAAIG,YACNH,EAAIG,YAAY,KAAOF,GAAM,WAE3BC,EAAGjE,KAAK+D,MAIVA,EAAII,iBAAiBH,EAAMC,GAAI,GAGnCH,EAAShB,OAAQ,UAAU,WAE/B,wBACQsB,EAAOC,UAAUC,IAAI,UAErBF,EAAOC,UAAUE,OAAO,eCnO8R,I,wBCQ1TC,EAAY,eACd,EACA,EACAf,GACA,EACA,KACA,WACA,MAIa,EAAAe,E,oBCnBX,EAAS,WAAa,IAAIvB,EAAIC,KAASC,EAAGF,EAAIG,eAAsBH,EAAIK,MAAMD,GAAO,OAAOJ,EAAIO,GAAG,IACnG,EAAkB,CAAC,WAAa,IAAIP,EAAIC,KAASC,EAAGF,EAAIG,eAAmBC,EAAGJ,EAAIK,MAAMD,IAAIF,EAAG,OAAOE,EAAG,MAAM,CAACA,EAAG,MAAM,CAACK,YAAY,MAAM,CAACL,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,GAAK,UAAUF,EAAG,MAAM,CAACK,YAAY,QAAQ,CAACL,EAAG,MAAM,CAACK,YAAY,OAAOH,MAAM,CAAC,GAAK,SAASF,EAAG,MAAM,CAACK,YAAY,QAAQ,CAACL,EAAG,MAAM,CAACK,YAAY,SAAS,CAACL,EAAG,MAAM,CAACE,MAAM,CAAC,IAAM,EAAQ,QAAmB,IAAM,QAAQF,EAAG,MAAM,CAACK,YAAY,UAAU,CAACL,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,WAAW,CAACF,EAAG,MAAM,CAACE,MAAM,CAAC,IAAM,EAAQ,QAAsB,IAAM,YAAYF,EAAG,MAAM,CAACK,YAAY,OAAOH,MAAM,CAAC,GAAK,WAAWF,EAAG,MAAM,CAACK,YAAY,QAAQ,CAACL,EAAG,MAAM,CAACK,YAAY,SAAS,CAACL,EAAG,MAAM,CAACA,EAAG,MAAM,CAACE,MAAM,CAAC,IAAM,EAAQ,QAAqB,IAAM,QAAQF,EAAG,MAAM,CAACK,YAAY,OAAO,CAACL,EAAG,MAAM,CAACE,MAAM,CAAC,IAAM,EAAQ,QAAqB,IAAM,QAAQF,EAAG,MAAM,CAACA,EAAG,MAAM,CAACE,MAAM,CAAC,IAAM,EAAQ,QAAqB,IAAM,UAAUF,EAAG,MAAM,CAACK,YAAY,UAAU,CAACL,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,WAAW,CAACF,EAAG,MAAM,CAACE,MAAM,CAAC,IAAM,EAAQ,QAAsB,IAAM,YAAYF,EAAG,MAAM,CAACK,YAAY,OAAOH,MAAM,CAAC,GAAK,WAAWF,EAAG,MAAM,CAACK,YAAY,QAAQ,CAACL,EAAG,MAAM,CAACK,YAAY,SAAS,CAACL,EAAG,MAAM,CAACE,MAAM,CAAC,IAAM,EAAQ,QAAmB,IAAM,UAAUF,EAAG,MAAM,CAACK,YAAY,QAAQH,MAAM,CAAC,GAAK,QAAQ,CAACF,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,SAAS,CAACF,EAAG,MAAM,CAACE,MAAM,CAAC,IAAM,EAAQ,QAAyB,IAAM,gBCuCz1C,GACEK,OADF,aAEEC,QAFF,WAGI,IAAJ,iCAEI,SAASC,EAASC,EAAKC,EAAMC,GAEvBF,EAAIG,YACNH,EAAIG,YAAY,KAAOF,GAAM,WAE3BC,EAAGjE,KAAK+D,MAIVA,EAAII,iBAAiBH,EAAMC,GAAI,GAInCH,EAAShB,OAAQ,UAAU,WAErBA,OAAO2B,aAAe,IACxBC,EAAIL,UAAUC,IAAI,SAElBI,EAAIL,UAAUE,OAAO,cC/DmT,ICQ5U,G,UAAY,eACd,EACA,EACA,GACA,EACA,KACA,WACA,OAIa,I,QCnBX,EAAS,WAAa,IAAItB,EAAIC,KAASC,EAAGF,EAAIG,eAAsBH,EAAIK,MAAMD,GAAO,OAAOJ,EAAIO,GAAG,IACnG,EAAkB,CAAC,WAAa,IAAIP,EAAIC,KAASC,EAAGF,EAAIG,eAAmBC,EAAGJ,EAAIK,MAAMD,IAAIF,EAAG,OAAOE,EAAG,MAAM,CAACA,EAAG,MAAM,CAACK,YAAY,MAAM,CAACL,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,GAAK,UAAUF,EAAG,MAAM,CAACK,YAAY,QAAQ,CAACL,EAAG,MAAM,CAACK,YAAY,WAAW,CAACL,EAAG,MAAM,CAACK,YAAY,OAAOH,MAAM,CAAC,GAAK,SAASF,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,cAAcN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,uxCAAuxCN,EAAG,MAAM,CAACK,YAAY,OAAOH,MAAM,CAAC,GAAK,UAAUF,EAAG,KAAK,CAACK,YAAY,UAAU,CAACT,EAAIU,GAAG,WAAWN,EAAG,IAAI,CAACK,YAAY,MAAMH,MAAM,CAAC,KAAO,SAAS,CAACF,EAAG,MAAM,CAACE,MAAM,CAAC,IAAM,EAAQ,QAAqB,IAAM,aAAaF,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,oOAAoON,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,8NAA8NN,EAAG,MAAM,CAACK,YAAY,OAAOH,MAAM,CAAC,GAAK,UAAUF,EAAG,KAAK,CAACK,YAAY,UAAU,CAACT,EAAIU,GAAG,WAAWN,EAAG,IAAI,CAACK,YAAY,MAAMH,MAAM,CAAC,KAAO,SAAS,CAACF,EAAG,MAAM,CAACE,MAAM,CAAC,IAAM,EAAQ,QAAqB,IAAM,aAAaF,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,mMAAmMN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,qNAAqNN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,qQAAqQN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,oEAAoEN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,yHAAyHN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,8EAA8EN,EAAG,MAAM,CAACK,YAAY,OAAOH,MAAM,CAAC,GAAK,UAAUF,EAAG,KAAK,CAACK,YAAY,UAAU,CAACT,EAAIU,GAAG,WAAWN,EAAG,IAAI,CAACK,YAAY,MAAMH,MAAM,CAAC,KAAO,SAAS,CAACF,EAAG,MAAM,CAACE,MAAM,CAAC,IAAM,EAAQ,QAAqB,IAAM,aAAaF,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,+EAA+EN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,kKAAkKN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,4RAA4RN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,iLAAiLN,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,MAAM,CAACK,YAAY,WAAWL,EAAG,MAAM,CAACK,YAAY,QAAQH,MAAM,CAAC,GAAK,QAAQ,CAACF,EAAG,KAAK,CAACK,YAAY,SAAS,CAACL,EAAG,KAAK,CAACA,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,SAAS,CAACN,EAAIU,GAAG,gBAAgBN,EAAG,KAAK,CAACA,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,UAAU,CAACN,EAAIU,GAAG,cAAcN,EAAG,KAAK,CAACA,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,UAAU,CAACN,EAAIU,GAAG,cAAcN,EAAG,KAAK,CAACA,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,UAAU,CAACN,EAAIU,GAAG,sBC8G7tK,GACEC,OADF,aAEEC,QAFF,WAGI,IAAJ,iCAEI,SAASC,EAASC,EAAKC,EAAMC,GAEvBF,EAAIG,YACNH,EAAIG,YAAY,KAAOF,GAAM,WAE3BC,EAAGjE,KAAK+D,MAIVA,EAAII,iBAAiBH,EAAMC,GAAI,GAInCH,EAAShB,OAAQ,UAAU,WAErBA,OAAO2B,aAAe,IACxBC,EAAIL,UAAUC,IAAI,SAElBI,EAAIL,UAAUE,OAAO,cCtIwT,ICQjV,G,UAAY,eACd,EACA,EACA,GACA,EACA,KACA,WACA,OAIa,I,QCnBX,EAAS,WAAa,IAAItB,EAAIC,KAASC,EAAGF,EAAIG,eAAsBH,EAAIK,MAAMD,GAAO,OAAOJ,EAAIO,GAAG,IACnG,EAAkB,CAAC,WAAa,IAAIP,EAAIC,KAASC,EAAGF,EAAIG,eAAmBC,EAAGJ,EAAIK,MAAMD,IAAIF,EAAG,OAAOE,EAAG,MAAM,CAACA,EAAG,MAAM,CAACK,YAAY,MAAM,CAACL,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,GAAK,UAAUF,EAAG,MAAM,CAACK,YAAY,QAAQ,CAACL,EAAG,MAAM,CAACK,YAAY,WAAW,CAACL,EAAG,MAAM,CAACK,YAAY,OAAOH,MAAM,CAAC,GAAK,SAASF,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,eAAeN,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,UAAUN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,2MAA2MN,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,IAAM,EAAQ,QAAwB,IAAM,YAAYF,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,KAAK,CAACK,YAAY,UAAU,CAACT,EAAIU,GAAG,UAAUN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,wVAAwVN,EAAG,IAAI,CAACK,YAAY,OAAO,CAACT,EAAIU,GAAG,2NAA2NN,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,IAAM,EAAQ,QAAwB,IAAM,YAAYF,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,IAAM,EAAQ,QAA0B,IAAM,YAAYF,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,KAAK,CAACK,YAAY,UAAU,CAACT,EAAIU,GAAG,UAAUN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,8FAA8FN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,iVAAiVN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,4HAA4HN,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,IAAM,EAAQ,QAAwB,IAAM,YAAYF,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,KAAK,CAACK,YAAY,UAAU,CAACT,EAAIU,GAAG,uBAAuBN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,+FAA+FN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,wHAAwHN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,0OAA0ON,EAAG,IAAI,CAACK,YAAY,OAAO,CAACT,EAAIU,GAAG,gOAAgON,EAAG,MAAM,CAACK,YAAY,OAAOH,MAAM,CAAC,GAAK,UAAUF,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,YAAYN,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,UAAUN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,0IAA0IN,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,IAAM,EAAQ,QAAwB,IAAM,YAAYF,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,UAAUN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,4MAA4MN,EAAG,IAAI,CAACK,YAAY,OAAO,CAACT,EAAIU,GAAG,yJAAyJN,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,IAAM,EAAQ,QAAwB,IAAM,YAAYF,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,UAAUN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,wIAAwIN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,iGAAiGN,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,IAAM,EAAQ,QAA0B,IAAM,YAAYF,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,mBAAmBN,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,IAAM,EAAQ,QAA0B,IAAM,YAAYF,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,eAAeN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,wMAAwMN,EAAG,MAAM,CAACK,YAAY,OAAOH,MAAM,CAAC,GAAK,UAAUF,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,QAAQN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,+LAA+LN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,2KAA2KN,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,MAAM,CAACK,YAAY,WAAWL,EAAG,MAAM,CAACK,YAAY,QAAQH,MAAM,CAAC,GAAK,QAAQ,CAACF,EAAG,KAAK,CAACK,YAAY,SAAS,CAACL,EAAG,KAAK,CAACA,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,SAAS,CAACN,EAAIU,GAAG,kBAAkBN,EAAG,KAAK,CAACA,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,UAAU,CAACN,EAAIU,GAAG,aAAaN,EAAG,KAAK,CAACA,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,UAAU,CAACN,EAAIU,GAAG,kBCwHrrM,GACEC,OADF,aAEEC,QAFF,WAGI,IAAJ,iCAEI,SAASC,EAASC,EAAKC,EAAMC,GAEvBF,EAAIG,YACNH,EAAIG,YAAY,KAAOF,GAAM,WAE3BC,EAAGjE,KAAK+D,MAIVA,EAAII,iBAAiBH,EAAMC,GAAI,GAInCH,EAAShB,OAAQ,UAAU,WAErBA,OAAO2B,aAAe,IACxBC,EAAIL,UAAUC,IAAI,SAElBI,EAAIL,UAAUE,OAAO,cChJmT,ICQ5U,G,UAAY,eACd,EACA,EACA,GACA,EACA,KACA,WACA,OAIa,I,QCnBX,EAAS,WAAa,IAAItB,EAAIC,KAASC,EAAGF,EAAIG,eAAsBH,EAAIK,MAAMD,GAAO,OAAOJ,EAAIO,GAAG,IACnG,EAAkB,CAAC,WAAa,IAAIP,EAAIC,KAASC,EAAGF,EAAIG,eAAmBC,EAAGJ,EAAIK,MAAMD,IAAIF,EAAG,OAAOE,EAAG,MAAM,CAACA,EAAG,MAAM,CAACK,YAAY,MAAM,CAACL,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,GAAK,UAAUF,EAAG,MAAM,CAACK,YAAY,QAAQ,CAACL,EAAG,MAAM,CAACK,YAAY,WAAW,CAACL,EAAG,MAAM,CAACK,YAAY,OAAOH,MAAM,CAAC,GAAK,SAASF,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,cAAcN,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,mDAAmDN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,0FAA0FN,EAAG,MAAM,CAACK,YAAY,OAAOH,MAAM,CAAC,GAAK,UAAUF,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,cAAcN,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,2KAA2KN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,mCAAmCN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,oGAAoGN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,+FAA+FN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,yKAAyKN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,oIAAoIN,EAAG,IAAI,CAACK,YAAY,YAAYL,EAAG,MAAM,CAACK,YAAY,OAAOH,MAAM,CAAC,GAAK,UAAUF,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,iBAAiBN,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,UAAUN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,uLAAuLN,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,UAAUN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,qDAAqDN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,sEAAsEN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,oEAAoEN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,wBAAwBN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,uCAAuCN,EAAG,MAAM,CAACK,YAAY,OAAOH,MAAM,CAAC,GAAK,UAAUF,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,eAAeN,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,UAAUN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,mIAAmIN,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,UAAUN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,6DAA6DN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,mEAAmEN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,qFAAqFN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,uFAAuFN,EAAG,MAAM,CAACK,YAAY,OAAOH,MAAM,CAAC,GAAK,UAAUF,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,UAAUN,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,uIAAuIN,EAAG,MAAM,CAACK,YAAY,OAAOH,MAAM,CAAC,GAAK,UAAUF,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,kBAAkBN,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,YAAYN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,6IAA6IN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,wJAAwJN,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,UAAUN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,kLAAkLN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,kMAAkMN,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,aAAaN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,iOAAiON,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,sLAAsLN,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,MAAM,CAACK,YAAY,WAAWL,EAAG,MAAM,CAACK,YAAY,QAAQH,MAAM,CAAC,GAAK,QAAQ,CAACF,EAAG,KAAK,CAACK,YAAY,SAAS,CAACL,EAAG,KAAK,CAACA,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,SAAS,CAACN,EAAIU,GAAG,gBAAgBN,EAAG,KAAK,CAACA,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,UAAU,CAACN,EAAIU,GAAG,eAAeN,EAAG,KAAK,CAACA,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,UAAU,CAACN,EAAIU,GAAG,oBAAoBN,EAAG,KAAK,CAACA,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,UAAU,CAACN,EAAIU,GAAG,iBAAiBN,EAAG,KAAK,CAACA,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,UAAU,CAACN,EAAIU,GAAG,YAAYN,EAAG,KAAK,CAACA,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,UAAU,CAACN,EAAIU,GAAG,4BCoJ75L,GACEC,OADF,aAEEC,QAFF,WAGI,IAAJ,iCAEI,SAASC,EAASC,EAAKC,EAAMC,GAEvBF,EAAIG,YACNH,EAAIG,YAAY,KAAOF,GAAM,WAE3BC,EAAGjE,KAAK+D,MAIVA,EAAII,iBAAiBH,EAAMC,GAAI,GAInCH,EAAShB,OAAQ,UAAU,WAErBA,OAAO2B,aAAe,IACxBC,EAAIL,UAAUC,IAAI,SAElBI,EAAIL,UAAUE,OAAO,cC5KkT,ICQ3U,G,UAAY,eACd,EACA,EACA,GACA,EACA,KACA,WACA,OAIa,I,QCnBX,EAAS,WAAa,IAAItB,EAAIC,KAASC,EAAGF,EAAIG,eAAsBH,EAAIK,MAAMD,GAAO,OAAOJ,EAAIO,GAAG,IACnG,EAAkB,CAAC,WAAa,IAAIP,EAAIC,KAASC,EAAGF,EAAIG,eAAmBC,EAAGJ,EAAIK,MAAMD,IAAIF,EAAG,OAAOE,EAAG,MAAM,CAACA,EAAG,MAAM,CAACK,YAAY,MAAM,CAACL,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,GAAK,UAAUF,EAAG,MAAM,CAACK,YAAY,QAAQ,CAACL,EAAG,MAAM,CAACK,YAAY,WAAW,CAACL,EAAG,MAAM,CAACK,YAAY,OAAOH,MAAM,CAAC,GAAK,SAASF,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,wGAAwGN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,8BAA8BN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACL,EAAG,KAAK,CAACA,EAAG,KAAK,CAACJ,EAAIU,GAAG,uBAAuBN,EAAG,KAAK,CAACJ,EAAIU,GAAG,uBAAuBN,EAAG,KAAK,CAACJ,EAAIU,GAAG,qBAAqBN,EAAG,KAAK,CAACJ,EAAIU,GAAG,yBAAyBN,EAAG,KAAK,CAACJ,EAAIU,GAAG,2BAA2BN,EAAG,KAAK,CAACJ,EAAIU,GAAG,iCAAiCN,EAAG,MAAM,CAACK,YAAY,OAAOH,MAAM,CAAC,GAAK,UAAUF,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,YAAYN,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,iBAAiBN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACL,EAAG,KAAK,CAACA,EAAG,KAAK,CAACJ,EAAIU,GAAG,8EAA8EN,EAAG,KAAK,CAACJ,EAAIU,GAAG,sEAAsEN,EAAG,KAAK,CAACJ,EAAIU,GAAG,4HAA4HN,EAAG,KAAK,CAACJ,EAAIU,GAAG,6KAA6KN,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,eAAeN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACL,EAAG,KAAK,CAACA,EAAG,KAAK,CAACJ,EAAIU,GAAG,gDAAgDN,EAAG,KAAK,CAACJ,EAAIU,GAAG,iEAAiEN,EAAG,KAAK,CAACJ,EAAIU,GAAG,gDAAgDN,EAAG,KAAK,CAACJ,EAAIU,GAAG,kBAAkBN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,0aAA0aN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,uEAAuEN,EAAG,MAAM,CAACK,YAAY,OAAOH,MAAM,CAAC,GAAK,UAAUF,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,UAAUN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACL,EAAG,KAAK,CAACA,EAAG,KAAK,CAACJ,EAAIU,GAAG,4DAA4DN,EAAG,KAAK,CAACJ,EAAIU,GAAG,uFAAuFN,EAAG,KAAK,CAACJ,EAAIU,GAAG,0CAA0CN,EAAG,KAAK,CAACJ,EAAIU,GAAG,uBAAuBN,EAAG,KAAK,CAACJ,EAAIU,GAAG,2FAA2FN,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,MAAM,CAACK,YAAY,WAAWL,EAAG,MAAM,CAACK,YAAY,QAAQH,MAAM,CAAC,GAAK,QAAQ,CAACF,EAAG,KAAK,CAACK,YAAY,SAAS,CAACL,EAAG,KAAK,CAACA,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,SAAS,CAACN,EAAIU,GAAG,WAAWN,EAAG,KAAK,CAACA,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,UAAU,CAACN,EAAIU,GAAG,cAAcN,EAAG,KAAK,CAACA,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,UAAU,CAACN,EAAIU,GAAG,oBCgHjyG,GACEC,OADF,aAEEC,QAFF,WAGI,IAAJ,iCAEI,SAASC,EAASC,EAAKC,EAAMC,GAEvBF,EAAIG,YACNH,EAAIG,YAAY,KAAOF,GAAM,WAE3BC,EAAGjE,KAAK+D,MAIVA,EAAII,iBAAiBH,EAAMC,GAAI,GAInCH,EAAShB,OAAQ,UAAU,WAErBA,OAAO2B,aAAe,IACxBC,EAAIL,UAAUC,IAAI,SAElBI,EAAIL,UAAUE,OAAO,cCxIuT,ICQhV,G,UAAY,eACd,EACA,EACA,GACA,EACA,KACA,WACA,OAIa,I,QCnBX,EAAS,WAAa,IAAItB,EAAIC,KAASC,EAAGF,EAAIG,eAAsBH,EAAIK,MAAMD,GAAO,OAAOJ,EAAIO,GAAG,IACnG,EAAkB,CAAC,WAAa,IAAIP,EAAIC,KAASC,EAAGF,EAAIG,eAAmBC,EAAGJ,EAAIK,MAAMD,IAAIF,EAAG,OAAOE,EAAG,MAAM,CAACA,EAAG,MAAM,CAACK,YAAY,MAAM,CAACL,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,GAAK,UAAUF,EAAG,MAAM,CAACK,YAAY,QAAQ,CAACL,EAAG,MAAM,CAACK,YAAY,WAAW,CAACL,EAAG,MAAM,CAACK,YAAY,OAAOH,MAAM,CAAC,GAAK,SAASF,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,4KAA4KN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,6IAA6IN,EAAG,MAAM,CAACK,YAAY,OAAOH,MAAM,CAAC,GAAK,UAAUF,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,aAAaN,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,eAAeN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,+LAA+LN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,gJAAgJN,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,IAAM,EAAQ,QAAuB,IAAM,YAAYF,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,IAAM,EAAQ,QAAuB,IAAM,YAAYF,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,iBAAiBN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,mMAAmMN,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,UAAUN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,iPAAiPN,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,IAAM,EAAQ,QAAuB,IAAM,YAAYF,EAAG,MAAM,CAACK,YAAY,OAAOH,MAAM,CAAC,GAAK,UAAUF,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,YAAYN,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,IAAM,EAAQ,QAAuB,IAAM,YAAYF,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,yBAAyBN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,wBAAwBN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,sBAAsBN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,mCAAmCN,EAAG,MAAM,CAACK,YAAY,OAAOH,MAAM,CAAC,GAAK,UAAUF,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,aAAaN,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,UAAUN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,6LAA6LN,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,UAAUN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,6OAA6ON,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,UAAUN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,qIAAqIN,EAAG,MAAM,CAACK,YAAY,OAAOH,MAAM,CAAC,GAAK,UAAUF,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,UAAUN,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,SAASN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,yHAAyHN,EAAG,IAAI,CAACK,YAAY,OAAO,CAACT,EAAIU,GAAG,6EAA6EN,EAAG,IAAI,CAACK,YAAY,OAAO,CAACT,EAAIU,GAAG,kFAAkFN,EAAG,IAAI,CAACK,YAAY,OAAO,CAACT,EAAIU,GAAG,kFAAkFN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,uFAAuFN,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,WAAWN,EAAG,KAAK,CAACK,YAAY,YAAY,CAACT,EAAIU,GAAG,UAAUN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,0IAA0IN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,0EAA0EN,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,KAAK,CAACK,YAAY,YAAY,CAACT,EAAIU,GAAG,WAAWN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,8GAA8GN,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,KAAK,CAACK,YAAY,YAAY,CAACT,EAAIU,GAAG,cAAcN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,2CAA2CN,EAAG,KAAK,CAACA,EAAG,KAAK,CAACJ,EAAIU,GAAG,8CAA8CN,EAAG,KAAK,CAACJ,EAAIU,GAAG,qCAAqCN,EAAG,KAAK,CAACJ,EAAIU,GAAG,0CAA0CN,EAAG,KAAK,CAACJ,EAAIU,GAAG,wDAAwDN,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,MAAM,CAACK,YAAY,WAAWL,EAAG,MAAM,CAACK,YAAY,QAAQH,MAAM,CAAC,GAAK,QAAQ,CAACF,EAAG,KAAK,CAACK,YAAY,SAAS,CAACL,EAAG,KAAK,CAACA,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,SAAS,CAACN,EAAIU,GAAG,YAAYN,EAAG,KAAK,CAACA,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,UAAU,CAACN,EAAIU,GAAG,cAAcN,EAAG,KAAK,CAACA,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,UAAU,CAACN,EAAIU,GAAG,cAAcN,EAAG,KAAK,CAACA,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,UAAU,CAACN,EAAIU,GAAG,gBAAgBN,EAAG,KAAK,CAACA,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,UAAU,CAACN,EAAIU,GAAG,oBCiJz7L,GACEC,OADF,aAEEC,QAFF,WAGI,IAAJ,iCAEI,SAASC,EAASC,EAAKC,EAAMC,GAEvBF,EAAIG,YACNH,EAAIG,YAAY,KAAOF,GAAM,WAE3BC,EAAGjE,KAAK+D,MAIVA,EAAII,iBAAiBH,EAAMC,GAAI,GAInCH,EAAShB,OAAQ,UAAU,WAErBA,OAAO2B,aAAe,IACxBC,EAAIL,UAAUC,IAAI,SAElBI,EAAIL,UAAUE,OAAO,cCzKmT,ICQ5U,G,UAAY,eACd,EACA,EACA,GACA,EACA,KACA,WACA,OAIa,I,QCnBX,EAAS,WAAa,IAAItB,EAAIC,KAASC,EAAGF,EAAIG,eAAsBH,EAAIK,MAAMD,GAAO,OAAOJ,EAAIO,GAAG,IACnG,EAAkB,CAAC,WAAa,IAAIP,EAAIC,KAASC,EAAGF,EAAIG,eAAmBC,EAAGJ,EAAIK,MAAMD,IAAIF,EAAG,OAAOE,EAAG,MAAM,CAACA,EAAG,MAAM,CAACK,YAAY,MAAM,CAACL,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,GAAK,UAAUF,EAAG,MAAM,CAACK,YAAY,QAAQ,CAACL,EAAG,MAAM,CAACK,YAAY,OAAOH,MAAM,CAAC,GAAK,SAASF,EAAG,MAAM,CAACK,YAAY,QAAQ,CAACL,EAAG,MAAM,CAACK,YAAY,SAAS,CAACL,EAAG,MAAM,CAACE,MAAM,CAAC,IAAM,EAAQ,QAAmB,IAAM,QAAQF,EAAG,MAAM,CAACK,YAAY,UAAU,CAACL,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,WAAW,CAACF,EAAG,MAAM,CAACE,MAAM,CAAC,IAAM,EAAQ,QAAsB,IAAM,YAAYF,EAAG,MAAM,CAACK,YAAY,OAAOH,MAAM,CAAC,GAAK,WAAWF,EAAG,MAAM,CAACK,YAAY,QAAQ,CAACL,EAAG,MAAM,CAACK,YAAY,SAAS,CAACL,EAAG,MAAM,CAACA,EAAG,MAAM,CAACE,MAAM,CAAC,IAAM,EAAQ,QAAqB,IAAM,QAAQF,EAAG,MAAM,CAACK,YAAY,OAAO,CAACL,EAAG,MAAM,CAACE,MAAM,CAAC,IAAM,EAAQ,QAAqB,IAAM,QAAQF,EAAG,MAAM,CAACA,EAAG,MAAM,CAACE,MAAM,CAAC,IAAM,EAAQ,QAAqB,IAAM,UAAUF,EAAG,MAAM,CAACK,YAAY,UAAU,CAACL,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,WAAW,CAACF,EAAG,MAAM,CAACE,MAAM,CAAC,IAAM,EAAQ,QAAsB,IAAM,YAAYF,EAAG,MAAM,CAACK,YAAY,OAAOH,MAAM,CAAC,GAAK,WAAWF,EAAG,MAAM,CAACK,YAAY,QAAQ,CAACL,EAAG,MAAM,CAACK,YAAY,SAAS,CAACL,EAAG,MAAM,CAACE,MAAM,CAAC,IAAM,EAAQ,QAAmB,IAAM,UAAUF,EAAG,MAAM,CAACK,YAAY,QAAQH,MAAM,CAAC,GAAK,QAAQ,CAACF,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,SAAS,CAACF,EAAG,MAAM,CAACE,MAAM,CAAC,IAAM,EAAQ,QAAyB,IAAM,gBCuCz1C,GACEK,OADF,aAEEC,QAFF,WAGI,IAAJ,iCAEI,SAASC,EAASC,EAAKC,EAAMC,GAEvBF,EAAIG,YACNH,EAAIG,YAAY,KAAOF,GAAM,WAE3BC,EAAGjE,KAAK+D,MAIVA,EAAII,iBAAiBH,EAAMC,GAAI,GAInCH,EAAShB,OAAQ,UAAU,WAErBA,OAAO2B,aAAe,IACxBC,EAAIL,UAAUC,IAAI,SAElBI,EAAIL,UAAUE,OAAO,cC/DkT,ICQ3U,I,UAAY,eACd,EACA,EACA,GACA,EACA,KACA,WACA,OAIa,M,QCnBX,GAAS,WAAa,IAAItB,EAAIC,KAASC,EAAGF,EAAIG,eAAmBC,EAAGJ,EAAIK,MAAMD,IAAIF,EAAG,OAAOE,EAAG,MAAM,CAACJ,EAAIO,GAAG,GAAGH,EAAG,MAAM,CAACK,YAAY,QAAQ,CAACL,EAAG,MAAM,CAACK,YAAY,WAAW,CAACL,EAAG,MAAM,CAACK,YAAY,OAAOH,MAAM,CAAC,GAAK,SAASF,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,eAAeN,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,IAAM,EAAQ,QAAuB,IAAM,YAAYF,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,IAAM,EAAQ,QAAuB,IAAM,YAAYF,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,IAAM,EAAQ,QAAuB,IAAM,YAAYF,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,6MAA6MN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,4LAA4LN,EAAG,MAAM,CAACK,YAAY,OAAOH,MAAM,CAAC,GAAK,UAAUF,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,eAAeN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,kCAAkCN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,kHAAkHN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,uDAAuDN,EAAG,IAAI,CAACK,YAAY,OAAO,CAACT,EAAIU,GAAG,8EAA8EN,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,IAAM,EAAQ,QAAyB,IAAM,YAAYF,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,IAAM,EAAQ,QAAyB,IAAM,YAAYF,EAAG,MAAM,CAACK,YAAY,OAAOH,MAAM,CAAC,GAAK,UAAUF,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,WAAWN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,qFAAqFN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,qEAAqEN,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,IAAM,EAAQ,QAAyB,IAAM,YAAYF,EAAG,MAAM,CAACK,YAAY,OAAOH,MAAM,CAAC,GAAK,UAAUF,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,WAAWN,EAAG,MAAM,CAACK,YAAY,WAAW,CAACL,EAAG,MAAM,CAACK,YAAY,QAAQ,CAACL,EAAG,MAAM,CAACK,YAAY,IAAIH,MAAM,CAAC,GAAK,MAAMoB,GAAG,CAAC,MAAQ,SAASC,GAAQ,OAAO3B,EAAI4B,SAAS,CAAC5B,EAAIU,GAAG,QAAQN,EAAG,MAAM,CAACK,YAAY,IAAIH,MAAM,CAAC,GAAK,MAAMoB,GAAG,CAAC,MAAQ,SAASC,GAAQ,OAAO3B,EAAI6B,SAAS,CAAC7B,EAAIU,GAAG,QAAQN,EAAG,MAAM,CAACK,YAAY,IAAIH,MAAM,CAAC,GAAK,MAAMoB,GAAG,CAAC,MAAQ,SAASC,GAAQ,OAAO3B,EAAI8B,SAAS,CAAC9B,EAAIU,GAAG,aAAaV,EAAIO,GAAG,KAAKH,EAAG,KAAK,CAACK,YAAY,YAAYL,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,MAAM,CAACK,YAAY,WAAWT,EAAIO,GAAG,MACnxF,GAAkB,CAAC,WAAa,IAAIP,EAAIC,KAASC,EAAGF,EAAIG,eAAmBC,EAAGJ,EAAIK,MAAMD,IAAIF,EAAG,OAAOE,EAAG,MAAM,CAACK,YAAY,MAAM,CAACL,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,GAAK,WAAW,WAAa,IAAIN,EAAIC,KAASC,EAAGF,EAAIG,eAAmBC,EAAGJ,EAAIK,MAAMD,IAAIF,EAAG,OAAOE,EAAG,MAAM,CAACK,YAAY,OAAO,CAACL,EAAG,MAAM,CAACK,YAAY,IAAIH,MAAM,CAAC,GAAK,OAAO,CAACF,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,yHAAyHN,EAAG,KAAK,CAACK,YAAY,UAAU,CAACT,EAAIU,GAAG,kBAAkBN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,wFAAwFN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,sEAAsEN,EAAG,KAAK,CAACK,YAAY,UAAU,CAACT,EAAIU,GAAG,kBAAkBN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,uBAAuBN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,kBAAkBN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,0EAA0EN,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,IAAM,EAAQ,QAAyB,IAAM,YAAYF,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,qKAAqKN,EAAG,MAAM,CAACK,YAAY,IAAIH,MAAM,CAAC,GAAK,OAAO,CAACF,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,iEAAiEN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,6GAA6GN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,0JAA0JN,EAAG,MAAM,CAACK,YAAY,IAAIH,MAAM,CAAC,GAAK,OAAO,CAACF,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,gNAAgNN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,mMAAmMN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,8OAA8ON,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,IAAM,EAAQ,QAAyB,IAAM,iBAAiB,WAAa,IAAIN,EAAIC,KAASC,EAAGF,EAAIG,eAAmBC,EAAGJ,EAAIK,MAAMD,IAAIF,EAAG,OAAOE,EAAG,MAAM,CAACK,YAAY,QAAQH,MAAM,CAAC,GAAK,QAAQ,CAACF,EAAG,KAAK,CAACK,YAAY,SAAS,CAACL,EAAG,KAAK,CAACA,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,SAAS,CAACN,EAAIU,GAAG,iBAAiBN,EAAG,KAAK,CAACA,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,UAAU,CAACN,EAAIU,GAAG,iBAAiBN,EAAG,KAAK,CAACA,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,UAAU,CAACN,EAAIU,GAAG,aAAaN,EAAG,KAAK,CAACA,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,UAAU,CAACN,EAAIU,GAAG,mBCiI3mG,IACEC,OADF,aAEEoB,QAAS,CACPH,IADJ,WAEM,IAAN,gCACA,gCACA,gCACMI,EAAGZ,UAAUC,IAAI,UACjBY,EAAGb,UAAUE,OAAO,UACpBY,EAAGd,UAAUE,OAAO,WAEtBO,IATJ,WAUM,IAAN,gCACA,gCACA,gCACMI,EAAGb,UAAUC,IAAI,UACjBW,EAAGZ,UAAUE,OAAO,UACpBY,EAAGd,UAAUE,OAAO,WAEtBQ,IAjBJ,WAkBM,IAAN,gCACA,gCACA,gCACMI,EAAGd,UAAUC,IAAI,UACjBY,EAAGb,UAAUE,OAAO,UACpBU,EAAGZ,UAAUE,OAAO,YAGxBV,QA5BF,WA6BI,IAAJ,iCAEI,SAASC,EAASC,EAAKC,EAAMC,GAEvBF,EAAIG,YACNH,EAAIG,YAAY,KAAOF,GAAM,WAE3BC,EAAGjE,KAAK+D,MAIVA,EAAII,iBAAiBH,EAAMC,GAAI,GAInCH,EAAShB,OAAQ,UAAU,WAErBA,OAAO2B,aAAe,IACxBC,EAAIL,UAAUC,IAAI,SAElBI,EAAIL,UAAUE,OAAO,cCnLuT,MCQhV,I,UAAY,eACd,GACA,GACA,IACA,EACA,KACA,WACA,OAIa,M,QCnBX,GAAS,WAAa,IAAItB,EAAIC,KAASC,EAAGF,EAAIG,eAAmBC,EAAGJ,EAAIK,MAAMD,IAAIF,EAAG,OAAOE,EAAG,MAAM,CAACJ,EAAIO,GAAG,GAAGH,EAAG,MAAM,CAACK,YAAY,QAAQ,CAACL,EAAG,MAAM,CAACK,YAAY,WAAW,CAACL,EAAG,MAAM,CAACK,YAAY,OAAOH,MAAM,CAAC,GAAK,SAASF,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,iBAAiBN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,oEAAoEN,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,IAAM,EAAQ,QAAwB,IAAM,YAAYF,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,uLAAuLN,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,IAAM,EAAQ,QAAwB,IAAM,YAAYF,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,6HAA6HN,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,IAAM,EAAQ,QAAwB,IAAM,YAAYF,EAAG,MAAM,CAACK,YAAY,OAAOH,MAAM,CAAC,GAAK,UAAUF,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,UAAUN,EAAG,MAAM,CAACK,YAAY,WAAW,CAACL,EAAG,MAAM,CAACK,YAAY,QAAQ,CAACL,EAAG,MAAM,CAACK,YAAY,IAAIH,MAAM,CAAC,GAAK,MAAMoB,GAAG,CAAC,MAAQ,SAASC,GAAQ,OAAO3B,EAAI4B,SAAS,CAAC5B,EAAIU,GAAG,UAAUN,EAAG,MAAM,CAACK,YAAY,IAAIH,MAAM,CAAC,GAAK,MAAMoB,GAAG,CAAC,MAAQ,SAASC,GAAQ,OAAO3B,EAAI6B,SAAS,CAAC7B,EAAIU,GAAG,UAAUN,EAAG,MAAM,CAACK,YAAY,IAAIH,MAAM,CAAC,GAAK,MAAMoB,GAAG,CAAC,MAAQ,SAASC,GAAQ,OAAO3B,EAAI8B,SAAS,CAAC9B,EAAIU,GAAG,cAAcN,EAAG,MAAM,CAACK,YAAY,IAAIH,MAAM,CAAC,GAAK,MAAMoB,GAAG,CAAC,MAAQ,SAASC,GAAQ,OAAO3B,EAAImC,SAAS,CAACnC,EAAIU,GAAG,YAAYV,EAAIO,GAAG,OAAOH,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,MAAM,CAACK,YAAY,WAAWT,EAAIO,GAAG,MAC9wD,GAAkB,CAAC,WAAa,IAAIP,EAAIC,KAASC,EAAGF,EAAIG,eAAmBC,EAAGJ,EAAIK,MAAMD,IAAIF,EAAG,OAAOE,EAAG,MAAM,CAACK,YAAY,MAAM,CAACL,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,GAAK,WAAW,WAAa,IAAIN,EAAIC,KAASC,EAAGF,EAAIG,eAAmBC,EAAGJ,EAAIK,MAAMD,IAAIF,EAAG,OAAOE,EAAG,MAAM,CAACK,YAAY,OAAO,CAACL,EAAG,MAAM,CAACK,YAAY,IAAIH,MAAM,CAAC,GAAK,OAAO,CAACF,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,6LAA6LN,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,IAAM,EAAQ,QAAwB,IAAM,YAAYF,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,+CAA+CN,EAAG,IAAI,CAACK,YAAY,OAAO,CAACT,EAAIU,GAAG,eAAeN,EAAG,IAAI,CAACK,YAAY,OAAO,CAACT,EAAIU,GAAG,sGAAsGN,EAAG,IAAI,CAACK,YAAY,OAAO,CAACT,EAAIU,GAAG,wDAAwDN,EAAG,MAAM,CAACK,YAAY,IAAIH,MAAM,CAAC,GAAK,OAAO,CAACF,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,+EAA+EN,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,IAAM,EAAQ,QAAwB,IAAM,cAAcF,EAAG,MAAM,CAACK,YAAY,IAAIH,MAAM,CAAC,GAAK,OAAO,CAACF,EAAG,IAAI,CAACK,YAAY,WAAW,CAACL,EAAG,KAAK,CAACA,EAAG,KAAK,CAACJ,EAAIU,GAAG,qIAAqIN,EAAG,KAAK,CAACJ,EAAIU,GAAG,mEAAmEN,EAAG,KAAK,CAACJ,EAAIU,GAAG,oJAAoJN,EAAG,KAAK,CAACJ,EAAIU,GAAG,wFAAwFN,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,IAAM,EAAQ,QAAwB,IAAM,cAAcF,EAAG,MAAM,CAACK,YAAY,IAAIH,MAAM,CAAC,GAAK,OAAO,CAACF,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,6KAA6KN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,+DAA+DN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,gDAAgDN,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,IAAM,EAAQ,QAAwB,IAAM,iBAAiB,WAAa,IAAIN,EAAIC,KAASC,EAAGF,EAAIG,eAAmBC,EAAGJ,EAAIK,MAAMD,IAAIF,EAAG,OAAOE,EAAG,MAAM,CAACK,YAAY,QAAQH,MAAM,CAAC,GAAK,QAAQ,CAACF,EAAG,KAAK,CAACK,YAAY,SAAS,CAACL,EAAG,KAAK,CAACA,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,SAAS,CAACN,EAAIU,GAAG,gBAAgBN,EAAG,KAAK,CAACA,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,UAAU,CAACN,EAAIU,GAAG,kBCsG7tF,IACEC,OADF,aAEEoB,QAAS,CACPH,IADJ,WAEM,IAAN,gCACA,gCACA,gCACA,gCACMI,EAAGZ,UAAUC,IAAI,UACjBY,EAAGb,UAAUE,OAAO,UACpBY,EAAGd,UAAUE,OAAO,UACpBc,EAAGhB,UAAUE,OAAO,WAEtBO,IAXJ,WAYM,IAAN,gCACA,gCACA,gCACA,gCACMI,EAAGb,UAAUC,IAAI,UACjBW,EAAGZ,UAAUE,OAAO,UACpBY,EAAGd,UAAUE,OAAO,UACpBc,EAAGhB,UAAUE,OAAO,WAEtBQ,IArBJ,WAsBM,IAAN,gCACA,gCACA,gCACA,gCACMI,EAAGd,UAAUC,IAAI,UACjBY,EAAGb,UAAUE,OAAO,UACpBU,EAAGZ,UAAUE,OAAO,UACpBc,EAAGhB,UAAUE,OAAO,WAEtBa,IA/BJ,WAgCM,IAAN,gCACA,gCACA,gCACA,gCACMC,EAAGhB,UAAUC,IAAI,UACjBY,EAAGb,UAAUE,OAAO,UACpBU,EAAGZ,UAAUE,OAAO,UACpBY,EAAGd,UAAUE,OAAO,YAGxBV,QA5CF,WA6CI,IAAJ,iCAEI,SAASC,EAASC,EAAKC,EAAMC,GAEvBF,EAAIG,YACNH,EAAIG,YAAY,KAAOF,GAAM,WAE3BC,EAAGjE,KAAK+D,MAIVA,EAAII,iBAAiBH,EAAMC,GAAI,GAInCH,EAAShB,OAAQ,UAAU,WAErBA,OAAO2B,aAAe,IACxBC,EAAIL,UAAUC,IAAI,SAElBI,EAAIL,UAAUE,OAAO,cCxK0T,MCQnV,I,UAAY,eACd,GACA,GACA,IACA,EACA,KACA,WACA,OAIa,M,QCnBX,GAAS,WAAa,IAAItB,EAAIC,KAASC,EAAGF,EAAIG,eAAmBC,EAAGJ,EAAIK,MAAMD,IAAIF,EAAG,OAAOE,EAAG,MAAM,CAACJ,EAAIO,GAAG,GAAGH,EAAG,MAAM,CAACK,YAAY,QAAQ,CAACL,EAAG,MAAM,CAACK,YAAY,WAAW,CAACL,EAAG,MAAM,CAACK,YAAY,OAAOH,MAAM,CAAC,GAAK,SAASF,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,eAAeN,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,yBAAyBN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,0KAA0KN,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,IAAM,EAAQ,QAAwB,IAAM,YAAYF,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,8NAA8NN,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,UAAUN,EAAG,MAAM,CAACK,YAAY,WAAW,CAACL,EAAG,MAAM,CAACK,YAAY,QAAQ,CAACL,EAAG,MAAM,CAACK,YAAY,IAAIH,MAAM,CAAC,GAAK,MAAMoB,GAAG,CAAC,MAAQ,SAASC,GAAQ,OAAO3B,EAAI4B,SAAS,CAAC5B,EAAIU,GAAG,WAAWN,EAAG,MAAM,CAACK,YAAY,IAAIH,MAAM,CAAC,GAAK,MAAMoB,GAAG,CAAC,MAAQ,SAASC,GAAQ,OAAO3B,EAAI6B,SAAS,CAAC7B,EAAIU,GAAG,aAAaV,EAAIO,GAAG,GAAGH,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,MAAM,CAACK,YAAY,OAAOH,MAAM,CAAC,GAAK,UAAUF,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,iBAAiBN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,uFAAuFN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,gJAAgJN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,kIAAkIN,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,IAAM,EAAQ,QAAwB,IAAM,kBAAkBN,EAAIO,GAAG,MACj9D,GAAkB,CAAC,WAAa,IAAIP,EAAIC,KAASC,EAAGF,EAAIG,eAAmBC,EAAGJ,EAAIK,MAAMD,IAAIF,EAAG,OAAOE,EAAG,MAAM,CAACK,YAAY,MAAM,CAACL,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,GAAK,WAAW,WAAa,IAAIN,EAAIC,KAASC,EAAGF,EAAIG,eAAmBC,EAAGJ,EAAIK,MAAMD,IAAIF,EAAG,OAAOE,EAAG,MAAM,CAACK,YAAY,OAAO,CAACL,EAAG,MAAM,CAACK,YAAY,IAAIH,MAAM,CAAC,GAAK,OAAO,CAACF,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,gPAAgPN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,yHAAyHN,EAAG,MAAM,CAACK,YAAY,IAAIH,MAAM,CAAC,GAAK,OAAO,CAACF,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,2NAA2NN,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,IAAM,EAAQ,QAAwB,IAAM,iBAAiB,WAAa,IAAIN,EAAIC,KAASC,EAAGF,EAAIG,eAAmBC,EAAGJ,EAAIK,MAAMD,IAAIF,EAAG,OAAOE,EAAG,MAAM,CAACK,YAAY,QAAQH,MAAM,CAAC,GAAK,QAAQ,CAACF,EAAG,KAAK,CAACK,YAAY,SAAS,CAACL,EAAG,KAAK,CAACA,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,SAAS,CAACN,EAAIU,GAAG,iBAAiBN,EAAG,KAAK,CAACA,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,UAAU,CAACN,EAAIU,GAAG,yBCkEr7C,IACEC,OADF,aAEEoB,QAAS,CACPH,IADJ,WAEM,IAAN,gCACA,gCAEMI,EAAGZ,UAAUC,IAAI,UACjBY,EAAGb,UAAUE,OAAO,WAEtBO,IARJ,WASM,IAAN,gCACA,gCAEMI,EAAGb,UAAUC,IAAI,UACjBW,EAAGZ,UAAUE,OAAO,YAGxBV,QAlBF,WAmBI,IAAJ,iCAEI,SAASC,EAASC,EAAKC,EAAMC,GAEvBF,EAAIG,YACNH,EAAIG,YAAY,KAAOF,GAAM,WAE3BC,EAAGjE,KAAK+D,MAIVA,EAAII,iBAAiBH,EAAMC,GAAI,GAInCH,EAAShB,OAAQ,UAAU,WAErBA,OAAO2B,aAAe,IACxBC,EAAIL,UAAUC,IAAI,SAElBI,EAAIL,UAAUE,OAAO,cC1GsT,MCQ/U,I,UAAY,eACd,GACA,GACA,IACA,EACA,KACA,WACA,OAIa,M,QCnBX,GAAS,WAAa,IAAItB,EAAIC,KAASC,EAAGF,EAAIG,eAAmBC,EAAGJ,EAAIK,MAAMD,IAAIF,EAAG,OAAOE,EAAG,MAAM,CAACJ,EAAIO,GAAG,GAAGH,EAAG,MAAM,CAACK,YAAY,QAAQ,CAACL,EAAG,MAAM,CAACK,YAAY,WAAW,CAACL,EAAG,MAAM,CAACK,YAAY,OAAOH,MAAM,CAAC,GAAK,SAASF,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,QAAQN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,oJAAoJN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,sHAAsHN,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,WAAWN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,mMAAmMN,EAAG,MAAM,CAACK,YAAY,WAAW,CAACL,EAAG,MAAM,CAACK,YAAY,QAAQ,CAACL,EAAG,MAAM,CAACK,YAAY,IAAIH,MAAM,CAAC,GAAK,MAAMoB,GAAG,CAAC,MAAQ,SAASC,GAAQ,OAAO3B,EAAI4B,SAAS,CAAC5B,EAAIU,GAAG,UAAUN,EAAG,MAAM,CAACK,YAAY,IAAIH,MAAM,CAAC,GAAK,MAAMoB,GAAG,CAAC,MAAQ,SAASC,GAAQ,OAAO3B,EAAI6B,SAAS,CAAC7B,EAAIU,GAAG,WAAWN,EAAG,MAAM,CAACK,YAAY,IAAIH,MAAM,CAAC,GAAK,MAAMoB,GAAG,CAAC,MAAQ,SAASC,GAAQ,OAAO3B,EAAI8B,SAAS,CAAC9B,EAAIU,GAAG,UAAUN,EAAG,MAAM,CAACK,YAAY,IAAIH,MAAM,CAAC,GAAK,MAAMoB,GAAG,CAAC,MAAQ,SAASC,GAAQ,OAAO3B,EAAImC,SAAS,CAACnC,EAAIU,GAAG,YAAYV,EAAIO,GAAG,KAAKH,EAAG,MAAM,CAACK,YAAY,OAAOH,MAAM,CAAC,GAAK,UAAUF,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,UAAUN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,kKAAkKN,EAAG,MAAM,CAACK,YAAY,OAAOH,MAAM,CAAC,GAAK,UAAUF,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,YAAYN,EAAG,KAAK,CAACK,YAAY,UAAU,CAACT,EAAIU,GAAG,QAAQN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,wHAAwHN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,8DAA8DN,EAAG,KAAK,CAACK,YAAY,UAAU,CAACT,EAAIU,GAAG,QAAQN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,8DAA8DN,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,MAAM,CAACK,YAAY,aAAaT,EAAIO,GAAG,MAC94E,GAAkB,CAAC,WAAa,IAAIP,EAAIC,KAASC,EAAGF,EAAIG,eAAmBC,EAAGJ,EAAIK,MAAMD,IAAIF,EAAG,OAAOE,EAAG,MAAM,CAACK,YAAY,MAAM,CAACL,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,GAAK,WAAW,WAAa,IAAIN,EAAIC,KAASC,EAAGF,EAAIG,eAAmBC,EAAGJ,EAAIK,MAAMD,IAAIF,EAAG,OAAOE,EAAG,MAAM,CAACK,YAAY,OAAO,CAACL,EAAG,MAAM,CAACK,YAAY,IAAIH,MAAM,CAAC,GAAK,OAAO,CAACF,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,wKAAwKN,EAAG,MAAM,CAACK,YAAY,IAAIH,MAAM,CAAC,GAAK,OAAO,CAACF,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,iLAAiLN,EAAG,MAAM,CAACK,YAAY,IAAIH,MAAM,CAAC,GAAK,OAAO,CAACF,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,6PAA6PN,EAAG,MAAM,CAACK,YAAY,IAAIH,MAAM,CAAC,GAAK,OAAO,CAACF,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,oGAAoGN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,wIAAwI,WAAa,IAAIV,EAAIC,KAASC,EAAGF,EAAIG,eAAmBC,EAAGJ,EAAIK,MAAMD,IAAIF,EAAG,OAAOE,EAAG,MAAM,CAACK,YAAY,QAAQH,MAAM,CAAC,GAAK,QAAQ,CAACF,EAAG,KAAK,CAACK,YAAY,SAAS,CAACL,EAAG,KAAK,CAACA,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,SAAS,CAACN,EAAIU,GAAG,UAAUN,EAAG,KAAK,CAACA,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,UAAU,CAACN,EAAIU,GAAG,aAAaN,EAAG,KAAK,CAACA,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,UAAU,CAACN,EAAIU,GAAG,YAAYN,EAAG,KAAK,CAACA,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,UAAU,CAACN,EAAIU,GAAG,oBC8Fl3D,IACEC,OADF,aAEEoB,QAAS,CACPH,IADJ,WAEM,IAAN,gCACA,gCACA,gCACA,gCACMI,EAAGZ,UAAUC,IAAI,UACjBY,EAAGb,UAAUE,OAAO,UACpBY,EAAGd,UAAUE,OAAO,UACpBc,EAAGhB,UAAUE,OAAO,WAEtBO,IAXJ,WAYM,IAAN,gCACA,gCACA,gCACA,gCACMI,EAAGb,UAAUC,IAAI,UACjBW,EAAGZ,UAAUE,OAAO,UACpBY,EAAGd,UAAUE,OAAO,UACpBc,EAAGhB,UAAUE,OAAO,WAEtBQ,IArBJ,WAsBM,IAAN,gCACA,gCACA,gCACA,gCACMI,EAAGd,UAAUC,IAAI,UACjBY,EAAGb,UAAUE,OAAO,UACpBU,EAAGZ,UAAUE,OAAO,UACpBc,EAAGhB,UAAUE,OAAO,WAEtBa,IA/BJ,WAgCM,IAAN,gCACA,gCACA,gCACA,gCACMC,EAAGhB,UAAUC,IAAI,UACjBY,EAAGb,UAAUE,OAAO,UACpBU,EAAGZ,UAAUE,OAAO,UACpBY,EAAGd,UAAUE,OAAO,YAGxBV,QA5CF,WA6CI,IAAJ,iCAEI,SAASC,EAASC,EAAKC,EAAMC,GAEvBF,EAAIG,YACNH,EAAIG,YAAY,KAAOF,GAAM,WAE3BC,EAAGjE,KAAK+D,MAIVA,EAAII,iBAAiBH,EAAMC,GAAI,GAInCH,EAAShB,OAAQ,UAAU,WAErBA,OAAO2B,aAAe,IACxBC,EAAIL,UAAUC,IAAI,SAElBI,EAAIL,UAAUE,OAAO,cChKwT,MCQjV,I,UAAY,eACd,GACA,GACA,IACA,EACA,KACA,WACA,OAIa,M,QCnBX,GAAS,WAAa,IAAItB,EAAIC,KAASC,EAAGF,EAAIG,eAAmBC,EAAGJ,EAAIK,MAAMD,IAAIF,EAAG,OAAOE,EAAG,MAAM,CAACJ,EAAIO,GAAG,GAAGH,EAAG,MAAM,CAACK,YAAY,QAAQ,CAACL,EAAG,MAAM,CAACK,YAAY,WAAW,CAACL,EAAG,MAAM,CAACK,YAAY,OAAOH,MAAM,CAAC,GAAK,SAASF,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,QAAQN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,gKAAgKN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,mLAAmLN,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,gBAAgBN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,8GAA8GN,EAAG,MAAM,CAACK,YAAY,WAAW,CAACL,EAAG,MAAM,CAACK,YAAY,QAAQ,CAACL,EAAG,MAAM,CAACK,YAAY,IAAIH,MAAM,CAAC,GAAK,MAAMoB,GAAG,CAAC,MAAQ,SAASC,GAAQ,OAAO3B,EAAI4B,SAAS,CAAC5B,EAAIU,GAAG,QAAQN,EAAG,MAAM,CAACK,YAAY,IAAIH,MAAM,CAAC,GAAK,MAAMoB,GAAG,CAAC,MAAQ,SAASC,GAAQ,OAAO3B,EAAI6B,SAAS,CAAC7B,EAAIU,GAAG,QAAQN,EAAG,MAAM,CAACK,YAAY,IAAIH,MAAM,CAAC,GAAK,MAAMoB,GAAG,CAAC,MAAQ,SAASC,GAAQ,OAAO3B,EAAI8B,SAAS,CAAC9B,EAAIU,GAAG,QAAQN,EAAG,MAAM,CAACK,YAAY,IAAIH,MAAM,CAAC,GAAK,MAAMoB,GAAG,CAAC,MAAQ,SAASC,GAAQ,OAAO3B,EAAImC,SAAS,CAACnC,EAAIU,GAAG,UAAUV,EAAIO,GAAG,KAAKH,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,8BAA8BN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,sGAAsGN,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,gBAAgBN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,uKAAuKN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,8HAA8HN,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,IAAM,EAAQ,QAAuB,IAAM,YAAYF,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,SAASV,EAAIO,GAAG,GAAGH,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,IAAM,EAAQ,QAAuB,IAAM,YAAYF,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,sHAAsHN,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,UAAUN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,iEAAiEV,EAAIO,GAAG,GAAGH,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,2EAA2EN,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,YAAYN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,iBAAiBV,EAAIO,GAAG,GAAGH,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,gBAAgBV,EAAIO,GAAG,GAAGH,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,qBAAqBV,EAAIO,GAAG,GAAGH,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,eAAeV,EAAIO,GAAG,GAAGH,EAAG,MAAM,CAACK,YAAY,OAAOH,MAAM,CAAC,GAAK,UAAUF,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,UAAUN,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,IAAM,EAAQ,QAAuB,IAAM,YAAYF,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,UAAUN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,wMAAwMN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,uCAAuCN,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,WAAWN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,wFAAwFN,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,IAAM,EAAQ,QAAuB,IAAM,YAAYF,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,cAAcN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,sBAAsBN,EAAG,MAAM,CAACK,YAAY,OAAOH,MAAM,CAAC,GAAK,UAAUF,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,UAAUN,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,cAAcN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,uBAAuBN,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,UAAUN,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,IAAM,EAAQ,QAAuB,IAAM,YAAYF,EAAG,MAAM,CAACK,YAAY,OAAOH,MAAM,CAAC,GAAK,UAAUF,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,UAAUN,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,WAAWN,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,IAAM,EAAQ,QAAuB,IAAM,YAAYF,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,UAAUN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,+MAA+MN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,8FAA8FN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,+BAA+BN,EAAG,MAAM,CAACK,YAAY,OAAOH,MAAM,CAAC,GAAK,UAAUF,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,UAAUN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,iFAAiFN,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,eAAeN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,6GAA6GN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,+GAA+GN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,oEAAoEN,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,IAAM,EAAQ,QAAuB,IAAM,YAAYF,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,IAAM,EAAQ,QAAuB,IAAM,YAAYF,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,oBAAoBN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,oHAAoHV,EAAIO,GAAG,GAAGH,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,4JAA4JN,EAAG,MAAM,CAACK,YAAY,OAAOH,MAAM,CAAC,GAAK,UAAUF,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,UAAUN,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,WAAWN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,8JAA8JN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,iBAAiBN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,kBAAkBN,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,YAAYN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,+DAA+DN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,sGAAsGN,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,aAAaN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,iFAAiFN,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,WAAWN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,kGAAkGN,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,IAAM,EAAQ,QAAuB,IAAM,YAAYF,EAAG,MAAM,CAACK,YAAY,OAAOH,MAAM,CAAC,GAAK,UAAUF,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,wBAAwBN,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,UAAUN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,+DAA+DN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,8CAA8CN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,+CAA+CN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,wDAAwDN,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,mBAAmBN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,yDAAyDN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,6BAA6BN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,iDAAiDN,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,MAAM,CAACK,YAAY,aAAaT,EAAIO,GAAG,MAC96R,GAAkB,CAAC,WAAa,IAAIP,EAAIC,KAASC,EAAGF,EAAIG,eAAmBC,EAAGJ,EAAIK,MAAMD,IAAIF,EAAG,OAAOE,EAAG,MAAM,CAACK,YAAY,MAAM,CAACL,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,GAAK,WAAW,WAAa,IAAIN,EAAIC,KAASC,EAAGF,EAAIG,eAAmBC,EAAGJ,EAAIK,MAAMD,IAAIF,EAAG,OAAOE,EAAG,MAAM,CAACK,YAAY,OAAO,CAACL,EAAG,MAAM,CAACK,YAAY,IAAIH,MAAM,CAAC,GAAK,OAAO,CAACF,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,+JAA+JN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,wIAAwIN,EAAG,MAAM,CAACK,YAAY,IAAIH,MAAM,CAAC,GAAK,OAAO,CAACF,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,wGAAwGN,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,IAAM,EAAQ,QAAuB,IAAM,YAAYF,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,IAAM,EAAQ,QAAuB,IAAM,cAAcF,EAAG,MAAM,CAACK,YAAY,IAAIH,MAAM,CAAC,GAAK,OAAO,CAACF,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,gIAAgIN,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,IAAM,EAAQ,QAAuB,IAAM,cAAcF,EAAG,MAAM,CAACK,YAAY,IAAIH,MAAM,CAAC,GAAK,OAAO,CAACF,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,4HAA4H,WAAa,IAAIV,EAAIC,KAASC,EAAGF,EAAIG,eAAmBC,EAAGJ,EAAIK,MAAMD,IAAIF,EAAG,OAAOE,EAAG,IAAI,CAACK,YAAY,WAAW,CAACL,EAAG,KAAK,CAACA,EAAG,KAAK,CAACJ,EAAIU,GAAG,aAAaN,EAAG,KAAK,CAACJ,EAAIU,GAAG,cAAcN,EAAG,KAAK,CAACJ,EAAIU,GAAG,kBAAkB,WAAa,IAAIV,EAAIC,KAASC,EAAGF,EAAIG,eAAmBC,EAAGJ,EAAIK,MAAMD,IAAIF,EAAG,OAAOE,EAAG,IAAI,CAACK,YAAY,WAAW,CAACL,EAAG,KAAK,CAACA,EAAG,KAAK,CAACJ,EAAIU,GAAG,6BAA6BN,EAAG,KAAK,CAACJ,EAAIU,GAAG,oCAAoCN,EAAG,KAAK,CAACJ,EAAIU,GAAG,sDAAsDN,EAAG,KAAK,CAACJ,EAAIU,GAAG,uCAAuCN,EAAG,KAAK,CAACJ,EAAIU,GAAG,gDAAgDN,EAAG,KAAK,CAACJ,EAAIU,GAAG,+CAA+CN,EAAG,KAAK,CAACJ,EAAIU,GAAG,mDAAmD,WAAa,IAAIV,EAAIC,KAASC,EAAGF,EAAIG,eAAmBC,EAAGJ,EAAIK,MAAMD,IAAIF,EAAG,OAAOE,EAAG,IAAI,CAACK,YAAY,WAAW,CAACL,EAAG,KAAK,CAACA,EAAG,KAAK,CAACJ,EAAIU,GAAG,oBAAoBN,EAAG,KAAK,CAACJ,EAAIU,GAAG,kBAAkBN,EAAG,KAAK,CAACJ,EAAIU,GAAG,kBAAkBN,EAAG,KAAK,CAACJ,EAAIU,GAAG,sBAAsB,WAAa,IAAIV,EAAIC,KAASC,EAAGF,EAAIG,eAAmBC,EAAGJ,EAAIK,MAAMD,IAAIF,EAAG,OAAOE,EAAG,IAAI,CAACK,YAAY,WAAW,CAACL,EAAG,KAAK,CAACA,EAAG,KAAK,CAACJ,EAAIU,GAAG,oBAAoBN,EAAG,KAAK,CAACJ,EAAIU,GAAG,qBAAqBN,EAAG,KAAK,CAACJ,EAAIU,GAAG,2BAA2B,WAAa,IAAIV,EAAIC,KAASC,EAAGF,EAAIG,eAAmBC,EAAGJ,EAAIK,MAAMD,IAAIF,EAAG,OAAOE,EAAG,IAAI,CAACK,YAAY,WAAW,CAACL,EAAG,KAAK,CAACA,EAAG,KAAK,CAACJ,EAAIU,GAAG,2BAA2BN,EAAG,KAAK,CAACJ,EAAIU,GAAG,yBAAyBN,EAAG,KAAK,CAACJ,EAAIU,GAAG,yBAAyB,WAAa,IAAIV,EAAIC,KAASC,EAAGF,EAAIG,eAAmBC,EAAGJ,EAAIK,MAAMD,IAAIF,EAAG,OAAOE,EAAG,IAAI,CAACK,YAAY,WAAW,CAACL,EAAG,KAAK,CAACA,EAAG,KAAK,CAACJ,EAAIU,GAAG,uBAAuBN,EAAG,KAAK,CAACJ,EAAIU,GAAG,kBAAkBN,EAAG,KAAK,CAACJ,EAAIU,GAAG,qBAAqB,WAAa,IAAIV,EAAIC,KAASC,EAAGF,EAAIG,eAAmBC,EAAGJ,EAAIK,MAAMD,IAAIF,EAAG,OAAOE,EAAG,IAAI,CAACK,YAAY,WAAW,CAACL,EAAG,KAAK,CAACA,EAAG,KAAK,CAACJ,EAAIU,GAAG,sBAAsBN,EAAG,KAAK,CAACJ,EAAIU,GAAG,0BAA0BN,EAAG,KAAK,CAACJ,EAAIU,GAAG,kBAAkBN,EAAG,KAAK,CAACJ,EAAIU,GAAG,8BAA8B,WAAa,IAAIV,EAAIC,KAASC,EAAGF,EAAIG,eAAmBC,EAAGJ,EAAIK,MAAMD,IAAIF,EAAG,OAAOE,EAAG,MAAM,CAACK,YAAY,QAAQH,MAAM,CAAC,GAAK,QAAQ,CAACF,EAAG,KAAK,CAACK,YAAY,SAAS,CAACL,EAAG,KAAK,CAACA,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,SAAS,CAACN,EAAIU,GAAG,UAAUN,EAAG,KAAK,CAACA,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,UAAU,CAACN,EAAIU,GAAG,YAAYN,EAAG,KAAK,CAACA,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,UAAU,CAACN,EAAIU,GAAG,YAAYN,EAAG,KAAK,CAACA,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,UAAU,CAACN,EAAIU,GAAG,YAAYN,EAAG,KAAK,CAACA,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,UAAU,CAACN,EAAIU,GAAG,YAAYN,EAAG,KAAK,CAACA,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,UAAU,CAACN,EAAIU,GAAG,YAAYN,EAAG,KAAK,CAACA,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,UAAU,CAACN,EAAIU,GAAG,oBCkU9mI,IACEC,OADF,aAEEoB,QAAS,CACPH,IADJ,WAEM,IAAN,gCACA,gCACA,gCACA,gCACMI,EAAGZ,UAAUC,IAAI,UACjBY,EAAGb,UAAUE,OAAO,UACpBY,EAAGd,UAAUE,OAAO,UACpBc,EAAGhB,UAAUE,OAAO,WAEtBO,IAXJ,WAYM,IAAN,gCACA,gCACA,gCACA,gCACMI,EAAGb,UAAUC,IAAI,UACjBW,EAAGZ,UAAUE,OAAO,UACpBY,EAAGd,UAAUE,OAAO,UACpBc,EAAGhB,UAAUE,OAAO,WAEtBQ,IArBJ,WAsBM,IAAN,gCACA,gCACA,gCACA,gCACMI,EAAGd,UAAUC,IAAI,UACjBY,EAAGb,UAAUE,OAAO,UACpBU,EAAGZ,UAAUE,OAAO,UACpBc,EAAGhB,UAAUE,OAAO,WAEtBa,IA/BJ,WAgCM,IAAN,gCACA,gCACA,gCACA,gCACMC,EAAGhB,UAAUC,IAAI,UACjBY,EAAGb,UAAUE,OAAO,UACpBU,EAAGZ,UAAUE,OAAO,UACpBY,EAAGd,UAAUE,OAAO,YAGxBV,QA5CF,WA6CI,IAAJ,iCAEI,SAASC,EAASC,EAAKC,EAAMC,GAEvBF,EAAIG,YACNH,EAAIG,YAAY,KAAOF,GAAM,WAE3BC,EAAGjE,KAAK+D,MAIVA,EAAII,iBAAiBH,EAAMC,GAAI,GAInCH,EAAShB,OAAQ,UAAU,WAErBA,OAAO2B,aAAe,IACxBC,EAAIL,UAAUC,IAAI,SAElBI,EAAIL,UAAUE,OAAO,cCpYkT,MCQ3U,I,UAAY,eACd,GACA,GACA,IACA,EACA,KACA,WACA,OAIa,M,QCnBX,GAAS,WAAa,IAAItB,EAAIC,KAASC,EAAGF,EAAIG,eAAsBH,EAAIK,MAAMD,GAAO,OAAOJ,EAAIO,GAAG,IACnG,GAAkB,CAAC,WAAa,IAAIP,EAAIC,KAASC,EAAGF,EAAIG,eAAmBC,EAAGJ,EAAIK,MAAMD,IAAIF,EAAG,OAAOE,EAAG,MAAM,CAACA,EAAG,MAAM,CAACK,YAAY,MAAM,CAACL,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,GAAK,UAAUF,EAAG,MAAM,CAACK,YAAY,QAAQ,CAACL,EAAG,MAAM,CAACK,YAAY,WAAW,CAACL,EAAG,MAAM,CAACK,YAAY,OAAOH,MAAM,CAAC,GAAK,SAASF,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,gCAAgCN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,oBAAoBN,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,IAAM,EAAQ,QAAsB,IAAM,YAAYF,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,SAASN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,gMAAgMN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,wBAAwBN,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,IAAM,EAAQ,QAAsB,IAAM,YAAYF,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,kBAAkBN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,eAAeN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,sBAAsBN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,gMAAgMN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,mHAAmHN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,oQAAoQN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,gHAAgHN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,6HAA6HN,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,MAAM,CAACK,YAAY,aAAaL,EAAG,MAAM,CAACK,YAAY,QAAQH,MAAM,CAAC,GAAK,QAAQ,CAACF,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,SAAS,CAACF,EAAG,MAAM,CAACE,MAAM,CAAC,IAAM,EAAQ,QAAyB,IAAM,cCwE/3E,IACEK,OADF,aAEEoB,QAAS,CACPH,IADJ,WAEM,IAAN,gCACA,gCACA,gCACA,gCACMI,EAAGZ,UAAUC,IAAI,UACjBY,EAAGb,UAAUE,OAAO,UACpBY,EAAGd,UAAUE,OAAO,UACpBc,EAAGhB,UAAUE,OAAO,WAEtBO,IAXJ,WAYM,IAAN,gCACA,gCACA,gCACA,gCACMI,EAAGb,UAAUC,IAAI,UACjBW,EAAGZ,UAAUE,OAAO,UACpBY,EAAGd,UAAUE,OAAO,UACpBc,EAAGhB,UAAUE,OAAO,WAEtBQ,IArBJ,WAsBM,IAAN,gCACA,gCACA,gCACA,gCACMI,EAAGd,UAAUC,IAAI,UACjBY,EAAGb,UAAUE,OAAO,UACpBU,EAAGZ,UAAUE,OAAO,UACpBc,EAAGhB,UAAUE,OAAO,WAEtBa,IA/BJ,WAgCM,IAAN,gCACA,gCACA,gCACA,gCACMC,EAAGhB,UAAUC,IAAI,UACjBY,EAAGb,UAAUE,OAAO,UACpBU,EAAGZ,UAAUE,OAAO,UACpBY,EAAGd,UAAUE,OAAO,YAGxBV,QA5CF,WA6CI,IAAJ,iCAEI,SAASC,EAASC,EAAKC,EAAMC,GAEvBF,EAAIG,YACNH,EAAIG,YAAY,KAAOF,GAAM,WAE3BC,EAAGjE,KAAK+D,MAIVA,EAAII,iBAAiBH,EAAMC,GAAI,GAInCH,EAAShB,OAAQ,UAAU,WAErBA,OAAO2B,aAAe,IACxBC,EAAIL,UAAUC,IAAI,SAElBI,EAAIL,UAAUE,OAAO,cC1IoT,MCQ7U,I,UAAY,eACd,GACA,GACA,IACA,EACA,KACA,WACA,OAIa,M,QCnBX,GAAS,WAAa,IAAItB,EAAIC,KAASC,EAAGF,EAAIG,eAAsBH,EAAIK,MAAMD,GAAO,OAAOJ,EAAIO,GAAG,IACnG,GAAkB,CAAC,WAAa,IAAIP,EAAIC,KAASC,EAAGF,EAAIG,eAAmBC,EAAGJ,EAAIK,MAAMD,IAAIF,EAAG,OAAOE,EAAG,MAAM,CAACA,EAAG,MAAM,CAACK,YAAY,MAAM,CAACL,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,GAAK,UAAUF,EAAG,MAAM,CAACK,YAAY,QAAQ,CAACL,EAAG,MAAM,CAACK,YAAY,WAAW,CAACL,EAAG,MAAM,CAACK,YAAY,OAAOH,MAAM,CAAC,GAAK,SAASF,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,oCAAoCN,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,UAAUN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,sLAAsLN,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,YAAYN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,6DAA6DN,EAAG,MAAM,CAACK,YAAY,OAAOH,MAAM,CAAC,IAAM,EAAQ,QAAsB,IAAM,YAAYF,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,8EAA8EN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,wIAAwIN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,qHAAqHN,EAAG,MAAM,CAACK,YAAY,OAAOH,MAAM,CAAC,IAAM,EAAQ,QAAsB,IAAM,YAAYF,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,+GAA+GN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,wCAAwCN,EAAG,MAAM,CAACK,YAAY,OAAOH,MAAM,CAAC,IAAM,EAAQ,QAAsB,IAAM,YAAYF,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,mCAAmCN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,oEAAoEN,EAAG,MAAM,CAACK,YAAY,OAAOH,MAAM,CAAC,IAAM,EAAQ,QAAsB,IAAM,YAAYF,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,mDAAmDN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,0BAA0BN,EAAG,MAAM,CAACK,YAAY,OAAOH,MAAM,CAAC,IAAM,EAAQ,QAAsB,IAAM,YAAYF,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,uCAAuCN,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,UAAUN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,yDAAyDN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,8EAA8EN,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,IAAM,EAAQ,QAAsB,IAAM,YAAYF,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,UAAUN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,6VAA6VN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,4EAA4EN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,MAAMN,EAAG,MAAM,CAACJ,EAAIU,GAAG,eAAeV,EAAIU,GAAG,0BAA0BN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,oBAAoBN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,mEAAmEN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,gCAAgCN,EAAG,MAAM,CAACJ,EAAIU,GAAG,QAAQV,EAAIU,GAAG,0BAA0BN,EAAG,MAAM,CAACJ,EAAIU,GAAG,SAASV,EAAIU,GAAG,8CAA8CN,EAAG,MAAM,CAACJ,EAAIU,GAAG,QAAQV,EAAIU,GAAG,6BAA6BN,EAAG,MAAM,CAACJ,EAAIU,GAAG,QAAQV,EAAIU,GAAG,2DAA2DN,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,UAAUN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,iCAAiCN,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,IAAM,EAAQ,QAAsB,IAAM,YAAYF,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,gIAAgIN,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,wBAAwBN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,2DAA2DN,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,IAAM,EAAQ,QAAsB,IAAM,YAAYF,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,8DAA8DN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,uCAAuCN,EAAG,MAAM,CAACJ,EAAIU,GAAG,QAAQV,EAAIU,GAAG,gBAAgBN,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,IAAM,EAAQ,QAAsB,IAAM,YAAYF,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,0EAA0EN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,mCAAmCN,EAAG,MAAM,CAACJ,EAAIU,GAAG,SAASV,EAAIU,GAAG,SAASN,EAAG,MAAM,CAACJ,EAAIU,GAAG,QAAQV,EAAIU,GAAG,gBAAgBN,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,IAAM,EAAQ,QAAuB,IAAM,YAAYF,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,gEAAgEN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,YAAYN,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,IAAM,EAAQ,QAAuB,IAAM,YAAYF,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,wBAAwBN,EAAG,MAAM,CAACK,YAAY,OAAOH,MAAM,CAAC,GAAK,UAAUF,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,wBAAwBN,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,UAAUN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,8KAA8KN,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,YAAYN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,wCAAwCN,EAAG,MAAM,CAACK,YAAY,OAAOH,MAAM,CAAC,IAAM,EAAQ,QAAuB,IAAM,YAAYF,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,6BAA6BN,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,UAAUN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,kFAAkFN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,iDAAiDN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,6DAA6DN,EAAG,MAAM,CAACJ,EAAIU,GAAG,UAAUV,EAAIU,GAAG,oBAAoBN,EAAG,MAAM,CAACJ,EAAIU,GAAG,SAASV,EAAIU,GAAG,yBAAyBN,EAAG,MAAM,CAACJ,EAAIU,GAAG,WAAWV,EAAIU,GAAG,yBAAyBN,EAAG,MAAM,CAACJ,EAAIU,GAAG,SAASV,EAAIU,GAAG,SAASN,EAAG,MAAM,CAACJ,EAAIU,GAAG,WAAWV,EAAIU,GAAG,mDAAmDN,EAAG,MAAM,CAACJ,EAAIU,GAAG,SAASV,EAAIU,GAAG,qCAAqCN,EAAG,MAAM,CAACJ,EAAIU,GAAG,SAASV,EAAIU,GAAG,yCAAyCN,EAAG,MAAM,CAACK,YAAY,OAAOH,MAAM,CAAC,IAAM,EAAQ,QAAuB,IAAM,YAAYF,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,oBAAoBN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,iCAAiCN,EAAG,MAAM,CAACJ,EAAIU,GAAG,UAAUV,EAAIU,GAAG,WAAWN,EAAG,MAAM,CAACJ,EAAIU,GAAG,SAASV,EAAIU,GAAG,sBAAsBN,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,IAAM,EAAQ,QAAsB,IAAM,YAAYF,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,SAASN,EAAG,MAAM,CAACJ,EAAIU,GAAG,WAAWV,EAAIU,GAAG,2CAA2CN,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,UAAUN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,0HAA0HN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,iGAAiGN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,wDAAwDN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,YAAYN,EAAG,MAAM,CAACJ,EAAIU,GAAG,UAAUV,EAAIU,GAAG,+BAA+BN,EAAG,MAAM,CAACJ,EAAIU,GAAG,UAAUV,EAAIU,GAAG,0DAA0DN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,uDAAuDN,EAAG,MAAM,CAACJ,EAAIU,GAAG,QAAQV,EAAIU,GAAG,yBAAyBN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,mBAAmBN,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,WAAWN,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,IAAM,EAAQ,QAAsB,IAAM,YAAYF,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,+OAA+ON,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,wBAAwBN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,kCAAkCN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,sCAAsCN,EAAG,MAAM,CAACJ,EAAIU,GAAG,SAASV,EAAIU,GAAG,2BAA2BN,EAAG,MAAM,CAACJ,EAAIU,GAAG,SAASV,EAAIU,GAAG,yCAAyCN,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,IAAM,EAAQ,QAAsB,IAAM,YAAYF,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,2EAA2EN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,0CAA0CN,EAAG,MAAM,CAACJ,EAAIU,GAAG,WAAWV,EAAIU,GAAG,6FAA6FN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,oDAAoDN,EAAG,MAAM,CAACJ,EAAIU,GAAG,SAASV,EAAIU,GAAG,SAASN,EAAG,MAAM,CAACJ,EAAIU,GAAG,QAAQV,EAAIU,GAAG,qBAAqBN,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,IAAM,EAAQ,QAAsB,IAAM,YAAYF,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,oEAAoEN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,SAASN,EAAG,MAAM,CAACJ,EAAIU,GAAG,WAAWV,EAAIU,GAAG,cAAcN,EAAG,MAAM,CAACJ,EAAIU,GAAG,QAAQV,EAAIU,GAAG,SAASN,EAAG,MAAM,CAACJ,EAAIU,GAAG,QAAQV,EAAIU,GAAG,+CAA+CN,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,IAAM,EAAQ,QAAsB,IAAM,YAAYF,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,YAAYN,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,IAAM,EAAQ,QAAsB,IAAM,YAAYF,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,YAAYN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACL,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,6DAA6D,CAACN,EAAIU,GAAG,QAAQV,EAAIU,GAAG,mBAAmBN,EAAG,IAAI,CAACK,YAAY,OAAO,CAACT,EAAIU,GAAG,aAAaN,EAAG,IAAI,CAACK,YAAY,OAAO,CAACT,EAAIU,GAAG,oKAAoKN,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,MAAMF,EAAG,IAAI,CAACK,YAAY,OAAO,CAACT,EAAIU,GAAG,sCAAsCN,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,8CAA8C,CAACN,EAAIU,GAAG,+CAA+CV,EAAIU,GAAG,QAAQN,EAAG,IAAI,CAACK,YAAY,OAAO,CAACT,EAAIU,GAAG,sCAAsCN,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,uEAAuE,CAACN,EAAIU,GAAG,wEAAwEV,EAAIU,GAAG,QAAQN,EAAG,IAAI,CAACK,YAAY,OAAO,CAACT,EAAIU,GAAG,sCAAsCN,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,uEAAuE,CAACN,EAAIU,GAAG,wEAAwEV,EAAIU,GAAG,QAAQN,EAAG,IAAI,CAACK,YAAY,OAAO,CAACT,EAAIU,GAAG,sCAAsCN,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,wEAAwE,CAACN,EAAIU,GAAG,yEAAyEV,EAAIU,GAAG,QAAQN,EAAG,IAAI,CAACK,YAAY,OAAO,CAACT,EAAIU,GAAG,wBAAwBN,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,0FAA0F,CAACN,EAAIU,GAAG,2FAA2FV,EAAIU,GAAG,QAAQN,EAAG,IAAI,CAACK,YAAY,OAAO,CAACT,EAAIU,GAAG,wJAAwJN,EAAG,IAAI,CAACK,YAAY,OAAO,CAACT,EAAIU,GAAG,8GAA8GN,EAAG,IAAI,CAACK,YAAY,OAAO,CAACT,EAAIU,GAAG,wMAAwMN,EAAG,IAAI,CAACK,YAAY,OAAO,CAACT,EAAIU,GAAG,mJAAmJN,EAAG,IAAI,CAACK,YAAY,OAAO,CAACT,EAAIU,GAAG,uCAAuCN,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,sEAAsE,CAACN,EAAIU,GAAG,uEAAuEV,EAAIU,GAAG,QAAQN,EAAG,IAAI,CAACK,YAAY,OAAO,CAACT,EAAIU,GAAG,uCAAuCN,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,uEAAuE,CAACN,EAAIU,GAAG,wEAAwEV,EAAIU,GAAG,QAAQN,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,MAAM,CAACK,YAAY,aAAaL,EAAG,MAAM,CAACK,YAAY,QAAQH,MAAM,CAAC,GAAK,QAAQ,CAACF,EAAG,KAAK,CAACK,YAAY,SAAS,CAACL,EAAG,KAAK,CAACA,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,SAAS,CAACN,EAAIU,GAAG,iBAAiBN,EAAG,KAAK,CAACA,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,UAAU,CAACN,EAAIU,GAAG,0BC+Rxvb,IACEC,OADF,aAEEoB,QAAS,CACPH,IADJ,WAEM,IAAN,gCACA,gCACA,gCACA,gCACMI,EAAGZ,UAAUC,IAAI,UACjBY,EAAGb,UAAUE,OAAO,UACpBY,EAAGd,UAAUE,OAAO,UACpBc,EAAGhB,UAAUE,OAAO,WAEtBO,IAXJ,WAYM,IAAN,gCACA,gCACA,gCACA,gCACMI,EAAGb,UAAUC,IAAI,UACjBW,EAAGZ,UAAUE,OAAO,UACpBY,EAAGd,UAAUE,OAAO,UACpBc,EAAGhB,UAAUE,OAAO,WAEtBQ,IArBJ,WAsBM,IAAN,gCACA,gCACA,gCACA,gCACMI,EAAGd,UAAUC,IAAI,UACjBY,EAAGb,UAAUE,OAAO,UACpBU,EAAGZ,UAAUE,OAAO,UACpBc,EAAGhB,UAAUE,OAAO,WAEtBa,IA/BJ,WAgCM,IAAN,gCACA,gCACA,gCACA,gCACMC,EAAGhB,UAAUC,IAAI,UACjBY,EAAGb,UAAUE,OAAO,UACpBU,EAAGZ,UAAUE,OAAO,UACpBY,EAAGd,UAAUE,OAAO,YAGxBV,QA5CF,WA6CI,IAAJ,iCAEI,SAASC,EAASC,EAAKC,EAAMC,GAEvBF,EAAIG,YACNH,EAAIG,YAAY,KAAOF,GAAM,WAE3BC,EAAGjE,KAAK+D,MAIVA,EAAII,iBAAiBH,EAAMC,GAAI,GAInCH,EAAShB,OAAQ,UAAU,WAErBA,OAAO2B,aAAe,IACxBC,EAAIL,UAAUC,IAAI,SAElBI,EAAIL,UAAUE,OAAO,cCjWkT,MCQ3U,I,UAAY,eACd,GACA,GACA,IACA,EACA,KACA,WACA,OAIa,M,Q5DlBXe,GAAS,GAKT,GAAY,eACdA,GACA,EACA,GACA,EACA,KACA,KACA,MAIa,M,Q6DjBX,GAAS,WAAa,IAAIrC,EAAIC,KAASC,EAAGF,EAAIG,eAAmBC,EAAGJ,EAAIK,MAAMD,IAAIF,EAAG,OAAOE,EAAG,MAAM,CAACJ,EAAIO,GAAG,GAAGH,EAAG,MAAM,CAACK,YAAY,QAAQ,CAACL,EAAG,MAAM,CAACK,YAAY,WAAW,CAACL,EAAG,MAAM,CAACK,YAAY,SAAST,EAAIO,GAAG,GAAGP,EAAIO,GAAG,GAAGH,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,2IAA2IN,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,MAAM,CAACK,YAAY,WAAW,CAACL,EAAG,MAAM,CAACK,YAAY,QAAQ,CAACL,EAAG,MAAM,CAACK,YAAY,IAAIH,MAAM,CAAC,GAAK,MAAMoB,GAAG,CAAC,MAAQ,SAASC,GAAQ,OAAO3B,EAAI4B,SAAS,CAAC5B,EAAIU,GAAG,UAAUN,EAAG,MAAM,CAACK,YAAY,IAAIH,MAAM,CAAC,GAAK,MAAMoB,GAAG,CAAC,MAAQ,SAASC,GAAQ,OAAO3B,EAAI6B,SAAS,CAAC7B,EAAIU,GAAG,UAAUN,EAAG,MAAM,CAACK,YAAY,IAAIH,MAAM,CAAC,GAAK,MAAMoB,GAAG,CAAC,MAAQ,SAASC,GAAQ,OAAO3B,EAAI8B,SAAS,CAAC9B,EAAIU,GAAG,UAAUN,EAAG,MAAM,CAACK,YAAY,IAAIH,MAAM,CAAC,GAAK,MAAMoB,GAAG,CAAC,MAAQ,SAASC,GAAQ,OAAO3B,EAAImC,SAAS,CAACnC,EAAIU,GAAG,YAAYV,EAAIO,GAAG,KAAKH,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,6MAA6MN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,8IAA8IN,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,oFAAoFN,EAAG,IAAI,CAACK,YAAY,OAAO,CAACT,EAAIU,GAAG,YAAYN,EAAG,IAAI,CAACK,YAAY,OAAO,CAACT,EAAIU,GAAG,4LAA4LN,EAAG,IAAI,CAACK,YAAY,OAAO,CAACT,EAAIU,GAAG,qGAAqGN,EAAG,IAAI,CAACK,YAAY,OAAO,CAACT,EAAIU,GAAG,sNAAsNN,EAAG,IAAI,CAACK,YAAY,OAAO,CAACT,EAAIU,GAAG,oPAAoPN,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,MAAM,CAACK,YAAY,aAAaT,EAAIO,GAAG,MAChjF,GAAkB,CAAC,WAAa,IAAIP,EAAIC,KAASC,EAAGF,EAAIG,eAAmBC,EAAGJ,EAAIK,MAAMD,IAAIF,EAAG,OAAOE,EAAG,MAAM,CAACK,YAAY,MAAM,CAACL,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,GAAK,WAAW,WAAa,IAAIN,EAAIC,KAASC,EAAGF,EAAIG,eAAmBC,EAAGJ,EAAIK,MAAMD,IAAIF,EAAG,OAAOE,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,6CAA6CN,EAAG,MAAM,CAACJ,EAAIU,GAAG,SAASV,EAAIU,GAAG,mEAAmEN,EAAG,MAAM,CAACJ,EAAIU,GAAG,SAASV,EAAIU,GAAG,SAAS,WAAa,IAAIV,EAAIC,KAASC,EAAGF,EAAIG,eAAmBC,EAAGJ,EAAIK,MAAMD,IAAIF,EAAG,OAAOE,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,6DAA6DN,EAAG,MAAM,CAACJ,EAAIU,GAAG,SAASV,EAAIU,GAAG,oCAAoCN,EAAG,MAAM,CAACJ,EAAIU,GAAG,SAASV,EAAIU,GAAG,oKAAoK,WAAa,IAAIV,EAAIC,KAASC,EAAGF,EAAIG,eAAmBC,EAAGJ,EAAIK,MAAMD,IAAIF,EAAG,OAAOE,EAAG,MAAM,CAACK,YAAY,OAAO,CAACL,EAAG,MAAM,CAACK,YAAY,IAAIH,MAAM,CAAC,GAAK,OAAO,CAACF,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,IAAM,EAAQ,QAAqB,IAAM,cAAcF,EAAG,MAAM,CAACK,YAAY,IAAIH,MAAM,CAAC,GAAK,OAAO,CAACF,EAAG,IAAI,CAACK,YAAY,WAAW,CAACT,EAAIU,GAAG,6GAA6GN,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,IAAM,EAAQ,QAAqB,IAAM,cAAcF,EAAG,MAAM,CAACK,YAAY,IAAIH,MAAM,CAAC,GAAK,OAAO,CAACF,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,IAAM,EAAQ,QAAqB,IAAM,cAAcF,EAAG,MAAM,CAACK,YAAY,IAAIH,MAAM,CAAC,GAAK,OAAO,CAACF,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,IAAM,EAAQ,QAAqB,IAAM,iBAAiB,WAAa,IAAIN,EAAIC,KAASC,EAAGF,EAAIG,eAAmBC,EAAGJ,EAAIK,MAAMD,IAAIF,EAAG,OAAOE,EAAG,MAAM,CAACK,YAAY,QAAQH,MAAM,CAAC,GAAK,QAAQ,CAACF,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,SAAS,CAACF,EAAG,MAAM,CAACE,MAAM,CAAC,IAAM,EAAQ,QAAyB,IAAM,YCyFv7D,IACEK,OADF,aAEE,QAAF,CACIiB,IADJ,WAEM,IAAN,gCACA,gCACA,gCACA,gCACMI,EAAGZ,UAAUC,IAAI,UACjBY,EAAGb,UAAUE,OAAO,UACpBY,EAAGd,UAAUE,OAAO,UACpBc,EAAGhB,UAAUE,OAAO,WAEtBO,IAXJ,WAYM,IAAN,gCACA,gCACA,gCACA,gCACMI,EAAGb,UAAUC,IAAI,UACjBW,EAAGZ,UAAUE,OAAO,UACpBY,EAAGd,UAAUE,OAAO,UACpBc,EAAGhB,UAAUE,OAAO,WAEtBQ,IArBJ,WAsBM,IAAN,gCACA,gCACA,gCACA,gCACMI,EAAGd,UAAUC,IAAI,UACjBY,EAAGb,UAAUE,OAAO,UACpBU,EAAGZ,UAAUE,OAAO,UACpBc,EAAGhB,UAAUE,OAAO,WAEtBa,IA/BJ,WAgCM,IAAN,gCACA,gCACA,gCACA,gCACMC,EAAGhB,UAAUC,IAAI,UACjBY,EAAGb,UAAUE,OAAO,UACpBU,EAAGZ,UAAUE,OAAO,UACpBY,EAAGd,UAAUE,OAAO,YAGxBV,QA5CF,WA6CI,IAAJ,iCAEI,SAASC,EAASC,EAAKC,EAAMC,GAEvBF,EAAIG,YACNH,EAAIG,YAAY,KAAOF,GAAM,WAE3BC,EAAGjE,KAAK+D,MAIVA,EAAII,iBAAiBH,EAAMC,GAAI,GAInCH,EAAShB,OAAQ,UAAU,WAErBA,OAAO2B,aAAe,IACxBC,EAAIL,UAAUC,IAAI,SAElBI,EAAIL,UAAUE,OAAO,cC3JqT,MCQ9U,I,UAAY,eACd,GACA,GACA,IACA,EACA,KACA,WACA,OAIa,M,QCnBX,GAAS,WAAa,IAAItB,EAAIC,KAASC,EAAGF,EAAIG,eAAsBH,EAAIK,MAAMD,GAAO,OAAOJ,EAAIO,GAAG,IACnG,GAAkB,CAAC,WAAa,IAAIP,EAAIC,KAASC,EAAGF,EAAIG,eAAmBC,EAAGJ,EAAIK,MAAMD,IAAIF,EAAG,OAAOE,EAAG,MAAM,CAACA,EAAG,MAAM,CAACK,YAAY,MAAM,CAACL,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,GAAK,UAAUF,EAAG,MAAM,CAACK,YAAY,QAAQ,CAACL,EAAG,MAAM,CAACK,YAAY,WAAW,CAACL,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,KAAK,CAACK,YAAY,SAAS,CAACT,EAAIU,GAAG,UAAUN,EAAG,MAAM,CAACK,YAAY,KAAKH,MAAM,CAAC,IAAM,EAAQ,QAAsB,IAAM,YAAYF,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,MAAM,CAACK,YAAY,SAASL,EAAG,MAAM,CAACK,YAAY,aAAaL,EAAG,MAAM,CAACK,YAAY,QAAQH,MAAM,CAAC,GAAK,QAAQ,CAACF,EAAG,IAAI,CAACE,MAAM,CAAC,KAAO,SAAS,CAACF,EAAG,MAAM,CAACE,MAAM,CAAC,IAAM,EAAQ,QAAyB,IAAM,cCqB3rB,IACEK,OADF,aAEE,QAAF,CACIiB,IADJ,WAEM,IAAN,gCACA,gCACA,gCACA,gCACMI,EAAGZ,UAAUC,IAAI,UACjBY,EAAGb,UAAUE,OAAO,UACpBY,EAAGd,UAAUE,OAAO,UACpBc,EAAGhB,UAAUE,OAAO,WAEtBO,IAXJ,WAYM,IAAN,gCACA,gCACA,gCACA,gCACMI,EAAGb,UAAUC,IAAI,UACjBW,EAAGZ,UAAUE,OAAO,UACpBY,EAAGd,UAAUE,OAAO,UACpBc,EAAGhB,UAAUE,OAAO,WAEtBQ,IArBJ,WAsBM,IAAN,gCACA,gCACA,gCACA,gCACMI,EAAGd,UAAUC,IAAI,UACjBY,EAAGb,UAAUE,OAAO,UACpBU,EAAGZ,UAAUE,OAAO,UACpBc,EAAGhB,UAAUE,OAAO,WAEtBa,IA/BJ,WAgCM,IAAN,gCACA,gCACA,gCACA,gCACMC,EAAGhB,UAAUC,IAAI,UACjBY,EAAGb,UAAUE,OAAO,UACpBU,EAAGZ,UAAUE,OAAO,UACpBY,EAAGd,UAAUE,OAAO,YAGxBV,QA5CF,WA6CI,IAAJ,iCAEI,SAASC,EAASC,EAAKC,EAAMC,GAEvBF,EAAIG,YACNH,EAAIG,YAAY,KAAOF,GAAM,WAE3BC,EAAGjE,KAAK+D,MAIVA,EAAII,iBAAiBH,EAAMC,GAAI,GAInCH,EAAShB,OAAQ,UAAU,WAErBA,OAAO2B,aAAe,IACxBC,EAAIL,UAAUC,IAAI,SAElBI,EAAIL,UAAUE,OAAO,cCvFiT,MCQ1U,I,UAAY,eACd,GACA,GACA,IACA,EACA,KACA,WACA,OAIa,M,QCMfgB,OAAIC,IAAIC,QACR,IAAMC,GAAS,IAAID,OAAU,CACzBE,OAAO,CACH,CAACC,KAAK,IAAIpB,UAAUqB,GACpB,CAACD,KAAK,UAAUpB,UAAUqB,GAC1B,CAACD,KAAK,eAAepB,UAAUsB,GAC/B,CAACF,KAAK,UAAUpB,UAAUuB,GAC1B,CAACH,KAAK,SAASpB,UAAUwB,GACzB,CAACJ,KAAK,cAAcpB,UAAUyB,GAC9B,CAACL,KAAK,UAAUpB,UAAU0B,GAC1B,CAACN,KAAK,SAASpB,UAAU2B,IAEzB,CAACP,KAAK,cAAcpB,UAAU4B,IAC9B,CAACR,KAAK,iBAAiBpB,UAAU6B,IACjC,CAACT,KAAK,aAAapB,UAAU8B,IAC7B,CAACV,KAAK,eAAepB,UAAU+B,IAC/B,CAACX,KAAK,SAASpB,UAAUgC,IACzB,CAACZ,KAAK,WAAWpB,UAAUiC,IAE3B,CAACb,KAAK,SAASpB,UAAUkC,IACzB,CAACd,KAAK,YAAYpB,UAAUmC,IAC5B,CAACf,KAAK,YAAYpB,UAAUoC,IAE5B,CAAChB,KAAK,QAAQpB,UAAUqC,OAMjBnB,MClDfH,OAAIuB,OAAOC,eAAgB,EAE3B,IAAIxB,OAAI,CACNyB,OAAQ,SAAAC,GAAC,OAAIA,EAAEC,IACfxB,YACCyB,OAAO,QAEV5B,OAAI6B,UAAU,SAAQ,SAASC,EAAGC,GAChCD,EAAGE,MAAMC,MAAQF,EAAQrF,U,uBCZ3Bd,EAAOD,QAAU,IAA0B,yB,kCCA3C,W,uBCAAC,EAAOD,QAAU,IAA0B,wB,8CCA3CC,EAAOD,QAAU,IAA0B,wB,uECA3CC,EAAOD,QAAU,IAA0B,yB,qBCA3CC,EAAOD,QAAU,08B,oCCAjB,W,uBCAAC,EAAOD,QAAU,IAA0B,0B,2DCA3C,W,gDCAAC,EAAOD,QAAU,IAA0B,0B,qBCA3CC,EAAOD,QAAU,s0H,uBCAjBC,EAAOD,QAAU,IAA0B,2B,uBCA3CC,EAAOD,QAAU,IAA0B,0B,uBCA3CC,EAAOD,QAAU,IAA0B,4B,uBCA3CC,EAAOD,QAAU,IAA0B,yB,8CCA3CC,EAAOD,QAAU,IAA0B,2B,qBCA3CC,EAAOD,QAAU,IAA0B,6B,qBCA3CC,EAAOD,QAAU,IAA0B,0B,uBCA3CC,EAAOD,QAAU,IAA0B,yB,uBCA3CC,EAAOD,QAAU,IAA0B,wB,qBCA3CC,EAAOD,QAAU,IAA0B,0B,uBCA3CC,EAAOD,QAAU,IAA0B,2B,uBCA3CC,EAAOD,QAAU,IAA0B,4B,qBCA3CC,EAAOD,QAAU,IAA0B,0B,qBCA3CC,EAAOD,QAAU,IAA0B,0B,qBCA3CC,EAAOD,QAAU,IAA0B,yB,qBCA3CC,EAAOD,QAAU,IAA0B,0B,qBCA3CC,EAAOD,QAAU,IAA0B,2B,qBCA3CC,EAAOD,QAAU,IAA0B,2B,qBCA3CC,EAAOD,QAAU,IAA0B,4B,qBCA3CC,EAAOD,QAAU,IAA0B,0B,qBCA3CC,EAAOD,QAAU,IAA0B,sB,qBCA3CC,EAAOD,QAAU,IAA0B,0B,qBCA3CC,EAAOD,QAAU,IAA0B,0B,qBCA3CC,EAAOD,QAAU,IAA0B,yB,qBCA3CC,EAAOD,QAAU,IAA0B,2B,qBCA3CC,EAAOD,QAAU,IAA0B,2B,yDCA3C,W,4CCAAC,EAAOD,QAAU,IAA0B,4B,kCCA3C,W,yDCAA,W,qBCAAC,EAAOD,QAAU,IAA0B,0B,qBCA3CC,EAAOD,QAAU,IAA0B,0B,qBCA3CC,EAAOD,QAAU,IAA0B,2B,qBCA3CC,EAAOD,QAAU,IAA0B,yB,qBCA3CC,EAAOD,QAAU,IAA0B,yB,mECA3CC,EAAOD,QAAU,IAA0B,6B,qBCA3CC,EAAOD,QAAU,IAA0B,yB,qBCA3CC,EAAOD,QAAU,IAA0B,0B,qBCA3CC,EAAOD,QAAU,IAA0B,2B,yDCA3C,W,qBCAAC,EAAOD,QAAU,IAA0B,6B,qBCA3CC,EAAOD,QAAU,IAA0B,2B,qBCA3CC,EAAOD,QAAU,IAA0B,yB,qBCA3CC,EAAOD,QAAU,IAA0B,yB,mBCA3CC,EAAOD,QAAU,kpG,kCCAjB,W,4CCAAC,EAAOD,QAAU,IAA0B,yB,qBCA3CC,EAAOD,QAAU,IAA0B,yB,qBCA3CC,EAAOD,QAAU,IAA0B,yB,kCCA3C,W,qBCAAC,EAAOD,QAAU,IAA0B,0B,mBCA3CC,EAAOD,QAAU,0gF,qBCAjBC,EAAOD,QAAU,IAA0B","file":"js/app.716e5802.js","sourcesContent":[" \t// install a JSONP callback for chunk loading\n \tfunction webpackJsonpCallback(data) {\n \t\tvar chunkIds = data[0];\n \t\tvar moreModules = data[1];\n \t\tvar executeModules = data[2];\n\n \t\t// add \"moreModules\" to the modules object,\n \t\t// then flag all \"chunkIds\" as loaded and fire callback\n \t\tvar moduleId, chunkId, i = 0, resolves = [];\n \t\tfor(;i < chunkIds.length; i++) {\n \t\t\tchunkId = chunkIds[i];\n \t\t\tif(Object.prototype.hasOwnProperty.call(installedChunks, chunkId) && installedChunks[chunkId]) {\n \t\t\t\tresolves.push(installedChunks[chunkId][0]);\n \t\t\t}\n \t\t\tinstalledChunks[chunkId] = 0;\n \t\t}\n \t\tfor(moduleId in moreModules) {\n \t\t\tif(Object.prototype.hasOwnProperty.call(moreModules, moduleId)) {\n \t\t\t\tmodules[moduleId] = moreModules[moduleId];\n \t\t\t}\n \t\t}\n \t\tif(parentJsonpFunction) parentJsonpFunction(data);\n\n \t\twhile(resolves.length) {\n \t\t\tresolves.shift()();\n \t\t}\n\n \t\t// add entry modules from loaded chunk to deferred list\n \t\tdeferredModules.push.apply(deferredModules, executeModules || []);\n\n \t\t// run deferred modules when all chunks ready\n \t\treturn checkDeferredModules();\n \t};\n \tfunction checkDeferredModules() {\n \t\tvar result;\n \t\tfor(var i = 0; i < deferredModules.length; i++) {\n \t\t\tvar deferredModule = deferredModules[i];\n \t\t\tvar fulfilled = true;\n \t\t\tfor(var j = 1; j < deferredModule.length; j++) {\n \t\t\t\tvar depId = deferredModule[j];\n \t\t\t\tif(installedChunks[depId] !== 0) fulfilled = false;\n \t\t\t}\n \t\t\tif(fulfilled) {\n \t\t\t\tdeferredModules.splice(i--, 1);\n \t\t\t\tresult = __webpack_require__(__webpack_require__.s = deferredModule[0]);\n \t\t\t}\n \t\t}\n\n \t\treturn result;\n \t}\n\n \t// The module cache\n \tvar installedModules = {};\n\n \t// object to store loaded and loading chunks\n \t// undefined = chunk not loaded, null = chunk preloaded/prefetched\n \t// Promise = chunk loading, 0 = chunk loaded\n \tvar installedChunks = {\n \t\t\"app\": 0\n \t};\n\n \tvar deferredModules = [];\n\n \t// The require function\n \tfunction __webpack_require__(moduleId) {\n\n \t\t// Check if module is in cache\n \t\tif(installedModules[moduleId]) {\n \t\t\treturn installedModules[moduleId].exports;\n \t\t}\n \t\t// Create a new module (and put it into the cache)\n \t\tvar module = installedModules[moduleId] = {\n \t\t\ti: moduleId,\n \t\t\tl: false,\n \t\t\texports: {}\n \t\t};\n\n \t\t// Execute the module function\n \t\tmodules[moduleId].call(module.exports, module, module.exports, __webpack_require__);\n\n \t\t// Flag the module as loaded\n \t\tmodule.l = true;\n\n \t\t// Return the exports of the module\n \t\treturn module.exports;\n \t}\n\n\n \t// expose the modules object (__webpack_modules__)\n \t__webpack_require__.m = modules;\n\n \t// expose the module cache\n \t__webpack_require__.c = installedModules;\n\n \t// define getter function for harmony exports\n \t__webpack_require__.d = function(exports, name, getter) {\n \t\tif(!__webpack_require__.o(exports, name)) {\n \t\t\tObject.defineProperty(exports, name, { enumerable: true, get: getter });\n \t\t}\n \t};\n\n \t// define __esModule on exports\n \t__webpack_require__.r = function(exports) {\n \t\tif(typeof Symbol !== 'undefined' && Symbol.toStringTag) {\n \t\t\tObject.defineProperty(exports, Symbol.toStringTag, { value: 'Module' });\n \t\t}\n \t\tObject.defineProperty(exports, '__esModule', { value: true });\n \t};\n\n \t// create a fake namespace object\n \t// mode & 1: value is a module id, require it\n \t// mode & 2: merge all properties of value into the ns\n \t// mode & 4: return value when already ns object\n \t// mode & 8|1: behave like require\n \t__webpack_require__.t = function(value, mode) {\n \t\tif(mode & 1) value = __webpack_require__(value);\n \t\tif(mode & 8) return value;\n \t\tif((mode & 4) && typeof value === 'object' && value && value.__esModule) return value;\n \t\tvar ns = Object.create(null);\n \t\t__webpack_require__.r(ns);\n \t\tObject.defineProperty(ns, 'default', { enumerable: true, value: value });\n \t\tif(mode & 2 && typeof value != 'string') for(var key in value) __webpack_require__.d(ns, key, function(key) { return value[key]; }.bind(null, key));\n \t\treturn ns;\n \t};\n\n \t// getDefaultExport function for compatibility with non-harmony modules\n \t__webpack_require__.n = function(module) {\n \t\tvar getter = module && module.__esModule ?\n \t\t\tfunction getDefault() { return module['default']; } :\n \t\t\tfunction getModuleExports() { return module; };\n \t\t__webpack_require__.d(getter, 'a', getter);\n \t\treturn getter;\n \t};\n\n \t// Object.prototype.hasOwnProperty.call\n \t__webpack_require__.o = function(object, property) { return Object.prototype.hasOwnProperty.call(object, property); };\n\n \t// __webpack_public_path__\n \t__webpack_require__.p = \"/\";\n\n \tvar jsonpArray = window[\"webpackJsonp\"] = window[\"webpackJsonp\"] || [];\n \tvar oldJsonpFunction = jsonpArray.push.bind(jsonpArray);\n \tjsonpArray.push = webpackJsonpCallback;\n \tjsonpArray = jsonpArray.slice();\n \tfor(var i = 0; i < jsonpArray.length; i++) webpackJsonpCallback(jsonpArray[i]);\n \tvar parentJsonpFunction = oldJsonpFunction;\n\n\n \t// add entry module to deferred list\n \tdeferredModules.push([0,\"chunk-vendors\"]);\n \t// run deferred modules when ready\n \treturn checkDeferredModules();\n","module.exports = __webpack_public_path__ + \"img/m1-11.61f7c52b.png\";","export * from \"-!../../node_modules/mini-css-extract-plugin/dist/loader.js??ref--7-oneOf-1-0!../../node_modules/css-loader/dist/cjs.js??ref--7-oneOf-1-1!../../node_modules/vue-loader/lib/loaders/stylePostLoader.js!../../node_modules/postcss-loader/src/index.js??ref--7-oneOf-1-2!../../node_modules/cache-loader/dist/cjs.js??ref--1-0!../../node_modules/vue-loader/lib/index.js??vue-loader-options!./inclusivity.vue?vue&type=style&index=0&id=d9b88b42&scoped=true&lang=css&\"","module.exports = __webpack_public_path__ + \"img/edu1-1.39e4ad85.png\";","module.exports = __webpack_public_path__ + \"img/com2-2.df1be0c0.png\";","module.exports = __webpack_public_path__ + \"img/in1-1.2e8fa438.png\";","export * from \"-!../../node_modules/mini-css-extract-plugin/dist/loader.js??ref--7-oneOf-1-0!../../node_modules/css-loader/dist/cjs.js??ref--7-oneOf-1-1!../../node_modules/vue-loader/lib/loaders/stylePostLoader.js!../../node_modules/postcss-loader/src/index.js??ref--7-oneOf-1-2!../../node_modules/cache-loader/dist/cjs.js??ref--1-0!../../node_modules/vue-loader/lib/index.js??vue-loader-options!./model.vue?vue&type=style&index=0&id=57a29492&scoped=true&lang=css&\"","module.exports = __webpack_public_path__ + \"img/2-1.a3d174fe.gif\";","export * from \"-!../../node_modules/mini-css-extract-plugin/dist/loader.js??ref--7-oneOf-1-0!../../node_modules/css-loader/dist/cjs.js??ref--7-oneOf-1-1!../../node_modules/vue-loader/lib/loaders/stylePostLoader.js!../../node_modules/postcss-loader/src/index.js??ref--7-oneOf-1-2!../../node_modules/cache-loader/dist/cjs.js??ref--1-0!../../node_modules/vue-loader/lib/index.js??vue-loader-options!./imple.vue?vue&type=style&index=0&id=3371a61d&scoped=true&lang=css&\"","module.exports = \"data:image/png;base64,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\"","module.exports = __webpack_public_path__ + \"img/m1-1.fc4c3aa6.png\";","module.exports = __webpack_public_path__ + \"img/en2-2.8ef68df8.png\";","module.exports = __webpack_public_path__ + \"img/des1-2.c04f4fed.png\";","export * from \"-!../../node_modules/mini-css-extract-plugin/dist/loader.js??ref--7-oneOf-1-0!../../node_modules/css-loader/dist/cjs.js??ref--7-oneOf-1-1!../../node_modules/vue-loader/lib/loaders/stylePostLoader.js!../../node_modules/postcss-loader/src/index.js??ref--7-oneOf-1-2!../../node_modules/cache-loader/dist/cjs.js??ref--1-0!../../node_modules/vue-loader/lib/index.js??vue-loader-options!./proof.vue?vue&type=style&index=0&id=01b4be6a&scoped=true&lang=css&\"","module.exports = __webpack_public_path__ + \"img/en3-2.40595c9f.png\";","module.exports = __webpack_public_path__ + \"img/com2-1.a5f43d16.png\";","module.exports = __webpack_public_path__ + \"img/in1-3.f5556912.png\";","module.exports = __webpack_public_path__ + \"img/2-3.e1e70c3a.gif\";","module.exports = __webpack_public_path__ + \"img/3.a9202ffc.gif\";","module.exports = __webpack_public_path__ + \"img/des2-2.c6395f11.png\";","module.exports = \"data:image/png;base64,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\"","module.exports = __webpack_public_path__ + \"img/ha2.44e4da0e.png\";","export * from \"-!../../node_modules/mini-css-extract-plugin/dist/loader.js??ref--7-oneOf-1-0!../../node_modules/css-loader/dist/cjs.js??ref--7-oneOf-1-1!../../node_modules/vue-loader/lib/loaders/stylePostLoader.js!../../node_modules/postcss-loader/src/index.js??ref--7-oneOf-1-2!../../node_modules/cache-loader/dist/cjs.js??ref--1-0!../../node_modules/vue-loader/lib/index.js??vue-loader-options!./entre.vue?vue&type=style&index=0&id=7ba500f8&scoped=true&lang=css&\"","module.exports = __webpack_public_path__ + \"img/2-2.ac84cbf7.gif\";","export * from \"-!../../node_modules/mini-css-extract-plugin/dist/loader.js??ref--7-oneOf-1-0!../../node_modules/css-loader/dist/cjs.js??ref--7-oneOf-1-1!../../node_modules/vue-loader/lib/loaders/stylePostLoader.js!../../node_modules/postcss-loader/src/index.js??ref--7-oneOf-1-2!../../node_modules/cache-loader/dist/cjs.js??ref--1-0!../../node_modules/vue-loader/lib/index.js??vue-loader-options!./sustain.vue?vue&type=style&index=0&id=0845c54b&scoped=true&lang=css&\"","module.exports = __webpack_public_path__ + \"img/en1-2.848ba090.png\";","export * from \"-!../../node_modules/mini-css-extract-plugin/dist/loader.js??ref--7-oneOf-1-0!../../node_modules/css-loader/dist/cjs.js??ref--7-oneOf-1-1!../../node_modules/vue-loader/lib/loaders/stylePostLoader.js!../../node_modules/postcss-loader/src/index.js??ref--7-oneOf-1-2!../../node_modules/cache-loader/dist/cjs.js??ref--1-0!../../node_modules/vue-loader/lib/index.js??vue-loader-options!./description.vue?vue&type=style&index=0&id=ab5d104e&scoped=true&lang=css&\"","module.exports = __webpack_public_path__ + \"img/sus2.d62f6b78.png\";","module.exports = \"data:image/png;base64,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\"","export * from \"-!../../node_modules/mini-css-extract-plugin/dist/loader.js??ref--7-oneOf-1-0!../../node_modules/css-loader/dist/cjs.js??ref--7-oneOf-1-1!../../node_modules/vue-loader/lib/loaders/stylePostLoader.js!../../node_modules/postcss-loader/src/index.js??ref--7-oneOf-1-2!../../node_modules/cache-loader/dist/cjs.js??ref--1-0!../../node_modules/vue-loader/lib/index.js??vue-loader-options!./design.vue?vue&type=style&index=0&id=e81954c0&scoped=true&lang=css&\"","var render, staticRenderFns\nvar script = {}\n\n\n/* normalize component */\nimport normalizer from \"!../../node_modules/vue-loader/lib/runtime/componentNormalizer.js\"\nvar component = normalizer(\n  script,\n  render,\n  staticRenderFns,\n  false,\n  null,\n  null,\n  null\n  \n)\n\nexport default component.exports","var render = function () {var _vm=this;var _h=_vm.$createElement;var _c=_vm._self._c||_h;return _c('div',{attrs:{\"id\":\"app\"}},[_vm._m(0),_c('router-view')],1)}\nvar staticRenderFns = [function () {var _vm=this;var _h=_vm.$createElement;var _c=_vm._self._c||_h;return _c('div',{staticClass:\"header\"},[_c('div',{staticClass:\"nav\",attrs:{\"id\":\"navbar\"}},[_c('img',{staticClass:\"logo\",attrs:{\"src\":require(\"@/assets/logo.png\"),\"alt\":\"logo\"}}),_c('ul',{staticClass:\"shell\",attrs:{\"id\":\"menu\"}},[_c('li',{staticClass:\"button hvr-radial-out\"},[_c('a',{staticClass:\"home\",attrs:{\"href\":\"#/myHome\"}},[_c('p',{staticClass:\"buttonP\"},[_vm._v(\"Home\")])])]),_c('li',{staticClass:\"button\"},[_c('p',{staticClass:\"buttonP\"},[_vm._v(\"Project\")]),_c('ul',[_c('li',[_c('a',{attrs:{\"href\":\"#/description\"}},[_vm._v(\"description\")])]),_c('li',[_c('a',{attrs:{\"href\":\"#/design\"}},[_vm._v(\"design\")])]),_c('li',[_c('a',{attrs:{\"href\":\"#/proof\"}},[_vm._v(\"proof\")])]),_c('li',[_c('a',{attrs:{\"href\":\"#/experiment\"}},[_vm._v(\"experiment\")])]),_c('li',[_c('a',{attrs:{\"href\":\"#/safety\"}},[_vm._v(\"safety\")])])])]),_c('li',{staticClass:\"button\"},[_c('a',{attrs:{\"href\":\"#/part\"}},[_c('p',{staticClass:\"buttonP\"},[_vm._v(\"Part\")])])]),_c('li',{staticClass:\"button\"},[_c('p',{staticClass:\"buttonP\"},[_vm._v(\"Drylab\")]),_c('ul',[_c('li',[_c('a',{attrs:{\"href\":\"#/model\"}},[_vm._v(\"Model\")])]),_c('li',[_c('a',{attrs:{\"href\":\"#/hardware\"}},[_vm._v(\"HardWare\")])])])]),_c('li',{staticClass:\"button\"},[_c('p',{staticClass:\"buttonP\"},[_vm._v(\"HumanPractice\")]),_c('ul',[_c('li',[_c('a',{attrs:{\"href\":\"#/Integrated\"}},[_vm._v(\"Integrated HP\")])]),_c('li',[_c('a',{attrs:{\"href\":\"#/communication\"}},[_vm._v(\"Comunication\")])]),_c('li',[_c('a',{attrs:{\"href\":\"#/education\"}},[_vm._v(\"Education\")])]),_c('li',[_c('a',{attrs:{\"href\":\"#/inclusivity\"}},[_vm._v(\"Inclusivity\")])]),_c('li',[_c('a',{attrs:{\"href\":\"#/entre\"}},[_vm._v(\"Entrepreneurship\")])]),_c('li',[_c('a',{attrs:{\"href\":\"#/sustain\"}},[_vm._v(\"Sustainable\")])])])]),_c('li',{staticClass:\"button\"},[_c('p',{staticClass:\"buttonP\"},[_vm._v(\"Team\")]),_c('ul',[_c('li',[_c('a',{attrs:{\"href\":\"#/imple\"}},[_vm._v(\"Team\")])]),_c('li',[_c('a',{attrs:{\"href\":\"#/imple\"}},[_vm._v(\"Attribution\")])])])])])])])}]\n\nexport { render, staticRenderFns }","<template>\n  <div id=\"app\">\n    <div class=\"header\">\n      <div id=\"navbar\" class='nav'>\n        <img class=\"logo\" src=\"@/assets/logo.png\" alt=\"logo\" />\n        <ul id=\"menu\" class=\"shell\">\n          <li class=\"button hvr-radial-out\">\n            <a href=\"#/myHome\" class=\"home\"><p class=\"buttonP\">Home</p></a>\n          </li>\n          <li class=\"button\">\n            <p class=\"buttonP\">Project</p>\n            <ul>\n              <li>\n                <a href=\"#/description\">description</a>\n              </li>\n               <li>\n                <a href=\"#/design\">design</a>\n              </li>\n              <li>\n                <a href=\"#/proof\">proof</a>\n              </li>\n              <li>\n                <a href=\"#/experiment\">experiment</a>\n              </li>\n              \n              <li>\n                <a href=\"#/safety\">safety</a>\n              </li>\n            </ul>\n          </li>\n          <li class=\"button\"><a href=\"#/part\"><p class=\"buttonP\">Part</p></a></li>\n          <li class=\"button\"><p class=\"buttonP\">Drylab</p>\n          <ul>\n              <li>\n                <a href=\"#/model\">Model</a>\n              </li>\n              <!-- <li>\n                <a href=\"#/software\">Software</a>\n              </li> -->\n              <li>\n                <a href=\"#/hardware\">HardWare</a>\n              </li>\n            </ul>\n          </li>\n          <li class=\"button\"><p class=\"buttonP\">HumanPractice</p>\n          <ul>\n            <li>\n                <a href=\"#/Integrated\">Integrated HP</a>\n            </li>\n            <li>\n                <a href=\"#/communication\">Comunication</a>\n            </li>\n            <li>\n                <a href=\"#/education\">Education</a>\n            </li>\n            <li>\n                <a href=\"#/inclusivity\">Inclusivity</a>\n            </li>\n            <li>\n                <a href=\"#/entre\">Entrepreneurship</a>\n            </li>\n            <li>\n                <a href=\"#/sustain\">Sustainable</a>\n            </li>\n            </ul>\n          \n          </li>\n          <li class=\"button\"><p class=\"buttonP\">Team</p>\n          <ul>\n              <li>\n                <a href=\"#/imple\">Team</a>\n              </li>\n              <li>\n                <a href=\"#/imple\">Attribution</a>\n              </li>\n            </ul>\n          </li>\n        </ul>\n      </div>\n    </div>\n    <router-view></router-view>\n  </div>\n</template>\n<style scoped>\n* {\n  font-size:20px;\n  margin: 0;\n  padding: 0;\n  box-sizing: border-box;\n}\np{\n  padding-left:10px;\n  padding-right:10px;\n  display:block;\n  height: 40px;\n  line-height: 40px;\n}\na{\n  font-size:15px;\n  text-decoration:none;\n  color:white;\n}\n.header {\n  margin:0;\n  width: 100%;\n  height:181.6px;\n  background-position: center;\n  background-size: cover;\n}\n.nav {\n  color: #CBEABB;\n  margin:0;\n  width: 100%;\n  background-color: #3B8975;\n  text-align: center;\n  cursor: pointer;\n  transition: all 1s;\n}\n.logo {\n height: 6rem;\n}\n.nav.sticky {\n  position: fixed;\n  top: 0;\n  left: 0;\n  background: #3B8975;\n  display: flex;\n  align-items: center;\n  justify-content: space-between;\n  transition: all 1s;\n}\n.nav.sticky ul {\n  width: auto;\n  margin-right:5px;\n}\n.buttonP{\n  color: #c4f3d9;\n}\n.shell li a{\n  color: #c4f3cc;\n}\n/* 导航栏下划线 */\n.button::after{\n    content: \"\";\n    width: 0px;\n    height: 2px;\n    background: #dafadd;;\n    position: absolute;\n    top: 90%;\n    left: 50%;\n    right: 50%;\n    \n}\n.button:hover::after{\n    left: 0;\n    width: 100%;\n    transition: all .6s;\n}\n/* 下拉菜单 */\n.shell {\n  position: relative;\n  background: #2F524A;\n  width: 100%;\n  margin-top: 0;\n  border-radius: 10px;\n  display: flex;\n  justify-content: center;\n}\n.button {\n  display: inline-block;\n  list-style: none;\n  margin: 20px 30px;\n  color: white;\n  transition: all 0.3s; \n}\n.button:hover {\n  border-radius: 5px;\n  background-color: #427468;\n   transform: scale(1.1); \n}\n.button ul li:hover{\n  background-color: #C6DCCA;\n  height:35px;\n}\n.button ul{\n  position:absolute;\n}\n.button ul li {\n  \n  list-style: none;\n  transition:  all 0.2s;\n  opacity: 0;\n  transform: translateY(-65px);\n  background-color: #4c7c71;\n  border-radius: 5px;\n  padding-left:5px;\n  padding-right: 5px;\n}\n.button:hover li {\n  opacity: 1;\n  transform: translateY(0);\n}\n\n \n</style>\n<script>\nexport default {\n  return() {},\n  mounted() {\n    let navbar = document.getElementById(\"navbar\");\n    function addEvent(obj, type, fn) {\n      undefined;\n      if (obj.attachEvent) {\n        obj.attachEvent(\"on\" + type, function () {\n          undefined;\n          fn.call(obj);\n        });\n      } else {\n        undefined;\n        obj.addEventListener(type, fn, false);\n      }\n    }\n    addEvent(window, \"scroll\", function () {\n      undefined;\n     if (window.pageYOffset >= 340) {\n        navbar.classList.add(\"sticky\");\n      } else {\n        navbar.classList.remove(\"sticky\");\n      }\n    });\n  },\n};\n</script>\n","import mod from \"-!../node_modules/cache-loader/dist/cjs.js??ref--13-0!../node_modules/thread-loader/dist/cjs.js!../node_modules/babel-loader/lib/index.js!../node_modules/cache-loader/dist/cjs.js??ref--1-0!../node_modules/vue-loader/lib/index.js??vue-loader-options!./App.vue?vue&type=script&lang=js&\"; export default mod; export * from \"-!../node_modules/cache-loader/dist/cjs.js??ref--13-0!../node_modules/thread-loader/dist/cjs.js!../node_modules/babel-loader/lib/index.js!../node_modules/cache-loader/dist/cjs.js??ref--1-0!../node_modules/vue-loader/lib/index.js??vue-loader-options!./App.vue?vue&type=script&lang=js&\"","import { render, staticRenderFns } from \"./App.vue?vue&type=template&id=33069531&scoped=true&\"\nimport script from \"./App.vue?vue&type=script&lang=js&\"\nexport * from \"./App.vue?vue&type=script&lang=js&\"\nimport style0 from \"./App.vue?vue&type=style&index=0&id=33069531&scoped=true&lang=css&\"\n\n\n/* normalize component */\nimport normalizer from \"!../node_modules/vue-loader/lib/runtime/componentNormalizer.js\"\nvar component = normalizer(\n  script,\n  render,\n  staticRenderFns,\n  false,\n  null,\n  \"33069531\",\n  null\n  \n)\n\nexport default component.exports","var render = function () {var _vm=this;var _h=_vm.$createElement;var _c=_vm._self._c||_h;return _vm._m(0)}\nvar staticRenderFns = [function () {var _vm=this;var _h=_vm.$createElement;var _c=_vm._self._c||_h;return _c('div',[_c('div',{staticClass:\"bg\"},[_c('div',{staticClass:\"im\",attrs:{\"id\":\"bg\"}})]),_c('div',{staticClass:\"back\"},[_c('div',{staticClass:\"ding\",attrs:{\"id\":\"top\"}}),_c('div',{staticClass:\"b b1\"},[_c('div',{staticClass:\"home1\"},[_c('img',{attrs:{\"src\":require(\"../assets/1.gif\"),\"alt\":\"\"}})]),_c('div',{staticClass:\"na na1\"},[_c('a',{attrs:{\"href\":\"#home2\"}},[_c('img',{attrs:{\"src\":require(\"../assets/down.png\"),\"alt\":\"\"}})])])]),_c('div',{staticClass:\"ding\",attrs:{\"id\":\"home2\"}}),_c('div',{staticClass:\"b b2\"},[_c('div',{staticClass:\"home2\"},[_c('div',[_c('img',{attrs:{\"src\":require(\"../assets/2-1.gif\"),\"alt\":\"\"}})]),_c('div',{staticClass:\"son\"},[_c('img',{attrs:{\"src\":require(\"../assets/2-2.gif\"),\"alt\":\"\"}})]),_c('div',[_c('img',{attrs:{\"src\":require(\"../assets/2-3.gif\"),\"alt\":\"\"}})])]),_c('div',{staticClass:\"na na2\"},[_c('a',{attrs:{\"href\":\"#home3\"}},[_c('img',{attrs:{\"src\":require(\"../assets/down.png\"),\"alt\":\"\"}})])])]),_c('div',{staticClass:\"ding\",attrs:{\"id\":\"home3\"}}),_c('div',{staticClass:\"b b3\"},[_c('div',{staticClass:\"home3\"},[_c('img',{attrs:{\"src\":require(\"../assets/3.gif\"),\"alt\":\"\"}})])]),_c('div',{staticClass:\"leftP\",attrs:{\"id\":\"lef\"}},[_c('a',{attrs:{\"href\":\"#top\"}},[_c('img',{attrs:{\"src\":require(\"../assets/homeTop.png\"),\"alt\":\"\"}})])])])])}]\n\nexport { render, staticRenderFns }","<template>\r\n  <div>\r\n    <div class=\"bg\"><div class=\"im\" id=\"bg\"></div></div>\r\n    <div class=\"back\">\r\n      <div id=\"top\" class=\"ding\"></div>\r\n\r\n      <div class=\"b b1\">\r\n        <div class=\"home1\"><img src=\"../assets/1.gif\" alt=\"\" /></div>\r\n        <div class=\"na na1\">\r\n          <a href=\"#home2\"><img src=\"../assets/down.png\" alt=\"\" /></a>\r\n        </div>\r\n      </div>\r\n\r\n      <div id=\"home2\" class=\"ding\"></div>\r\n\r\n      <div class=\"b b2\">\r\n        <div class=\"home2\">\r\n          <div><img src=\"../assets/2-1.gif\" alt=\"\" /></div>\r\n          <div class=\"son\"><img src=\"../assets/2-2.gif\" alt=\"\" /></div>\r\n          <div><img src=\"../assets/2-3.gif\" alt=\"\" /></div>\r\n        </div>\r\n        <div class=\"na na2\">\r\n          <a href=\"#home3\"><img src=\"../assets/down.png\" alt=\"\" /></a>\r\n        </div>\r\n      </div>\r\n\r\n      <div id=\"home3\" class=\"ding\"></div>\r\n      <div class=\"b b3\">\r\n        <div class=\"home3\"><img src=\"../assets/3.gif\" alt=\"\" /></div>\r\n      </div>\r\n\r\n      \r\n    \r\n    <div id=\"lef\" class=\"leftP\">\r\n      <a href=\"#top\"><img src=\"../assets/homeTop.png\" alt=\"\" /></a>\r\n    </div>\r\n  </div>\r\n  </div>\r\n</template>\r\n<script>\r\nexport default {\r\n  return() {},\r\n  mounted() {\r\n    let lef = document.getElementById(\"lef\");\r\n\r\n    function addEvent(obj, type, fn) {\r\n      undefined;\r\n      if (obj.attachEvent) {\r\n        obj.attachEvent(\"on\" + type, function () {\r\n          undefined;\r\n          fn.call(obj);\r\n        });\r\n      } else {\r\n        undefined;\r\n        obj.addEventListener(type, fn, false);\r\n      }\r\n    }\r\n\r\n    addEvent(window, \"scroll\", function () {\r\n      undefined;\r\n      if (window.pageYOffset >= 455) {\r\n        lef.classList.add(\"stick\");\r\n      } else {\r\n        lef.classList.remove(\"stick\");\r\n      }\r\n    });\r\n  },\r\n};\r\n</script>\r\n<style scoped>\r\n.b{\r\n  width: 100%;\r\n  height:auto;\r\n  margin:0;\r\n}\r\n.b1{\r\n  background-color: white;\r\n}\r\n.b2{\r\n  background-color: #8cd4cd;\r\n}\r\n.b3{\r\n  background-color: white;\r\n}\r\n#top {\r\n  background-color: white;\r\n  border-top-left-radius:40px;\r\n  border-top-right-radius:40px;\r\n}\r\n#home2 {\r\n  background-image: linear-gradient(white, #8cd4cd);\r\n}\r\n#home3 {\r\n  background-image: linear-gradient(#8cd4cd, white);\r\n}\r\n* {\r\n  margin: 0;\r\n  padding: 0;\r\n}\r\n.na {\r\n  margin-top: 50px;\r\n  width: 100%;\r\n  height: auto;\r\n  text-align: center;\r\n  padding-bottom: 70px;\r\n}\r\n.na a img:hover {\r\n  transform: scale(1.2);\r\n  transition: 0.6s;\r\n}\r\n.ding {\r\n  height: 96px;\r\n}\r\n.home1 {\r\n  width: 70%;\r\n  height: auto;\r\n  margin-left: 15%;\r\n  margin-right: 15%;\r\n  padding-top: 50px;\r\n  border-radius: 30px;\r\n}\r\n.home1 img {\r\n  width: 100%;\r\n  object-fit: cover;\r\n  border-radius: 30px;\r\n  transition: 1s;\r\n}\r\n.home2 {\r\n  width: 70%;\r\n  height: auto;\r\n  margin-left: 15%;\r\n  margin-right: 15%;\r\n  padding-top: 100px;\r\n  border-radius: 30px;\r\n}\r\n.home2 div {\r\n  display: inline-block;\r\n  width: 28%;\r\n  height: auto;\r\n  border-radius: 30px;\r\n}\r\n.son {\r\n  margin-left: 8%;\r\n  margin-right: 8%;\r\n}\r\n.home2 div img {\r\n  width: 100%;\r\n  object-fit: cover;\r\n  border-radius: 30px;\r\n  transition: 1s;\r\n}\r\n\r\n.home3 {\r\n  width: 70%;\r\n  height: auto;\r\n  margin-left: 15%;\r\n  margin-right: 15%;\r\n  padding-top: 100px;\r\n  padding-bottom: 200px;\r\n  border-radius: 30px;\r\n}\r\n.home3 img {\r\n  width: 100%;\r\n  object-fit: cover;\r\n  border-radius: 30px;\r\n}\r\n\r\n.back {\r\n  width: 100%;\r\n  height: 100%;\r\n  border-top-left-radius:40px;\r\n  border-top-right-radius:40px;\r\n}\r\n.bg .im {\r\n  background-attachment: fixed;\r\n  width: 100%;\r\n  height: 100vh;\r\n  background-size: cover;\r\n  background-image: url(../assets/homeBanner.gif);\r\n}\r\n\r\n#lef.stick {\r\n  opacity: 1;\r\n  transition: all 1s;\r\n}\r\n#lef.stick:hover {\r\n  transform: scale(1.2);\r\n  transition: all 0.6s;\r\n}\r\n.leftP {\r\n  position: fixed;\r\n  left: 10px;\r\n  top: 30%;\r\n  opacity: 0;\r\n  height: 100px;\r\n  width: 100px;\r\n}\r\n</style>\r\n","import mod from \"-!../../node_modules/cache-loader/dist/cjs.js??ref--13-0!../../node_modules/thread-loader/dist/cjs.js!../../node_modules/babel-loader/lib/index.js!../../node_modules/cache-loader/dist/cjs.js??ref--1-0!../../node_modules/vue-loader/lib/index.js??vue-loader-options!./myHome.vue?vue&type=script&lang=js&\"; export default mod; export * from \"-!../../node_modules/cache-loader/dist/cjs.js??ref--13-0!../../node_modules/thread-loader/dist/cjs.js!../../node_modules/babel-loader/lib/index.js!../../node_modules/cache-loader/dist/cjs.js??ref--1-0!../../node_modules/vue-loader/lib/index.js??vue-loader-options!./myHome.vue?vue&type=script&lang=js&\"","import { render, staticRenderFns } from \"./myHome.vue?vue&type=template&id=77e52305&scoped=true&\"\nimport script from \"./myHome.vue?vue&type=script&lang=js&\"\nexport * from \"./myHome.vue?vue&type=script&lang=js&\"\nimport style0 from \"./myHome.vue?vue&type=style&index=0&id=77e52305&scoped=true&lang=css&\"\n\n\n/* normalize component */\nimport normalizer from \"!../../node_modules/vue-loader/lib/runtime/componentNormalizer.js\"\nvar component = normalizer(\n  script,\n  render,\n  staticRenderFns,\n  false,\n  null,\n  \"77e52305\",\n  null\n  \n)\n\nexport default component.exports","var render = function () {var _vm=this;var _h=_vm.$createElement;var _c=_vm._self._c||_h;return _vm._m(0)}\nvar staticRenderFns = [function () {var _vm=this;var _h=_vm.$createElement;var _c=_vm._self._c||_h;return _c('div',[_c('div',{staticClass:\"bg\"},[_c('div',{staticClass:\"im\",attrs:{\"id\":\"bg\"}})]),_c('div',{staticClass:\"back\"},[_c('div',{staticClass:\"content\"},[_c('div',{staticClass:\"ding\",attrs:{\"id\":\"top\"}}),_c('h1',{staticClass:\"title\"},[_vm._v(\"Abstract\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" Parkinson’s disease (PD) is a neurodegenerative disorder that affects a significant portion of elderly populations in the world. Current therape utic approaches include surgery, medication, and supportive therapies. Howeve r, these therapeutic approaches are not useful for everyone, and they also have side effects. Therefore, we decided to develop a multi-target therapy t o treat PD. Our therapy is based on two different adeno-associated virus (AA V) vectors containing different plasmids. For the first vector, we applied a n AND gate minigene circuit to achieve SNCA gene silencing and Hsc70 overexpr ession, specifically in dopaminergic (DA) neurons. This vector can reduce the toxic α-synuclein aggregates in DA neurons, and therefore relieve the PD sympto ms. For another vector, we designed a PTB gene silencing circuit based on the d Cas9-DNMT3A DNA methylation system. This vector will target astrocytes in the brain, effectively inducing these cells to convert to functional neurons. In ou r project, we also designed tissue-specific promoters, suicide switches, and sp ecific virus capsid to ensure safety in clinical practice. Both vectors we desi gned can be used to treat patients under different pathogenesis, which may provi de clues for a potential cure for PD in the future. \")]),_c('div',{staticClass:\"ding\",attrs:{\"id\":\"des1\"}}),_c('h1',{staticClass:\"title2\"},[_vm._v(\" 帕金森病简介\"),_c('a',{staticClass:\"top\",attrs:{\"href\":\"#top\"}},[_c('img',{attrs:{\"src\":require(\"../assets/top.png\"),\"alt\":\"top\"}})])]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 帕金森病(Parkinson’s disease, PD)是一种好发于中老年神经系统的变性疾病, 是继阿尔茨海默病之后的第二大常见神经退行性疾病。其病理特征包括黑质纹状体多巴胺能通路的进行性退化、黑质致密部神经元的大量丢失以及多巴胺的耗竭。PD的临床症状主要表现为静止性震颤、肢体僵硬、运动迟缓和缺乏自主性运动。大量证据表明, 由于运动性的退化, PD患者继而出现如自主功能不全、认知缺损、抑郁、嗅觉丧失、精神和睡眠障碍等非运动特征的并发症 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 世界PD协会资料和流行病学调查显示, 全球已有500多万PD患者。其中, 55岁以上人群中PD患病率为1.4%, 75岁以上人群中患病率为3.4%, 85岁以上人群中患病率可4.0%。自20世纪90年代末以来，尽管生物技术和医学取得了进步，但死亡率已经翻了一番。随着人口平均年龄的逐年增长，帕金森氏症和其他神经退行性疾病的威胁只会加剧。但目前为止，帕金森氏症的治疗只能减轻症状和减缓疾病的进展，但并不能阻止神经变性，更无法治愈。 \")]),_c('div',{staticClass:\"ding\",attrs:{\"id\":\"des2\"}}),_c('h1',{staticClass:\"title2\"},[_vm._v(\" 现有治疗方式\"),_c('a',{staticClass:\"top\",attrs:{\"href\":\"#top\"}},[_c('img',{attrs:{\"src\":require(\"../assets/top.png\"),\"alt\":\"top\"}})])]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 当前帕金森病的传统方法包括药物、手术和基因疗法。选择以左旋多巴为代表的多巴胺能药物及抗胆碱能药物为目前药物治疗的主要手段，其缺点为人体逐渐对药物建立耐受，无法实现可持续的治疗效果，因此药物治疗不是最理想的治疗途径。帕金森的手术治疗主要依靠脑深部刺激术，虽然副作用较小但价格昂贵，因而并不适合于所有的帕金森病人。通过进一步研究调查，我们把目光转向了逐渐走入人们视野的基因疗法。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 腺相关病毒（adeno-associated virus，AAV）是一种单链DNA病毒，隶属细小病毒科。这是一类无法自主复制、无被膜的二十面体病毒，直径很小，约为20nm。野生型的AAV基因组大小为5kb左右，包含两侧存在反向末端重复序列（inverted terminal repeats，ITRs）的rep基因和cap基因。前者主要控制病毒基因组复制和病毒颗粒组装，而后者控制的则是其衣壳蛋白的合成与组装。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 在基因治疗中使用的AAV载体是经过人工改造的重组AAV（rAAV），其只保留了145bp的ITRs序列，这也意味着其余约96%的基因组都可以被基因治疗需要的基因序列替换，使其拥有非常强大的包装能力。除此之外，AAV还有种类繁多、免疫原性极低、安全性高、宿主细胞范围广、扩散感染能力强、基因表达时间长等优点。正是这些优点，使得AAV被作为一个常用的载体用于基因治疗中。目前，基于AAV载体的多项眼病、血友病以及肌肉疾病治疗方案已经进入临床试验阶段，这也充分证明了使用AAV作为载体的基因治疗的安全性和有效性。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 在帕金森病的基因治疗中，当前热点的目的基因主要有影响多巴胺代谢的相关基因、神经营养因子基因、神经递质平衡调节相关基因等。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 代谢通路的关键基因包括酪氨酸羟化酶（tyrosine Hydroxylase,TH）、GTP环化水解酶1（GTP cyclization hydrolase 1,GCH-1）等。通过导入此类基因增加多巴胺含量以治疗帕金森症状。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 神经营养因子基因如GDNF、BDNF等可通过特异性保护多巴胺能神经元来实现多巴胺的正常表达，通过导入此类基因也是帕金森病治疗的常用策略之一。 \")]),_c('div',{staticClass:\"ding\",attrs:{\"id\":\"des3\"}}),_c('h1',{staticClass:\"title2\"},[_vm._v(\" 项目设计简介\"),_c('a',{staticClass:\"top\",attrs:{\"href\":\"#top\"}},[_c('img',{attrs:{\"src\":require(\"../assets/top.png\"),\"alt\":\"top\"}})])]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 此次我们关注到了代谢通路中的α-syn通路治疗以及神经元再生的PTB通路，通过AAV载体，在代谢与细胞再生两个层面实现帕金森病的长效稳定治疗。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 我们的项目开发了两种不同的腺相关病毒载体，分别针对不同的致病机理，旨在进行帕金森疾病的多靶点治疗。我们选用了2022年新开发的AAV-CAP-B10腺相关病毒载体，它能够通过静脉注射进入人体，穿过血脑屏障，对中枢神经系统具有高度特异性，且对肝脏具有低靶向性。我们同时修饰了病毒衣壳，增加其对目标组织的靶向性。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 在我们的设计中，其中一种病毒载体是靶向中脑黑质多巴胺能神经元的载体，我们选用了Pitx3、Foxa2特异性启动子并构建了与门电路，两个启动子在细胞中同时启动时，我们设计的基因线路才会表达。基因线路是基于CRISPReader的微型基因环路，当xxx, xxx启动子同时启动时，shRNA表达，特异性沉默SNCA基因，减少α-syn蛋白的产生，从而减少α-syn蛋白不正常的聚集；同时病毒质粒上含有的Hsp70基因将会被表达，通过分子伴侣调控的细胞自噬途径降解α-syn蛋白聚集体，恢复被α-syn蛋白聚集体毒性阻断的细胞信号通路，减轻帕金森疾病的症状。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 另一种病毒载体靶向脑内的星形胶质细胞，我们选用了GFAP星形胶质细胞特异性启动子增强靶向性。我们基于dCas9-DNMT3A系统，实现PTB基因的甲基化修饰，以沉默PTB基因。PTB基因沉默后，部分星形胶质细胞被诱导转化为多巴胺能神经元，重建帕金森病人脑中中断的中脑-多巴胺能神经元回路，恢复病人的运动功能，是一种稳定长效的治疗方法。 \")])]),_c('div',{staticClass:\"ding\"}),_c('div',{staticClass:\"ding\"}),_c('div',{staticClass:\"ding\"})]),_c('div',{staticClass:\"leftP\",attrs:{\"id\":\"lef\"}},[_c('ul',{staticClass:\"Shell\"},[_c('li',[_c('a',{attrs:{\"href\":\"#top\"}},[_vm._v(\"Abstract\")])]),_c('li',[_c('a',{attrs:{\"href\":\"#des1\"}},[_vm._v(\"帕金森病简介\")])]),_c('li',[_c('a',{attrs:{\"href\":\"#des2\"}},[_vm._v(\"现有治疗方式\")])]),_c('li',[_c('a',{attrs:{\"href\":\"#des3\"}},[_vm._v(\"项目设计简介\")])])])])])}]\n\nexport { render, staticRenderFns }","<template>\r\n  <div>\r\n    <div class=\"bg\"><div class=\"im\" id=\"bg\"></div></div>\r\n    <div class=\"back\">\r\n      <div class=\"content\">\r\n        <div id=\"top\" class=\"ding\"></div>\r\n        <h1 class=\"title\">Abstract</h1>\r\n        <p class=\"pagraph\">\r\n          Parkinson’s disease (PD) is a neurodegenerative disorder that affects\r\n          a significant portion of elderly populations in the world. Current\r\n          therape utic approaches include surgery, medication, and supportive\r\n          therapies. Howeve r, these therapeutic approaches are not useful for\r\n          everyone, and they also have side effects. Therefore, we decided to\r\n          develop a multi-target therapy t o treat PD. Our therapy is based on\r\n          two different adeno-associated virus (AA V) vectors containing\r\n          different plasmids. For the first vector, we applied a n AND gate\r\n          minigene circuit to achieve SNCA gene silencing and Hsc70 overexpr\r\n          ession, specifically in dopaminergic (DA) neurons. This vector can\r\n          reduce the toxic α-synuclein aggregates in DA neurons, and therefore\r\n          relieve the PD sympto ms. For another vector, we designed a PTB gene\r\n          silencing circuit based on the d Cas9-DNMT3A DNA methylation system.\r\n          This vector will target astrocytes in the brain, effectively inducing\r\n          these cells to convert to functional neurons. In ou r project, we also\r\n          designed tissue-specific promoters, suicide switches, and sp ecific\r\n          virus capsid to ensure safety in clinical practice. Both vectors we\r\n          desi gned can be used to treat patients under different pathogenesis,\r\n          which may provi de clues for a potential cure for PD in the future.\r\n        </p>\r\n\r\n        <div id=\"des1\" class=\"ding\"></div>\r\n        <h1 class=\"title2\">\r\n          帕金森病简介<a class=\"top\" href=\"#top\"\r\n            ><img src=\"../assets/top.png\" alt=\"top\"\r\n          /></a>\r\n        </h1>\r\n        <p class=\"pagraph\">\r\n          帕金森病(Parkinson’s disease, PD)是一种好发于中老年神经系统的变性疾病,\r\n          是继阿尔茨海默病之后的第二大常见神经退行性疾病。其病理特征包括黑质纹状体多巴胺能通路的进行性退化、黑质致密部神经元的大量丢失以及多巴胺的耗竭。PD的临床症状主要表现为静止性震颤、肢体僵硬、运动迟缓和缺乏自主性运动。大量证据表明,\r\n          由于运动性的退化,\r\n          PD患者继而出现如自主功能不全、认知缺损、抑郁、嗅觉丧失、精神和睡眠障碍等非运动特征的并发症\r\n        </p>\r\n        <p class=\"pagraph\">\r\n          世界PD协会资料和流行病学调查显示, 全球已有500多万PD患者。其中,\r\n          55岁以上人群中PD患病率为1.4%, 75岁以上人群中患病率为3.4%,\r\n          85岁以上人群中患病率可4.0%。自20世纪90年代末以来，尽管生物技术和医学取得了进步，但死亡率已经翻了一番。随着人口平均年龄的逐年增长，帕金森氏症和其他神经退行性疾病的威胁只会加剧。但目前为止，帕金森氏症的治疗只能减轻症状和减缓疾病的进展，但并不能阻止神经变性，更无法治愈。\r\n        </p>\r\n        <div id=\"des2\" class=\"ding\"></div>\r\n        <h1 class=\"title2\">\r\n          现有治疗方式<a class=\"top\" href=\"#top\"\r\n            ><img src=\"../assets/top.png\" alt=\"top\"\r\n          /></a>\r\n        </h1>\r\n        <p class=\"pagraph\">\r\n          当前帕金森病的传统方法包括药物、手术和基因疗法。选择以左旋多巴为代表的多巴胺能药物及抗胆碱能药物为目前药物治疗的主要手段，其缺点为人体逐渐对药物建立耐受，无法实现可持续的治疗效果，因此药物治疗不是最理想的治疗途径。帕金森的手术治疗主要依靠脑深部刺激术，虽然副作用较小但价格昂贵，因而并不适合于所有的帕金森病人。通过进一步研究调查，我们把目光转向了逐渐走入人们视野的基因疗法。\r\n        </p>\r\n        <p class=\"pagraph\">\r\n          腺相关病毒（adeno-associated\r\n          virus，AAV）是一种单链DNA病毒，隶属细小病毒科。这是一类无法自主复制、无被膜的二十面体病毒，直径很小，约为20nm。野生型的AAV基因组大小为5kb左右，包含两侧存在反向末端重复序列（inverted\r\n          terminal\r\n          repeats，ITRs）的rep基因和cap基因。前者主要控制病毒基因组复制和病毒颗粒组装，而后者控制的则是其衣壳蛋白的合成与组装。\r\n        </p>\r\n        <p class=\"pagraph\">\r\n          在基因治疗中使用的AAV载体是经过人工改造的重组AAV（rAAV），其只保留了145bp的ITRs序列，这也意味着其余约96%的基因组都可以被基因治疗需要的基因序列替换，使其拥有非常强大的包装能力。除此之外，AAV还有种类繁多、免疫原性极低、安全性高、宿主细胞范围广、扩散感染能力强、基因表达时间长等优点。正是这些优点，使得AAV被作为一个常用的载体用于基因治疗中。目前，基于AAV载体的多项眼病、血友病以及肌肉疾病治疗方案已经进入临床试验阶段，这也充分证明了使用AAV作为载体的基因治疗的安全性和有效性。\r\n        </p>\r\n        <p class=\"pagraph\">\r\n          在帕金森病的基因治疗中，当前热点的目的基因主要有影响多巴胺代谢的相关基因、神经营养因子基因、神经递质平衡调节相关基因等。\r\n        </p>\r\n        <p class=\"pagraph\">\r\n          代谢通路的关键基因包括酪氨酸羟化酶（tyrosine\r\n          Hydroxylase,TH）、GTP环化水解酶1（GTP cyclization hydrolase\r\n          1,GCH-1）等。通过导入此类基因增加多巴胺含量以治疗帕金森症状。\r\n        </p>\r\n        <p class=\"pagraph\">\r\n          神经营养因子基因如GDNF、BDNF等可通过特异性保护多巴胺能神经元来实现多巴胺的正常表达，通过导入此类基因也是帕金森病治疗的常用策略之一。\r\n        </p>\r\n\r\n        <div id=\"des3\" class=\"ding\"></div>\r\n        <h1 class=\"title2\">\r\n          项目设计简介<a class=\"top\" href=\"#top\"\r\n            ><img src=\"../assets/top.png\" alt=\"top\"\r\n          /></a>\r\n        </h1>\r\n        <p class=\"pagraph\">\r\n          此次我们关注到了代谢通路中的α-syn通路治疗以及神经元再生的PTB通路，通过AAV载体，在代谢与细胞再生两个层面实现帕金森病的长效稳定治疗。\r\n        </p>\r\n        <p class=\"pagraph\">\r\n          我们的项目开发了两种不同的腺相关病毒载体，分别针对不同的致病机理，旨在进行帕金森疾病的多靶点治疗。我们选用了2022年新开发的AAV-CAP-B10腺相关病毒载体，它能够通过静脉注射进入人体，穿过血脑屏障，对中枢神经系统具有高度特异性，且对肝脏具有低靶向性。我们同时修饰了病毒衣壳，增加其对目标组织的靶向性。\r\n        </p>\r\n        <p class=\"pagraph\">\r\n          在我们的设计中，其中一种病毒载体是靶向中脑黑质多巴胺能神经元的载体，我们选用了Pitx3、Foxa2特异性启动子并构建了与门电路，两个启动子在细胞中同时启动时，我们设计的基因线路才会表达。基因线路是基于CRISPReader的微型基因环路，当xxx,\r\n          xxx启动子同时启动时，shRNA表达，特异性沉默SNCA基因，减少α-syn蛋白的产生，从而减少α-syn蛋白不正常的聚集；同时病毒质粒上含有的Hsp70基因将会被表达，通过分子伴侣调控的细胞自噬途径降解α-syn蛋白聚集体，恢复被α-syn蛋白聚集体毒性阻断的细胞信号通路，减轻帕金森疾病的症状。\r\n        </p>\r\n        <p class=\"pagraph\">\r\n          另一种病毒载体靶向脑内的星形胶质细胞，我们选用了GFAP星形胶质细胞特异性启动子增强靶向性。我们基于dCas9-DNMT3A系统，实现PTB基因的甲基化修饰，以沉默PTB基因。PTB基因沉默后，部分星形胶质细胞被诱导转化为多巴胺能神经元，重建帕金森病人脑中中断的中脑-多巴胺能神经元回路，恢复病人的运动功能，是一种稳定长效的治疗方法。\r\n        </p>\r\n      </div>\r\n      <div class=\"ding\"></div>\r\n      <div class=\"ding\"></div>\r\n      <div class=\"ding\"></div>\r\n    </div>\r\n    <div id=\"lef\" class=\"leftP\">\r\n      <ul class=\"Shell\">\r\n        <li><a href=\"#top\">Abstract</a></li>\r\n        <li><a href=\"#des1\">帕金森病简介</a></li>\r\n        <li><a href=\"#des2\">现有治疗方式</a></li>\r\n        <li><a href=\"#des3\">项目设计简介</a></li>\r\n      </ul>\r\n    </div>\r\n  </div>\r\n</template>\r\n<script>\r\nexport default {\r\n  return() {},\r\n  mounted() {\r\n    let lef = document.getElementById(\"lef\");\r\n\r\n    function addEvent(obj, type, fn) {\r\n      undefined;\r\n      if (obj.attachEvent) {\r\n        obj.attachEvent(\"on\" + type, function () {\r\n          undefined;\r\n          fn.call(obj);\r\n        });\r\n      } else {\r\n        undefined;\r\n        obj.addEventListener(type, fn, false);\r\n      }\r\n    }\r\n\r\n    addEvent(window, \"scroll\", function () {\r\n      undefined;\r\n      if (window.pageYOffset >= 455) {\r\n        lef.classList.add(\"stick\");\r\n      } else {\r\n        lef.classList.remove(\"stick\");\r\n      }\r\n    });\r\n  },\r\n};\r\n</script>\r\n<style scoped>\r\n#lef.stick {\r\n  opacity: 0.7;\r\n  transition: all 1s;\r\n}\r\n.showBox .box .p {\r\n  display: none;\r\n  margin-bottom:20px;\r\n  margin-top:20px;\r\n}\r\n.leftP {\r\n  position: fixed;\r\n  left: 10px;\r\n  top: 30%;\r\n  opacity: 0;\r\n  height: 40vh;\r\n  width: 200px;\r\n  background-color: #3c6b6d;\r\n  border-radius: 20px;\r\n}\r\n.Shell {\r\n  margin: 0;\r\n  padding: 0;\r\n  color: inherit;\r\n  background-color: inherit;\r\n}\r\n.Shell:first-child {\r\n  margin-top: 4vh;\r\n}\r\n.Shell li a{\r\n  display: block;\r\n  width: 150px;\r\n}\r\n.Shell li {\r\n  list-style: none;\r\n  height: 8vh;\r\n  line-height: 8vh;\r\n  padding-left: 20px;\r\n  color: inherit;\r\n  background-color: inherit;\r\n}\r\n.Shell li:hover {\r\n  /* transform:scale(1,1.2); */\r\n  background-color: #89cfd1;\r\n  border-radius: 10px;\r\n  color: #253f17;\r\n  transition: all 0.6s;\r\n}\r\n.Shell li:hover a {\r\n  color: white;\r\n}\r\n.Shell li a {\r\n  text-decoration: none;\r\n  color: #8ad6bd;\r\n}\r\n.ding {\r\n  height: 96px;\r\n}\r\n.top img {\r\n  float: right;\r\n  line-height: 60px;\r\n}\r\n.top img:hover {\r\n  transform: scale(1.3);\r\n  transition: all 0.4s;\r\n}\r\n.back {\r\n  width: 100%;\r\n  background-color: #C5DDD9;\r\n}\r\n.bg .im {\r\n  background-attachment: fixed;\r\n  width: 100%;\r\n  height: 100vh;\r\n  background-size: cover;\r\n  background-image: url(../assets/homeBanner.gif);\r\n}\r\n.content {\r\n  background-color: inherit;\r\n  width: 900px;\r\n  margin: 0 auto;\r\n  align-content: center;\r\n  padding: 20px;\r\n}\r\n.title {\r\n  color: #1d5a56;\r\n  font-family: Comic Sans MS;\r\n  margin: 10px;\r\n  border-bottom: solid 2px #7faba0;\r\n  padding-bottom: 0.6em;\r\n}\r\n.title2 {\r\n  color: #1d5a56;\r\n  font-family: Comic Sans MS;\r\n  margin: 10px;\r\n  margin-top: 50px;\r\n  border-bottom: solid 2px #a9ccc3;\r\n  padding-bottom: 0.6em;\r\n}\r\n.title:first-letter {\r\n  font-size: 50px;\r\n  text-shadow: 2px 2px 5px #444;\r\n}\r\n.title2:first-letter {\r\n  font-size: 50px;\r\n  text-shadow: 2px 2px 5px #444;\r\n}\r\n.pagraph {\r\n  font-family: \"Century Gothic\";\r\n  letter-spacing: 0.05em !important;\r\n  text-indent: 2em;\r\n  display: block;\r\n  transition: all 2s;\r\n  margin-left: 40px;\r\n  letter-spacing: 1.3px;\r\n  line-height: 1.8;\r\n  word-spacing: 3px;\r\n  color: #386f6c;\r\n}\r\n</style>\r\n","import mod from \"-!../../node_modules/cache-loader/dist/cjs.js??ref--13-0!../../node_modules/thread-loader/dist/cjs.js!../../node_modules/babel-loader/lib/index.js!../../node_modules/cache-loader/dist/cjs.js??ref--1-0!../../node_modules/vue-loader/lib/index.js??vue-loader-options!./description.vue?vue&type=script&lang=js&\"; export default mod; export * from \"-!../../node_modules/cache-loader/dist/cjs.js??ref--13-0!../../node_modules/thread-loader/dist/cjs.js!../../node_modules/babel-loader/lib/index.js!../../node_modules/cache-loader/dist/cjs.js??ref--1-0!../../node_modules/vue-loader/lib/index.js??vue-loader-options!./description.vue?vue&type=script&lang=js&\"","import { render, staticRenderFns } from \"./description.vue?vue&type=template&id=ab5d104e&scoped=true&\"\nimport script from \"./description.vue?vue&type=script&lang=js&\"\nexport * from \"./description.vue?vue&type=script&lang=js&\"\nimport style0 from \"./description.vue?vue&type=style&index=0&id=ab5d104e&scoped=true&lang=css&\"\n\n\n/* normalize component */\nimport normalizer from \"!../../node_modules/vue-loader/lib/runtime/componentNormalizer.js\"\nvar component = normalizer(\n  script,\n  render,\n  staticRenderFns,\n  false,\n  null,\n  \"ab5d104e\",\n  null\n  \n)\n\nexport default component.exports","var render = function () {var _vm=this;var _h=_vm.$createElement;var _c=_vm._self._c||_h;return _vm._m(0)}\nvar staticRenderFns = [function () {var _vm=this;var _h=_vm.$createElement;var _c=_vm._self._c||_h;return _c('div',[_c('div',{staticClass:\"bg\"},[_c('div',{staticClass:\"im\",attrs:{\"id\":\"bg\"}})]),_c('div',{staticClass:\"back\"},[_c('div',{staticClass:\"content\"},[_c('div',{staticClass:\"ding\",attrs:{\"id\":\"top\"}}),_c('h1',{staticClass:\"topic\"},[_vm._v(\"α-syn蛋白通路\")]),_c('div',{staticClass:\"ding\"}),_c('h1',{staticClass:\"title\"},[_vm._v(\"作用机理\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 帕金森病的典型病例特征是中枢神经系统以异常α-突触核蛋白（α-synuclein，α-syn）不溶性聚集体为主要成分的路易小体（Lewy body， LB）的形成，导致多巴胺能神经元的进行性死亡和丢失。编码α-syn的SNCA基因是帕金森的关键致病基因之一。该基因的突变可引起α-syn 的过表达，进而形成路易小体，导致帕金森病的发生。因此，SNCA基因被认为是对帕金森进行治疗的有效靶点。 \")]),_c('img',{staticClass:\"tu\",attrs:{\"src\":require(\"../assets/des1-1.png\"),\"alt\":\"no pic\"}}),_c('div',{staticClass:\"ding\"}),_c('h1',{staticClass:\"title2\"},[_vm._v(\"解决方案\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 结合α-syn聚集体的形成和其调控基因，我们设计了两条通路来抑制路易小体的形成：1）促进α-syn聚集体的解聚：分子伴侣介导的自噬被证明能够有效促进α-syn的降解，其中hsp70的高表达可以促进这一过程，缓解α-syn蛋白的聚集毒性（Witt, S. N. Hsp70 molecular chaperones and Parkinson’s disease. 2010，Biopolymers，93:218–228.）；2）减少α-syn的表达水平：通过调控SNCA基因的转录和翻译过程，可有效降低α-syn的表达水平，减少α-syn的积累和聚集体的形成。我们选择使用短发夹RNA（shRNA）来干扰SNCA的表达。ShRNA较普遍使用的siRNA具有更长的药效潜力。 \")]),_c('p',{staticClass:\"ref\"},[_vm._v(\" ENG H, LIU N, YANG Y Y, et al. Lentivirus-mediated downregulation of α-synuclein reduces neuroinflammation and pro[1]motes functional recovery in rats with spinal cord injury.2019, Neuroinflammation, 16(1): 283. \")]),_c('img',{staticClass:\"tu\",attrs:{\"src\":require(\"../assets/des1-2.png\"),\"alt\":\"no pic\"}}),_c('img',{staticClass:\"tu\",attrs:{\"src\":require(\"../assets/des1-2-2.png\"),\"alt\":\"no pic\"}}),_c('div',{staticClass:\"ding\"}),_c('h1',{staticClass:\"title2\"},[_vm._v(\"基因线路\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 在基因线路设计上，我们参考前人文章[1]设计了一个基于CRISPR/Cas9系统的与门电路，以保证我们的治疗只会在表达特定转录因子的靶细胞（大脑黑质多巴胺能神经元）中进行。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 该与门电路的初始表达由两个特异性表达在靶细胞中的转录因子PITX3和FOXA2驱动。当该电路进入靶细胞后，其中的特异性转录因子PITX3和FOXA2会驱动下游所有蛋白/RNA的少量表达，少量的Cas9/VP64会与sgRNA1一起，在VP64结构域激活下正反馈促进这两个物质自身的转录，同理，sgRNA2也能激活自身的转录。正反馈转录完成后，高浓度的Cas9/VP64会与sgRNA2一起，在Cas9结构域的催化下，敲除LacI基因，这样，由LacO启动子启动的shRNA就可被表达，沉默SNCA基因，降低α-syn蛋白的表达；sgRNA3也能与Cas9/VP64一起，在VP64结构域的激活下激活Hsp70，促进错误折叠α-syn蛋白重新折叠或诱导其降解。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 当该与门电路进入非靶细胞时，由于缺少Pitx3/Foxa2转录因子中的一个或两个，Cas9/VP64和sgRNA不能被同时表达，本底表达的LacI会抑制shRNA和sgRNA3的表达，最大程度减少外源基因的泄露表达和治疗的脱靶效应。 \")]),_c('img',{staticClass:\"tu\",attrs:{\"src\":require(\"../assets/des1-3.png\"),\"alt\":\"no pic\"}}),_c('div',{staticClass:\"ding\"}),_c('h1',{staticClass:\"title2\"},[_vm._v(\"AAV. CAP. B10载体介绍\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 血脑屏障（BBB）是指脑毛细血管壁与神经胶质细胞形成的血浆与脑细胞之间的屏障，和由脉络丛形成的血浆和脑脊液之间的屏障，仅允许特定类型的分子从血流进入大脑神经元和其他周围细胞。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 血脑屏障的存在，对于阻止有害物质由血液进入大脑具有重要意义，然而，血脑屏障同时也阻止了绝大部分小分子和大分子（例如多肽，蛋白质和核酸）的转移，严重限制了神经中枢系统疾病（例如神经退行性疾病、脑肿瘤，脑部感染和中风等）的治疗。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 为了使我们的AAV能够突破血脑屏障的阻碍，我们选择了加州理工学院Viviana Gradinaru 团队通过定向进化开发的AAV.CAP-B10这一AAV变体。该载体能够通过血液注射突破血脑屏障，靶向神经细胞，同时不会在肝脏富集，避免了可能引起的肝脏毒性副作用。该载体目前不仅在小鼠上得到了证实，在非人灵长类动物狨猴上也得到了证实。同时，该载体在中脑神经元中的表达量是其他脑区的五倍多。这为我们利用AAV来治疗帕金森提供了一种更安全、更有效的治疗选择。 \")]),_c('p',{staticClass:\"ref\"},[_vm._v(\" Goertsen, D., Flytzanis, N.C., Goeden, N. et al. AAV capsid variants with brain-wide transgene expression and decreased liver targeting after intravenous delivery in mouse and marmoset. 2021, Nat Neurosci 25:106–115. \")]),_c('div',{staticClass:\"ding\",attrs:{\"id\":\"des1\"}}),_c('h1',{staticClass:\"topic\"},[_vm._v(\" PTB途径\")]),_c('div',{staticClass:\"ding\"}),_c('h1',{staticClass:\"title\"},[_vm._v(\"作用机理\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\"通过替换丢失的多巴胺能神经元以重建中断的中脑-多巴胺能神经元回路是一种稳定长效的治疗方法。[1]有文献表明，RNA结合蛋白PTB及其神经元类似物nPTB在控制神经元诱导和成熟中具有重要作用，通过连续消耗PTB实现了星形胶质细胞向多巴胺能神经元的转化[2][3]。 \")]),_c('img',{staticClass:\"tu\",attrs:{\"src\":require(\"../assets/des2-1.jpg\"),\"alt\":\"no pic\"}}),_c('div',{staticClass:\"ding\"}),_c('h1',{staticClass:\"title\"},[_vm._v(\"解决方案\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 为了沉默PTB基因，我们选择了一种基于dCas9-DNMT3A的DNA甲基化修饰策略。与其他基因沉默的方法不同，DNA甲基化对基因表达的作用更稳定和长期。dCas9-DNMT3A系统由Vojta等开发，是由dCas9(核酸酶缺陷，不能切割DNA)与DNMT3A的催化结构域(一种能够在体内甲基化CpG位点的活性DNA甲基转移酶）融合，可以在gRNA的指导下仍能以相同的精确度靶向和结合DNA。 \")]),_c('p',{staticClass:\"ref\"},[_vm._v(\" Vojta A,Dobrinié P, Tadic V,et al.Repurposing the CRISPR-Cas9 system for targeted DNA methylation Nucleic Acids Research, 2016,44 (12):5615-5628. \")]),_c('img',{staticClass:\"tu\",attrs:{\"src\":require(\"../assets/des2-2.png\"),\"alt\":\"no pic\"}}),_c('div',{staticClass:\"ding\"}),_c('h1',{staticClass:\"title\"},[_vm._v(\"基因线路\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 在具体的通路设计上，首先根据PTB基因，设计相应的sgRNA序列，以靶向目的基因。其次，运用星形胶质细胞的特异性启动子GFAP，控制dCas和DNMT3A融合蛋白的转录。最后加上合适的核定位序列（NLS）和转录增强子等腺相关病毒转导表达元件，完成载体设计。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" ①通路：hU6-sgRNA-GFAP-dCas-DNMT3A-WPRE （hU6 一种人类非编码RNA启动子，GFAP星形胶质细胞特异性启动子，WPRE是腺相关病毒的转录增强子） \")]),_c('img',{staticClass:\"tu\",attrs:{\"src\":require(\"../assets/des2-3-1.png\"),\"alt\":\"no pic\"}}),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 甲基化沉默基因作用原理 \")]),_c('img',{staticClass:\"tu\",attrs:{\"src\":require(\"../assets/des2-3-2.png\"),\"alt\":\"no pic\"}}),_c('div',{staticClass:\"ding\"}),_c('h1',{staticClass:\"title\"},[_vm._v(\"rAAV6载体介绍\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 神经胶质细胞，特别是星形胶质细胞，在利用AAV或rAAV载体进行感染时，速率非常低，且靶向性较弱。为了克服这一局限性，提高侵染效率，我们选择已商用的rAAV6载体。根据研究，市售的rAAV6在体外和体内均对大鼠星形胶质细胞具有高倾向性，并且可以相当有选择性地转导大鼠皮质细胞。在体内，rAAV6在受感染的大脑区域转导>90%的GFAP +星形胶质细胞，能够确保星形胶质细胞的高侵染率。 \")]),_c('div',{staticClass:\"ding\",attrs:{\"id\":\"des2\"}}),_c('h1',{staticClass:\"topic\"},[_vm._v(\"检测\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 通过检测多中心大样本队列，发现相对于健康人，帕金森病患者的脑脊液中含有α-syn的胞外囊泡会显著降低。使用纳米流式细胞检测技术及EVs内标记技术，一种稳定、快速的测定方法，用于定量测定脑脊液中含有α-syn的EVs；此创新性纳米流式细胞检测技术的方法不仅比传统的免疫测定法检测更具灵敏度、提高了检测效率，还为快速体液诊断及早期体液诊断提供了新的技术方法和新的标志物。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 创新性纳米流式细胞检测技术，是在流式细胞仪上对样本进行检测，相较于PET等影像学手段，花费低，能够给患者极大减轻经济负担。同时，该项新技术能够检测微囊泡内外的标记物，可达到多标记物快速联合检测的效果，若结合中枢神经系统来源标志物与疾病相关标志物，能够有效避免外周蛋白的干扰，精准检测神经系统来源携带有疾病相关蛋白的微囊泡。 \")])]),_c('div',{staticClass:\"ding\"}),_c('div',{staticClass:\"ding\"}),_c('div',{staticClass:\"ding\"})]),_c('div',{staticClass:\"leftP\",attrs:{\"id\":\"lef\"}},[_c('ul',{staticClass:\"Shell\"},[_c('li',[_c('a',{attrs:{\"href\":\"#top\"}},[_vm._v(\" α-syn蛋白通路\")])]),_c('li',[_c('a',{attrs:{\"href\":\"#des1\"}},[_vm._v(\"PTB途径\")])]),_c('li',[_c('a',{attrs:{\"href\":\"#des2\"}},[_vm._v(\"检测\")])])])])])}]\n\nexport { render, staticRenderFns }","<template>\r\n  <div>\r\n    <div class=\"bg\"><div class=\"im\" id=\"bg\"></div></div>\r\n    <div class=\"back\">\r\n      <div class=\"content\">\r\n        \r\n\r\n        <div id=\"top\" class=\"ding\"></div>\r\n        <h1 class=\"topic\">α-syn蛋白通路</h1>\r\n        <div class=\"ding\"></div>\r\n        <h1 class=\"title\">作用机理</h1>\r\n        <p class=\"pagraph\">\r\n          帕金森病的典型病例特征是中枢神经系统以异常α-突触核蛋白（α-synuclein，α-syn）不溶性聚集体为主要成分的路易小体（Lewy\r\n          body，\r\n          LB）的形成，导致多巴胺能神经元的进行性死亡和丢失。编码α-syn的SNCA基因是帕金森的关键致病基因之一。该基因的突变可引起α-syn\r\n          的过表达，进而形成路易小体，导致帕金森病的发生。因此，SNCA基因被认为是对帕金森进行治疗的有效靶点。\r\n        </p>\r\n        <img src=\"../assets/des1-1.png\" class=\"tu\" alt=\"no pic\">\r\n        <div class=\"ding\"></div>\r\n        <h1 class=\"title2\">解决方案</h1>\r\n        <p class=\"pagraph\">\r\n         结合α-syn聚集体的形成和其调控基因，我们设计了两条通路来抑制路易小体的形成：1）促进α-syn聚集体的解聚：分子伴侣介导的自噬被证明能够有效促进α-syn的降解，其中hsp70的高表达可以促进这一过程，缓解α-syn蛋白的聚集毒性（Witt, S. N. Hsp70 molecular chaperones and Parkinson’s disease. 2010，Biopolymers，93:218–228.）；2）减少α-syn的表达水平：通过调控SNCA基因的转录和翻译过程，可有效降低α-syn的表达水平，减少α-syn的积累和聚集体的形成。我们选择使用短发夹RNA（shRNA）来干扰SNCA的表达。ShRNA较普遍使用的siRNA具有更长的药效潜力。\r\n        </p>\r\n        <p class=\"ref\">\r\n          ENG H, LIU N, YANG Y Y, et al. Lentivirus-mediated downregulation of α-synuclein reduces neuroinflammation and pro[1]motes functional recovery in rats with spinal cord injury.2019, Neuroinflammation, 16(1): 283.\r\n        </p>\r\n        <img src=\"../assets/des1-2.png\" class=\"tu\" alt=\"no pic\">\r\n        <img src=\"../assets/des1-2-2.png\" class=\"tu\" alt=\"no pic\">\r\n        <div class=\"ding\"></div>\r\n        <h1 class=\"title2\">基因线路</h1>\r\n        <p class=\"pagraph\">\r\n          在基因线路设计上，我们参考前人文章[1]设计了一个基于CRISPR/Cas9系统的与门电路，以保证我们的治疗只会在表达特定转录因子的靶细胞（大脑黑质多巴胺能神经元）中进行。\r\n        </p>\r\n        <p class=\"pagraph\">\r\n          该与门电路的初始表达由两个特异性表达在靶细胞中的转录因子PITX3和FOXA2驱动。当该电路进入靶细胞后，其中的特异性转录因子PITX3和FOXA2会驱动下游所有蛋白/RNA的少量表达，少量的Cas9/VP64会与sgRNA1一起，在VP64结构域激活下正反馈促进这两个物质自身的转录，同理，sgRNA2也能激活自身的转录。正反馈转录完成后，高浓度的Cas9/VP64会与sgRNA2一起，在Cas9结构域的催化下，敲除LacI基因，这样，由LacO启动子启动的shRNA就可被表达，沉默SNCA基因，降低α-syn蛋白的表达；sgRNA3也能与Cas9/VP64一起，在VP64结构域的激活下激活Hsp70，促进错误折叠α-syn蛋白重新折叠或诱导其降解。\r\n        </p>\r\n        <p class=\"pagraph\">\r\n          当该与门电路进入非靶细胞时，由于缺少Pitx3/Foxa2转录因子中的一个或两个，Cas9/VP64和sgRNA不能被同时表达，本底表达的LacI会抑制shRNA和sgRNA3的表达，最大程度减少外源基因的泄露表达和治疗的脱靶效应。\r\n        </p>\r\n        <img src=\"../assets/des1-3.png\" class=\"tu\" alt=\"no pic\">\r\n        <div class=\"ding\"></div>\r\n        <h1 class=\"title2\">AAV. CAP. B10载体介绍</h1>\r\n        <p class=\"pagraph\">\r\n          血脑屏障（BBB）是指脑毛细血管壁与神经胶质细胞形成的血浆与脑细胞之间的屏障，和由脉络丛形成的血浆和脑脊液之间的屏障，仅允许特定类型的分子从血流进入大脑神经元和其他周围细胞。\r\n        </p>\r\n        <p class=\"pagraph\">\r\n          血脑屏障的存在，对于阻止有害物质由血液进入大脑具有重要意义，然而，血脑屏障同时也阻止了绝大部分小分子和大分子（例如多肽，蛋白质和核酸）的转移，严重限制了神经中枢系统疾病（例如神经退行性疾病、脑肿瘤，脑部感染和中风等）的治疗。\r\n        </p>\r\n        <p class=\"pagraph\">\r\n          为了使我们的AAV能够突破血脑屏障的阻碍，我们选择了加州理工学院Viviana\r\n          Gradinaru\r\n          团队通过定向进化开发的AAV.CAP-B10这一AAV变体。该载体能够通过血液注射突破血脑屏障，靶向神经细胞，同时不会在肝脏富集，避免了可能引起的肝脏毒性副作用。该载体目前不仅在小鼠上得到了证实，在非人灵长类动物狨猴上也得到了证实。同时，该载体在中脑神经元中的表达量是其他脑区的五倍多。这为我们利用AAV来治疗帕金森提供了一种更安全、更有效的治疗选择。\r\n        </p>\r\n        <p class=\"ref\">\r\n          Goertsen, D., Flytzanis, N.C., Goeden, N. et al. AAV capsid variants\r\n          with brain-wide transgene expression and decreased liver targeting\r\n          after intravenous delivery in mouse and marmoset. 2021, Nat\r\n          Neurosci 25:106–115.\r\n        </p>\r\n\r\n        <div id=\"des1\" class=\"ding\"></div>\r\n        <h1 class=\"topic\"> PTB途径</h1>\r\n        <div class=\"ding\"></div>\r\n        <h1 class=\"title\">作用机理</h1>\r\n        <p class=\"pagraph\">通过替换丢失的多巴胺能神经元以重建中断的中脑-多巴胺能神经元回路是一种稳定长效的治疗方法。[1]有文献表明，RNA结合蛋白PTB及其神经元类似物nPTB在控制神经元诱导和成熟中具有重要作用，通过连续消耗PTB实现了星形胶质细胞向多巴胺能神经元的转化[2][3]。\r\n\r\n        </p>\r\n        <img src=\"../assets/des2-1.jpg\" class=\"tu\" alt=\"no pic\">\r\n        <div class=\"ding\"></div>\r\n        <h1 class=\"title\">解决方案</h1>\r\n        <p class=\"pagraph\">\r\n         为了沉默PTB基因，我们选择了一种基于dCas9-DNMT3A的DNA甲基化修饰策略。与其他基因沉默的方法不同，DNA甲基化对基因表达的作用更稳定和长期。dCas9-DNMT3A系统由Vojta等开发，是由dCas9(核酸酶缺陷，不能切割DNA)与DNMT3A的催化结构域(一种能够在体内甲基化CpG位点的活性DNA甲基转移酶）融合，可以在gRNA的指导下仍能以相同的精确度靶向和结合DNA。\r\n        </p> \r\n        <p class=\"ref\">\r\n         Vojta A,Dobrinié P, Tadic V,et al.Repurposing the CRISPR-Cas9 system for targeted DNA methylation Nucleic Acids Research, 2016,44 (12):5615-5628.\r\n        </p> \r\n<img src=\"../assets/des2-2.png\" class=\"tu\" alt=\"no pic\">\r\n      <div class=\"ding\"></div>\r\n        <h1 class=\"title\">基因线路</h1>\r\n        <p class=\"pagraph\">\r\n         在具体的通路设计上，首先根据PTB基因，设计相应的sgRNA序列，以靶向目的基因。其次，运用星形胶质细胞的特异性启动子GFAP，控制dCas和DNMT3A融合蛋白的转录。最后加上合适的核定位序列（NLS）和转录增强子等腺相关病毒转导表达元件，完成载体设计。\r\n        </p> \r\n        <p class=\"pagraph\">\r\n         ①通路：hU6-sgRNA-GFAP-dCas-DNMT3A-WPRE\r\n（hU6 一种人类非编码RNA启动子，GFAP星形胶质细胞特异性启动子，WPRE是腺相关病毒的转录增强子）\r\n        </p> \r\n        <img src=\"../assets/des2-3-1.png\" class=\"tu\" alt=\"no pic\">\r\n        <p class=\"pagraph\">\r\n         甲基化沉默基因作用原理\r\n        </p> \r\n        <img src=\"../assets/des2-3-2.png\" class=\"tu\" alt=\"no pic\">\r\n\r\n        <div class=\"ding\"></div>\r\n        <h1 class=\"title\">rAAV6载体介绍</h1>\r\n        <p class=\"pagraph\">\r\n         神经胶质细胞，特别是星形胶质细胞，在利用AAV或rAAV载体进行感染时，速率非常低，且靶向性较弱。为了克服这一局限性，提高侵染效率，我们选择已商用的rAAV6载体。根据研究，市售的rAAV6在体外和体内均对大鼠星形胶质细胞具有高倾向性，并且可以相当有选择性地转导大鼠皮质细胞。在体内，rAAV6在受感染的大脑区域转导>90%的GFAP +星形胶质细胞，能够确保星形胶质细胞的高侵染率。\r\n        </p> \r\n\r\n        <div id=\"des2\" class=\"ding\"></div>\r\n         <h1 class=\"topic\">检测</h1>\r\n        <p class=\"pagraph\">\r\n         通过检测多中心大样本队列，发现相对于健康人，帕金森病患者的脑脊液中含有α-syn的胞外囊泡会显著降低。使用纳米流式细胞检测技术及EVs内标记技术，一种稳定、快速的测定方法，用于定量测定脑脊液中含有α-syn的EVs；此创新性纳米流式细胞检测技术的方法不仅比传统的免疫测定法检测更具灵敏度、提高了检测效率，还为快速体液诊断及早期体液诊断提供了新的技术方法和新的标志物。\r\n        </p> \r\n        <p class=\"pagraph\">\r\n         创新性纳米流式细胞检测技术，是在流式细胞仪上对样本进行检测，相较于PET等影像学手段，花费低，能够给患者极大减轻经济负担。同时，该项新技术能够检测微囊泡内外的标记物，可达到多标记物快速联合检测的效果，若结合中枢神经系统来源标志物与疾病相关标志物，能够有效避免外周蛋白的干扰，精准检测神经系统来源携带有疾病相关蛋白的微囊泡。\r\n        </p>\r\n      </div>\r\n      <div class=\"ding\"></div>\r\n      <div class=\"ding\"></div>\r\n      <div class=\"ding\"></div>\r\n    </div>\r\n    <div id=\"lef\" class=\"leftP\">\r\n      <ul class=\"Shell\">\r\n        <li><a href=\"#top\"> α-syn蛋白通路</a></li>\r\n        <li><a href=\"#des1\">PTB途径</a></li>\r\n        <li><a href=\"#des2\">检测</a></li>\r\n      </ul>\r\n    </div>\r\n  </div>\r\n</template>\r\n<script>\r\nexport default {\r\n  return() {},\r\n  mounted() {\r\n    let lef = document.getElementById(\"lef\");\r\n\r\n    function addEvent(obj, type, fn) {\r\n      undefined;\r\n      if (obj.attachEvent) {\r\n        obj.attachEvent(\"on\" + type, function () {\r\n          undefined;\r\n          fn.call(obj);\r\n        });\r\n      } else {\r\n        undefined;\r\n        obj.addEventListener(type, fn, false);\r\n      }\r\n    }\r\n\r\n    addEvent(window, \"scroll\", function () {\r\n      undefined;\r\n      if (window.pageYOffset >= 455) {\r\n        lef.classList.add(\"stick\");\r\n      } else {\r\n        lef.classList.remove(\"stick\");\r\n      }\r\n    });\r\n  },\r\n};\r\n</script>\r\n<style scoped>\r\n.tu{\r\n  margin-right: auto;\r\n  margin-left: auto;\r\n  display: block;\r\n  margin-top: 20px;\r\n  width: 600px;\r\n  height: auto;\r\n  border-radius: 30px;\r\n  border: #1d5a56;\r\n  background-size: 5px;\r\n}\r\n.showBox .box .p {\r\n  display: none;\r\n  margin-bottom:20px;\r\n  margin-top:20px;\r\n}\r\n.topic {\r\n  color: #1d3f5a;\r\n  font-size: 60px;\r\n  text-align: center;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  font-family: \"Arial\";\r\n  letter-spacing: 15px;\r\n}\r\n#lef.stick {\r\n  opacity: 0.7;\r\n  transition: all 1s;\r\n}\r\n.Shell li a{\r\n  display: block;\r\n  width: 150px;\r\n}\r\n.leftP {\r\n  position: fixed;\r\n  left: 10px;\r\n  top: 30%;\r\n  opacity: 0;\r\n  height: 32vh;\r\n  width: 200px;\r\n  background-color: #3c6b6d;\r\n  border-radius: 20px;\r\n}\r\n.Shell {\r\n  margin: 0;\r\n  padding: 0;\r\n  color: inherit;\r\n  background-color: inherit;\r\n}\r\n.Shell:first-child {\r\n  margin-top: 4vh;\r\n}\r\n.Shell li {\r\n  list-style: none;\r\n  height: 8vh;\r\n  line-height: 8vh;\r\n  padding-left: 20px;\r\n  color: inherit;\r\n  background-color: inherit;\r\n}\r\n.Shell li:hover {\r\n  /* transform:scale(1,1.2); */\r\n  background-color: #89cfd1;\r\n  border-radius: 10px;\r\n  color: #253f17;\r\n  transition: all 0.6s;\r\n}\r\n.Shell li:hover a {\r\n  color: white;\r\n}\r\n.Shell li a {\r\n  text-decoration: none;\r\n  color: #8ad6bd;\r\n}\r\n.ding {\r\n  height: 96px;\r\n}\r\n.top img {\r\n  float: right;\r\n  line-height: 60px;\r\n}\r\n.top img:hover {\r\n  transform: scale(1.3);\r\n  transition: all 0.4s;\r\n}\r\n.back {\r\n  width: 100%;\r\n  background-color: #c5ddd9;\r\n}\r\n.bg .im {\r\n  background-attachment: fixed;\r\n  width: 100%;\r\n  height: 100vh;\r\n  background-size: cover;\r\n  background-image: url(../assets/homeBanner.gif);\r\n}\r\n.content {\r\n  background-color: inherit;\r\n  width: 900px;\r\n  margin: 0 auto;\r\n  align-content: center;\r\n  padding: 20px;\r\n}\r\n.title {\r\n  color: #1d5a56;\r\n  font-family: Comic Sans MS;\r\n  margin: 10px;\r\n  border-bottom: solid 2px #7faba0;\r\n  padding-bottom: 0.6em;\r\n}\r\n.title2 {\r\n  color: #1d5a56;\r\n  font-family: Comic Sans MS;\r\n  margin: 10px;\r\n  margin-top: 50px;\r\n  border-bottom: solid 2px #a9ccc3;\r\n  padding-bottom: 0.8em;\r\n}\r\n.title:first-letter {\r\n  font-size: 50px;\r\n  text-shadow: 2px 2px 5px #444;\r\n}\r\n.title2:first-letter {\r\n  font-size: 50px;\r\n  text-shadow: 2px 2px 5px #444;\r\n}\r\n.pagraph {\r\n  font-family: \"Century Gothic\";\r\n  letter-spacing: 0.05em !important;\r\n  text-indent: 2em;\r\n  display: block;\r\n  transition: all 2s;\r\n  margin-left: 40px;\r\n  letter-spacing: 1.3px;\r\n  line-height: 1.8;\r\n  word-spacing: 3px;\r\n  color: #386f6c;\r\n}\r\n.ref {\r\n  font-style: italic;\r\n  font-family: Times New Roman, Times, serif !important;\r\n  padding-left: 2em;\r\n  text-align: left;\r\n  font-size: 0.8em;\r\n  color: #7d7d7d;\r\n  letter-spacing: 0.018em;\r\n}\r\n</style>\r\n","import mod from \"-!../../node_modules/cache-loader/dist/cjs.js??ref--13-0!../../node_modules/thread-loader/dist/cjs.js!../../node_modules/babel-loader/lib/index.js!../../node_modules/cache-loader/dist/cjs.js??ref--1-0!../../node_modules/vue-loader/lib/index.js??vue-loader-options!./design.vue?vue&type=script&lang=js&\"; export default mod; export * from \"-!../../node_modules/cache-loader/dist/cjs.js??ref--13-0!../../node_modules/thread-loader/dist/cjs.js!../../node_modules/babel-loader/lib/index.js!../../node_modules/cache-loader/dist/cjs.js??ref--1-0!../../node_modules/vue-loader/lib/index.js??vue-loader-options!./design.vue?vue&type=script&lang=js&\"","import { render, staticRenderFns } from \"./design.vue?vue&type=template&id=e81954c0&scoped=true&\"\nimport script from \"./design.vue?vue&type=script&lang=js&\"\nexport * from \"./design.vue?vue&type=script&lang=js&\"\nimport style0 from \"./design.vue?vue&type=style&index=0&id=e81954c0&scoped=true&lang=css&\"\n\n\n/* normalize component */\nimport normalizer from \"!../../node_modules/vue-loader/lib/runtime/componentNormalizer.js\"\nvar component = normalizer(\n  script,\n  render,\n  staticRenderFns,\n  false,\n  null,\n  \"e81954c0\",\n  null\n  \n)\n\nexport default component.exports","var render = function () {var _vm=this;var _h=_vm.$createElement;var _c=_vm._self._c||_h;return _vm._m(0)}\nvar staticRenderFns = [function () {var _vm=this;var _h=_vm.$createElement;var _c=_vm._self._c||_h;return _c('div',[_c('div',{staticClass:\"bg\"},[_c('div',{staticClass:\"im\",attrs:{\"id\":\"bg\"}})]),_c('div',{staticClass:\"back\"},[_c('div',{staticClass:\"content\"},[_c('div',{staticClass:\"ding\",attrs:{\"id\":\"top\"}}),_c('h1',{staticClass:\"topic\"},[_vm._v(\"Overview\")]),_c('div',{staticClass:\"ding\"}),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 我们的整个项目旨在通过α-syn聚集体的形成以及促进多巴胺能神经元再生来治疗帕金森病。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 我们的实验室工作将主要集中在提高各个通路的作用效率上。我们已经确认了关键部件功能的可靠性。我们的模型证明了hsp70过表达对于促进α-syn蛋白聚集体降解的有效性。 \")]),_c('div',{staticClass:\"ding\",attrs:{\"id\":\"des1\"}}),_c('h1',{staticClass:\"topic\"},[_vm._v(\" AAV应用前景\")]),_c('div',{staticClass:\"ding\"}),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 基因病毒载体有慢病毒载体、腺病毒载体、腺相关病毒载体、逆转录病毒载体、杆状病毒载体等，其中腺相关病毒载体应用较广。从2019年9月的190个增长到2021年7月的256个，这一变化也可见AAV目前的热度。靶器官为肝脏的静脉注射基因疗法用于治疗代谢和血液病、帕金森病、A型和B型血友病是目前国际临床研究在研最热的3个主要适应证。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 目前，三款以重组AAV为载体的基因治疗药物已获批上市。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 1.2012年，被EMA批准Glybera用于治疗脂蛋白脂肪酶缺乏症(LPLD)，为第一个正式批准上市的人用AAV基因治疗产品，售价120万美元，因销售情况堪忧，于2017年黯然退市。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 2.2017年底，FDA批准Spark Therapeutics公司的Luxturna 用于治疗遗传性视网膜疾病，成为首款在美国获批的“体内给药型”基因疗法，定价85万美元。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 3.2019年5月24日，诺华的Zolgensma获美国FDA批准上市，用于治疗2岁以下脊髓性肌萎缩症(SMA)患儿，患者存活运动神经元1 (SMN1)基因存在双等位基因突变；定价212.5万美元，成为全球最为昂贵的药物，是目前为止FDA批准用于治疗SMA患者（包括在诊断时尚未出现症状的患者）的首个也是唯一一个基因疗法。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 除此之外，2021年9月艾伯维高达17.5亿美元购买AAV项目RGX-314更是让AAV项目在国内备受关注。RGX-314是一种潜在的一次性基因疗法，用于治疗湿性年龄相关性黄斑变性 (wAMD)、糖尿病性视网膜病变 (DR) 和其他慢性视网膜疾病。 \")]),_c('p',{staticClass:\"pagraph\"}),_c('div',{staticClass:\"ding\",attrs:{\"id\":\"des2\"}}),_c('h1',{staticClass:\"topic\"},[_vm._v(\"α-syn通路的可行性\")]),_c('div',{staticClass:\"ding\"}),_c('h1',{staticClass:\"title\"},[_vm._v(\"理论基础\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" α-syn通路是通过过表达Hsp70和沉默α-syn的编码基因SNCA来实现的。Hsp70是热休克蛋白家族成员，属于一种分子伴侣蛋白，在检测到蛋白质错误折叠后会辅助蛋白质重新折叠或将其送入蛋白降解途径进行降解。现有的研究表明，在表达有错误SCNA基因的细胞系中过表达Hsp70后，会显著降低α-syn聚集体在胞内的数量，证明该通路可以用于我们的治疗。 \")]),_c('div',{staticClass:\"ding\"}),_c('h1',{staticClass:\"title\"},[_vm._v(\"实验操作\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" ①构建m-α-syn:EGFP融合表达载体，在特定细胞系内进行表达，观察聚集体分布及数量。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" ②在该细胞系中进一步过表达Hsp70，观察聚集体分布及数量。若聚集体减少则说明过表达Hsp70能促进突变型α-syn的减少。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" ③在表达有m-α-syn的细胞系中进一步表达shRNA，检测SNCA的表达水平和蛋白翻译水平，并观察聚集体的分布及数量。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" ④验证与门开关在细胞内的工作情况 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" ⑤验证AAV-CAP-B10侵染细胞的情况以及最终能否实现目标 \")]),_c('div',{staticClass:\"ding\",attrs:{\"id\":\"des3\"}}),_c('h1',{staticClass:\"topic\"},[_vm._v(\"PTB通路的可行性\")]),_c('div',{staticClass:\"ding\"}),_c('h1',{staticClass:\"title\"},[_vm._v(\"理论基础\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" PTB通路的实现是通过消耗PTB实现星形胶质细胞的转分化，其依据是星形胶质细胞内存在PTB与nPTB调节环路，该环路同样在成纤维细胞中存在，其转化原理可在多种细胞中得到验证，即较高的可重复性。另外，通过该环路进行实验分析的程序较成熟，可操作性强。 \")]),_c('div',{staticClass:\"ding\"}),_c('h1',{staticClass:\"title\"},[_vm._v(\"实验操作\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" ①本实验所需的载体、dCas系统的原理与具体通路基因搭建均有详细来源，方便实验人员构建本实验所需的基因部件 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" ②验证新生多巴胺能神经元的免疫细胞化学、HPLC量化法及各项行为学检测均有详细的操作步骤与较简洁清晰的实验操作流程参考 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" ③实验结果在微观层面可通过染色进行观测，宏观层面则可通过行为学测试和纹状体的解剖大体观察进行分析，在多层面上印证实验结果，使得该通路的观测的科学性得以增强 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" ④经文献研究，该通路的转化效率不会过高（10%），因而难以出现实验过程中星形胶质细胞转化过多而影响其他脑区功能的现象，因而实验对象可在稳定的状态下接受各项操作 \")]),_c('div',{staticClass:\"ding\",attrs:{\"id\":\"des4\"}}),_c('h1',{staticClass:\"topic\"},[_vm._v(\"模型结果\")]),_c('div',{staticClass:\"ding\"}),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 我们的模型主要针对hsp70通路进行验证。该模型考虑了hsp70和α-syn结合以及酶促反应的动力学。模型中的参数主要来自已发表的论文以及BRENDA等数据库。根据建模结果，hsp70的过表达可以有效降低α-syn蛋白的聚集， 且能够在短时间内发生效应。 \")]),_c('div',{staticClass:\"ding\",attrs:{\"id\":\"des5\"}}),_c('h1',{staticClass:\"topic\"},[_vm._v(\"AAV基因治疗现存的挑战\")]),_c('div',{staticClass:\"ding\"}),_c('h1',{staticClass:\"title\"},[_vm._v(\"抗体中和风险\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 与脑实质内（IPa）给药、鞘内（IT）或脑室内（ICV）给药不同，AAV载体的静脉内给药（IV）具有将基因非侵入性地转移至整个中枢神经系统（CNS）并且更均匀分布的潜力。迄今为止，IV给药在I型SMA婴儿中是成功的，其中非常适度水平的转基因表达可能足以获得治疗益处。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 但IV注射使AAV暴露于预先感染天然AAV的受试者，具有抗体中和的潜在风险，估计有90％的成年人接触过AAV，这可能对AAV载体应用产生深远的负面影响。目前，通过衣壳工程修饰衣壳表面表位可以更好地逃避中和抗体的识别。对于年龄较大的儿童和成人进行CNS疾病的给药，还需要考虑所需的高剂量。  \")]),_c('div',{staticClass:\"ding\"}),_c('h1',{staticClass:\"title\"},[_vm._v(\"安全风险\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 治疗性转基因在非靶组织中的表达或在靶细胞内过表达，均有可能导致基因置换的潜在毒性作用。例如，MECP2（编码甲基-CpG结合蛋白2）中的突变导致女性的Rett综合征，但该基因的重复也导致男孩的智力发育障碍。小鼠模型中的MeCP2过表达导致行为异常、学习障碍和癫痫发作。因此，对Rett综合征的成功治疗需要转基因表达保持在非常狭窄的治疗窗内。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 与基因沉默相关的潜在毒性作用还将取决于内源蛋白的功能、干预的时间和miRNA的表达水平以及由此产生的沉默。尽管AAV基因治疗在迄今为止的一系列疾病中已被很好地耐受，但是调节表达仍然是靶标和疾病选择的重要安全考虑因素。另外，在接受基因治疗后免疫应答和转基因持久表达可能妨碍受试者参与其他临床试验。因此，具有高度未满足的临床需求和符合风险效益的疾病更加适合使用AAV基因治疗。 \")]),_c('div',{staticClass:\"ding\"}),_c('h1',{staticClass:\"title\"},[_vm._v(\"生产成本和效率\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 用于治疗神经疾病的成功的AAV基因疗法需要一个生产平台，该生产平台可重复地提供在多个批次中具有足够和相当质量的载体，并且可用于晚期临床开发和商业化。哺乳动物细胞（如HEK293细胞）中的传统生产系统可以产生高质量载体，但产量有限。相比之下，使用杆状病毒-Sf9昆虫细胞生产AAV载体已被证明可将载体产量提高约10倍至100倍。然而，对于一些衣壳，昆虫细胞产生的载体的效力可能低于哺乳动物细胞中产生的载体，但这可以通过分子工程成功克服。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 对于需要有限量载体的CNS应用，例如脑实质内给予的AAV载体，使用哺乳动物系统可能就足够了。然而，对于静脉内（IV）和鞘内（IT）给予的AAV载体，哺乳动物系统提供临床开发所需的量都是一个重要的挑战，更不用说扩大到商业化。目前，可以扩展以满足这些需求的AAV载体生产系统包括杆状病毒-Sf9系统、基于重组HSV的系统和腺病毒-HeLa细胞系统。 \")])]),_c('div',{staticClass:\"ding\"}),_c('div',{staticClass:\"ding\"}),_c('div',{staticClass:\"ding\"})]),_c('div',{staticClass:\"leftP\",attrs:{\"id\":\"lef\"}},[_c('ul',{staticClass:\"Shell\"},[_c('li',[_c('a',{attrs:{\"href\":\"#top\"}},[_vm._v(\"Overview\")])]),_c('li',[_c('a',{attrs:{\"href\":\"#des1\"}},[_vm._v(\"AAV应用前景\")])]),_c('li',[_c('a',{attrs:{\"href\":\"#des2\"}},[_vm._v(\" α-syn通路的可行性\")])]),_c('li',[_c('a',{attrs:{\"href\":\"#des3\"}},[_vm._v(\"PTB通路的可行性\")])]),_c('li',[_c('a',{attrs:{\"href\":\"#des4\"}},[_vm._v(\"模型结果\")])]),_c('li',[_c('a',{attrs:{\"href\":\"#des5\"}},[_vm._v(\"AAV基因治疗现存的挑战\")])])])])])}]\n\nexport { render, staticRenderFns }","<template>\r\n  <div>\r\n    <div class=\"bg\"><div class=\"im\" id=\"bg\"></div></div>\r\n    <div class=\"back\">\r\n      <div class=\"content\">\r\n        \r\n\r\n        <div id=\"top\" class=\"ding\"></div>\r\n       <h1 class=\"topic\">Overview</h1>\r\n        <div class=\"ding\"></div>\r\n        <p class=\"pagraph\">\r\n         我们的整个项目旨在通过α-syn聚集体的形成以及促进多巴胺能神经元再生来治疗帕金森病。\r\n        </p>\r\n        <p class=\"pagraph\">\r\n         我们的实验室工作将主要集中在提高各个通路的作用效率上。我们已经确认了关键部件功能的可靠性。我们的模型证明了hsp70过表达对于促进α-syn蛋白聚集体降解的有效性。\r\n        </p>\r\n       \r\n        \r\n\r\n        <div id=\"des1\" class=\"ding\"></div>\r\n        <h1 class=\"topic\"> AAV应用前景</h1>\r\n        <div class=\"ding\"></div>\r\n        <p class=\"pagraph\">\r\n基因病毒载体有慢病毒载体、腺病毒载体、腺相关病毒载体、逆转录病毒载体、杆状病毒载体等，其中腺相关病毒载体应用较广。从2019年9月的190个增长到2021年7月的256个，这一变化也可见AAV目前的热度。靶器官为肝脏的静脉注射基因疗法用于治疗代谢和血液病、帕金森病、A型和B型血友病是目前国际临床研究在研最热的3个主要适应证。\r\n        </p>\r\n        <p class=\"pagraph\">\r\n目前，三款以重组AAV为载体的基因治疗药物已获批上市。\r\n\r\n        </p>\r\n        <p class=\"pagraph\">\r\n1.2012年，被EMA批准Glybera用于治疗脂蛋白脂肪酶缺乏症(LPLD)，为第一个正式批准上市的人用AAV基因治疗产品，售价120万美元，因销售情况堪忧，于2017年黯然退市。\r\n\r\n        </p>\r\n        <p class=\"pagraph\">\r\n2.2017年底，FDA批准Spark Therapeutics公司的Luxturna 用于治疗遗传性视网膜疾病，成为首款在美国获批的“体内给药型”基因疗法，定价85万美元。\r\n\r\n        </p>\r\n        <p class=\"pagraph\">\r\n3.2019年5月24日，诺华的Zolgensma获美国FDA批准上市，用于治疗2岁以下脊髓性肌萎缩症(SMA)患儿，患者存活运动神经元1 (SMN1)基因存在双等位基因突变；定价212.5万美元，成为全球最为昂贵的药物，是目前为止FDA批准用于治疗SMA患者（包括在诊断时尚未出现症状的患者）的首个也是唯一一个基因疗法。\r\n\r\n        </p>\r\n        <p class=\"pagraph\">\r\n除此之外，2021年9月艾伯维高达17.5亿美元购买AAV项目RGX-314更是让AAV项目在国内备受关注。RGX-314是一种潜在的一次性基因疗法，用于治疗湿性年龄相关性黄斑变性 (wAMD)、糖尿病性视网膜病变 (DR) 和其他慢性视网膜疾病。\r\n\r\n        </p>\r\n        <p class=\"pagraph\">\r\n\r\n        </p>\r\n       \r\n        <div id=\"des2\" class=\"ding\"></div>\r\n         <h1 class=\"topic\">α-syn通路的可行性</h1>\r\n         <div class=\"ding\"></div>\r\n        <h1 class=\"title\">理论基础</h1>\r\n        <p class=\"pagraph\">\r\n         α-syn通路是通过过表达Hsp70和沉默α-syn的编码基因SNCA来实现的。Hsp70是热休克蛋白家族成员，属于一种分子伴侣蛋白，在检测到蛋白质错误折叠后会辅助蛋白质重新折叠或将其送入蛋白降解途径进行降解。现有的研究表明，在表达有错误SCNA基因的细胞系中过表达Hsp70后，会显著降低α-syn聚集体在胞内的数量，证明该通路可以用于我们的治疗。\r\n        </p>\r\n        <div class=\"ding\"></div>\r\n        <h1 class=\"title\">实验操作</h1>\r\n        <p class=\"pagraph\">\r\n         ①构建m-α-syn:EGFP融合表达载体，在特定细胞系内进行表达，观察聚集体分布及数量。\r\n        </p>    \r\n        <p class=\"pagraph\">\r\n         ②在该细胞系中进一步过表达Hsp70，观察聚集体分布及数量。若聚集体减少则说明过表达Hsp70能促进突变型α-syn的减少。\r\n        </p>  \r\n        <p class=\"pagraph\">\r\n         ③在表达有m-α-syn的细胞系中进一步表达shRNA，检测SNCA的表达水平和蛋白翻译水平，并观察聚集体的分布及数量。\r\n        </p>  \r\n        <p class=\"pagraph\">\r\n         ④验证与门开关在细胞内的工作情况\r\n        </p>  \r\n        <p class=\"pagraph\">\r\n         ⑤验证AAV-CAP-B10侵染细胞的情况以及最终能否实现目标\r\n        </p>  \r\n\r\n        <div id=\"des3\" class=\"ding\"></div>\r\n       <h1 class=\"topic\">PTB通路的可行性</h1>\r\n        <div class=\"ding\"></div>\r\n        <h1 class=\"title\">理论基础</h1>\r\n        <p class=\"pagraph\">\r\n         PTB通路的实现是通过消耗PTB实现星形胶质细胞的转分化，其依据是星形胶质细胞内存在PTB与nPTB调节环路，该环路同样在成纤维细胞中存在，其转化原理可在多种细胞中得到验证，即较高的可重复性。另外，通过该环路进行实验分析的程序较成熟，可操作性强。\r\n        </p>    \r\n<div class=\"ding\"></div>\r\n        <h1 class=\"title\">实验操作</h1>\r\n        <p class=\"pagraph\">\r\n         ①本实验所需的载体、dCas系统的原理与具体通路基因搭建均有详细来源，方便实验人员构建本实验所需的基因部件\r\n        </p>  \r\n        <p class=\"pagraph\">\r\n         ②验证新生多巴胺能神经元的免疫细胞化学、HPLC量化法及各项行为学检测均有详细的操作步骤与较简洁清晰的实验操作流程参考\r\n        </p>\r\n        <p class=\"pagraph\">\r\n         ③实验结果在微观层面可通过染色进行观测，宏观层面则可通过行为学测试和纹状体的解剖大体观察进行分析，在多层面上印证实验结果，使得该通路的观测的科学性得以增强\r\n        </p>\r\n        <p class=\"pagraph\">\r\n         ④经文献研究，该通路的转化效率不会过高（10%），因而难以出现实验过程中星形胶质细胞转化过多而影响其他脑区功能的现象，因而实验对象可在稳定的状态下接受各项操作\r\n        </p>    \r\n<div id=\"des4\" class=\"ding\"></div>\r\n        <h1 class=\"topic\">模型结果</h1>\r\n        <div class=\"ding\"></div>\r\n        <p class=\"pagraph\">\r\n         我们的模型主要针对hsp70通路进行验证。该模型考虑了hsp70和α-syn结合以及酶促反应的动力学。模型中的参数主要来自已发表的论文以及BRENDA等数据库。根据建模结果，hsp70的过表达可以有效降低α-syn蛋白的聚集， 且能够在短时间内发生效应。\r\n        </p>    \r\n<div id=\"des5\" class=\"ding\"></div>\r\n         <h1 class=\"topic\">AAV基因治疗现存的挑战</h1>\r\n        <div class=\"ding\"></div>\r\n        <h1 class=\"title\">抗体中和风险</h1>\r\n        <p class=\"pagraph\">\r\n         与脑实质内（IPa）给药、鞘内（IT）或脑室内（ICV）给药不同，AAV载体的静脉内给药（IV）具有将基因非侵入性地转移至整个中枢神经系统（CNS）并且更均匀分布的潜力。迄今为止，IV给药在I型SMA婴儿中是成功的，其中非常适度水平的转基因表达可能足以获得治疗益处。\r\n        </p>    \r\n        <p class=\"pagraph\">\r\n         但IV注射使AAV暴露于预先感染天然AAV的受试者，具有抗体中和的潜在风险，估计有90％的成年人接触过AAV，这可能对AAV载体应用产生深远的负面影响。目前，通过衣壳工程修饰衣壳表面表位可以更好地逃避中和抗体的识别。对于年龄较大的儿童和成人进行CNS疾病的给药，还需要考虑所需的高剂量。 \r\n        </p>   \r\n\r\n        <div class=\"ding\"></div>\r\n        <h1 class=\"title\">安全风险</h1>\r\n        <p class=\"pagraph\">\r\n         治疗性转基因在非靶组织中的表达或在靶细胞内过表达，均有可能导致基因置换的潜在毒性作用。例如，MECP2（编码甲基-CpG结合蛋白2）中的突变导致女性的Rett综合征，但该基因的重复也导致男孩的智力发育障碍。小鼠模型中的MeCP2过表达导致行为异常、学习障碍和癫痫发作。因此，对Rett综合征的成功治疗需要转基因表达保持在非常狭窄的治疗窗内。\r\n        </p>   \r\n        <p class=\"pagraph\">\r\n         与基因沉默相关的潜在毒性作用还将取决于内源蛋白的功能、干预的时间和miRNA的表达水平以及由此产生的沉默。尽管AAV基因治疗在迄今为止的一系列疾病中已被很好地耐受，但是调节表达仍然是靶标和疾病选择的重要安全考虑因素。另外，在接受基因治疗后免疫应答和转基因持久表达可能妨碍受试者参与其他临床试验。因此，具有高度未满足的临床需求和符合风险效益的疾病更加适合使用AAV基因治疗。\r\n\r\n        </p>  \r\n\r\n        <div class=\"ding\"></div>\r\n        <h1 class=\"title\">生产成本和效率</h1>\r\n        <p class=\"pagraph\">\r\n         用于治疗神经疾病的成功的AAV基因疗法需要一个生产平台，该生产平台可重复地提供在多个批次中具有足够和相当质量的载体，并且可用于晚期临床开发和商业化。哺乳动物细胞（如HEK293细胞）中的传统生产系统可以产生高质量载体，但产量有限。相比之下，使用杆状病毒-Sf9昆虫细胞生产AAV载体已被证明可将载体产量提高约10倍至100倍。然而，对于一些衣壳，昆虫细胞产生的载体的效力可能低于哺乳动物细胞中产生的载体，但这可以通过分子工程成功克服。\r\n        </p>        \r\n        <p class=\"pagraph\">\r\n          对于需要有限量载体的CNS应用，例如脑实质内给予的AAV载体，使用哺乳动物系统可能就足够了。然而，对于静脉内（IV）和鞘内（IT）给予的AAV载体，哺乳动物系统提供临床开发所需的量都是一个重要的挑战，更不用说扩大到商业化。目前，可以扩展以满足这些需求的AAV载体生产系统包括杆状病毒-Sf9系统、基于重组HSV的系统和腺病毒-HeLa细胞系统。\r\n        </p> \r\n\r\n      </div>\r\n      <div class=\"ding\"></div>\r\n      <div class=\"ding\"></div>\r\n      <div class=\"ding\"></div>\r\n    </div>\r\n    <div id=\"lef\" class=\"leftP\">\r\n      <ul class=\"Shell\">\r\n        <li><a href=\"#top\">Overview</a></li>\r\n        <li><a href=\"#des1\">AAV应用前景</a></li>\r\n        <li><a href=\"#des2\"> α-syn通路的可行性</a></li>\r\n        <li><a href=\"#des3\">PTB通路的可行性</a></li>\r\n        <li><a href=\"#des4\">模型结果</a></li>\r\n        <li><a href=\"#des5\">AAV基因治疗现存的挑战</a></li>\r\n      </ul>\r\n    </div>\r\n  </div>\r\n</template>\r\n<script>\r\nexport default {\r\n  return() {},\r\n  mounted() {\r\n    let lef = document.getElementById(\"lef\");\r\n\r\n    function addEvent(obj, type, fn) {\r\n      undefined;\r\n      if (obj.attachEvent) {\r\n        obj.attachEvent(\"on\" + type, function () {\r\n          undefined;\r\n          fn.call(obj);\r\n        });\r\n      } else {\r\n        undefined;\r\n        obj.addEventListener(type, fn, false);\r\n      }\r\n    }\r\n\r\n    addEvent(window, \"scroll\", function () {\r\n      undefined;\r\n      if (window.pageYOffset >= 455) {\r\n        lef.classList.add(\"stick\");\r\n      } else {\r\n        lef.classList.remove(\"stick\");\r\n      }\r\n    });\r\n  },\r\n};\r\n</script>\r\n<style scoped>\r\n.tu{\r\n  margin-right: auto;\r\n  margin-left: auto;\r\n  display: block;\r\n  margin-top: 20px;\r\n  width: 600px;\r\n  height: auto;\r\n  border-radius: 30px;\r\n  border: #1d5a56;\r\n  background-size: 5px;\r\n}\r\n.topic {\r\n  color: #1d3f5a;\r\n  font-size: 60px;\r\n  text-align: center;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  font-family: \"Arial\";\r\n  letter-spacing: 15px;\r\n}\r\n#lef.stick {\r\n  opacity: 0.7;\r\n  transition: all 1s;\r\n}\r\n.Shell li a{\r\n  display: block;\r\n  width: 260px;\r\n}\r\n.leftP {\r\n  position: fixed;\r\n  left: 10px;\r\n  top: 30%;\r\n  opacity: 0;\r\n  height: 56vh;\r\n  width: 280px;\r\n  background-color: #3c6b6d;\r\n  border-radius: 20px;\r\n}\r\n.Shell {\r\n  margin: 0;\r\n  padding: 0;\r\n  color: inherit;\r\n  background-color: inherit;\r\n}\r\n.Shell:first-child {\r\n  margin-top: 4vh;\r\n}\r\n.Shell li {\r\n  list-style: none;\r\n  height: 8vh;\r\n  line-height: 8vh;\r\n  padding-left: 20px;\r\n  color: inherit;\r\n  background-color: inherit;\r\n}\r\n.Shell li:hover {\r\n  /* transform:scale(1,1.2); */\r\n  background-color: #89cfd1;\r\n  border-radius: 10px;\r\n  color: #253f17;\r\n  transition: all 0.6s;\r\n}\r\n.Shell li:hover a {\r\n  color: white;\r\n}\r\n.Shell li a {\r\n  text-decoration: none;\r\n  color: #8ad6bd;\r\n}\r\n.ding {\r\n  height: 96px;\r\n}\r\n.top img {\r\n  float: right;\r\n  line-height: 60px;\r\n}\r\n.top img:hover {\r\n  transform: scale(1.3);\r\n  transition: all 0.4s;\r\n}\r\n.back {\r\n  width: 100%;\r\n  background-color: #c5ddd9;\r\n}\r\n.bg .im {\r\n  background-attachment: fixed;\r\n  width: 100%;\r\n  height: 100vh;\r\n  background-size: cover;\r\n  background-image: url(../assets/homeBanner.gif);\r\n}\r\n.content {\r\n  background-color: inherit;\r\n  width: 900px;\r\n  margin: 0 auto;\r\n  align-content: center;\r\n  padding: 20px;\r\n}\r\n.title {\r\n  color: #1d5a56;\r\n  font-family: Comic Sans MS;\r\n  margin: 10px;\r\n  border-bottom: solid 2px #7faba0;\r\n  padding-bottom: 0.6em;\r\n}\r\n.title2 {\r\n  color: #1d5a56;\r\n  font-family: Comic Sans MS;\r\n  margin: 10px;\r\n  margin-top: 50px;\r\n  border-bottom: solid 2px #a9ccc3;\r\n  padding-bottom: 0.6em;\r\n}\r\n.title:first-letter {\r\n  font-size: 50px;\r\n  text-shadow: 2px 2px 5px #444;\r\n}\r\n.title2:first-letter {\r\n  font-size: 50px;\r\n  text-shadow: 2px 2px 5px #444;\r\n}\r\n.pagraph {\r\n  font-family: \"Century Gothic\";\r\n  letter-spacing: 0.05em !important;\r\n  text-indent: 2em;\r\n  display: block;\r\n  transition: all 2s;\r\n  margin-left: 40px;\r\n  letter-spacing: 1.3px;\r\n  line-height: 1.8;\r\n  word-spacing: 3px;\r\n  color: #386f6c;\r\n}\r\n</style>\r\n","import mod from \"-!../../node_modules/cache-loader/dist/cjs.js??ref--13-0!../../node_modules/thread-loader/dist/cjs.js!../../node_modules/babel-loader/lib/index.js!../../node_modules/cache-loader/dist/cjs.js??ref--1-0!../../node_modules/vue-loader/lib/index.js??vue-loader-options!./proof.vue?vue&type=script&lang=js&\"; export default mod; export * from \"-!../../node_modules/cache-loader/dist/cjs.js??ref--13-0!../../node_modules/thread-loader/dist/cjs.js!../../node_modules/babel-loader/lib/index.js!../../node_modules/cache-loader/dist/cjs.js??ref--1-0!../../node_modules/vue-loader/lib/index.js??vue-loader-options!./proof.vue?vue&type=script&lang=js&\"","import { render, staticRenderFns } from \"./proof.vue?vue&type=template&id=01b4be6a&scoped=true&\"\nimport script from \"./proof.vue?vue&type=script&lang=js&\"\nexport * from \"./proof.vue?vue&type=script&lang=js&\"\nimport style0 from \"./proof.vue?vue&type=style&index=0&id=01b4be6a&scoped=true&lang=css&\"\n\n\n/* normalize component */\nimport normalizer from \"!../../node_modules/vue-loader/lib/runtime/componentNormalizer.js\"\nvar component = normalizer(\n  script,\n  render,\n  staticRenderFns,\n  false,\n  null,\n  \"01b4be6a\",\n  null\n  \n)\n\nexport default component.exports","var render = function () {var _vm=this;var _h=_vm.$createElement;var _c=_vm._self._c||_h;return _vm._m(0)}\nvar staticRenderFns = [function () {var _vm=this;var _h=_vm.$createElement;var _c=_vm._self._c||_h;return _c('div',[_c('div',{staticClass:\"bg\"},[_c('div',{staticClass:\"im\",attrs:{\"id\":\"bg\"}})]),_c('div',{staticClass:\"back\"},[_c('div',{staticClass:\"content\"},[_c('div',{staticClass:\"ding\",attrs:{\"id\":\"top\"}}),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 我们的设计实现的目标有两个，一是通过降低α-syn蛋白的表达和诱导自噬，减少由于α-syn的聚集对黑质多巴胺能神经元造成的毒性；二是通过诱导神经胶质细胞转化为多巴胺能神经元，补充死亡的神经元。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 从实验上具体来说，我们构建了如下parts： \")]),_c('p',{staticClass:\"pagraph\"},[_c('ul',[_c('li',[_vm._v(\"人类野生型SNCA基因的编码序列 \")]),_c('li',[_vm._v(\"人类突变型SNCA基因的编码序列 \")]),_c('li',[_vm._v(\"人类Hsp70基因的编码序列 \")]),_c('li',[_vm._v(\"靶向沉默SNCA基因的shRNA序列 \")]),_c('li',[_vm._v(\"基于CRISPReader的与门逻辑电路 \")]),_c('li',[_vm._v(\"使用甲基化沉默PTB基因表达的dCas9系统 \")])])]),_c('div',{staticClass:\"ding\",attrs:{\"id\":\"des1\"}}),_c('h1',{staticClass:\"topic\"},[_vm._v(\"初步实验设计\")]),_c('div',{staticClass:\"ding\"}),_c('h1',{staticClass:\"title\"},[_vm._v(\"α-syn通路实验设计\")]),_c('p',{staticClass:\"pagraph\"},[_c('ol',[_c('li',[_vm._v(\" 分别将Hsp70过表达质粒、野生型SNCA:EGFP融合蛋白质粒、突变型SNCA:EGFP融合蛋白质粒转染进VERO细胞系中，并培养一段时间。\")]),_c('li',[_vm._v(\" ②WB验证Hsp70过表达成功，并观察野生型α-syn蛋白的细胞定位和聚集情况以及突变型α-syn蛋白的细胞定位和聚集情况。 \")]),_c('li',[_vm._v(\" ③在表达有突变型α-syn蛋白的细胞系中分别过表达Hsp70和SNCA shRNA，与对照对比观察突变型α-syn蛋白的分布情况和聚集情况。同时可以在过表达Hsp70的细胞中进行自噬信号的检测，验证Hsp70能提高α-syn的自噬。 \")]),_c('li',[_vm._v(\" ④以AAV-CAP-B10为底盘生物设计最终的质粒，并包装病毒载体。在不同种类的细胞中观察其侵染效率和侵染情况，验证特异性（有条件的话这一步最好使用合适的报告基因作为最终的效应基因以较好的量化差异，但是会导致要多包装一次病毒）和最终的治疗效果。同时检测AAV侵染后神经细胞的凋亡信号，验证侵染后不会对神经元的活动造成损伤。 \")])])]),_c('div',{staticClass:\"ding\"}),_c('h1',{staticClass:\"title\"},[_vm._v(\"PTB通路实验设计\")]),_c('p',{staticClass:\"pagraph\"},[_c('ol',[_c('li',[_vm._v(\" 将dCas9工具导入体外培养星形胶质细胞中，通过RT-qPCR验证PTB的沉默。 \")]),_c('li',[_vm._v(\" 将hU6-sgRNA-GFAP-dCas-DNMT3A-WPRE质粒包装成病毒，侵染星形胶质细胞，观察星形胶质细胞 \")]),_c('li',[_vm._v(\" 计算被诱导分化为多巴胺能神经元的概率以及分化出的神经元的电生理等一系列生理特性。 \")]),_c('li',[_vm._v(\" 免疫细胞化学 \")])])]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 在载玻片上生长的培养细胞在室温下用 4% 多聚甲醛（PFA，Affymetrix）固定 15 分钟，然后在冰上用 PBS 中的 0.1% Triton X-100 渗透 15 分钟。用 PBS 洗涤两次后，在室温下将细胞在含有 3% BSA 的 PBS 中封闭 1 小时。固定细胞与一抗一起孵育。 在 4 °C 下在含有 3% BSA 的 PBS 中过夜。用 PBS 洗涤两次后，将细胞与与 Alexa Fluor 488、Alexa Fluor 546、Alexa Fluor 594 或 Alexa Fluor 647（1:500，Molecular Probes）缀合的二抗孵育 1 小时。在室温下将 DAPI（300 nM 在 PBS 中）应用于细胞 20 分钟以标记细胞核。用 PBS 清洗 3 次后，将 Fluoromount-G 封固剂涂在载玻片上，并在 Olympus FluoView FV1000 下检查和记录图像。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 预期结果：经过免疫染色，发现中脑来源的星形胶质细胞产生TH+神经元的比例较其他脑区更高（5倍），且具有一定的转化效率（10%） \")]),_c('div',{staticClass:\"ding\",attrs:{\"id\":\"des2\"}}),_c('h1',{staticClass:\"topic\"},[_vm._v(\"实验流程\")]),_c('p',{staticClass:\"pagraph\"},[_c('ol',[_c('li',[_vm._v(\" 培养星形胶质细胞、多巴胺能神经元（可能不太能实现？不知道能不能构建有α-syn聚集的多巴胺能神经元模型） \")]),_c('li',[_vm._v(\" 构建质粒（SNCA shRNA, Hsp70基因,hU6-sgRNA-GFAP-dCas-DNMT3A-WPRE,W-SCNA:GFP,m-SCNA:GFP） \")]),_c('li',[_vm._v(\" 验证质粒成功构建（琼脂糖凝胶电泳；转化进大肠杆菌，摇菌+送公司测序） \")]),_c('li',[_vm._v(\"提取质粒，转化进细胞，培养一段时间\")]),_c('li',[_vm._v(\"qRT-PCR检测SNCA mRNA的量（转染了SNCA shRNA质粒/转染空质粒 对照） 质粒转染神经元/星胶/其他细胞，验证启动子特异性（表达水平差异）\")])])])]),_c('div',{staticClass:\"ding\"}),_c('div',{staticClass:\"ding\"}),_c('div',{staticClass:\"ding\"})]),_c('div',{staticClass:\"leftP\",attrs:{\"id\":\"lef\"}},[_c('ul',{staticClass:\"Shell\"},[_c('li',[_c('a',{attrs:{\"href\":\"#top\"}},[_vm._v(\"TOP\")])]),_c('li',[_c('a',{attrs:{\"href\":\"#des1\"}},[_vm._v(\"初步实验设计\")])]),_c('li',[_c('a',{attrs:{\"href\":\"#des2\"}},[_vm._v(\"实验流程\")])])])])])}]\n\nexport { render, staticRenderFns }","<template>\r\n  <div>\r\n    <div class=\"bg\"><div class=\"im\" id=\"bg\"></div></div>\r\n    <div class=\"back\">\r\n      <div class=\"content\">\r\n        \r\n\r\n        <div id=\"top\" class=\"ding\"></div>\r\n        <p class=\"pagraph\">\r\n          我们的设计实现的目标有两个，一是通过降低α-syn蛋白的表达和诱导自噬，减少由于α-syn的聚集对黑质多巴胺能神经元造成的毒性；二是通过诱导神经胶质细胞转化为多巴胺能神经元，补充死亡的神经元。\r\n        </p>\r\n       <p class=\"pagraph\">\r\n从实验上具体来说，我们构建了如下parts：\r\n\r\n    </p>\r\n    <p class=\"pagraph\">\r\n<ul>\r\n  <li>人类野生型SNCA基因的编码序列\r\n</li>\r\n  <li>人类突变型SNCA基因的编码序列\r\n</li>\r\n  <li>人类Hsp70基因的编码序列\r\n</li>\r\n  <li>靶向沉默SNCA基因的shRNA序列\r\n</li>\r\n  <li>基于CRISPReader的与门逻辑电路\r\n</li>\r\n  <li>使用甲基化沉默PTB基因表达的dCas9系统\r\n</li>\r\n</ul>\r\n    </p>\r\n\r\n\r\n        <div id=\"des1\" class=\"ding\"></div>\r\n        <h1 class=\"topic\">初步实验设计</h1>\r\n        <div class=\"ding\"></div>\r\n        <h1 class=\"title\">α-syn通路实验设计</h1>\r\n        <p class=\"pagraph\">\r\n            <ol>\r\n                <li>\r\n                    分别将Hsp70过表达质粒、野生型SNCA:EGFP融合蛋白质粒、突变型SNCA:EGFP融合蛋白质粒转染进VERO细胞系中，并培养一段时间。</li>\r\n                <li>\r\n                    ②WB验证Hsp70过表达成功，并观察野生型α-syn蛋白的细胞定位和聚集情况以及突变型α-syn蛋白的细胞定位和聚集情况。\r\n                </li>\r\n                <li>\r\n                    ③在表达有突变型α-syn蛋白的细胞系中分别过表达Hsp70和SNCA shRNA，与对照对比观察突变型α-syn蛋白的分布情况和聚集情况。同时可以在过表达Hsp70的细胞中进行自噬信号的检测，验证Hsp70能提高α-syn的自噬。\r\n                </li>\r\n                <li>\r\n                    ④以AAV-CAP-B10为底盘生物设计最终的质粒，并包装病毒载体。在不同种类的细胞中观察其侵染效率和侵染情况，验证特异性（有条件的话这一步最好使用合适的报告基因作为最终的效应基因以较好的量化差异，但是会导致要多包装一次病毒）和最终的治疗效果。同时检测AAV侵染后神经细胞的凋亡信号，验证侵染后不会对神经元的活动造成损伤。\r\n                </li>\r\n            </ol>\r\n        </p>\r\n        \r\n        <div class=\"ding\"></div>\r\n        <h1 class=\"title\">PTB通路实验设计</h1>\r\n        <p class=\"pagraph\">\r\n         <ol>\r\n             <li>\r\n                 将dCas9工具导入体外培养星形胶质细胞中，通过RT-qPCR验证PTB的沉默。\r\n             </li>\r\n             <li>\r\n                 将hU6-sgRNA-GFAP-dCas-DNMT3A-WPRE质粒包装成病毒，侵染星形胶质细胞，观察星形胶质细胞\r\n             </li>\r\n             <li>\r\n                 计算被诱导分化为多巴胺能神经元的概率以及分化出的神经元的电生理等一系列生理特性。\r\n             </li>\r\n             <li>\r\n                 免疫细胞化学\r\n             </li>\r\n         </ol>\r\n        </p> \r\n        <p class=\"pagraph\">\r\n         在载玻片上生长的培养细胞在室温下用 4% 多聚甲醛（PFA，Affymetrix）固定 15 分钟，然后在冰上用 PBS 中的 0.1% Triton X-100 渗透 15 分钟。用 PBS 洗涤两次后，在室温下将细胞在含有 3% BSA 的 PBS 中封闭 1 小时。固定细胞与一抗一起孵育。 在 4 °C 下在含有 3% BSA 的 PBS 中过夜。用 PBS 洗涤两次后，将细胞与与 Alexa Fluor 488、Alexa Fluor 546、Alexa Fluor 594 或 Alexa Fluor 647（1:500，Molecular Probes）缀合的二抗孵育 1 小时。在室温下将 DAPI（300 nM 在 PBS 中）应用于细胞 20 分钟以标记细胞核。用 PBS 清洗 3 次后，将 Fluoromount-G 封固剂涂在载玻片上，并在 Olympus FluoView FV1000 下检查和记录图像。\r\n        </p> \r\n<p class=\"pagraph\">\r\n         预期结果：经过免疫染色，发现中脑来源的星形胶质细胞产生TH+神经元的比例较其他脑区更高（5倍），且具有一定的转化效率（10%）\r\n        </p>  \r\n\r\n\r\n\r\n        <div id=\"des2\" class=\"ding\"></div>\r\n         <h1 class=\"topic\">实验流程</h1>\r\n        <p class=\"pagraph\">\r\n         <ol>\r\n             <li>\r\n                 培养星形胶质细胞、多巴胺能神经元（可能不太能实现？不知道能不能构建有α-syn聚集的多巴胺能神经元模型）\r\n             </li>\r\n             <li>\r\n                 构建质粒（SNCA shRNA, Hsp70基因,hU6-sgRNA-GFAP-dCas-DNMT3A-WPRE,W-SCNA:GFP,m-SCNA:GFP）\r\n             </li>\r\n             <li>\r\n                 验证质粒成功构建（琼脂糖凝胶电泳；转化进大肠杆菌，摇菌+送公司测序）\r\n             </li>\r\n             <li>提取质粒，转化进细胞，培养一段时间</li>\r\n             <li>qRT-PCR检测SNCA mRNA的量（转染了SNCA shRNA质粒/转染空质粒 对照）\r\n质粒转染神经元/星胶/其他细胞，验证启动子特异性（表达水平差异）</li>\r\n         </ol>\r\n        </p> \r\n      </div>\r\n      <div class=\"ding\"></div>\r\n      <div class=\"ding\"></div>\r\n      <div class=\"ding\"></div>\r\n    </div>\r\n    <div id=\"lef\" class=\"leftP\">\r\n      <ul class=\"Shell\">\r\n        <li><a href=\"#top\">TOP</a></li>\r\n        <li><a href=\"#des1\">初步实验设计</a></li>\r\n        <li><a href=\"#des2\">实验流程</a></li>\r\n      </ul>\r\n    </div>\r\n  </div>\r\n</template>\r\n<script>\r\nexport default {\r\n  return() {},\r\n  mounted() {\r\n    let lef = document.getElementById(\"lef\");\r\n\r\n    function addEvent(obj, type, fn) {\r\n      undefined;\r\n      if (obj.attachEvent) {\r\n        obj.attachEvent(\"on\" + type, function () {\r\n          undefined;\r\n          fn.call(obj);\r\n        });\r\n      } else {\r\n        undefined;\r\n        obj.addEventListener(type, fn, false);\r\n      }\r\n    }\r\n\r\n    addEvent(window, \"scroll\", function () {\r\n      undefined;\r\n      if (window.pageYOffset >= 455) {\r\n        lef.classList.add(\"stick\");\r\n      } else {\r\n        lef.classList.remove(\"stick\");\r\n      }\r\n    });\r\n  },\r\n};\r\n</script>\r\n<style scoped>\r\n.p li{\r\n  text-indent: 0;\r\n}\r\n.tu{\r\n  margin-right: auto;\r\n  margin-left: auto;\r\n  display: block;\r\n  margin-top: 20px;\r\n  width: 600px;\r\n  height: auto;\r\n  border-radius: 30px;\r\n  border: #1d5a56;\r\n  background-size: 5px;\r\n}\r\n.topic {\r\n  color: #1d3f5a;\r\n  font-size: 60px;\r\n  text-align: center;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  font-family: \"Arial\";\r\n  letter-spacing: 15px;\r\n}\r\n#lef.stick {\r\n  opacity: 0.7;\r\n  transition: all 1s;\r\n}\r\n.Shell li a{\r\n  display: block;\r\n  width: 150px;\r\n}\r\n.showBox .box .p {\r\n  display: none;\r\n  margin-bottom:20px;\r\n  margin-top:20px;\r\n}\r\n.leftP {\r\n  position: fixed;\r\n  left: 10px;\r\n  top: 30%;\r\n  opacity: 0;\r\n  height: 32vh;\r\n  width: 200px;\r\n  background-color: #3c6b6d;\r\n  border-radius: 20px;\r\n}\r\n.Shell {\r\n  margin: 0;\r\n  padding: 0;\r\n  color: inherit;\r\n  background-color: inherit;\r\n}\r\n.Shell:first-child {\r\n  margin-top: 4vh;\r\n}\r\n.Shell li {\r\n  list-style: none;\r\n  height: 8vh;\r\n  line-height: 8vh;\r\n  padding-left: 20px;\r\n  color: inherit;\r\n  background-color: inherit;\r\n}\r\n.Shell li:hover {\r\n  /* transform:scale(1,1.2); */\r\n  background-color: #89cfd1;\r\n  border-radius: 10px;\r\n  color: #253f17;\r\n  transition: all 0.6s;\r\n}\r\n.Shell li:hover a {\r\n  color: white;\r\n}\r\n.Shell li a {\r\n  text-decoration: none;\r\n  color: #8ad6bd;\r\n}\r\n.ding {\r\n  height: 96px;\r\n}\r\n.top img {\r\n  float: right;\r\n  line-height: 60px;\r\n}\r\n.top img:hover {\r\n  transform: scale(1.3);\r\n  transition: all 0.4s;\r\n}\r\n.back {\r\n  width: 100%;\r\n  background-color: #c5ddd9;\r\n}\r\n.bg .im {\r\n  background-attachment: fixed;\r\n  width: 100%;\r\n  height: 100vh;\r\n  background-size: cover;\r\n  background-image: url(../assets/homeBanner.gif);\r\n}\r\n.content {\r\n  background-color: inherit;\r\n  width: 900px;\r\n  margin: 0 auto;\r\n  align-content: center;\r\n  padding: 20px;\r\n}\r\n.title {\r\n  color: #1d5a56;\r\n  font-family: Comic Sans MS;\r\n  margin: 10px;\r\n  border-bottom: solid 2px #7faba0;\r\n  padding-bottom: 0.6em;\r\n}\r\n.title2 {\r\n  color: #1d5a56;\r\n  font-family: Comic Sans MS;\r\n  margin: 10px;\r\n  margin-top: 50px;\r\n  border-bottom: solid 2px #a9ccc3;\r\n  padding-bottom: 0.8em;\r\n}\r\n.title:first-letter {\r\n  font-size: 50px;\r\n  text-shadow: 2px 2px 5px #444;\r\n}\r\n.title2:first-letter {\r\n  font-size: 50px;\r\n  text-shadow: 2px 2px 5px #444;\r\n}\r\n.pagraph ol li{\r\n    text-indent: 0;\r\n}\r\n.pagraph {\r\n  font-family: \"Century Gothic\";\r\n  letter-spacing: 0.05em !important;\r\n  text-indent: 2em;\r\n  display: block;\r\n  transition: all 2s;\r\n  margin-left: 40px;\r\n  letter-spacing: 1.3px;\r\n  line-height: 1.8;\r\n  word-spacing: 3px;\r\n  color: #386f6c;\r\n}\r\n</style>\r\n","import mod from \"-!../../node_modules/cache-loader/dist/cjs.js??ref--13-0!../../node_modules/thread-loader/dist/cjs.js!../../node_modules/babel-loader/lib/index.js!../../node_modules/cache-loader/dist/cjs.js??ref--1-0!../../node_modules/vue-loader/lib/index.js??vue-loader-options!./experiment.vue?vue&type=script&lang=js&\"; export default mod; export * from \"-!../../node_modules/cache-loader/dist/cjs.js??ref--13-0!../../node_modules/thread-loader/dist/cjs.js!../../node_modules/babel-loader/lib/index.js!../../node_modules/cache-loader/dist/cjs.js??ref--1-0!../../node_modules/vue-loader/lib/index.js??vue-loader-options!./experiment.vue?vue&type=script&lang=js&\"","import { render, staticRenderFns } from \"./experiment.vue?vue&type=template&id=375954a2&scoped=true&\"\nimport script from \"./experiment.vue?vue&type=script&lang=js&\"\nexport * from \"./experiment.vue?vue&type=script&lang=js&\"\nimport style0 from \"./experiment.vue?vue&type=style&index=0&id=375954a2&scoped=true&lang=css&\"\n\n\n/* normalize component */\nimport normalizer from \"!../../node_modules/vue-loader/lib/runtime/componentNormalizer.js\"\nvar component = normalizer(\n  script,\n  render,\n  staticRenderFns,\n  false,\n  null,\n  \"375954a2\",\n  null\n  \n)\n\nexport default component.exports","var render = function () {var _vm=this;var _h=_vm.$createElement;var _c=_vm._self._c||_h;return _vm._m(0)}\nvar staticRenderFns = [function () {var _vm=this;var _h=_vm.$createElement;var _c=_vm._self._c||_h;return _c('div',[_c('div',{staticClass:\"bg\"},[_c('div',{staticClass:\"im\",attrs:{\"id\":\"bg\"}})]),_c('div',{staticClass:\"back\"},[_c('div',{staticClass:\"content\"},[_c('div',{staticClass:\"ding\",attrs:{\"id\":\"top\"}}),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 我们的项目 TheraParkin 意在解决神经退行性疾病帕金森的治疗问题。TheraParkin作为一种药物，需要充分保证安全性和有效性，所以我们在病毒基因层面作出了多项安全保障设计，具体详见“项目安全设计”模块。另外，我们考虑到设计最终会用于临床实施，需要兼顾实施过程中的安全问题，这将在我们的“实施安全设计”部分进行讨论。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 我们考虑到，TheraParkin在使用过程中可能对人体环境造成危害，我们针对项目具体讨论了这一情况的可能性，这将在“人体、环境安全”显示。同时，实验过程中保证规范的生物安全也非常重要，在“生物安全”部分我们将展示我们为保证生物安全在两用与实验室安全方面做出的努力。 \")]),_c('div',{staticClass:\"ding\",attrs:{\"id\":\"des1\"}}),_c('h1',{staticClass:\"topic\"},[_vm._v(\" 项目安全设计\")]),_c('div',{staticClass:\"ding\"}),_c('h1',{staticClass:\"title\"},[_vm._v(\"底盘生物与病毒衣壳\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 我们选择了腺相关病毒（AAV）作为底盘生物，它是目前免疫治疗和基因治疗研究中广泛使用的。腺相关病毒是RG1（最安全级别）的基因治疗载体，基本不具有潜在致病性，不能自我复制。现行AAV相关疗法中，目前已有3个基于AAV的基因治疗产品获批上市，上百个在研疗法已进入临床开发阶段，安全性具有一定保障。根据项目需求，我们选用了两种载体——AAV-CAP-B10和rAAV6。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 我们在载体的基础上对其外壳蛋白进行设计，以便具有更高的组织特异性。使用脑组织特异性的AAV衣壳蛋白AAV CAP-B10，能够穿透血脑屏障，特异性表达于中脑多巴胺能神经元；rAAV6具有穿越血脑屏障，高特异性靶向星形胶质细胞的能力，通过外壳蛋白设计，可以实现脑组织特异性。 \")]),_c('img',{staticClass:\"tu\",attrs:{\"src\":require(\"../assets/sa2-1.png\"),\"alt\":\"no pic\"}}),_c('img',{staticClass:\"tu\",attrs:{\"src\":require(\"../assets/sa2-2.png\"),\"alt\":\"no pic\"}}),_c('div',{staticClass:\"ding\"}),_c('h1',{staticClass:\"title\"},[_vm._v(\"特异性启动子与转录因子\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 为了减少AAV侵染过程中带来的风险泄露问题，我们对两条线路都有独特的特异性转录因子或启动子设计。在α-syn蛋白通路中，我们选择了两个特异性表达在多巴胺能神经元中的转录因子PITX3和FOXA2，来驱动“与门”线路的表达；在PTB途径中，我们选择了星形胶质细胞的特异性启动子GFAP。这两类因子对于靶细胞和非靶细胞来说有足够的特异性，从而使得基因的表达量维持一个安全的状态。 \")]),_c('div',{staticClass:\"ding\"}),_c('h1',{staticClass:\"title\"},[_vm._v(\"给药方式\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 我们的项目采用静脉注射（IV）的方式进行给药。迄今为止的研究表明AAV载体的静脉注射方式具有将基因非侵入性地转移并且更均匀分布的潜力，适度水平的转基因表达具有治疗方面的益处。但是，即使AAV已经具有较低的免疫原性，由于IV注射会使AAV暴露于预先感染天然AAV的受试者，AAV仍具有抗体中和的潜在风险。基于此，我们在腺相关病毒基因组中插入TLR9i（短单链DNA寡核苷酸序列），对AAV实现“伪装”作用，从而更好地逃避中和抗体的识别，降低免疫原性，提高项目的安全性。 \")]),_c('img',{staticClass:\"tu\",attrs:{\"src\":require(\"../assets/sa2-3.png\"),\"alt\":\"no pic\"}}),_c('div',{staticClass:\"ding\",attrs:{\"id\":\"des2\"}}),_c('h1',{staticClass:\"topic\"},[_vm._v(\"实施安全设计\")]),_c('img',{staticClass:\"tu\",attrs:{\"src\":require(\"../assets/sa3-1.png\"),\"alt\":\"no pic\"}}),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 制造：优化生产工艺，获得高纯度载体 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 运输：使用冰袋运载，减少泄露风险 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 使用：接触、信息风险、滥用… \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 处理：使用完的产品残留的正确回收，特定回收处与回收方法 \")]),_c('div',{staticClass:\"ding\",attrs:{\"id\":\"des3\"}}),_c('h1',{staticClass:\"topic\"},[_vm._v(\"人体、环境安全\")]),_c('div',{staticClass:\"ding\"}),_c('h1',{staticClass:\"title\"},[_vm._v(\"基因毒性\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 腺相关病毒(AAV)作为基因治疗载体，在人体中具有低遗传毒性特征，AAV基因组主要以附加体的形式存在于宿主细胞核，基本不引起载体基因组介导的宿主遗传毒性。由于AAV在临床试验中的安全记录和在该领域内的共识，很少有工作专门针对限制基因毒性整合事件的策略。尽管如此，我们也可以通过调节控制盒限制附近基因反式激活的绝缘子元件的设计来减少由于杂散整合引起的遗传毒性效应。 \")]),_c('div',{staticClass:\"ding\"}),_c('h1',{staticClass:\"title\"},[_vm._v(\"载体毒性\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" AAV作为基因载体，首先考虑自身的毒力恢复问题，由于AAV本身并不具有致病性，故在人体环境中较为安全。AAV 病毒的基因组是单链 DNA，在体外环境形成双链并转录翻译外源基因的效率很低，一般采用同时感染辅助病毒（如 Ad5 型腺病毒）或者终浓度 10~50 mM 的丁酸钠等方法提高细胞实验的 AAV 表达量。若采用前者方式提高表达量，需要考虑腺病毒等辅助病毒对人体和环境的风险，这里可以参考iGEM 2021 ZJU-China 团队关于腺病毒的安全讨论。 \")]),_c('div',{staticClass:\"ding\"}),_c('h1',{staticClass:\"title\"},[_vm._v(\"肝脏毒性\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 有研究曾指出，AAV载体给药可能会积累肝脏毒性，原因在于原AAV设计靶向性不高，需要高剂量给药才能达到既定药效。我们的设计从底盘、衣壳设计和启动子设计等方面增强AAV靶向特异性，在低剂量范围内即可呈现效果，能够有效地降低肝脏毒性，保证人体环境的安全。 \")]),_c('div',{staticClass:\"ding\",attrs:{\"id\":\"des4\"}}),_c('h1',{staticClass:\"topic\"},[_vm._v(\"生物安全\")]),_c('div',{staticClass:\"ding\"}),_c('h1',{staticClass:\"title\"},[_vm._v(\"两用性\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" iGEM 重视安全和生物安全，并明确指出团队应管理任何风险。 在这些风险中，iGEM 建议可以通过双重使用实践来管理误用风险。即使是低毒性的设计，也应保证生物技术不能被滥用。在生物安全领域，我们承诺遵守中国现行的相关法律法规。 \")]),_c('p',{staticClass:\"ref\"},[_vm._v(\" 中华人民共和国生物安全法（http://www.gov.cn/xinwen/2020-10/18/content_5552108.htm） \")]),_c('p',{staticClass:\"ref\"},[_vm._v(\" 中华人民共和国药品管理法实施条例（http://www.gov.cn/zhengce/2020-12/26/content_5573533.htm） \")]),_c('p',{staticClass:\"ref\"},[_vm._v(\" 病原微生物实验室生物安全管理规定（http://www.gov.cn/zhengce/2020-12/27/content_5574545.htm） \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 作为一个负责任的团队，我们考虑到如下可能发生生物安全滥用的风险条目：第一，关于AAV载体的剂量问题；第二，环境释放腺相关病毒问题；第三，知识和数据库滥用问题。 \")]),_c('div',{staticClass:\"ding\"}),_c('h1',{staticClass:\"title\"},[_vm._v(\"实验室安全\")]),_c('h3',{staticClass:\"secTitle\"},[_vm._v(\"基本安全\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 根据iGEM比赛的需求，团队成员学习了实验室安全培训，在被允许在实验室进行任何实验之前，完成涵盖所有相关活动、化学品、生物体和其他相关安全信息的一般安全报告的核验工作， 所有获得的生物部分（基因、质粒、菌株）首先在该机构的本地存储库中注册，并在订购前获得批准。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 实验室配备应急洒水器、洗眼器、通风柜等设备，确保我们的安全。 实验室还拥有完善的安全应急设施，满足生物安全一级实验室的安全防护要求。 \")]),_c('div',{staticClass:\"ding\"}),_c('h3',{staticClass:\"secTitle\"},[_vm._v(\"BSL-1\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 我们将在生物安全一级实验室进行实验。我们使用的底盘生物AAV-CAP-B10和rAAV6属于BSL-1，经过安全研究，确认其不会对人类健康或环境造成严重的威胁。在实验室进行工作时，始终有主管或指导员在场。 \")]),_c('div',{staticClass:\"ding\"}),_c('h3',{staticClass:\"secTitle\"},[_vm._v(\"COVID-19\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 为了确保我们团队成员在 COVID-19 方面的安全，我们采取了以下措施： \"),_c('ul',[_c('li',[_vm._v(\"团队成员定时核酸检测，在出现与 COVID-19 相关的症状时及时接受隔离处理。\")]),_c('li',[_vm._v(\"遵循多项卫生规则和清洁措施，例如经常清洁手部、工作场所和厕所。\")]),_c('li',[_vm._v(\"团队成员和其他进入大楼的人员在从一个地方转移到另一个地方时必须戴上口罩。\")]),_c('li',[_vm._v(\"实验室只允许同时有少量学生在场，我们制定了实验时间表，以清楚地显示实验人员的排班情况。 \")])])])]),_c('div',{staticClass:\"ding\"}),_c('div',{staticClass:\"ding\"}),_c('div',{staticClass:\"ding\"})]),_c('div',{staticClass:\"leftP\",attrs:{\"id\":\"lef\"}},[_c('ul',{staticClass:\"Shell\"},[_c('li',[_c('a',{attrs:{\"href\":\"#top\"}},[_vm._v(\" Top\")])]),_c('li',[_c('a',{attrs:{\"href\":\"#des1\"}},[_vm._v(\"项目安全设计\")])]),_c('li',[_c('a',{attrs:{\"href\":\"#des2\"}},[_vm._v(\"实施安全设计\")])]),_c('li',[_c('a',{attrs:{\"href\":\"#des3\"}},[_vm._v(\" 人体、环境安全\")])]),_c('li',[_c('a',{attrs:{\"href\":\"#des4\"}},[_vm._v(\"生物安全\")])])])])])}]\n\nexport { render, staticRenderFns }","<template>\r\n  <div>\r\n    <div class=\"bg\"><div class=\"im\" id=\"bg\"></div></div>\r\n    <div class=\"back\">\r\n      <div class=\"content\">\r\n        \r\n\r\n        <div id=\"top\" class=\"ding\"></div>\r\n        <p class=\"pagraph\">\r\n          我们的项目 TheraParkin 意在解决神经退行性疾病帕金森的治疗问题。TheraParkin作为一种药物，需要充分保证安全性和有效性，所以我们在病毒基因层面作出了多项安全保障设计，具体详见“项目安全设计”模块。另外，我们考虑到设计最终会用于临床实施，需要兼顾实施过程中的安全问题，这将在我们的“实施安全设计”部分进行讨论。\r\n        </p>\r\n        <p class=\"pagraph\">\r\n          我们考虑到，TheraParkin在使用过程中可能对人体环境造成危害，我们针对项目具体讨论了这一情况的可能性，这将在“人体、环境安全”显示。同时，实验过程中保证规范的生物安全也非常重要，在“生物安全”部分我们将展示我们为保证生物安全在两用与实验室安全方面做出的努力。\r\n        </p>\r\n       \r\n\r\n        <div id=\"des1\" class=\"ding\"></div>\r\n        <h1 class=\"topic\"> 项目安全设计</h1>\r\n        <div class=\"ding\"></div>\r\n        <h1 class=\"title\">底盘生物与病毒衣壳</h1>\r\n        <p class=\"pagraph\">\r\n我们选择了腺相关病毒（AAV）作为底盘生物，它是目前免疫治疗和基因治疗研究中广泛使用的。腺相关病毒是RG1（最安全级别）的基因治疗载体，基本不具有潜在致病性，不能自我复制。现行AAV相关疗法中，目前已有3个基于AAV的基因治疗产品获批上市，上百个在研疗法已进入临床开发阶段，安全性具有一定保障。根据项目需求，我们选用了两种载体——AAV-CAP-B10和rAAV6。\r\n        </p>\r\n        <p class=\"pagraph\">\r\n我们在载体的基础上对其外壳蛋白进行设计，以便具有更高的组织特异性。使用脑组织特异性的AAV衣壳蛋白AAV CAP-B10，能够穿透血脑屏障，特异性表达于中脑多巴胺能神经元；rAAV6具有穿越血脑屏障，高特异性靶向星形胶质细胞的能力，通过外壳蛋白设计，可以实现脑组织特异性。\r\n        </p>\r\n        <img src=\"../assets/sa2-1.png\" class=\"tu\" alt=\"no pic\">\r\n         <img src=\"../assets/sa2-2.png\" class=\"tu\" alt=\"no pic\">\r\n        <div class=\"ding\"></div>\r\n        <h1 class=\"title\">特异性启动子与转录因子</h1>\r\n        <p class=\"pagraph\">\r\n         为了减少AAV侵染过程中带来的风险泄露问题，我们对两条线路都有独特的特异性转录因子或启动子设计。在α-syn蛋白通路中，我们选择了两个特异性表达在多巴胺能神经元中的转录因子PITX3和FOXA2，来驱动“与门”线路的表达；在PTB途径中，我们选择了星形胶质细胞的特异性启动子GFAP。这两类因子对于靶细胞和非靶细胞来说有足够的特异性，从而使得基因的表达量维持一个安全的状态。\r\n        </p> \r\n        \r\n      <div class=\"ding\"></div>\r\n        <h1 class=\"title\">给药方式</h1>\r\n        <p class=\"pagraph\">\r\n         我们的项目采用静脉注射（IV）的方式进行给药。迄今为止的研究表明AAV载体的静脉注射方式具有将基因非侵入性地转移并且更均匀分布的潜力，适度水平的转基因表达具有治疗方面的益处。但是，即使AAV已经具有较低的免疫原性，由于IV注射会使AAV暴露于预先感染天然AAV的受试者，AAV仍具有抗体中和的潜在风险。基于此，我们在腺相关病毒基因组中插入TLR9i（短单链DNA寡核苷酸序列），对AAV实现“伪装”作用，从而更好地逃避中和抗体的识别，降低免疫原性，提高项目的安全性。\r\n        </p> \r\n      \r\n        <img src=\"../assets/sa2-3.png\" class=\"tu\" alt=\"no pic\">\r\n        \r\n\r\n        <div id=\"des2\" class=\"ding\"></div>\r\n         <h1 class=\"topic\">实施安全设计</h1>\r\n         <img src=\"../assets/sa3-1.png\" class=\"tu\" alt=\"no pic\">\r\n        <p class=\"pagraph\">\r\n        制造：优化生产工艺，获得高纯度载体\r\n        </p> \r\n        <p class=\"pagraph\">\r\n        运输：使用冰袋运载，减少泄露风险\r\n        </p> \r\n        <p class=\"pagraph\">\r\n        使用：接触、信息风险、滥用…\r\n        </p> \r\n        <p class=\"pagraph\">\r\n        处理：使用完的产品残留的正确回收，特定回收处与回收方法\r\n        </p> \r\n\r\n <div id=\"des3\" class=\"ding\"></div>\r\n         <h1 class=\"topic\">人体、环境安全</h1>\r\n        <div class=\"ding\"></div>\r\n        <h1 class=\"title\">基因毒性</h1>\r\n        <p class=\"pagraph\">\r\n         腺相关病毒(AAV)作为基因治疗载体，在人体中具有低遗传毒性特征，AAV基因组主要以附加体的形式存在于宿主细胞核，基本不引起载体基因组介导的宿主遗传毒性。由于AAV在临床试验中的安全记录和在该领域内的共识，很少有工作专门针对限制基因毒性整合事件的策略。尽管如此，我们也可以通过调节控制盒限制附近基因反式激活的绝缘子元件的设计来减少由于杂散整合引起的遗传毒性效应。\r\n        </p>    \r\n        \r\n\r\n        <div class=\"ding\"></div>\r\n        <h1 class=\"title\">载体毒性</h1>\r\n        <p class=\"pagraph\">\r\n         AAV作为基因载体，首先考虑自身的毒力恢复问题，由于AAV本身并不具有致病性，故在人体环境中较为安全。AAV 病毒的基因组是单链 DNA，在体外环境形成双链并转录翻译外源基因的效率很低，一般采用同时感染辅助病毒（如 Ad5 型腺病毒）或者终浓度 10~50 mM 的丁酸钠等方法提高细胞实验的 AAV 表达量。若采用前者方式提高表达量，需要考虑腺病毒等辅助病毒对人体和环境的风险，这里可以参考iGEM 2021 ZJU-China 团队关于腺病毒的安全讨论。\r\n        </p> \r\n        \r\n        <div class=\"ding\"></div>\r\n        <h1 class=\"title\">肝脏毒性</h1>\r\n        <p class=\"pagraph\">\r\n         有研究曾指出，AAV载体给药可能会积累肝脏毒性，原因在于原AAV设计靶向性不高，需要高剂量给药才能达到既定药效。我们的设计从底盘、衣壳设计和启动子设计等方面增强AAV靶向特异性，在低剂量范围内即可呈现效果，能够有效地降低肝脏毒性，保证人体环境的安全。\r\n        </p>  \r\n\r\n <div id=\"des4\" class=\"ding\"></div>\r\n        <h1 class=\"topic\">生物安全</h1>\r\n        <div class=\"ding\"></div>\r\n        <h1 class=\"title\">两用性</h1>\r\n        <p class=\"pagraph\">\r\n         iGEM 重视安全和生物安全，并明确指出团队应管理任何风险。 在这些风险中，iGEM 建议可以通过双重使用实践来管理误用风险。即使是低毒性的设计，也应保证生物技术不能被滥用。在生物安全领域，我们承诺遵守中国现行的相关法律法规。\r\n        </p>   \r\n        <p class=\"ref\">\r\n            中华人民共和国生物安全法（http://www.gov.cn/xinwen/2020-10/18/content_5552108.htm）\r\n        </p>\r\n        <p class=\"ref\">\r\n            中华人民共和国药品管理法实施条例（http://www.gov.cn/zhengce/2020-12/26/content_5573533.htm）\r\n        </p>\r\n        <p class=\"ref\">\r\n            病原微生物实验室生物安全管理规定（http://www.gov.cn/zhengce/2020-12/27/content_5574545.htm）\r\n        </p>\r\n <p class=\"pagraph\">\r\n         作为一个负责任的团队，我们考虑到如下可能发生生物安全滥用的风险条目：第一，关于AAV载体的剂量问题；第二，环境释放腺相关病毒问题；第三，知识和数据库滥用问题。\r\n        </p>  \r\n\r\n<div class=\"ding\"></div>\r\n        <h1 class=\"title\">实验室安全</h1>\r\n        <h3 class=\"secTitle\">基本安全</h3>\r\n        <p class=\"pagraph\">\r\n         根据iGEM比赛的需求，团队成员学习了实验室安全培训，在被允许在实验室进行任何实验之前，完成涵盖所有相关活动、化学品、生物体和其他相关安全信息的一般安全报告的核验工作， 所有获得的生物部分（基因、质粒、菌株）首先在该机构的本地存储库中注册，并在订购前获得批准。\r\n        </p> \r\n<p class=\"pagraph\">\r\n         实验室配备应急洒水器、洗眼器、通风柜等设备，确保我们的安全。 实验室还拥有完善的安全应急设施，满足生物安全一级实验室的安全防护要求。\r\n        </p>  \r\n\r\n        <div class=\"ding\"></div>\r\n        <h3 class=\"secTitle\">BSL-1</h3>\r\n        <p class=\"pagraph\">\r\n         我们将在生物安全一级实验室进行实验。我们使用的底盘生物AAV-CAP-B10和rAAV6属于BSL-1，经过安全研究，确认其不会对人类健康或环境造成严重的威胁。在实验室进行工作时，始终有主管或指导员在场。 \r\n        </p>  \r\n\r\n\r\n         <div class=\"ding\"></div>\r\n        <h3 class=\"secTitle\">COVID-19</h3>\r\n        <p class=\"pagraph\">\r\n         为了确保我们团队成员在 COVID-19 方面的安全，我们采取了以下措施： \r\n         <ul>\r\n             <li>团队成员定时核酸检测，在出现与 COVID-19 相关的症状时及时接受隔离处理。</li>\r\n             <li>遵循多项卫生规则和清洁措施，例如经常清洁手部、工作场所和厕所。</li>\r\n             <li>团队成员和其他进入大楼的人员在从一个地方转移到另一个地方时必须戴上口罩。</li>\r\n             <li>实验室只允许同时有少量学生在场，我们制定了实验时间表，以清楚地显示实验人员的排班情况。 </li>\r\n         </ul>\r\n        </p>  \r\n\r\n      </div>\r\n      <div class=\"ding\"></div>\r\n      <div class=\"ding\"></div>\r\n      <div class=\"ding\"></div>\r\n    </div>\r\n    <div id=\"lef\" class=\"leftP\">\r\n      <ul class=\"Shell\">\r\n        <li><a href=\"#top\"> Top</a></li>\r\n        <li><a href=\"#des1\">项目安全设计</a></li>\r\n        <li><a href=\"#des2\">实施安全设计</a></li>\r\n        <li><a href=\"#des3\"> 人体、环境安全</a></li>\r\n        <li><a href=\"#des4\">生物安全</a></li>\r\n      </ul>\r\n    </div>\r\n  </div>\r\n</template>\r\n<script>\r\nexport default {\r\n  return() {},\r\n  mounted() {\r\n    let lef = document.getElementById(\"lef\");\r\n\r\n    function addEvent(obj, type, fn) {\r\n      undefined;\r\n      if (obj.attachEvent) {\r\n        obj.attachEvent(\"on\" + type, function () {\r\n          undefined;\r\n          fn.call(obj);\r\n        });\r\n      } else {\r\n        undefined;\r\n        obj.addEventListener(type, fn, false);\r\n      }\r\n    }\r\n\r\n    addEvent(window, \"scroll\", function () {\r\n      undefined;\r\n      if (window.pageYOffset >= 455) {\r\n        lef.classList.add(\"stick\");\r\n      } else {\r\n        lef.classList.remove(\"stick\");\r\n      }\r\n    });\r\n  },\r\n};\r\n</script>\r\n<style scoped>\r\n.ref{\r\n    font-style: italic;\r\n    font-family: Times New Roman,Times,serif!important;\r\n    padding-left: 2em;\r\n    text-align: left;\r\n    font-size: 0.8em;\r\n    color: #7d7d7d;\r\n    letter-spacing: .018em;\r\n}\r\n.secTitle{\r\n  padding-left:10px;\r\n  border-radius: 3px;\r\n    color: #c5e2e0;\r\n  font-family: Comic Sans MS;\r\n  margin: 10px;\r\n  background-color: #1d5a56;\r\n}\r\n.tu{\r\n  margin-right: auto;\r\n  margin-left: auto;\r\n  display: block;\r\n  margin-top: 20px;\r\n  width: 600px;\r\n  height: auto;\r\n  border-radius: 30px;\r\n  border: #1d5a56;\r\n  background-size: 5px;\r\n}\r\n.topic {\r\n  color: #1d3f5a;\r\n  font-size: 60px;\r\n  text-align: center;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  font-family: \"Arial\";\r\n  letter-spacing: 15px;\r\n}\r\n#lef.stick {\r\n  opacity: 0.7;\r\n  transition: all 1s;\r\n}\r\n.Shell li a{\r\n  display: block;\r\n  width: 150px;\r\n}\r\n.leftP {\r\n  position: fixed;\r\n  left: 10px;\r\n  top: 30%;\r\n  opacity: 0;\r\n  height: 48vh;\r\n  width: 200px;\r\n  background-color: #3c6b6d;\r\n  border-radius: 20px;\r\n}\r\n.Shell {\r\n  margin: 0;\r\n  padding: 0;\r\n  color: inherit;\r\n  background-color: inherit;\r\n}\r\n.Shell:first-child {\r\n  margin-top: 4vh;\r\n}\r\n.Shell li {\r\n  list-style: none;\r\n  height: 8vh;\r\n  line-height: 8vh;\r\n  padding-left: 20px;\r\n  color: inherit;\r\n  background-color: inherit;\r\n}\r\n.Shell li:hover {\r\n  /* transform:scale(1,1.2); */\r\n  background-color: #89cfd1;\r\n  border-radius: 10px;\r\n  color: #253f17;\r\n  transition: all 0.6s;\r\n}\r\n.Shell li:hover a {\r\n  color: white;\r\n}\r\n.Shell li a {\r\n  text-decoration: none;\r\n  color: #8ad6bd;\r\n}\r\n.ding {\r\n  height: 96px;\r\n}\r\n.top img {\r\n  float: right;\r\n  line-height: 60px;\r\n}\r\n.top img:hover {\r\n  transform: scale(1.3);\r\n  transition: all 0.4s;\r\n}\r\n.back {\r\n  width: 100%;\r\n  background-color: #c5ddd9;\r\n}\r\n.bg .im {\r\n  background-attachment: fixed;\r\n  width: 100%;\r\n  height: 100vh;\r\n  background-size: cover;\r\n  background-image: url(../assets/homeBanner.gif);\r\n}\r\n.content {\r\n  background-color: inherit;\r\n  width: 900px;\r\n  margin: 0 auto;\r\n  align-content: center;\r\n  padding: 20px;\r\n}\r\n.title {\r\n  color: #1d5a56;\r\n  font-family: Comic Sans MS;\r\n  margin: 10px;\r\n  border-bottom: solid 2px #7faba0;\r\n  padding-bottom: 0.6em;\r\n}\r\n.title2 {\r\n  color: #1d5a56;\r\n  font-family: Comic Sans MS;\r\n  margin: 10px;\r\n  margin-top: 50px;\r\n  border-bottom: solid 2px #a9ccc3;\r\n  padding-bottom: 0.6em;\r\n}\r\n.title:first-letter {\r\n  font-size: 50px;\r\n  text-shadow: 2px 2px 5px #444;\r\n}\r\n.title2:first-letter {\r\n  font-size: 50px;\r\n  text-shadow: 2px 2px 5px #444;\r\n}\r\n.pagraph {\r\n  font-family: \"Century Gothic\";\r\n  letter-spacing: 0.05em !important;\r\n  text-indent: 2em;\r\n  display: block;\r\n  transition: all 2s;\r\n  margin-left: 40px;\r\n  letter-spacing: 1.3px;\r\n  line-height: 1.8;\r\n  word-spacing: 3px;\r\n  color: #386f6c;\r\n}\r\n</style>\r\n","import mod from \"-!../../node_modules/cache-loader/dist/cjs.js??ref--13-0!../../node_modules/thread-loader/dist/cjs.js!../../node_modules/babel-loader/lib/index.js!../../node_modules/cache-loader/dist/cjs.js??ref--1-0!../../node_modules/vue-loader/lib/index.js??vue-loader-options!./safety.vue?vue&type=script&lang=js&\"; export default mod; export * from \"-!../../node_modules/cache-loader/dist/cjs.js??ref--13-0!../../node_modules/thread-loader/dist/cjs.js!../../node_modules/babel-loader/lib/index.js!../../node_modules/cache-loader/dist/cjs.js??ref--1-0!../../node_modules/vue-loader/lib/index.js??vue-loader-options!./safety.vue?vue&type=script&lang=js&\"","import { render, staticRenderFns } from \"./safety.vue?vue&type=template&id=6cf105e4&scoped=true&\"\nimport script from \"./safety.vue?vue&type=script&lang=js&\"\nexport * from \"./safety.vue?vue&type=script&lang=js&\"\nimport style0 from \"./safety.vue?vue&type=style&index=0&id=6cf105e4&scoped=true&lang=css&\"\n\n\n/* normalize component */\nimport normalizer from \"!../../node_modules/vue-loader/lib/runtime/componentNormalizer.js\"\nvar component = normalizer(\n  script,\n  render,\n  staticRenderFns,\n  false,\n  null,\n  \"6cf105e4\",\n  null\n  \n)\n\nexport default component.exports","var render = function () {var _vm=this;var _h=_vm.$createElement;var _c=_vm._self._c||_h;return _vm._m(0)}\nvar staticRenderFns = [function () {var _vm=this;var _h=_vm.$createElement;var _c=_vm._self._c||_h;return _c('div',[_c('div',{staticClass:\"bg\"},[_c('div',{staticClass:\"im\",attrs:{\"id\":\"bg\"}})]),_c('div',{staticClass:\"back\"},[_c('div',{staticClass:\"ding\",attrs:{\"id\":\"top\"}}),_c('div',{staticClass:\"b b1\"},[_c('div',{staticClass:\"home1\"},[_c('img',{attrs:{\"src\":require(\"../assets/1.gif\"),\"alt\":\"\"}})]),_c('div',{staticClass:\"na na1\"},[_c('a',{attrs:{\"href\":\"#home2\"}},[_c('img',{attrs:{\"src\":require(\"../assets/down.png\"),\"alt\":\"\"}})])])]),_c('div',{staticClass:\"ding\",attrs:{\"id\":\"home2\"}}),_c('div',{staticClass:\"b b2\"},[_c('div',{staticClass:\"home2\"},[_c('div',[_c('img',{attrs:{\"src\":require(\"../assets/2-1.gif\"),\"alt\":\"\"}})]),_c('div',{staticClass:\"son\"},[_c('img',{attrs:{\"src\":require(\"../assets/2-2.gif\"),\"alt\":\"\"}})]),_c('div',[_c('img',{attrs:{\"src\":require(\"../assets/2-3.gif\"),\"alt\":\"\"}})])]),_c('div',{staticClass:\"na na2\"},[_c('a',{attrs:{\"href\":\"#home3\"}},[_c('img',{attrs:{\"src\":require(\"../assets/down.png\"),\"alt\":\"\"}})])])]),_c('div',{staticClass:\"ding\",attrs:{\"id\":\"home3\"}}),_c('div',{staticClass:\"b b3\"},[_c('div',{staticClass:\"home3\"},[_c('img',{attrs:{\"src\":require(\"../assets/3.gif\"),\"alt\":\"\"}})])]),_c('div',{staticClass:\"leftP\",attrs:{\"id\":\"lef\"}},[_c('a',{attrs:{\"href\":\"#top\"}},[_c('img',{attrs:{\"src\":require(\"../assets/homeTop.png\"),\"alt\":\"\"}})])])])])}]\n\nexport { render, staticRenderFns }","<template>\r\n  <div>\r\n    <div class=\"bg\"><div class=\"im\" id=\"bg\"></div></div>\r\n    <div class=\"back\">\r\n      <div id=\"top\" class=\"ding\"></div>\r\n\r\n      <div class=\"b b1\">\r\n        <div class=\"home1\"><img src=\"../assets/1.gif\" alt=\"\" /></div>\r\n        <div class=\"na na1\">\r\n          <a href=\"#home2\"><img src=\"../assets/down.png\" alt=\"\" /></a>\r\n        </div>\r\n      </div>\r\n\r\n      <div id=\"home2\" class=\"ding\"></div>\r\n\r\n      <div class=\"b b2\">\r\n        <div class=\"home2\">\r\n          <div><img src=\"../assets/2-1.gif\" alt=\"\" /></div>\r\n          <div class=\"son\"><img src=\"../assets/2-2.gif\" alt=\"\" /></div>\r\n          <div><img src=\"../assets/2-3.gif\" alt=\"\" /></div>\r\n        </div>\r\n        <div class=\"na na2\">\r\n          <a href=\"#home3\"><img src=\"../assets/down.png\" alt=\"\" /></a>\r\n        </div>\r\n      </div>\r\n\r\n      <div id=\"home3\" class=\"ding\"></div>\r\n      <div class=\"b b3\">\r\n        <div class=\"home3\"><img src=\"../assets/3.gif\" alt=\"\" /></div>\r\n      </div>\r\n\r\n      \r\n    \r\n    <div id=\"lef\" class=\"leftP\">\r\n      <a href=\"#top\"><img src=\"../assets/homeTop.png\" alt=\"\" /></a>\r\n    </div>\r\n  </div>\r\n  </div>\r\n</template>\r\n<script>\r\nexport default {\r\n  return() {},\r\n  mounted() {\r\n    let lef = document.getElementById(\"lef\");\r\n\r\n    function addEvent(obj, type, fn) {\r\n      undefined;\r\n      if (obj.attachEvent) {\r\n        obj.attachEvent(\"on\" + type, function () {\r\n          undefined;\r\n          fn.call(obj);\r\n        });\r\n      } else {\r\n        undefined;\r\n        obj.addEventListener(type, fn, false);\r\n      }\r\n    }\r\n\r\n    addEvent(window, \"scroll\", function () {\r\n      undefined;\r\n      if (window.pageYOffset >= 455) {\r\n        lef.classList.add(\"stick\");\r\n      } else {\r\n        lef.classList.remove(\"stick\");\r\n      }\r\n    });\r\n  },\r\n};\r\n</script>\r\n<style scoped>\r\n.b{\r\n  width: 100%;\r\n  height:auto;\r\n  margin:0;\r\n}\r\n.b1{\r\n  background-color: white;\r\n}\r\n.b2{\r\n  background-color: #8cd4cd;\r\n}\r\n.b3{\r\n  background-color: white;\r\n}\r\n#top {\r\n  background-color: white;\r\n  border-top-left-radius:40px;\r\n  border-top-right-radius:40px;\r\n}\r\n#home2 {\r\n  background-image: linear-gradient(white, #8cd4cd);\r\n}\r\n#home3 {\r\n  background-image: linear-gradient(#8cd4cd, white);\r\n}\r\n* {\r\n  margin: 0;\r\n  padding: 0;\r\n}\r\n.na {\r\n  margin-top: 50px;\r\n  width: 100%;\r\n  height: auto;\r\n  text-align: center;\r\n  padding-bottom: 70px;\r\n}\r\n.na a img:hover {\r\n  transform: scale(1.2);\r\n  transition: 0.6s;\r\n}\r\n.ding {\r\n  height: 96px;\r\n}\r\n.home1 {\r\n  width: 70%;\r\n  height: auto;\r\n  margin-left: 15%;\r\n  margin-right: 15%;\r\n  padding-top: 50px;\r\n  border-radius: 30px;\r\n}\r\n.home1 img {\r\n  width: 100%;\r\n  object-fit: cover;\r\n  border-radius: 30px;\r\n  transition: 1s;\r\n}\r\n.home2 {\r\n  width: 70%;\r\n  height: auto;\r\n  margin-left: 15%;\r\n  margin-right: 15%;\r\n  padding-top: 100px;\r\n  border-radius: 30px;\r\n}\r\n.home2 div {\r\n  display: inline-block;\r\n  width: 28%;\r\n  height: auto;\r\n  border-radius: 30px;\r\n}\r\n.son {\r\n  margin-left: 8%;\r\n  margin-right: 8%;\r\n}\r\n.home2 div img {\r\n  width: 100%;\r\n  object-fit: cover;\r\n  border-radius: 30px;\r\n  transition: 1s;\r\n}\r\n\r\n.home3 {\r\n  width: 70%;\r\n  height: auto;\r\n  margin-left: 15%;\r\n  margin-right: 15%;\r\n  padding-top: 100px;\r\n  padding-bottom: 200px;\r\n  border-radius: 30px;\r\n}\r\n.home3 img {\r\n  width: 100%;\r\n  object-fit: cover;\r\n  border-radius: 30px;\r\n}\r\n.showBox .box .p {\r\n  display: none;\r\n  margin-bottom:20px;\r\n  margin-top:20px;\r\n}\r\n.back {\r\n  width: 100%;\r\n  height: 100%;\r\n  border-top-left-radius:40px;\r\n  border-top-right-radius:40px;\r\n}\r\n.bg .im {\r\n  background-attachment: fixed;\r\n  width: 100%;\r\n  height: 100vh;\r\n  background-size: cover;\r\n  background-image: url(../assets/homeBanner.gif);\r\n}\r\n\r\n#lef.stick {\r\n  opacity: 1;\r\n  transition: all 1s;\r\n}\r\n#lef.stick:hover {\r\n  transform: scale(1.2);\r\n  transition: all 0.6s;\r\n}\r\n.leftP {\r\n  position: fixed;\r\n  left: 10px;\r\n  top: 30%;\r\n  opacity: 0;\r\n  height: 100px;\r\n  width: 100px;\r\n}\r\n</style>\r\n","import mod from \"-!../../node_modules/cache-loader/dist/cjs.js??ref--13-0!../../node_modules/thread-loader/dist/cjs.js!../../node_modules/babel-loader/lib/index.js!../../node_modules/cache-loader/dist/cjs.js??ref--1-0!../../node_modules/vue-loader/lib/index.js??vue-loader-options!./imple.vue?vue&type=script&lang=js&\"; export default mod; export * from \"-!../../node_modules/cache-loader/dist/cjs.js??ref--13-0!../../node_modules/thread-loader/dist/cjs.js!../../node_modules/babel-loader/lib/index.js!../../node_modules/cache-loader/dist/cjs.js??ref--1-0!../../node_modules/vue-loader/lib/index.js??vue-loader-options!./imple.vue?vue&type=script&lang=js&\"","import { render, staticRenderFns } from \"./imple.vue?vue&type=template&id=3371a61d&scoped=true&\"\nimport script from \"./imple.vue?vue&type=script&lang=js&\"\nexport * from \"./imple.vue?vue&type=script&lang=js&\"\nimport style0 from \"./imple.vue?vue&type=style&index=0&id=3371a61d&scoped=true&lang=css&\"\n\n\n/* normalize component */\nimport normalizer from \"!../../node_modules/vue-loader/lib/runtime/componentNormalizer.js\"\nvar component = normalizer(\n  script,\n  render,\n  staticRenderFns,\n  false,\n  null,\n  \"3371a61d\",\n  null\n  \n)\n\nexport default component.exports","var render = function () {var _vm=this;var _h=_vm.$createElement;var _c=_vm._self._c||_h;return _c('div',[_vm._m(0),_c('div',{staticClass:\"back\"},[_c('div',{staticClass:\"content\"},[_c('div',{staticClass:\"ding\",attrs:{\"id\":\"top\"}}),_c('h1',{staticClass:\"topic\"},[_vm._v(\"我们的项目和价值观\")]),_c('img',{staticClass:\"tu\",attrs:{\"src\":require(\"../assets/in1-1.png\"),\"alt\":\"no pic\"}}),_c('img',{staticClass:\"tu\",attrs:{\"src\":require(\"../assets/in1-2.png\"),\"alt\":\"no pic\"}}),_c('img',{staticClass:\"tu\",attrs:{\"src\":require(\"../assets/in1-3.png\"),\"alt\":\"no pic\"}}),_c('div',{staticClass:\"ding\"}),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 帕金森病 (Parkinson’s disease, PD) 是一种高发于中老年神经系统的变性疾病, 是继阿尔茨海默病之后的第二大常见神经退行性疾病。PD患者运动功能受到阻碍，且会进一步出现如自主功能不全、认知缺损等非运动特征的并发症，严重影响了患者的生活质量。我们试图通过改造腺相关病毒，从不同通路上多靶点治疗帕金森氏症，希望能为帕金森氏症甚至其他神经退行性疾病未来的治愈提供可能的解决方案。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 我们将责任和人性化定义为我们的核心价值观。人类实践团队在整个项目周期中不断强调我们核心价值观的实现。我们将通过调研问卷、走访调查等形式探讨项目的道德与伦理。我们联系了利益相关者，包括地方政府、临床医生、专家、商业人员，以确认我们正在开发一个对世界负责且有益的项目。通过他们的指导，我们能够评估我们项目设计的有效性、安全性、可行性，旨在为科学研究和医疗做出贡献。 \")]),_c('div',{staticClass:\"ding\",attrs:{\"id\":\"des1\"}}),_c('h1',{staticClass:\"title\"},[_vm._v(\"Storyline\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\"问题理解->项目构思->实验设计->总体评估->应用实践\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 由于Storyline有较强的时间逻辑（项目进行后具体产生了问题，才能进一步和专家讨论、解决），我们设想在真正项目实践后按照Storyline撰写Integrated Human Practices 的wiki。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 具体形式参考2021年KCL_UK Integrated Human Practices模块。 \")]),_c('p',{staticClass:\"ref\"},[_vm._v(\" https://2021.igem.org/Team:KCL_UK/Human_Practices#Human-centric-design \")]),_c('img',{staticClass:\"tu\",attrs:{\"src\":require(\"../assets/in1-2-1.png\"),\"alt\":\"no pic\"}}),_c('img',{staticClass:\"tu\",attrs:{\"src\":require(\"../assets/in1-2-1.png\"),\"alt\":\"no pic\"}}),_c('div',{staticClass:\"ding\",attrs:{\"id\":\"des2\"}}),_c('h1',{staticClass:\"title\"},[_vm._v(\"道德与伦理\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 我们设计了调研问卷并进行了一对一采访，在社会群体（分年龄段，18岁以下，18~30岁，30岁以上）中调研公众对病毒载体医疗以及基因治疗的了解度及接受程度。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 我们和专家会谈，向他们介绍我们的项目，并探讨基于腺相关病毒的基因治疗的安全性与道德伦理问题、相关病毒治疗产品的风险与周期。 \")]),_c('img',{staticClass:\"tu\",attrs:{\"src\":require(\"../assets/in1-3-1.png\"),\"alt\":\"no pic\"}}),_c('div',{staticClass:\"ding\",attrs:{\"id\":\"des3\"}}),_c('h1',{staticClass:\"title\"},[_vm._v(\"利益相关者\")]),_c('div',{staticClass:\"showBox\"},[_c('div',{staticClass:\"head\"},[_c('div',{staticClass:\"c\",attrs:{\"id\":\"c1\"},on:{\"click\":function($event){return _vm.ch1()}}},[_vm._v(\"患者\")]),_c('div',{staticClass:\"c\",attrs:{\"id\":\"c2\"},on:{\"click\":function($event){return _vm.ch2()}}},[_vm._v(\"医生\")]),_c('div',{staticClass:\"c\",attrs:{\"id\":\"c3\"},on:{\"click\":function($event){return _vm.ch3()}}},[_vm._v(\"政府与社区\")])]),_vm._m(1)]),_c('h1',{staticClass:\"topic\"})]),_c('div',{staticClass:\"ding\"}),_c('div',{staticClass:\"ding\"}),_c('div',{staticClass:\"ding\"})]),_vm._m(2)])}\nvar staticRenderFns = [function () {var _vm=this;var _h=_vm.$createElement;var _c=_vm._self._c||_h;return _c('div',{staticClass:\"bg\"},[_c('div',{staticClass:\"im\",attrs:{\"id\":\"bg\"}})])},function () {var _vm=this;var _h=_vm.$createElement;var _c=_vm._self._c||_h;return _c('div',{staticClass:\"box\"},[_c('div',{staticClass:\"p\",attrs:{\"id\":\"p1\"}},[_c('p',{staticClass:\"pagraph\"},[_vm._v(\" iGEM队员通过在浙二医院的见习，了解了帕金森患者的生活状态与关切问题。我们了解到早期帕金森病患者一般采取多巴胺类似药物左旋多巴进行治疗，而晚期患者一般采取手术电生理介入治疗。因此，我们针对不同发病阶段的患者开展两份问卷调查。 \")]),_c('h1',{staticClass:\"title3\"},[_vm._v(\"早期帕金森病患者问卷设计\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 第一次确诊PD的时间（年龄段选择） 用药过程中遇到的最棘手的问题：药品昂贵、定时服药麻烦、药效不良、不良反应 对目前PD疗法的了解：药物疗法、手术疗法、基因疗法 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 用药过程中遇到的最棘手的问题：药品昂贵、定时服药麻烦、药效不良、不良反应 对目前PD疗法的了解：药物疗法、手术疗法、基因疗法 \")]),_c('h1',{staticClass:\"title3\"},[_vm._v(\"晚期帕金森病患者问卷设计\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\"第一次确诊PD的时间（年龄段选择）\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\"目前是否接受手术介入治疗\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 用药过程中遇到的最棘手的问题：药品昂贵、定时服药麻烦、药效不良、不良反应 手术过程中遇到的最棘手的问题：费用昂贵、不良反应、效果不佳 \")]),_c('img',{staticClass:\"tu\",attrs:{\"src\":require(\"../assets/in1-4-1.png\"),\"alt\":\"no pic\"}}),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 在了解患者群体的过程中，我们特别关注患者及其家属在治疗过程中，出现的心理问题以及他们对于经济社会因素的考量，希望在医院得到何种非医疗资源的帮助，是否存在心理与人文关怀的特殊需求等等。我们希望通过调查与临床医生与院方交流，完善基于生物-心理-社会医学模式的治疗，让患者在治疗之外，感受到更多的人文关怀和情感支持。 \")])]),_c('div',{staticClass:\"p\",attrs:{\"id\":\"p2\"}},[_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 我们向内科和外科医生询问目前用药和手术层面对PD的治疗措施，了解在临床层面两种治疗方式的优势和各自有待解决的问题。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 在了解了临床方面的治疗措施后，我们向医生们介绍IGEM项目的产品，就给药方式、替代现有治疗措施的可能性与其进行探讨，挖掘我们产品可进一步提升的空间，以及基因治疗目前在临床的应用情况，目前遇到的瓶颈等等。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 除此之外，我们特别就PD患者在治疗过程中最大的心理问题以及经济社会因素的考量与临床医生开展探讨，针对已经开展的基因治疗询问目前患者的接受度以及目前临床的普及率。通过医生的介绍，我们对已经开展基因治疗的患者进行问卷调查，向其介绍我们的产品，询问其对我们产品的顾虑，以及其使用我们产品的意愿。 \")])]),_c('div',{staticClass:\"p\",attrs:{\"id\":\"p3\"}},[_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 由于老年帕金森患者占帕金森患者群体的大部分，我们拟通过杭州较具有影响力的临终关怀组织——晒福绿郡·沐椿生命关爱义工之家，开展生命关爱-认识帕金森的讲座与相关活动宣传，积累初期受众群体。在讲座前期通过问卷收集帕金森患者治疗过程中关心的问题并予以解答，同时向其详细介绍帕金森的致病机理以及可能的预防措施。在介绍了帕金森的现有疗法后，介绍TheraParkin项目，向观众普及基因治疗帕金森的可能实现路径。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 我们通过讲座进一步收集帕金森患者的问题，进行研究与解答。另外，通过沐椿生命关怀组织和在场观众，获得杭州地区帕金森患者家属组织的联系方式，与负责人取得联系。后续可通过线上线下等方式，邀请不同地区帕金森亲友会的组织负责人参与会议，收集了解帕金森病人以及家属关心的问题，并向其介绍TheraParkin项目，重点就项目的理论可行性与负责人进行探讨，收集负责人反馈的项目可行性问题。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 之后，在会议的基础上进一步推进，积极促成民间组织到官方政府的合作与宣传，通过各个负责人或杭州的生命关爱组织，联系对项目感兴趣的政府部门，开展TheraParkin介绍会和帕金森病交流会，通过撰文、视频以及义诊反馈增加政府对我们项目的兴趣。积极推进患者-组织负责人-政府三级宣传与实践模式的落地，团队成员希望成立TheraParkin了解平台，让更多的患者、家属以及对帕金森病与合成生物学疗法感兴趣的人，通过这个三级式的了解平台获得不同层次的治疗信息与情感帮助。 \")]),_c('img',{staticClass:\"tu\",attrs:{\"src\":require(\"../assets/in1-4-2.png\"),\"alt\":\"no pic\"}})])])},function () {var _vm=this;var _h=_vm.$createElement;var _c=_vm._self._c||_h;return _c('div',{staticClass:\"leftP\",attrs:{\"id\":\"lef\"}},[_c('ul',{staticClass:\"Shell\"},[_c('li',[_c('a',{attrs:{\"href\":\"#top\"}},[_vm._v(\"我们的项目和价值观\")])]),_c('li',[_c('a',{attrs:{\"href\":\"#des1\"}},[_vm._v(\"Storyline\")])]),_c('li',[_c('a',{attrs:{\"href\":\"#des2\"}},[_vm._v(\"道德与伦理\")])]),_c('li',[_c('a',{attrs:{\"href\":\"#des3\"}},[_vm._v(\"利益相关者\")])])])])}]\n\nexport { render, staticRenderFns }","<template>\r\n  <div>\r\n    <div class=\"bg\"><div class=\"im\" id=\"bg\"></div></div>\r\n    <div class=\"back\">\r\n      <div class=\"content\">\r\n        <div id=\"top\" class=\"ding\"></div>\r\n        <h1 class=\"topic\">我们的项目和价值观</h1>\r\n        <img src=\"../assets/in1-1.png\" class=\"tu\" alt=\"no pic\" />\r\n        <img src=\"../assets/in1-2.png\" class=\"tu\" alt=\"no pic\" />\r\n        <img src=\"../assets/in1-3.png\" class=\"tu\" alt=\"no pic\" />\r\n        <div class=\"ding\"></div>\r\n        <p class=\"pagraph\">\r\n          帕金森病 (Parkinson’s disease, PD)\r\n          是一种高发于中老年神经系统的变性疾病,\r\n          是继阿尔茨海默病之后的第二大常见神经退行性疾病。PD患者运动功能受到阻碍，且会进一步出现如自主功能不全、认知缺损等非运动特征的并发症，严重影响了患者的生活质量。我们试图通过改造腺相关病毒，从不同通路上多靶点治疗帕金森氏症，希望能为帕金森氏症甚至其他神经退行性疾病未来的治愈提供可能的解决方案。\r\n        </p>\r\n        <p class=\"pagraph\">\r\n          我们将责任和人性化定义为我们的核心价值观。人类实践团队在整个项目周期中不断强调我们核心价值观的实现。我们将通过调研问卷、走访调查等形式探讨项目的道德与伦理。我们联系了利益相关者，包括地方政府、临床医生、专家、商业人员，以确认我们正在开发一个对世界负责且有益的项目。通过他们的指导，我们能够评估我们项目设计的有效性、安全性、可行性，旨在为科学研究和医疗做出贡献。\r\n        </p>\r\n\r\n\r\n      <div id=\"des1\" class=\"ding\"></div>\r\n        <h1 class=\"title\">Storyline</h1>\r\n        <p class=\"pagraph\">问题理解->项目构思->实验设计->总体评估->应用实践</p>\r\n        <p class=\"pagraph\">\r\n          由于Storyline有较强的时间逻辑（项目进行后具体产生了问题，才能进一步和专家讨论、解决），我们设想在真正项目实践后按照Storyline撰写Integrated\r\n          Human Practices 的wiki。\r\n        </p>\r\n        <p class=\"pagraph\">\r\n          具体形式参考2021年KCL_UK Integrated Human Practices模块。\r\n        </p>\r\n        <p class=\"ref\">\r\n          https://2021.igem.org/Team:KCL_UK/Human_Practices#Human-centric-design\r\n        </p>\r\n        <img src=\"../assets/in1-2-1.png\" class=\"tu\" alt=\"no pic\" />\r\n        <img src=\"../assets/in1-2-1.png\" class=\"tu\" alt=\"no pic\" />\r\n\r\n\r\n<div id=\"des2\" class=\"ding\"></div>\r\n        <h1 class=\"title\">道德与伦理</h1>\r\n        <p class=\"pagraph\">\r\n          我们设计了调研问卷并进行了一对一采访，在社会群体（分年龄段，18岁以下，18~30岁，30岁以上）中调研公众对病毒载体医疗以及基因治疗的了解度及接受程度。\r\n        </p>\r\n        <p class=\"pagraph\">\r\n          我们和专家会谈，向他们介绍我们的项目，并探讨基于腺相关病毒的基因治疗的安全性与道德伦理问题、相关病毒治疗产品的风险与周期。\r\n        </p>\r\n        <img src=\"../assets/in1-3-1.png\" class=\"tu\" alt=\"no pic\" />\r\n\r\n\r\n<div id=\"des3\" class=\"ding\"></div>\r\n        <h1 class=\"title\">利益相关者</h1>\r\n        <div class=\"showBox\">\r\n          <div class=\"head\">\r\n            <div id=\"c1\" class=\"c\" @click=\"ch1()\">患者</div>\r\n            <div id=\"c2\" class=\"c\" @click=\"ch2()\">医生</div>\r\n            <div id=\"c3\" class=\"c\" @click=\"ch3()\">政府与社区</div>\r\n          </div>\r\n          <div class=\"box\">\r\n            <div id=\"p1\" class=\"p\">\r\n              <p class=\"pagraph\">\r\n                iGEM队员通过在浙二医院的见习，了解了帕金森患者的生活状态与关切问题。我们了解到早期帕金森病患者一般采取多巴胺类似药物左旋多巴进行治疗，而晚期患者一般采取手术电生理介入治疗。因此，我们针对不同发病阶段的患者开展两份问卷调查。\r\n              </p>\r\n              <h1 class=\"title3\">早期帕金森病患者问卷设计</h1>\r\n              <p class=\"pagraph\">\r\n                第一次确诊PD的时间（年龄段选择）\r\n                用药过程中遇到的最棘手的问题：药品昂贵、定时服药麻烦、药效不良、不良反应\r\n                对目前PD疗法的了解：药物疗法、手术疗法、基因疗法\r\n              </p>\r\n              <p class=\"pagraph\">\r\n                用药过程中遇到的最棘手的问题：药品昂贵、定时服药麻烦、药效不良、不良反应\r\n                对目前PD疗法的了解：药物疗法、手术疗法、基因疗法\r\n              </p>\r\n              <h1 class=\"title3\">晚期帕金森病患者问卷设计</h1>\r\n              <p class=\"pagraph\">第一次确诊PD的时间（年龄段选择）</p>\r\n              <p class=\"pagraph\">目前是否接受手术介入治疗</p>\r\n              <p class=\"pagraph\">\r\n                用药过程中遇到的最棘手的问题：药品昂贵、定时服药麻烦、药效不良、不良反应\r\n                手术过程中遇到的最棘手的问题：费用昂贵、不良反应、效果不佳\r\n              </p>\r\n              <img src=\"../assets/in1-4-1.png\" class=\"tu\" alt=\"no pic\" />\r\n              <p class=\"pagraph\">\r\n                在了解患者群体的过程中，我们特别关注患者及其家属在治疗过程中，出现的心理问题以及他们对于经济社会因素的考量，希望在医院得到何种非医疗资源的帮助，是否存在心理与人文关怀的特殊需求等等。我们希望通过调查与临床医生与院方交流，完善基于生物-心理-社会医学模式的治疗，让患者在治疗之外，感受到更多的人文关怀和情感支持。\r\n              </p>\r\n            </div>\r\n            <div id=\"p2\" class=\"p\">\r\n              <p class=\"pagraph\">\r\n                我们向内科和外科医生询问目前用药和手术层面对PD的治疗措施，了解在临床层面两种治疗方式的优势和各自有待解决的问题。\r\n              </p>\r\n              <p class=\"pagraph\">\r\n                在了解了临床方面的治疗措施后，我们向医生们介绍IGEM项目的产品，就给药方式、替代现有治疗措施的可能性与其进行探讨，挖掘我们产品可进一步提升的空间，以及基因治疗目前在临床的应用情况，目前遇到的瓶颈等等。\r\n              </p>\r\n              <p class=\"pagraph\">\r\n                除此之外，我们特别就PD患者在治疗过程中最大的心理问题以及经济社会因素的考量与临床医生开展探讨，针对已经开展的基因治疗询问目前患者的接受度以及目前临床的普及率。通过医生的介绍，我们对已经开展基因治疗的患者进行问卷调查，向其介绍我们的产品，询问其对我们产品的顾虑，以及其使用我们产品的意愿。\r\n              </p>\r\n            </div>\r\n            <div id=\"p3\" class=\"p\">\r\n              <p class=\"pagraph\">\r\n                由于老年帕金森患者占帕金森患者群体的大部分，我们拟通过杭州较具有影响力的临终关怀组织——晒福绿郡·沐椿生命关爱义工之家，开展生命关爱-认识帕金森的讲座与相关活动宣传，积累初期受众群体。在讲座前期通过问卷收集帕金森患者治疗过程中关心的问题并予以解答，同时向其详细介绍帕金森的致病机理以及可能的预防措施。在介绍了帕金森的现有疗法后，介绍TheraParkin项目，向观众普及基因治疗帕金森的可能实现路径。\r\n              </p>\r\n              <p class=\"pagraph\">\r\n                我们通过讲座进一步收集帕金森患者的问题，进行研究与解答。另外，通过沐椿生命关怀组织和在场观众，获得杭州地区帕金森患者家属组织的联系方式，与负责人取得联系。后续可通过线上线下等方式，邀请不同地区帕金森亲友会的组织负责人参与会议，收集了解帕金森病人以及家属关心的问题，并向其介绍TheraParkin项目，重点就项目的理论可行性与负责人进行探讨，收集负责人反馈的项目可行性问题。\r\n              </p>\r\n\r\n              <p class=\"pagraph\">\r\n                之后，在会议的基础上进一步推进，积极促成民间组织到官方政府的合作与宣传，通过各个负责人或杭州的生命关爱组织，联系对项目感兴趣的政府部门，开展TheraParkin介绍会和帕金森病交流会，通过撰文、视频以及义诊反馈增加政府对我们项目的兴趣。积极推进患者-组织负责人-政府三级宣传与实践模式的落地，团队成员希望成立TheraParkin了解平台，让更多的患者、家属以及对帕金森病与合成生物学疗法感兴趣的人，通过这个三级式的了解平台获得不同层次的治疗信息与情感帮助。\r\n              </p>\r\n              <img src=\"../assets/in1-4-2.png\" class=\"tu\" alt=\"no pic\" />\r\n            </div>\r\n          </div>\r\n        </div>\r\n\r\n        \r\n\r\n        <h1 class=\"topic\"></h1>\r\n      </div>\r\n      <div class=\"ding\"></div>\r\n      <div class=\"ding\"></div>\r\n      <div class=\"ding\"></div>\r\n    </div>\r\n    <div id=\"lef\" class=\"leftP\">\r\n      <ul class=\"Shell\">\r\n        <li><a href=\"#top\">我们的项目和价值观</a></li>\r\n        <li><a href=\"#des1\">Storyline</a></li>\r\n        <li><a href=\"#des2\">道德与伦理</a></li>\r\n        <li><a href=\"#des3\">利益相关者</a></li>\r\n      </ul>\r\n    </div>\r\n  </div>\r\n</template>\r\n<script>\r\nexport default {\r\n  return() {},\r\n  methods: {\r\n    ch1() {\r\n      let p1 = document.getElementById(\"p1\");\r\n      let p2 = document.getElementById(\"p2\");\r\n      let p3 = document.getElementById(\"p3\");\r\n      p1.classList.add(\"showup\");\r\n      p2.classList.remove(\"showup\");\r\n      p3.classList.remove(\"showup\");\r\n    },\r\n    ch2() {\r\n      let p1 = document.getElementById(\"p1\");\r\n      let p2 = document.getElementById(\"p2\");\r\n      let p3 = document.getElementById(\"p3\");\r\n      p2.classList.add(\"showup\");\r\n      p1.classList.remove(\"showup\");\r\n      p3.classList.remove(\"showup\");\r\n    },\r\n    ch3() {\r\n      let p1 = document.getElementById(\"p1\");\r\n      let p2 = document.getElementById(\"p2\");\r\n      let p3 = document.getElementById(\"p3\");\r\n      p3.classList.add(\"showup\");\r\n      p2.classList.remove(\"showup\");\r\n      p1.classList.remove(\"showup\");\r\n    },\r\n  },\r\n  mounted() {\r\n    let lef = document.getElementById(\"lef\");\r\n\r\n    function addEvent(obj, type, fn) {\r\n      undefined;\r\n      if (obj.attachEvent) {\r\n        obj.attachEvent(\"on\" + type, function () {\r\n          undefined;\r\n          fn.call(obj);\r\n        });\r\n      } else {\r\n        undefined;\r\n        obj.addEventListener(type, fn, false);\r\n      }\r\n    }\r\n\r\n    addEvent(window, \"scroll\", function () {\r\n      undefined;\r\n      if (window.pageYOffset >= 455) {\r\n        lef.classList.add(\"stick\");\r\n      } else {\r\n        lef.classList.remove(\"stick\");\r\n      }\r\n    });\r\n  },\r\n};\r\n</script>\r\n<style scoped>\r\n.title3 {\r\n  color: #3485a5;\r\n  font-family: Comic Sans MS;\r\n  margin: 10px;\r\n  font-size: 25px;\r\n  border-bottom: solid 2px #7fa2ab;\r\n  padding-bottom: 0.6em;\r\n}\r\n.showBox {\r\n  width: 100%;\r\n}\r\n.showBox .head .c {\r\n  width: 300px;\r\n  height: 40px;\r\n  line-height: 40px;\r\n  text-align: center;\r\n  display: inline-block;\r\n  margin: auto;\r\n  border-radius: 30px;\r\n  color: rgb(169, 207, 199);\r\n}\r\n.showBox .head .c:hover {\r\n  transform: scale(1.1);\r\n  transition: 0.6s;\r\n  background-color: #fff;\r\n  color: rgb(23, 97, 85);\r\n}\r\n.showBox .head #c1 {\r\n  background-color: #6ab480;\r\n}\r\n.showBox .head #c2 {\r\n  background-color: #6aafb4;\r\n}\r\n.showBox .head #c3 {\r\n  background-color: #6a7eb4;\r\n}\r\n.showBox .box {\r\n  margin-top: 10px;\r\n  padding-left: 15px;\r\n  padding-right: 15px;\r\n  background-color: #d2e8eb;\r\n  width: 880px;\r\n  margin: auto;\r\n  border-radius: 30px;\r\n}\r\n.showBox .box .p {\r\n  display: none;\r\n  margin-bottom:20px;\r\n  margin-top:20px;\r\n}\r\n.showBox .box #p1.showup {\r\n  display: block;\r\n  transition: 1s;\r\n}\r\n.showBox .box #p2.showup {\r\n  display: block;\r\n  transition: 1s;\r\n}\r\n.showBox .box #p3.showup {\r\n  display: block;\r\n  transition: 1s;\r\n}\r\n.showBox .box .p {\r\n  display: none;\r\n  margin-bottom:20px;\r\n  margin-top:20px;\r\n}\r\n.tu {\r\n  margin-right: auto;\r\n  margin-left: auto;\r\n  display: block;\r\n  margin-top: 20px;\r\n  width: 600px;\r\n  height: auto;\r\n  border-radius: 30px;\r\n  border: #1d5a56;\r\n  background-size: 5px;\r\n}\r\n.topic {\r\n  color: #1d3f5a;\r\n  font-size: 60px;\r\n  text-align: center;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  font-family: \"Arial\";\r\n  letter-spacing: 15px;\r\n}\r\n#lef.stick {\r\n  opacity: 0.7;\r\n  transition: all 1s;\r\n}\r\n.Shell li a {\r\n  display: block;\r\n  width: 260px;\r\n}\r\n.pagraph ol li{\r\n  text-indent: 0;\r\n}\r\n.leftP {\r\n  position: fixed;\r\n  left: 10px;\r\n  top: 30%;\r\n  opacity: 0;\r\n  height: 40vh;\r\n  width: 280px;\r\n  background-color: #3c6b6d;\r\n  border-radius: 20px;\r\n}\r\n.Shell {\r\n  margin: 0;\r\n  padding: 0;\r\n  color: inherit;\r\n  background-color: inherit;\r\n}\r\n.Shell:first-child {\r\n  margin-top: 4vh;\r\n}\r\n.Shell li {\r\n  list-style: none;\r\n  height: 8vh;\r\n  line-height: 8vh;\r\n  padding-left: 20px;\r\n  color: inherit;\r\n  background-color: inherit;\r\n}\r\n.Shell li:hover {\r\n  /* transform:scale(1,1.2); */\r\n  background-color: #89cfd1;\r\n  border-radius: 10px;\r\n  color: #253f17;\r\n  transition: all 0.6s;\r\n}\r\n.Shell li:hover a {\r\n  color: white;\r\n}\r\n.Shell li a {\r\n  text-decoration: none;\r\n  color: #8ad6bd;\r\n}\r\n.ding {\r\n  height: 96px;\r\n}\r\n.top img {\r\n  float: right;\r\n  line-height: 60px;\r\n}\r\n.top img:hover {\r\n  transform: scale(1.3);\r\n  transition: all 0.4s;\r\n}\r\n.back {\r\n  width: 100%;\r\n  background-color: #c5ddd9;\r\n}\r\n.bg .im {\r\n  background-attachment: fixed;\r\n  width: 100%;\r\n  height: 100vh;\r\n  background-size: cover;\r\n  background-image: url(../assets/homeBanner.gif);\r\n}\r\n.content {\r\n  background-color: inherit;\r\n  width: 900px;\r\n  margin: 0 auto;\r\n  align-content: center;\r\n  padding: 20px;\r\n}\r\n.title {\r\n  color: #1d5a56;\r\n  font-family: Comic Sans MS;\r\n  margin: 10px;\r\n  border-bottom: solid 2px #7faba0;\r\n  padding-bottom: 0.6em;\r\n}\r\n.title2 {\r\n  color: #1d5a56;\r\n  font-family: Comic Sans MS;\r\n  margin: 10px;\r\n  margin-top: 50px;\r\n  border-bottom: solid 2px #a9ccc3;\r\n  padding-bottom: 0.6em;\r\n}\r\n.title:first-letter {\r\n  font-size: 50px;\r\n  text-shadow: 2px 2px 5px #444;\r\n}\r\n.title2:first-letter {\r\n  font-size: 50px;\r\n  text-shadow: 2px 2px 5px #444;\r\n}\r\n.pagraph {\r\n  font-family: \"Century Gothic\";\r\n  letter-spacing: 0.05em !important;\r\n  text-indent: 2em;\r\n  display: block;\r\n  transition: all 2s;\r\n  margin-left: 40px;\r\n  letter-spacing: 1.3px;\r\n  line-height: 1.8;\r\n  word-spacing: 3px;\r\n  color: #386f6c;\r\n}\r\n</style>\r\n","import mod from \"-!../../node_modules/cache-loader/dist/cjs.js??ref--13-0!../../node_modules/thread-loader/dist/cjs.js!../../node_modules/babel-loader/lib/index.js!../../node_modules/cache-loader/dist/cjs.js??ref--1-0!../../node_modules/vue-loader/lib/index.js??vue-loader-options!./Integrated.vue?vue&type=script&lang=js&\"; export default mod; export * from \"-!../../node_modules/cache-loader/dist/cjs.js??ref--13-0!../../node_modules/thread-loader/dist/cjs.js!../../node_modules/babel-loader/lib/index.js!../../node_modules/cache-loader/dist/cjs.js??ref--1-0!../../node_modules/vue-loader/lib/index.js??vue-loader-options!./Integrated.vue?vue&type=script&lang=js&\"","import { render, staticRenderFns } from \"./Integrated.vue?vue&type=template&id=3695d588&scoped=true&\"\nimport script from \"./Integrated.vue?vue&type=script&lang=js&\"\nexport * from \"./Integrated.vue?vue&type=script&lang=js&\"\nimport style0 from \"./Integrated.vue?vue&type=style&index=0&id=3695d588&scoped=true&lang=css&\"\n\n\n/* normalize component */\nimport normalizer from \"!../../node_modules/vue-loader/lib/runtime/componentNormalizer.js\"\nvar component = normalizer(\n  script,\n  render,\n  staticRenderFns,\n  false,\n  null,\n  \"3695d588\",\n  null\n  \n)\n\nexport default component.exports","var render = function () {var _vm=this;var _h=_vm.$createElement;var _c=_vm._self._c||_h;return _c('div',[_vm._m(0),_c('div',{staticClass:\"back\"},[_c('div',{staticClass:\"content\"},[_c('div',{staticClass:\"ding\",attrs:{\"id\":\"top\"}}),_c('h1',{staticClass:\"title\"},[_vm._v(\"iGEM Team合作\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 我们和其他的iGEM团队合作，进行了线上会议，探讨了我们团队项目的设计合理性、实验可行性。（后面是他们给我们的具体建议） \")]),_c('img',{staticClass:\"tu\",attrs:{\"src\":require(\"../assets/com1-1.png\"),\"alt\":\"no pic\"}}),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 我们和各地iGEM团队合作，开展可持续性目标合作项目，共同完成团队的可持续性目标。我们组织了与可持续性目标相关的会议，在会议中交流了各团队项目与可持续性目标的关联性，并发布系列微博/推文在社交媒体上进行介绍，并相互合作，帮助大家完成任务。（例如，我们设想在不同地区宣传我们的教育网站/软件，可以邀请其他团队合作，共同宣传，完成可持续性目标4和17。） \")]),_c('img',{staticClass:\"tu\",attrs:{\"src\":require(\"../assets/com1-2.png\"),\"alt\":\"no pic\"}}),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 我们还开展了针对部分可持续性目标的队际辩论（或是和学院/学校）辩论赛事主办方联系，设定生物学伦理/道德/法律/政策/可持续性目标/人类重大健康问题等内容相关的辩题，有助于进一步了解相关内容/可持续性目标，为未来重大问题的解决提供思路。 \")]),_c('img',{staticClass:\"tu\",attrs:{\"src\":require(\"../assets/com1-3.png\"),\"alt\":\"no pic\"}}),_c('div',{staticClass:\"ding\",attrs:{\"id\":\"des1\"}}),_c('h1',{staticClass:\"title\"},[_vm._v(\"行业合作\")]),_c('div',{staticClass:\"showBox\"},[_c('div',{staticClass:\"head\"},[_c('div',{staticClass:\"c\",attrs:{\"id\":\"c1\"},on:{\"click\":function($event){return _vm.ch1()}}},[_vm._v(\"养老行业\")]),_c('div',{staticClass:\"c\",attrs:{\"id\":\"c2\"},on:{\"click\":function($event){return _vm.ch2()}}},[_vm._v(\"人性关爱\")]),_c('div',{staticClass:\"c\",attrs:{\"id\":\"c3\"},on:{\"click\":function($event){return _vm.ch3()}}},[_vm._v(\"期刊/公众号合作\")]),_c('div',{staticClass:\"c\",attrs:{\"id\":\"c4\"},on:{\"click\":function($event){return _vm.ch4()}}},[_vm._v(\"商业合作\")])]),_vm._m(1)])]),_c('div',{staticClass:\"ding\"}),_c('div',{staticClass:\"ding\"}),_c('div',{staticClass:\"ding\"}),_c('div',{staticClass:\"ding\"})]),_vm._m(2)])}\nvar staticRenderFns = [function () {var _vm=this;var _h=_vm.$createElement;var _c=_vm._self._c||_h;return _c('div',{staticClass:\"bg\"},[_c('div',{staticClass:\"im\",attrs:{\"id\":\"bg\"}})])},function () {var _vm=this;var _h=_vm.$createElement;var _c=_vm._self._c||_h;return _c('div',{staticClass:\"box\"},[_c('div',{staticClass:\"p\",attrs:{\"id\":\"p1\"}},[_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 我们和不同层次的养老机构合作，进行了相关调研和采访。我们调研了神经退行性疾病患者在养老机构的生活状态，包括他们的基础生活情况，以及交友等社会活动情况，以及他们的相关医疗情况，包括是否经过医疗、患者个人及家人是否选择治疗、疗效如何等等。我们让老人们试用了我们开发的相关科普软件，在老年人这个神经退行性疾病高发人群进行疾病及预防知识的科普，同时验证我们产品的包容性。 \")]),_c('img',{staticClass:\"tu\",attrs:{\"src\":require(\"../assets/com2-1.png\"),\"alt\":\"no pic\"}}),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 备选养老机构（包含不同层次，甚至可以包含不同地市，可以和其他iGEM团队合作） \")]),_c('p',{staticClass:\"ref\"},[_vm._v(\" 公立养老机构： \")]),_c('p',{staticClass:\"ref\"},[_vm._v(\" e.g., 杭州市第三社会福利院（杭州市规模最大的公办养老机构，若需选择患病人数较多的养老机构或可选择杭州市第一社会福利院）。负责人：但志婷，联系电话：88137720 私立高端养老机构： \")]),_c('p',{staticClass:\"ref\"},[_vm._v(\" e.g., 杭州朗和国际医养公寓（杭州最好的养老机构，高端医养）。联系电话：89706666 \")])]),_c('div',{staticClass:\"p\",attrs:{\"id\":\"p2\"}},[_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 我们和临终关怀团队合作，了解神经退行性疾病及中枢神经系统神经相关疾病患者的具体临终关怀，为我们的教育模块及项目的设计与实现提供更深层次的思路。 \")]),_c('img',{staticClass:\"tu\",attrs:{\"src\":require(\"../assets/com2-2.png\"),\"alt\":\"no pic\"}})]),_c('div',{staticClass:\"p\",attrs:{\"id\":\"p3\"}},[_c('p',{staticClass:\"pagraph\"},[_c('ol',[_c('li',[_vm._v(\"“偶尔治愈”栏目：在采访神经退行性疾病患者及家人后，根据患者经历及内心感受撰文，讲述与神经退行性疾病相关的故事，转递积极向上的精神。 （丁香医生偶尔治愈栏目聚焦医疗健康深度报道，讲述与疾病、衰老、死亡相关故事。投稿邮箱：features@dxy.cn） \")]),_c('li',[_vm._v(\"“原来如此”栏目：团队同学撰文，通过查阅文献与整理总结，探索与生活相关的科学小问题。（投稿邮箱：laijj@dxy.cn）\")]),_c('li',[_vm._v(\" “医生你好”栏目：记录对医院的好奇与疑惑，可以以医学生/患者/家属的视角分享故事或者问题。故事可以是自己的亲身经历，也可以是旁观见闻，有助于帮助人们进一步理解医生、拉近医生与患者的距离，为我国医患关系的改善作出贡献。（投稿字数：500字以内。投稿邮箱：health@dxy.cn） \")]),_c('li',[_vm._v(\" 我们团队成员撰写/邀请相关领域博士生撰写神经退行性疾病科普文章，进行投稿（这个途径的可行性有待商榷，这一类文章没有明确的投稿途径，可能是特约作者撰稿）。 \")])])]),_c('img',{staticClass:\"tu\",attrs:{\"src\":require(\"../assets/com2-3.png\"),\"alt\":\"no pic\"}})]),_c('div',{staticClass:\"p\",attrs:{\"id\":\"p4\"}},[_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 蓝晶实验室具有成熟的合成生物学主题营地、课外科研实践等合成生物学教育平台，我们或许可以和蓝晶实验室合作，参与主题营地的培训等（就是不知道能不能让我们参与，但他们主要面对高中生，而且老师应该需要小助手之类的（最坏打算或许是免费打工……，最好的预期是我们可以参与主题营地项目的方案定制，和他们共同举办合成生物学教育类夏令营/冬令营）） \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 合成生物学主题营地详情见http://lab.bluepha.com/camp （认识师资力量一栏中的赵老师） \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 我们也可以和他们的iGEM团队合作，他们对于商业与教育部分或许有不同角度的见解。 \")]),_c('img',{staticClass:\"tu\",attrs:{\"src\":require(\"../assets/com2-4.png\"),\"alt\":\"no pic\"}})])])},function () {var _vm=this;var _h=_vm.$createElement;var _c=_vm._self._c||_h;return _c('div',{staticClass:\"leftP\",attrs:{\"id\":\"lef\"}},[_c('ul',{staticClass:\"Shell\"},[_c('li',[_c('a',{attrs:{\"href\":\"#top\"}},[_vm._v(\"igem团队合作\")])]),_c('li',[_c('a',{attrs:{\"href\":\"#des1\"}},[_vm._v(\"行业合作\")])])])])}]\n\nexport { render, staticRenderFns }","<template>\r\n  <div>\r\n    <div class=\"bg\"><div class=\"im\" id=\"bg\"></div></div>\r\n    <div class=\"back\">\r\n      <div class=\"content\">\r\n        <div class=\"ding\" id=\"top\"></div>\r\n        <h1 class=\"title\">iGEM Team合作</h1>\r\n        <p class=\"pagraph\">\r\n          我们和其他的iGEM团队合作，进行了线上会议，探讨了我们团队项目的设计合理性、实验可行性。（后面是他们给我们的具体建议）\r\n        </p>\r\n        <img class=\"tu\" src=\"../assets/com1-1.png\" alt=\"no pic\" />\r\n        <p class=\"pagraph\">\r\n          我们和各地iGEM团队合作，开展可持续性目标合作项目，共同完成团队的可持续性目标。我们组织了与可持续性目标相关的会议，在会议中交流了各团队项目与可持续性目标的关联性，并发布系列微博/推文在社交媒体上进行介绍，并相互合作，帮助大家完成任务。（例如，我们设想在不同地区宣传我们的教育网站/软件，可以邀请其他团队合作，共同宣传，完成可持续性目标4和17。）\r\n        </p>\r\n        <img class=\"tu\" src=\"../assets/com1-2.png\" alt=\"no pic\" />\r\n        <p class=\"pagraph\">\r\n          我们还开展了针对部分可持续性目标的队际辩论（或是和学院/学校）辩论赛事主办方联系，设定生物学伦理/道德/法律/政策/可持续性目标/人类重大健康问题等内容相关的辩题，有助于进一步了解相关内容/可持续性目标，为未来重大问题的解决提供思路。\r\n        </p>\r\n        <img class=\"tu\" src=\"../assets/com1-3.png\" alt=\"no pic\" />\r\n\r\n        <div class=\"ding\" id=\"des1\"></div>\r\n        <h1 class=\"title\">行业合作</h1>\r\n        <div class=\"showBox\">\r\n          <div class=\"head\">\r\n            <div id=\"c1\" class=\"c\" @click=\"ch1()\">养老行业</div>\r\n            <div id=\"c2\" class=\"c\" @click=\"ch2()\">人性关爱</div>\r\n            <div id=\"c3\" class=\"c\" @click=\"ch3()\">期刊/公众号合作</div>\r\n            <div id=\"c4\" class=\"c\" @click=\"ch4()\">商业合作</div>\r\n          </div>\r\n          <div class=\"box\">\r\n            <div id=\"p1\" class=\"p\">\r\n              <p class=\"pagraph\">\r\n我们和不同层次的养老机构合作，进行了相关调研和采访。我们调研了神经退行性疾病患者在养老机构的生活状态，包括他们的基础生活情况，以及交友等社会活动情况，以及他们的相关医疗情况，包括是否经过医疗、患者个人及家人是否选择治疗、疗效如何等等。我们让老人们试用了我们开发的相关科普软件，在老年人这个神经退行性疾病高发人群进行疾病及预防知识的科普，同时验证我们产品的包容性。\r\n              </p>\r\n              <img class=\"tu\" src=\"../assets/com2-1.png\" alt=\"no pic\"> \r\n              <p class=\"pagraph\">\r\n备选养老机构（包含不同层次，甚至可以包含不同地市，可以和其他iGEM团队合作）\r\n              </p>\r\n              <p class=\"ref\">\r\n公立养老机构：\r\n              </p>\r\n               <p class=\"ref\">\r\ne.g., 杭州市第三社会福利院（杭州市规模最大的公办养老机构，若需选择患病人数较多的养老机构或可选择杭州市第一社会福利院）。负责人：但志婷，联系电话：88137720\r\n私立高端养老机构：\r\n              </p>\r\n               <p class=\"ref\">\r\ne.g., 杭州朗和国际医养公寓（杭州最好的养老机构，高端医养）。联系电话：89706666\r\n              </p>\r\n       \r\n            </div>\r\n            <div id=\"p2\" class=\"p\">\r\n                <p class=\"pagraph\">\r\n我们和临终关怀团队合作，了解神经退行性疾病及中枢神经系统神经相关疾病患者的具体临终关怀，为我们的教育模块及项目的设计与实现提供更深层次的思路。\r\n    </p>\r\n    <img class=\"tu\" src=\"../assets/com2-2.png\" alt=\"no pic\"> \r\n            </div>\r\n            <div id=\"p3\" class=\"p\">\r\n<p class=\"pagraph\">\r\n<ol>\r\n    <li>“偶尔治愈”栏目：在采访神经退行性疾病患者及家人后，根据患者经历及内心感受撰文，讲述与神经退行性疾病相关的故事，转递积极向上的精神。\r\n        （丁香医生偶尔治愈栏目聚焦医疗健康深度报道，讲述与疾病、衰老、死亡相关故事。投稿邮箱：features@dxy.cn）\r\n    </li>\r\n    <li>“原来如此”栏目：团队同学撰文，通过查阅文献与整理总结，探索与生活相关的科学小问题。（投稿邮箱：laijj@dxy.cn）</li>\r\n    <li>\r\n        “医生你好”栏目：记录对医院的好奇与疑惑，可以以医学生/患者/家属的视角分享故事或者问题。故事可以是自己的亲身经历，也可以是旁观见闻，有助于帮助人们进一步理解医生、拉近医生与患者的距离，为我国医患关系的改善作出贡献。（投稿字数：500字以内。投稿邮箱：health@dxy.cn）\r\n    </li>\r\n    <li>\r\n        我们团队成员撰写/邀请相关领域博士生撰写神经退行性疾病科普文章，进行投稿（这个途径的可行性有待商榷，这一类文章没有明确的投稿途径，可能是特约作者撰稿）。\r\n    </li>\r\n</ol>\r\n    </p>\r\n    <img class=\"tu\" src=\"../assets/com2-3.png\" alt=\"no pic\"> \r\n            </div>\r\n            <div id=\"p4\" class=\"p\">\r\n                 <p class=\"pagraph\">\r\n蓝晶实验室具有成熟的合成生物学主题营地、课外科研实践等合成生物学教育平台，我们或许可以和蓝晶实验室合作，参与主题营地的培训等（就是不知道能不能让我们参与，但他们主要面对高中生，而且老师应该需要小助手之类的（最坏打算或许是免费打工……，最好的预期是我们可以参与主题营地项目的方案定制，和他们共同举办合成生物学教育类夏令营/冬令营））\r\n    </p>\r\n     <p class=\"pagraph\">\r\n合成生物学主题营地详情见http://lab.bluepha.com/camp （认识师资力量一栏中的赵老师）\r\n    </p>\r\n     <p class=\"pagraph\">\r\n我们也可以和他们的iGEM团队合作，他们对于商业与教育部分或许有不同角度的见解。\r\n    </p>\r\n    <img class=\"tu\" src=\"../assets/com2-4.png\" alt=\"no pic\"> \r\n            </div>\r\n          </div>\r\n        </div>\r\n      </div>\r\n      <div class=\"ding\"></div>\r\n      <div class=\"ding\"></div>\r\n      <div class=\"ding\"></div>\r\n      <div class=\"ding\"></div>\r\n    </div>\r\n\r\n    <div id=\"lef\" class=\"leftP\">\r\n      <ul class=\"Shell\">\r\n        <li><a href=\"#top\">igem团队合作</a></li>\r\n        <li><a href=\"#des1\">行业合作</a></li>\r\n      </ul>\r\n    </div>\r\n  </div>\r\n</template>\r\n<script>\r\nexport default {\r\n  return() {},\r\n  methods: {\r\n    ch1() {\r\n      let p1 = document.getElementById(\"p1\");\r\n      let p2 = document.getElementById(\"p2\");\r\n      let p3 = document.getElementById(\"p3\");\r\n      let p4 = document.getElementById(\"p4\");\r\n      p1.classList.add(\"showup\");\r\n      p2.classList.remove(\"showup\");\r\n      p3.classList.remove(\"showup\");\r\n      p4.classList.remove(\"showup\");\r\n    },\r\n    ch2() {\r\n      let p1 = document.getElementById(\"p1\");\r\n      let p2 = document.getElementById(\"p2\");\r\n      let p3 = document.getElementById(\"p3\");\r\n      let p4 = document.getElementById(\"p4\");\r\n      p2.classList.add(\"showup\");\r\n      p1.classList.remove(\"showup\");\r\n      p3.classList.remove(\"showup\");\r\n      p4.classList.remove(\"showup\");\r\n    },\r\n    ch3() {\r\n      let p1 = document.getElementById(\"p1\");\r\n      let p2 = document.getElementById(\"p2\");\r\n      let p3 = document.getElementById(\"p3\");\r\n      let p4 = document.getElementById(\"p4\");\r\n      p3.classList.add(\"showup\");\r\n      p2.classList.remove(\"showup\");\r\n      p1.classList.remove(\"showup\");\r\n      p4.classList.remove(\"showup\");\r\n    },\r\n    ch4() {\r\n      let p1 = document.getElementById(\"p1\");\r\n      let p2 = document.getElementById(\"p2\");\r\n      let p3 = document.getElementById(\"p3\");\r\n      let p4 = document.getElementById(\"p4\");\r\n      p4.classList.add(\"showup\");\r\n      p2.classList.remove(\"showup\");\r\n      p1.classList.remove(\"showup\");\r\n      p3.classList.remove(\"showup\");\r\n    },\r\n  },\r\n  mounted() {\r\n    let lef = document.getElementById(\"lef\");\r\n\r\n    function addEvent(obj, type, fn) {\r\n      undefined;\r\n      if (obj.attachEvent) {\r\n        obj.attachEvent(\"on\" + type, function () {\r\n          undefined;\r\n          fn.call(obj);\r\n        });\r\n      } else {\r\n        undefined;\r\n        obj.addEventListener(type, fn, false);\r\n      }\r\n    }\r\n\r\n    addEvent(window, \"scroll\", function () {\r\n      undefined;\r\n      if (window.pageYOffset >= 455) {\r\n        lef.classList.add(\"stick\");\r\n      } else {\r\n        lef.classList.remove(\"stick\");\r\n      }\r\n    });\r\n  },\r\n};\r\n</script>\r\n<style scoped>\r\n.showBox .box .p {\r\n  display: none;\r\n  margin-bottom:20px;\r\n  margin-top:20px;\r\n}\r\n.title3 {\r\n  color: #3485a5;\r\n  font-family: Comic Sans MS;\r\n  margin: 10px;\r\n  font-size: 25px;\r\n  border-bottom: solid 2px #7fa2ab;\r\n  padding-bottom: 0.6em;\r\n}\r\n.showBox {\r\n  width: 100%;\r\n}\r\n.showBox .head .c {\r\n  width: 200px;\r\n  height: 40px;\r\n  line-height: 40px;\r\n  text-align: center;\r\n  display: inline-block;\r\n  margin: auto;\r\n  border-radius: 30px;\r\n  color: rgb(169, 207, 199);\r\n}\r\n.showBox .head .c:hover {\r\n  transform: scale(1.1);\r\n  transition: 0.6s;\r\n  background-color: #fff;\r\n  color: rgb(23, 97, 85);\r\n}\r\n.showBox .head #c1 {\r\n  background-color: #6ab480;\r\n}\r\n.showBox .head #c2 {\r\n  background-color: #6aafb4;\r\n}\r\n.showBox .head #c3 {\r\n  background-color: #2851aa;\r\n}\r\n.showBox .head #c4 {\r\n  background-color: #5636ad;\r\n}\r\n.showBox .box {\r\n  margin-top: 10px;\r\n  padding-left: 15px;\r\n  padding-right: 15px;\r\n  background-color: #d2e8eb;\r\n  width: 880px;\r\n  margin: auto;\r\n  border-radius: 30px;\r\n}\r\n.showBox .box .p {\r\n  display: none;\r\n}\r\n.showBox .box #p1.showup {\r\n  display: block;\r\n  transition: 1s;\r\n}\r\n.showBox .box #p2.showup {\r\n  display: block;\r\n  transition: 1s;\r\n}\r\n.showBox .box #p3.showup {\r\n  display: block;\r\n  transition: 1s;\r\n}\r\n.showBox .box #p4.showup {\r\n  display: block;\r\n  transition: 1s;\r\n}\r\n.ref{\r\n    font-style: italic;\r\n    font-family: Times New Roman,Times,serif!important;\r\n    padding-left: 2em;\r\n    text-align: left;\r\n    font-size: 0.8em;\r\n    color: #7d7d7d;\r\n    letter-spacing: .018em;\r\n}\r\n.tu {\r\n  margin-right: auto;\r\n  margin-left: auto;\r\n  display: block;\r\n  margin-top: 20px;\r\n  width: 600px;\r\n  height: auto;\r\n  border-radius: 30px;\r\n  border: #1d5a56;\r\n  background-size: 5px;\r\n}\r\n.topic {\r\n  color: #1d3f5a;\r\n  font-size: 60px;\r\n  text-align: center;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  font-family: \"Arial\";\r\n  letter-spacing: 15px;\r\n}\r\n#lef.stick {\r\n  opacity: 0.7;\r\n  transition: all 1s;\r\n}\r\n.Shell li a {\r\n  display: block;\r\n  width: 260px;\r\n}\r\n.leftP {\r\n  position: fixed;\r\n  left: 10px;\r\n  top: 30%;\r\n  opacity: 0;\r\n  height: 24vh;\r\n  width: 200px;\r\n  background-color: #3c6b6d;\r\n  border-radius: 20px;\r\n}\r\n.Shell {\r\n  margin: 0;\r\n  padding: 0;\r\n  color: inherit;\r\n  background-color: inherit;\r\n}\r\n.Shell:first-child {\r\n  margin-top: 4vh;\r\n}\r\n.Shell li {\r\n  list-style: none;\r\n  height: 8vh;\r\n  line-height: 8vh;\r\n  padding-left: 20px;\r\n  color: inherit;\r\n  background-color: inherit;\r\n}\r\n.Shell li:hover {\r\n  /* transform:scale(1,1.2); */\r\n  background-color: #89cfd1;\r\n  border-radius: 10px;\r\n  color: #253f17;\r\n  transition: all 0.6s;\r\n}\r\n.Shell li:hover a {\r\n  color: white;\r\n}\r\n.Shell li a {\r\n  text-decoration: none;\r\n  color: #8ad6bd;\r\n}\r\n.ding {\r\n  height: 96px;\r\n}\r\n.top img {\r\n  float: right;\r\n  line-height: 60px;\r\n}\r\n.top img:hover {\r\n  transform: scale(1.3);\r\n  transition: all 0.4s;\r\n}\r\n.back {\r\n  width: 100%;\r\n  background-color: #c5ddd9;\r\n}\r\n.bg .im {\r\n  background-attachment: fixed;\r\n  width: 100%;\r\n  height: 100vh;\r\n  background-size: cover;\r\n  background-image: url(../assets/homeBanner.gif);\r\n}\r\n.content {\r\n  background-color: inherit;\r\n  width: 900px;\r\n  margin: 0 auto;\r\n  align-content: center;\r\n  padding: 20px;\r\n}\r\n.title {\r\n  color: #1d5a56;\r\n  font-family: Comic Sans MS;\r\n  margin: 10px;\r\n  border-bottom: solid 2px #7faba0;\r\n  padding-bottom: 0.6em;\r\n}\r\n.title2 {\r\n  color: #1d5a56;\r\n  font-family: Comic Sans MS;\r\n  margin: 10px;\r\n  margin-top: 50px;\r\n  border-bottom: solid 2px #a9ccc3;\r\n  padding-bottom: 0.6em;\r\n}\r\n.title:first-letter {\r\n  font-size: 50px;\r\n  text-shadow: 2px 2px 5px #444;\r\n}\r\n.title2:first-letter {\r\n  font-size: 50px;\r\n  text-shadow: 2px 2px 5px #444;\r\n}\r\n.pagraph {\r\n  font-family: \"Century Gothic\";\r\n  letter-spacing: 0.05em !important;\r\n  text-indent: 2em;\r\n  display: block;\r\n  transition: all 2s;\r\n  margin-left: 40px;\r\n  letter-spacing: 1.3px;\r\n  line-height: 1.8;\r\n  word-spacing: 3px;\r\n  color: #386f6c;\r\n}\r\n</style>\r\n","import mod from \"-!../../node_modules/cache-loader/dist/cjs.js??ref--13-0!../../node_modules/thread-loader/dist/cjs.js!../../node_modules/babel-loader/lib/index.js!../../node_modules/cache-loader/dist/cjs.js??ref--1-0!../../node_modules/vue-loader/lib/index.js??vue-loader-options!./communication.vue?vue&type=script&lang=js&\"; export default mod; export * from \"-!../../node_modules/cache-loader/dist/cjs.js??ref--13-0!../../node_modules/thread-loader/dist/cjs.js!../../node_modules/babel-loader/lib/index.js!../../node_modules/cache-loader/dist/cjs.js??ref--1-0!../../node_modules/vue-loader/lib/index.js??vue-loader-options!./communication.vue?vue&type=script&lang=js&\"","import { render, staticRenderFns } from \"./communication.vue?vue&type=template&id=43689d2d&scoped=true&\"\nimport script from \"./communication.vue?vue&type=script&lang=js&\"\nexport * from \"./communication.vue?vue&type=script&lang=js&\"\nimport style0 from \"./communication.vue?vue&type=style&index=0&id=43689d2d&scoped=true&lang=css&\"\n\n\n/* normalize component */\nimport normalizer from \"!../../node_modules/vue-loader/lib/runtime/componentNormalizer.js\"\nvar component = normalizer(\n  script,\n  render,\n  staticRenderFns,\n  false,\n  null,\n  \"43689d2d\",\n  null\n  \n)\n\nexport default component.exports","var render = function () {var _vm=this;var _h=_vm.$createElement;var _c=_vm._self._c||_h;return _c('div',[_vm._m(0),_c('div',{staticClass:\"back\"},[_c('div',{staticClass:\"content\"},[_c('div',{staticClass:\"ding\",attrs:{\"id\":\"top\"}}),_c('h1',{staticClass:\"topic\"},[_vm._v(\"公众教育与同伴教育\")]),_c('h1',{staticClass:\"title\"},[_vm._v(\"校内开展的TheraParkin介绍会\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 我们通过浙江大学医学院职规中心邀请浙大系附属医院的神经内/外科医生，通过辅导员以及医学院团委开展宣传，以科室介绍的方式吸引校内医学生团体的参与。另外，我们开展了与生科院、农科院相关社团的合作，通过联合宣传，我们吸引了较为庞大的观众群体。我们拟邀请刘畅学姐介绍iGEM与她的八年医学生涯，分享介绍合成生物学与临床科研工作生活。 \")]),_c('img',{staticClass:\"tu\",attrs:{\"src\":require(\"../assets/edu1-1.png\"),\"alt\":\"no pic\"}}),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 我们按照神经内/外科介绍-帕金森介绍-TheraParkin-合成生物学与医学线路完成介绍会，通过具体的临床工作为入口，以传统疗法的难点作为问题抛出，引入TheraParkin项目疗法，最终以合成生物学为落脚点向大家介绍合成生物学与医学。团队成员希望通过这次在校内较有影响力的介绍会，让更多同学了解到帕金森，了解到合成生物学与医学，吸引到更多不同专业的同学加入我们，为TheraParkin项目的完善提供更多不同专业方向的支持。 \")]),_c('div',{staticClass:\"ding\"}),_c('h1',{staticClass:\"title\"},[_vm._v(\"支教活动\")]),_c('div',{staticClass:\"showBox\"},[_c('div',{staticClass:\"head\"},[_c('div',{staticClass:\"c\",attrs:{\"id\":\"c1\"},on:{\"click\":function($event){return _vm.ch1()}}},[_vm._v(\"高年级教育\")]),_c('div',{staticClass:\"c\",attrs:{\"id\":\"c2\"},on:{\"click\":function($event){return _vm.ch2()}}},[_vm._v(\"低年级教育\")])]),_vm._m(1),_c('div',{staticClass:\"ding\"}),_c('div',{staticClass:\"ding\",attrs:{\"id\":\"des1\"}}),_c('h1',{staticClass:\"topic\"},[_vm._v(\"可持续的人文关怀与记录\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 我们联系了广播电视与传媒专业的同学，通过跟进一位帕金森患者或一户帕金森家庭，用纪录片与访谈的方式近距离观察与了解帕金森患者与其家属，用镜头记录下了更多的故事。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 纪录片的内容更多聚焦帕金森患者运动功能的紊乱所造成的生活不便，以及患者和家属生理心理问题。我们拟参考美国关于COPD患者的纪录片，以对比的手法开展默片式宣传；也将适当参考《凉子访谈录》的拍摄手法，以跟拍与访谈的形式作为纪录片的基调，以日常场景的搭建与还原作为纪录片的主体。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 拍摄完成后的影片将上传B站、推特等国内外网络平台，吸引更多人了解与关注这一群体。 待有一定播放量后通过B站开展网络直播，向公众宣传帕金森病以及TheraParkin项目，之后我们拟邀请刘畅学姐作为B站直播的嘉宾，积极推进纪录片的公众化和社会化。 \")]),_c('img',{staticClass:\"tu\",attrs:{\"src\":require(\"../assets/edu3-1.png\"),\"alt\":\"no pic\"}})])])]),_vm._m(2)])}\nvar staticRenderFns = [function () {var _vm=this;var _h=_vm.$createElement;var _c=_vm._self._c||_h;return _c('div',{staticClass:\"bg\"},[_c('div',{staticClass:\"im\",attrs:{\"id\":\"bg\"}})])},function () {var _vm=this;var _h=_vm.$createElement;var _c=_vm._self._c||_h;return _c('div',{staticClass:\"box\"},[_c('div',{staticClass:\"p\",attrs:{\"id\":\"p1\"}},[_c('p',{staticClass:\"pagraph\"},[_vm._v(\" iGEM队员通过暑期支教机会，向支教地的同学们介绍合成生物学、帕金森病与TheraParkin。我们设计乐高积块向同学们介绍Biobrick与合成生物学的核心思想。通过信息技术课程，我们将合成生物学思想与编程思想融合，设计相应生物模块，融入帕金森病元素。利用TheraParkin的两条治疗模块，构建治疗线路模块，引导同学们利用TheraParkin元件实现帕金森病的治疗。我们希望以此成为同学们编程思想的启蒙课，同时也让他们感受到合成生物学模块化、标准化的思想。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 除此之外团队成员拟联系杭州支教服务团队---醒山薪火联盟，去往杭州郊区学校调研，向同学们介绍合成生物学与高中生物学的异同，向其普及帕金森病以及TheraParkin项目，并收集高中段同学的对项目的疑问，留待团队进一步改进。 \")])]),_c('div',{staticClass:\"p\",attrs:{\"id\":\"p2\"}},[_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 对于低年级的支教地学生，我们希望将合成生物学与美术课程和劳动与技术课程融合，引导同学们画出自己喜爱的TheraParkin的模块图标，通过教师的iPad，用教学示范的方式引起同学对合成生物学的兴趣以及对团队项目的了解。另外，我们积极推进平面化图形向立体化模块的转变，利用乐高积块，设计合适的缺口模型，引导小朋友完善TheraParkin治疗线路，通过模块的插入、移植和互作，让小朋友们感受到合成生物学模块化、标准化的思想。 \")]),_c('img',{staticClass:\"tu\",attrs:{\"src\":require(\"../assets/edu2-1.png\"),\"alt\":\"no pic\"}})])])},function () {var _vm=this;var _h=_vm.$createElement;var _c=_vm._self._c||_h;return _c('div',{staticClass:\"leftP\",attrs:{\"id\":\"lef\"}},[_c('ul',{staticClass:\"Shell\"},[_c('li',[_c('a',{attrs:{\"href\":\"#top\"}},[_vm._v(\"公众教育与同伴教育\")])]),_c('li',[_c('a',{attrs:{\"href\":\"#des1\"}},[_vm._v(\"可持续的人文关怀与记录\")])])])])}]\n\nexport { render, staticRenderFns }","<template>\r\n  <div>\r\n    <div class=\"bg\"><div class=\"im\" id=\"bg\"></div></div>\r\n    <div class=\"back\">\r\n      <div class=\"content\">\r\n        <div class=\"ding\" id=\"top\"></div>\r\n        <h1 class=\"topic\">公众教育与同伴教育</h1>\r\n        <h1 class=\"title\">校内开展的TheraParkin介绍会</h1>\r\n        <p class=\"pagraph\">\r\n          我们通过浙江大学医学院职规中心邀请浙大系附属医院的神经内/外科医生，通过辅导员以及医学院团委开展宣传，以科室介绍的方式吸引校内医学生团体的参与。另外，我们开展了与生科院、农科院相关社团的合作，通过联合宣传，我们吸引了较为庞大的观众群体。我们拟邀请刘畅学姐介绍iGEM与她的八年医学生涯，分享介绍合成生物学与临床科研工作生活。\r\n        </p>\r\n        <img class=\"tu\" src=\"../assets/edu1-1.png\" alt=\"no pic\" />\r\n        <p class=\"pagraph\">\r\n          我们按照神经内/外科介绍-帕金森介绍-TheraParkin-合成生物学与医学线路完成介绍会，通过具体的临床工作为入口，以传统疗法的难点作为问题抛出，引入TheraParkin项目疗法，最终以合成生物学为落脚点向大家介绍合成生物学与医学。团队成员希望通过这次在校内较有影响力的介绍会，让更多同学了解到帕金森，了解到合成生物学与医学，吸引到更多不同专业的同学加入我们，为TheraParkin项目的完善提供更多不同专业方向的支持。\r\n        </p>\r\n        <div class=\"ding\"></div>\r\n        <h1 class=\"title\">支教活动</h1>\r\n        <div class=\"showBox\">\r\n          <div class=\"head\">\r\n            <div id=\"c1\" class=\"c\" @click=\"ch1()\">高年级教育</div>\r\n            <div id=\"c2\" class=\"c\" @click=\"ch2()\">低年级教育</div>\r\n          </div>\r\n          <div class=\"box\">\r\n            <div id=\"p1\" class=\"p\">\r\n              <p class=\"pagraph\">\r\n                iGEM队员通过暑期支教机会，向支教地的同学们介绍合成生物学、帕金森病与TheraParkin。我们设计乐高积块向同学们介绍Biobrick与合成生物学的核心思想。通过信息技术课程，我们将合成生物学思想与编程思想融合，设计相应生物模块，融入帕金森病元素。利用TheraParkin的两条治疗模块，构建治疗线路模块，引导同学们利用TheraParkin元件实现帕金森病的治疗。我们希望以此成为同学们编程思想的启蒙课，同时也让他们感受到合成生物学模块化、标准化的思想。\r\n              </p>\r\n              <p class=\"pagraph\">\r\n                除此之外团队成员拟联系杭州支教服务团队---醒山薪火联盟，去往杭州郊区学校调研，向同学们介绍合成生物学与高中生物学的异同，向其普及帕金森病以及TheraParkin项目，并收集高中段同学的对项目的疑问，留待团队进一步改进。\r\n              </p>\r\n            </div>\r\n            <div id=\"p2\" class=\"p\">\r\n              <p class=\"pagraph\">\r\n                对于低年级的支教地学生，我们希望将合成生物学与美术课程和劳动与技术课程融合，引导同学们画出自己喜爱的TheraParkin的模块图标，通过教师的iPad，用教学示范的方式引起同学对合成生物学的兴趣以及对团队项目的了解。另外，我们积极推进平面化图形向立体化模块的转变，利用乐高积块，设计合适的缺口模型，引导小朋友完善TheraParkin治疗线路，通过模块的插入、移植和互作，让小朋友们感受到合成生物学模块化、标准化的思想。\r\n              </p>\r\n              <img class=\"tu\" src=\"../assets/edu2-1.png\" alt=\"no pic\" />\r\n            </div>\r\n             </div>\r\n             <div class=\"ding\"></div>\r\n\r\n            <div id=\"des1\" class=\"ding\"></div>\r\n            <h1 class=\"topic\">可持续的人文关怀与记录</h1>\r\n            <p class=\"pagraph\">\r\n              我们联系了广播电视与传媒专业的同学，通过跟进一位帕金森患者或一户帕金森家庭，用纪录片与访谈的方式近距离观察与了解帕金森患者与其家属，用镜头记录下了更多的故事。\r\n            </p>\r\n            <p class=\"pagraph\">\r\n              纪录片的内容更多聚焦帕金森患者运动功能的紊乱所造成的生活不便，以及患者和家属生理心理问题。我们拟参考美国关于COPD患者的纪录片，以对比的手法开展默片式宣传；也将适当参考《凉子访谈录》的拍摄手法，以跟拍与访谈的形式作为纪录片的基调，以日常场景的搭建与还原作为纪录片的主体。\r\n            </p>\r\n            <p class=\"pagraph\">\r\n              拍摄完成后的影片将上传B站、推特等国内外网络平台，吸引更多人了解与关注这一群体。\r\n              待有一定播放量后通过B站开展网络直播，向公众宣传帕金森病以及TheraParkin项目，之后我们拟邀请刘畅学姐作为B站直播的嘉宾，积极推进纪录片的公众化和社会化。\r\n            </p>\r\n            <img class=\"tu\" src=\"../assets/edu3-1.png\" alt=\"no pic\" />\r\n          </div>\r\n       \r\n      </div>\r\n    </div>\r\n\r\n    <div id=\"lef\" class=\"leftP\">\r\n      <ul class=\"Shell\">\r\n        <li><a href=\"#top\">公众教育与同伴教育</a></li>\r\n        <li><a href=\"#des1\">可持续的人文关怀与记录</a></li>\r\n      </ul>\r\n    </div>\r\n  </div>\r\n</template>\r\n<script>\r\nexport default {\r\n  return() {},\r\n  methods: {\r\n    ch1() {\r\n      let p1 = document.getElementById(\"p1\");\r\n      let p2 = document.getElementById(\"p2\");\r\n\r\n      p1.classList.add(\"showup\");\r\n      p2.classList.remove(\"showup\");\r\n    },\r\n    ch2() {\r\n      let p1 = document.getElementById(\"p1\");\r\n      let p2 = document.getElementById(\"p2\");\r\n\r\n      p2.classList.add(\"showup\");\r\n      p1.classList.remove(\"showup\");\r\n    },\r\n  },\r\n  mounted() {\r\n    let lef = document.getElementById(\"lef\");\r\n\r\n    function addEvent(obj, type, fn) {\r\n      undefined;\r\n      if (obj.attachEvent) {\r\n        obj.attachEvent(\"on\" + type, function () {\r\n          undefined;\r\n          fn.call(obj);\r\n        });\r\n      } else {\r\n        undefined;\r\n        obj.addEventListener(type, fn, false);\r\n      }\r\n    }\r\n\r\n    addEvent(window, \"scroll\", function () {\r\n      undefined;\r\n      if (window.pageYOffset >= 455) {\r\n        lef.classList.add(\"stick\");\r\n      } else {\r\n        lef.classList.remove(\"stick\");\r\n      }\r\n    });\r\n  },\r\n};\r\n</script>\r\n<style scoped>\r\n.showBox .box .p {\r\n  display: none;\r\n  margin-bottom:20px;\r\n  margin-top:20px;\r\n}\r\n.title3 {\r\n  color: #3485a5;\r\n  font-family: Comic Sans MS;\r\n  margin: 10px;\r\n  font-size: 25px;\r\n  border-bottom: solid 2px #7fa2ab;\r\n  padding-bottom: 0.6em;\r\n}\r\n.showBox {\r\n  width: 100%;\r\n}\r\n.showBox .head .c {\r\n  width: 400px;\r\n  height: 40px;\r\n  line-height: 40px;\r\n  text-align: center;\r\n  display: inline-block;\r\n  margin: auto;\r\n  border-radius: 30px;\r\n  color: rgb(169, 207, 199);\r\n}\r\n.showBox .head .c:hover {\r\n  transform: scale(1.1);\r\n  transition: 0.6s;\r\n  background-color: #fff;\r\n  color: rgb(23, 97, 85);\r\n}\r\n.showBox .head #c1 {\r\n  background-color: #6ab480;\r\n}\r\n.showBox .head #c2 {\r\n  background-color: #6aafb4;\r\n}\r\n.showBox .head #c3 {\r\n  background-color: #2851aa;\r\n}\r\n.showBox .head #c4 {\r\n  background-color: #5636ad;\r\n}\r\n.showBox .box {\r\n  margin-top: 10px;\r\n  padding-left: 15px;\r\n  padding-right: 15px;\r\n  background-color: #d2e8eb;\r\n  width: 880px;\r\n  margin: auto;\r\n  border-radius: 30px;\r\n}\r\n.showBox .box .p {\r\n  display: none;\r\n}\r\n.showBox .box #p1.showup {\r\n  display: block;\r\n  transition: 1s;\r\n}\r\n.showBox .box #p2.showup {\r\n  display: block;\r\n  transition: 1s;\r\n}\r\n.showBox .box #p3.showup {\r\n  display: block;\r\n  transition: 1s;\r\n}\r\n.showBox .box #p4.showup {\r\n  display: block;\r\n  transition: 1s;\r\n}\r\n.ref {\r\n  font-style: italic;\r\n  font-family: Times New Roman, Times, serif !important;\r\n  padding-left: 2em;\r\n  text-align: left;\r\n  font-size: 0.8em;\r\n  color: #7d7d7d;\r\n  letter-spacing: 0.018em;\r\n}\r\n.tu {\r\n  margin-right: auto;\r\n  margin-left: auto;\r\n  display: block;\r\n  margin-top: 20px;\r\n  width: 600px;\r\n  height: auto;\r\n  border-radius: 30px;\r\n  border: #1d5a56;\r\n  background-size: 5px;\r\n}\r\n.topic {\r\n  color: #1d3f5a;\r\n  font-size: 60px;\r\n  text-align: center;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  font-family: \"Arial\";\r\n  letter-spacing: 15px;\r\n}\r\n#lef.stick {\r\n  opacity: 0.7;\r\n  transition: all 1s;\r\n}\r\n.Shell li a {\r\n  display: block;\r\n  width: 260px;\r\n}\r\n.leftP {\r\n  position: fixed;\r\n  left: 10px;\r\n  top: 30%;\r\n  opacity: 0;\r\n  height: 24vh;\r\n  width: 280px;\r\n  background-color: #3c6b6d;\r\n  border-radius: 20px;\r\n}\r\n.Shell {\r\n  margin: 0;\r\n  padding: 0;\r\n  color: inherit;\r\n  background-color: inherit;\r\n}\r\n.Shell:first-child {\r\n  margin-top: 4vh;\r\n}\r\n.Shell li {\r\n  list-style: none;\r\n  height: 8vh;\r\n  line-height: 8vh;\r\n  padding-left: 20px;\r\n  color: inherit;\r\n  background-color: inherit;\r\n}\r\n.Shell li:hover {\r\n  /* transform:scale(1,1.2); */\r\n  background-color: #89cfd1;\r\n  border-radius: 10px;\r\n  color: #253f17;\r\n  transition: all 0.6s;\r\n}\r\n.Shell li:hover a {\r\n  color: white;\r\n}\r\n.Shell li a {\r\n  text-decoration: none;\r\n  color: #8ad6bd;\r\n}\r\n.ding {\r\n  height: 96px;\r\n}\r\n.top img {\r\n  float: right;\r\n  line-height: 60px;\r\n}\r\n.top img:hover {\r\n  transform: scale(1.3);\r\n  transition: all 0.4s;\r\n}\r\n.back {\r\n  width: 100%;\r\n  background-color: #c5ddd9;\r\n}\r\n.bg .im {\r\n  background-attachment: fixed;\r\n  width: 100%;\r\n  height: 100vh;\r\n  background-size: cover;\r\n  background-image: url(../assets/homeBanner.gif);\r\n}\r\n.content {\r\n  background-color: inherit;\r\n  width: 900px;\r\n  margin: 0 auto;\r\n  align-content: center;\r\n  padding: 20px;\r\n}\r\n.title {\r\n  color: #1d5a56;\r\n  font-family: Comic Sans MS;\r\n  margin: 10px;\r\n  border-bottom: solid 2px #7faba0;\r\n  padding-bottom: 0.6em;\r\n}\r\n.title2 {\r\n  color: #1d5a56;\r\n  font-family: Comic Sans MS;\r\n  margin: 10px;\r\n  margin-top: 50px;\r\n  border-bottom: solid 2px #a9ccc3;\r\n  padding-bottom: 0.6em;\r\n}\r\n.title:first-letter {\r\n  font-size: 50px;\r\n  text-shadow: 2px 2px 5px #444;\r\n}\r\n.title2:first-letter {\r\n  font-size: 50px;\r\n  text-shadow: 2px 2px 5px #444;\r\n}\r\n.pagraph {\r\n  font-family: \"Century Gothic\";\r\n  letter-spacing: 0.05em !important;\r\n  text-indent: 2em;\r\n  display: block;\r\n  transition: all 2s;\r\n  margin-left: 40px;\r\n  letter-spacing: 1.3px;\r\n  line-height: 1.8;\r\n  word-spacing: 3px;\r\n  color: #386f6c;\r\n}\r\n</style>\r\n","import mod from \"-!../../node_modules/cache-loader/dist/cjs.js??ref--13-0!../../node_modules/thread-loader/dist/cjs.js!../../node_modules/babel-loader/lib/index.js!../../node_modules/cache-loader/dist/cjs.js??ref--1-0!../../node_modules/vue-loader/lib/index.js??vue-loader-options!./education.vue?vue&type=script&lang=js&\"; export default mod; export * from \"-!../../node_modules/cache-loader/dist/cjs.js??ref--13-0!../../node_modules/thread-loader/dist/cjs.js!../../node_modules/babel-loader/lib/index.js!../../node_modules/cache-loader/dist/cjs.js??ref--1-0!../../node_modules/vue-loader/lib/index.js??vue-loader-options!./education.vue?vue&type=script&lang=js&\"","import { render, staticRenderFns } from \"./education.vue?vue&type=template&id=3318ef58&scoped=true&\"\nimport script from \"./education.vue?vue&type=script&lang=js&\"\nexport * from \"./education.vue?vue&type=script&lang=js&\"\nimport style0 from \"./education.vue?vue&type=style&index=0&id=3318ef58&scoped=true&lang=css&\"\n\n\n/* normalize component */\nimport normalizer from \"!../../node_modules/vue-loader/lib/runtime/componentNormalizer.js\"\nvar component = normalizer(\n  script,\n  render,\n  staticRenderFns,\n  false,\n  null,\n  \"3318ef58\",\n  null\n  \n)\n\nexport default component.exports","var render = function () {var _vm=this;var _h=_vm.$createElement;var _c=_vm._self._c||_h;return _c('div',[_vm._m(0),_c('div',{staticClass:\"back\"},[_c('div',{staticClass:\"content\"},[_c('div',{staticClass:\"ding\",attrs:{\"id\":\"top\"}}),_c('h1',{staticClass:\"title\"},[_vm._v(\"概述\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 在TheraParkin项目中， 我们致力于打造包容的学习环境，让合成生物学社区更加开放。我们希望影响尽可能多的人，因此我们面向社会的不同群体开展了相关活动。在包容性模块，我们的主要焦点群体是一类特殊群体——帕金森患者，他们具有特殊的症状，我们致力于打造患者友好的创业与教育形式。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 另外，由于帕金森患者中老年人群体居多，我们专门开展了面向老年人的教育模式。目前人口老龄化程度不断加深，打造老年友好型的包容体系也是很有意义的。我们在教育和创业部分，从内容和形式两个方面构造了具有包容性和多元性的活动体系。 \")]),_c('div',{staticClass:\"ding\"}),_c('h1',{staticClass:\"title\"},[_vm._v(\"帕金森患者\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 2022年，我们针对帕金森患者群体，在不同的时间地点进行了宣传教育。在时间的选择上，我们将活动时间尽可能定在周末，同时在4月11日——帕金森日举办了大型的活动。在地点的选择上我们尽可能覆盖较多的群体，考虑到患者间的差异性，有的患者由于身体原因无法来到现场参与讲座，我们决定前往养老院，医院，甚至老人家中进行宣传教育。我们力求让每一位想了解帕金森治愈和生物学的患者都收获知识。 \")]),_c('div',{staticClass:\"showBox\"},[_c('div',{staticClass:\"head\"},[_c('div',{staticClass:\"c\",attrs:{\"id\":\"c1\"},on:{\"click\":function($event){return _vm.ch1()}}},[_vm._v(\"社区讲座\")]),_c('div',{staticClass:\"c\",attrs:{\"id\":\"c2\"},on:{\"click\":function($event){return _vm.ch2()}}},[_vm._v(\"养老院会谈\")]),_c('div',{staticClass:\"c\",attrs:{\"id\":\"c3\"},on:{\"click\":function($event){return _vm.ch3()}}},[_vm._v(\"家中对话\")]),_c('div',{staticClass:\"c\",attrs:{\"id\":\"c4\"},on:{\"click\":function($event){return _vm.ch4()}}},[_vm._v(\"青年群体\")])]),_vm._m(1)]),_c('div',{staticClass:\"ding\",attrs:{\"id\":\"des2\"}}),_c('h1',{staticClass:\"title\"},[_vm._v(\"老年群体\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 我国65岁以上人群PD的患病率大约是1.7%，这是一个比较高的比例，因此我们希望向整个老年群体科普有关于帕金森和合成生物学的知识。我们联系了杭州市有名的临终关怀组织，在他们的帮助下我们进行了分批次的老年群体公众教育。对于项目介绍，我们用简化版、大字版的介绍为活动资料发放给大家，并且删除了其中晦涩难懂的词语。 \")]),_c('div',{staticClass:\"ding\",attrs:{\"id\":\"des3\"}}),_c('h1',{staticClass:\"title\"},[_vm._v(\"其他公众群体\")]),_c('h3',{staticClass:\"title4\"},[_vm._v(\"家属\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 我们对帕金森患者的家属也开展了相关活动。重点在于心态把握和对患者的关怀，并且向他们表示关心。他们基于亲人的情况，对于帕金森知识抱有极大的好奇，我们向他们科普了帕金森与合成生物学的知识，帮助他们了解帕金森现状和未来的发展趋向。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 另外，我们与部分家属讲述了我们的创业活动，他们十分期待我们的药物能够最终推广，并且有意向使用我们的药物产品。 \")]),_c('h3',{staticClass:\"title4\"},[_vm._v(\"大众\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 对于大众的科普，我们从帕金森的自测和预防，和心态处理两个方面进行介绍科普。从心态上把握，从生活的小事中做到。 \")]),_c('div',{staticClass:\"ding\"}),_c('div',{staticClass:\"ding\"}),_c('div',{staticClass:\"ding\"}),_c('div',{staticClass:\"ding\"})])]),_vm._m(2)])}\nvar staticRenderFns = [function () {var _vm=this;var _h=_vm.$createElement;var _c=_vm._self._c||_h;return _c('div',{staticClass:\"bg\"},[_c('div',{staticClass:\"im\",attrs:{\"id\":\"bg\"}})])},function () {var _vm=this;var _h=_vm.$createElement;var _c=_vm._self._c||_h;return _c('div',{staticClass:\"box\"},[_c('div',{staticClass:\"p\",attrs:{\"id\":\"p1\"}},[_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 我们请有能力来到社区会议现场的朋友们进入现场，佩戴口罩，隔位就坐。会议每隔一段时间，就请他们休息一下，在期间夹杂部分康复训练。康复训练包括头颈部的训练，手部训练和站立坐下训练，我们在讲台和人群中间进行相关演示，确保他们无论有没有基础都能学会这些练习。会议的最后我们送给他们大字版的宣传单，以及一些适合康复训练的道具。 \")])]),_c('div',{staticClass:\"p\",attrs:{\"id\":\"p2\"}},[_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 部分患者由于身体原因可能不能来到会议现场，因此我们决定前往养老院进行交谈活动。在这里，我们印象颇深，他们表现出明显的震颤和行动迟缓的症状，这也增强了我们的使命感。我们以做志愿者护工的形式，小心搀扶着他们，并在交谈中讲述了我们的项目。我们亲切地了解每一位患者的情况，并且承诺下次再见。最后我们给他们分享了相关案例，让他们对康复充满希望。 \")])]),_c('div',{staticClass:\"p\",attrs:{\"id\":\"p3\"}},[_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 我们曾加入当地的帕友群进行活动的宣传。群友们都非常支持我们的活动。但由于时间、地点的安排，社区活动并不能兼顾到群内的每一位患者。此时有一位患者的儿子通过电话联系我们，他在群内看到了我们的消息，并表明他父亲非常希望能够参与此次活动，问是否能进行单独的知识传授。我们同意了这一请求。我们带着礼物来到这位老爷爷的家中，从他的口中我们了解到这么多年来他与帕金森之间的斗争，在谈话的间隙，他时不时地哽咽。我们感同身受，并表明我们项目的价值观念。在讲座的最后我们给他送了我们的手册和一面定制的小旗。 \")])]),_c('div',{staticClass:\"p\",attrs:{\"id\":\"p4\"}},[_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 在帕金森患者群体中，还有少部分的青年人，他们中的部分人由于工作忙无法来到我们的活动现场。我们通过邮箱、短信、群聊等形式发送我们的介绍信息和项目wiki。同时附上了电子版的康复训练指南。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 他们当中的一部分对我们的项目很感兴趣，并且希望得到更深一步的了解。我们考虑到这一点，对我们的项目wiki进行了高层次的设计，来方便患者人群的查看。我们改进了普通版本的wiki，加入了自动播放、大字版、简化版、夜间版等模式。这也是我们的包容性所在。 \")])])])},function () {var _vm=this;var _h=_vm.$createElement;var _c=_vm._self._c||_h;return _c('div',{staticClass:\"leftP\",attrs:{\"id\":\"lef\"}},[_c('ul',{staticClass:\"Shell\"},[_c('li',[_c('a',{attrs:{\"href\":\"#top\"}},[_vm._v(\"概述\")])]),_c('li',[_c('a',{attrs:{\"href\":\"#des1\"}},[_vm._v(\"帕金森患者\")])]),_c('li',[_c('a',{attrs:{\"href\":\"#des2\"}},[_vm._v(\"老年群体\")])]),_c('li',[_c('a',{attrs:{\"href\":\"#des3\"}},[_vm._v(\"其他公众群体\")])])])])}]\n\nexport { render, staticRenderFns }","<template>\r\n  <div>\r\n    <div class=\"bg\"><div class=\"im\" id=\"bg\"></div></div>\r\n    <div class=\"back\">\r\n      <div class=\"content\">\r\n        <div class=\"ding\" id=\"top\"></div>\r\n        <h1 class=\"title\">概述</h1>\r\n        <p class=\"pagraph\">\r\n          在TheraParkin项目中，\r\n          我们致力于打造包容的学习环境，让合成生物学社区更加开放。我们希望影响尽可能多的人，因此我们面向社会的不同群体开展了相关活动。在包容性模块，我们的主要焦点群体是一类特殊群体——帕金森患者，他们具有特殊的症状，我们致力于打造患者友好的创业与教育形式。\r\n        </p>\r\n        <p class=\"pagraph\">\r\n          另外，由于帕金森患者中老年人群体居多，我们专门开展了面向老年人的教育模式。目前人口老龄化程度不断加深，打造老年友好型的包容体系也是很有意义的。我们在教育和创业部分，从内容和形式两个方面构造了具有包容性和多元性的活动体系。\r\n        </p>\r\n\r\n        <div class=\"ding\"></div>\r\n        <h1 class=\"title\">帕金森患者</h1>\r\n        <p class=\"pagraph\">\r\n          2022年，我们针对帕金森患者群体，在不同的时间地点进行了宣传教育。在时间的选择上，我们将活动时间尽可能定在周末，同时在4月11日——帕金森日举办了大型的活动。在地点的选择上我们尽可能覆盖较多的群体，考虑到患者间的差异性，有的患者由于身体原因无法来到现场参与讲座，我们决定前往养老院，医院，甚至老人家中进行宣传教育。我们力求让每一位想了解帕金森治愈和生物学的患者都收获知识。\r\n        </p>\r\n\r\n        <div class=\"showBox\">\r\n          <div class=\"head\">\r\n            <div id=\"c1\" class=\"c\" @click=\"ch1()\">社区讲座</div>\r\n            <div id=\"c2\" class=\"c\" @click=\"ch2()\">养老院会谈</div>\r\n            <div id=\"c3\" class=\"c\" @click=\"ch3()\">家中对话</div>\r\n             <div id=\"c4\" class=\"c\" @click=\"ch4()\">青年群体</div>\r\n          </div>\r\n          <div class=\"box\">\r\n            <div id=\"p1\" class=\"p\">\r\n              <p class=\"pagraph\">\r\n我们请有能力来到社区会议现场的朋友们进入现场，佩戴口罩，隔位就坐。会议每隔一段时间，就请他们休息一下，在期间夹杂部分康复训练。康复训练包括头颈部的训练，手部训练和站立坐下训练，我们在讲台和人群中间进行相关演示，确保他们无论有没有基础都能学会这些练习。会议的最后我们送给他们大字版的宣传单，以及一些适合康复训练的道具。\r\n\r\n              </p>\r\n            </div>\r\n            <div id=\"p2\" class=\"p\">\r\n                <p class=\"pagraph\">\r\n                 部分患者由于身体原因可能不能来到会议现场，因此我们决定前往养老院进行交谈活动。在这里，我们印象颇深，他们表现出明显的震颤和行动迟缓的症状，这也增强了我们的使命感。我们以做志愿者护工的形式，小心搀扶着他们，并在交谈中讲述了我们的项目。我们亲切地了解每一位患者的情况，并且承诺下次再见。最后我们给他们分享了相关案例，让他们对康复充满希望。 \r\n              </p>\r\n            </div>\r\n            <div id=\"p3\" class=\"p\">\r\n                <p class=\"pagraph\">\r\n                  我们曾加入当地的帕友群进行活动的宣传。群友们都非常支持我们的活动。但由于时间、地点的安排，社区活动并不能兼顾到群内的每一位患者。此时有一位患者的儿子通过电话联系我们，他在群内看到了我们的消息，并表明他父亲非常希望能够参与此次活动，问是否能进行单独的知识传授。我们同意了这一请求。我们带着礼物来到这位老爷爷的家中，从他的口中我们了解到这么多年来他与帕金森之间的斗争，在谈话的间隙，他时不时地哽咽。我们感同身受，并表明我们项目的价值观念。在讲座的最后我们给他送了我们的手册和一面定制的小旗。\r\n              </p>\r\n            </div>\r\n            <div id=\"p4\" class=\"p\">\r\n                <p class=\"pagraph\">\r\n                  在帕金森患者群体中，还有少部分的青年人，他们中的部分人由于工作忙无法来到我们的活动现场。我们通过邮箱、短信、群聊等形式发送我们的介绍信息和项目wiki。同时附上了电子版的康复训练指南。\r\n              </p>\r\n              <p class=\"pagraph\">\r\n                  他们当中的一部分对我们的项目很感兴趣，并且希望得到更深一步的了解。我们考虑到这一点，对我们的项目wiki进行了高层次的设计，来方便患者人群的查看。我们改进了普通版本的wiki，加入了自动播放、大字版、简化版、夜间版等模式。这也是我们的包容性所在。\r\n              </p>\r\n            </div>\r\n          </div>\r\n        </div>\r\n        <div class=\"ding\" id=\"des2\"></div>\r\n    <h1 class=\"title\">老年群体</h1>\r\n    <p class=\"pagraph\">\r\n我国65岁以上人群PD的患病率大约是1.7%，这是一个比较高的比例，因此我们希望向整个老年群体科普有关于帕金森和合成生物学的知识。我们联系了杭州市有名的临终关怀组织，在他们的帮助下我们进行了分批次的老年群体公众教育。对于项目介绍，我们用简化版、大字版的介绍为活动资料发放给大家，并且删除了其中晦涩难懂的词语。\r\n    </p>\r\n    <div class=\"ding\" id=\"des3\"></div>\r\n    <h1 class=\"title\">其他公众群体</h1>\r\n    <h3 class=\"title4\">家属</h3>\r\n    <p class=\"pagraph\">\r\n我们对帕金森患者的家属也开展了相关活动。重点在于心态把握和对患者的关怀，并且向他们表示关心。他们基于亲人的情况，对于帕金森知识抱有极大的好奇，我们向他们科普了帕金森与合成生物学的知识，帮助他们了解帕金森现状和未来的发展趋向。\r\n    </p>\r\n    <p class=\"pagraph\">\r\n另外，我们与部分家属讲述了我们的创业活动，他们十分期待我们的药物能够最终推广，并且有意向使用我们的药物产品。\r\n\r\n    </p>\r\n    <h3 class=\"title4\">大众</h3>\r\n    \r\n     <p class=\"pagraph\">\r\n对于大众的科普，我们从帕金森的自测和预防，和心态处理两个方面进行介绍科普。从心态上把握，从生活的小事中做到。\r\n    </p>\r\n\r\n        <div class=\"ding\"></div>\r\n        <div class=\"ding\"></div>\r\n        <div class=\"ding\"></div>\r\n        <div class=\"ding\"></div>\r\n      </div>\r\n    </div>\r\n\r\n    <div id=\"lef\" class=\"leftP\">\r\n      <ul class=\"Shell\">\r\n        <li><a href=\"#top\">概述</a></li>\r\n        <li><a href=\"#des1\">帕金森患者</a></li>\r\n        <li><a href=\"#des2\">老年群体</a></li>\r\n        <li><a href=\"#des3\">其他公众群体</a></li>\r\n\r\n      </ul>\r\n    </div>\r\n  </div>\r\n</template>\r\n<script>\r\nexport default {\r\n  return() {},\r\n  methods: {\r\n    ch1() {\r\n      let p1 = document.getElementById(\"p1\");\r\n      let p2 = document.getElementById(\"p2\");\r\n      let p3 = document.getElementById(\"p3\");\r\n      let p4 = document.getElementById(\"p4\");\r\n      p1.classList.add(\"showup\");\r\n      p2.classList.remove(\"showup\");\r\n      p3.classList.remove(\"showup\");\r\n      p4.classList.remove(\"showup\");\r\n    },\r\n    ch2() {\r\n      let p1 = document.getElementById(\"p1\");\r\n      let p2 = document.getElementById(\"p2\");\r\n      let p3 = document.getElementById(\"p3\");\r\n      let p4 = document.getElementById(\"p4\");\r\n      p2.classList.add(\"showup\");\r\n      p1.classList.remove(\"showup\");\r\n      p3.classList.remove(\"showup\");\r\n      p4.classList.remove(\"showup\");\r\n    },\r\n    ch3() {\r\n      let p1 = document.getElementById(\"p1\");\r\n      let p2 = document.getElementById(\"p2\");\r\n      let p3 = document.getElementById(\"p3\");\r\n      let p4 = document.getElementById(\"p4\");\r\n      p3.classList.add(\"showup\");\r\n      p2.classList.remove(\"showup\");\r\n      p1.classList.remove(\"showup\");\r\n      p4.classList.remove(\"showup\");\r\n    },\r\n    ch4() {\r\n      let p1 = document.getElementById(\"p1\");\r\n      let p2 = document.getElementById(\"p2\");\r\n      let p3 = document.getElementById(\"p3\");\r\n      let p4 = document.getElementById(\"p4\");\r\n      p4.classList.add(\"showup\");\r\n      p2.classList.remove(\"showup\");\r\n      p1.classList.remove(\"showup\");\r\n      p3.classList.remove(\"showup\");\r\n    },\r\n  },\r\n  mounted() {\r\n    let lef = document.getElementById(\"lef\");\r\n\r\n    function addEvent(obj, type, fn) {\r\n      undefined;\r\n      if (obj.attachEvent) {\r\n        obj.attachEvent(\"on\" + type, function () {\r\n          undefined;\r\n          fn.call(obj);\r\n        });\r\n      } else {\r\n        undefined;\r\n        obj.addEventListener(type, fn, false);\r\n      }\r\n    }\r\n\r\n    addEvent(window, \"scroll\", function () {\r\n      undefined;\r\n      if (window.pageYOffset >= 455) {\r\n        lef.classList.add(\"stick\");\r\n      } else {\r\n        lef.classList.remove(\"stick\");\r\n      }\r\n    });\r\n  },\r\n};\r\n</script>\r\n<style scoped>\r\n.title4{\r\n    color: #1d445a;\r\n  font-family: Comic Sans MS;\r\n  margin: 10px;\r\n  font-size: 20px;\r\n}\r\n.showBox .box .p {\r\n  display: none;\r\n  margin-bottom:20px;\r\n  margin-top:20px;\r\n}\r\n.p ul li {\r\n  text-indent: 0;\r\n}\r\n.title3 {\r\n  color: #3485a5;\r\n  font-family: Comic Sans MS;\r\n  margin: 10px;\r\n  font-size: 35px;\r\n  border-bottom: solid 2px #7fa2ab;\r\n  padding-bottom: 0.6em;\r\n}\r\n.showBox {\r\n  width: 100%;\r\n}\r\n.showBox .head .c {\r\n  width: 200px;\r\n  height: 40px;\r\n  line-height: 40px;\r\n  text-align: center;\r\n  display: inline-block;\r\n  margin: auto;\r\n  border-radius: 30px;\r\n  color: rgb(169, 207, 199);\r\n}\r\n.showBox .head .c:hover {\r\n  transform: scale(1.1);\r\n  transition: 0.6s;\r\n  background-color: #fff;\r\n  color: rgb(23, 97, 85);\r\n}\r\n.showBox .head #c1 {\r\n  background-color: #6ab480;\r\n}\r\n.showBox .head #c2 {\r\n  background-color: #6aafb4;\r\n}\r\n.showBox .head #c3 {\r\n  background-color: #2851aa;\r\n}\r\n.showBox .head #c4 {\r\n  background-color: #5636ad;\r\n}\r\n.showBox .box {\r\n  margin-top: 10px;\r\n  padding-left: 15px;\r\n  padding-right: 15px;\r\n  background-color: #d2e8eb;\r\n  width: 880px;\r\n  margin: auto;\r\n  border-radius: 30px;\r\n}\r\n.showBox .box .p {\r\n  display: none;\r\n}\r\n.showBox .box #p1.showup {\r\n  display: block;\r\n  transition: 1s;\r\n}\r\n.showBox .box #p2.showup {\r\n  display: block;\r\n  transition: 1s;\r\n}\r\n.showBox .box #p3.showup {\r\n  display: block;\r\n  transition: 1s;\r\n}\r\n.showBox .box #p4.showup {\r\n  display: block;\r\n  transition: 1s;\r\n}\r\n.ref {\r\n  font-style: italic;\r\n  font-family: Times New Roman, Times, serif !important;\r\n  padding-left: 2em;\r\n  text-align: left;\r\n  font-size: 0.8em;\r\n  color: #7d7d7d;\r\n  letter-spacing: 0.018em;\r\n}\r\n.tu {\r\n  margin-right: auto;\r\n  margin-left: auto;\r\n  display: block;\r\n  margin-top: 20px;\r\n  width: 600px;\r\n  height: auto;\r\n  border-radius: 10px;\r\n  border: #1d5a56;\r\n  background-size: 5px;\r\n}\r\n.topic {\r\n  color: #1d3f5a;\r\n  font-size: 60px;\r\n  text-align: center;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  font-family: \"Arial\";\r\n  letter-spacing: 15px;\r\n}\r\n#lef.stick {\r\n  opacity: 0.7;\r\n  transition: all 1s;\r\n}\r\n.Shell li a {\r\n  display: block;\r\n  width: 260px;\r\n}\r\n.leftP {\r\n  position: fixed;\r\n  left: 10px;\r\n  top: 30%;\r\n  opacity: 0;\r\n  height: 40vh;\r\n  width: 200px;\r\n  background-color: #3c6b6d;\r\n  border-radius: 20px;\r\n}\r\n.Shell {\r\n  margin: 0;\r\n  padding: 0;\r\n  color: inherit;\r\n  background-color: inherit;\r\n}\r\n.Shell:first-child {\r\n  margin-top: 4vh;\r\n}\r\n.Shell li {\r\n  list-style: none;\r\n  height: 8vh;\r\n  line-height: 8vh;\r\n  padding-left: 20px;\r\n  color: inherit;\r\n  background-color: inherit;\r\n}\r\n.Shell li:hover {\r\n  /* transform:scale(1,1.2); */\r\n  background-color: #89cfd1;\r\n  border-radius: 10px;\r\n  color: #253f17;\r\n  transition: all 0.6s;\r\n}\r\n.Shell li:hover a {\r\n  color: white;\r\n}\r\n.Shell li a {\r\n  text-decoration: none;\r\n  color: #8ad6bd;\r\n}\r\n.ding {\r\n  height: 96px;\r\n}\r\n.top img {\r\n  float: right;\r\n  line-height: 60px;\r\n}\r\n.top img:hover {\r\n  transform: scale(1.3);\r\n  transition: all 0.4s;\r\n}\r\n.back {\r\n  width: 100%;\r\n  background-color: #c5ddd9;\r\n}\r\n.bg .im {\r\n  background-attachment: fixed;\r\n  width: 100%;\r\n  height: 100vh;\r\n  background-size: cover;\r\n  background-image: url(../assets/homeBanner.gif);\r\n}\r\n.content {\r\n  background-color: inherit;\r\n  width: 900px;\r\n  margin: 0 auto;\r\n  align-content: center;\r\n  padding: 20px;\r\n}\r\n.title {\r\n  color: #1d5a56;\r\n  font-family: Comic Sans MS;\r\n  margin: 10px;\r\n  border-bottom: solid 2px #7faba0;\r\n  padding-bottom: 0.6em;\r\n}\r\n.title2 {\r\n  color: #1d5a56;\r\n  font-family: Comic Sans MS;\r\n  margin: 10px;\r\n  margin-top: 50px;\r\n  border-bottom: solid 2px #a9ccc3;\r\n  padding-bottom: 0.6em;\r\n}\r\n.title:first-letter {\r\n  font-size: 50px;\r\n  text-shadow: 2px 2px 5px #444;\r\n}\r\n.title2:first-letter {\r\n  font-size: 50px;\r\n  text-shadow: 2px 2px 5px #444;\r\n}\r\n.pagraph {\r\n  font-family: \"Century Gothic\";\r\n  letter-spacing: 0.05em !important;\r\n  text-indent: 2em;\r\n  display: block;\r\n  transition: all 2s;\r\n  margin-left: 40px;\r\n  letter-spacing: 1.3px;\r\n  line-height: 1.8;\r\n  word-spacing: 3px;\r\n  color: #386f6c;\r\n}\r\n</style>\r\n","import mod from \"-!../../node_modules/cache-loader/dist/cjs.js??ref--13-0!../../node_modules/thread-loader/dist/cjs.js!../../node_modules/babel-loader/lib/index.js!../../node_modules/cache-loader/dist/cjs.js??ref--1-0!../../node_modules/vue-loader/lib/index.js??vue-loader-options!./inclusivity.vue?vue&type=script&lang=js&\"; export default mod; export * from \"-!../../node_modules/cache-loader/dist/cjs.js??ref--13-0!../../node_modules/thread-loader/dist/cjs.js!../../node_modules/babel-loader/lib/index.js!../../node_modules/cache-loader/dist/cjs.js??ref--1-0!../../node_modules/vue-loader/lib/index.js??vue-loader-options!./inclusivity.vue?vue&type=script&lang=js&\"","import { render, staticRenderFns } from \"./inclusivity.vue?vue&type=template&id=d9b88b42&scoped=true&\"\nimport script from \"./inclusivity.vue?vue&type=script&lang=js&\"\nexport * from \"./inclusivity.vue?vue&type=script&lang=js&\"\nimport style0 from \"./inclusivity.vue?vue&type=style&index=0&id=d9b88b42&scoped=true&lang=css&\"\n\n\n/* normalize component */\nimport normalizer from \"!../../node_modules/vue-loader/lib/runtime/componentNormalizer.js\"\nvar component = normalizer(\n  script,\n  render,\n  staticRenderFns,\n  false,\n  null,\n  \"d9b88b42\",\n  null\n  \n)\n\nexport default component.exports","var render = function () {var _vm=this;var _h=_vm.$createElement;var _c=_vm._self._c||_h;return _c('div',[_vm._m(0),_c('div',{staticClass:\"back\"},[_c('div',{staticClass:\"content\"},[_c('div',{staticClass:\"ding\",attrs:{\"id\":\"top\"}}),_c('h1',{staticClass:\"topic\"},[_vm._v(\"概述\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 今年，ZJU-China团队开发了对抗帕金森疾病的一款药物——TheraParkin，在整个研究周期中，我们充分关注了项目的安全性和可行性，并做出了出色的实验设计和验证。然而，如何让这些实验成果走向现实社会，是我们需要重视的问题。为此，我们站在企业家的角度进行了全方位的创业考虑，并对未来发展作出了规划。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 作为一家由大学生创办的未来创业型医药企业，我们在实践过程中不断向各类主体吸收意见。我们遵循负责任、人性化的原则，制定了药物产品的商业计划和专利策略，期望达到推广产品，保障健康的目标。另外，我们与各大行业机构建立了广泛的商业合作，并积极参与创新创业类活动。根据可持续性原则，我们建立了专项的创业学习资源分享平台，希望这些资源能够为之后团队所用。 \")]),_c('div',{staticClass:\"ding\"}),_c('h1',{staticClass:\"title\"},[_vm._v(\"帕金森创新药市场环境\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" TheraParkin是一款抗帕金森病的药物，隶属于医药行业中的创新药领域。我们注意到这款由我们自主研发的药物在创新药市场中具有极大的推广潜力。下面我们将借助PEST模型来对帕金森创新药市场环境进行评估。 \")]),_c('div',{staticClass:\"showBox\"},[_c('div',{staticClass:\"head\"},[_c('div',{staticClass:\"c\",attrs:{\"id\":\"c1\"},on:{\"click\":function($event){return _vm.ch1()}}},[_vm._v(\"政策\")]),_c('div',{staticClass:\"c\",attrs:{\"id\":\"c2\"},on:{\"click\":function($event){return _vm.ch2()}}},[_vm._v(\"经济\")]),_c('div',{staticClass:\"c\",attrs:{\"id\":\"c3\"},on:{\"click\":function($event){return _vm.ch3()}}},[_vm._v(\"社会\")]),_c('div',{staticClass:\"c\",attrs:{\"id\":\"c4\"},on:{\"click\":function($event){return _vm.ch4()}}},[_vm._v(\"技术\")])]),_vm._m(1)]),_c('div',{staticClass:\"ding\"}),_c('h1',{staticClass:\"title\"},[_vm._v(\"ZJU-TheraParkin公司在市场中的定位\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" ZJU-TheraParkin公司致力于帕金森中期、晚期的药物研发工作，并在早期提供检测服务（详情可见硬件部分）。我们根据实际情况选择了“VIC“的研发模式，并明确了公司在产业链中的定位。 \")]),_c('div',{staticClass:\"ding\"}),_c('h1',{staticClass:\"title\"},[_vm._v(\"研发模式：“VIC”\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 目前现有的制药公司研制创新药的研发模式主要有三种形式：大而强的Bigpharma模式、小而美的Biotech模式和新颖的“VIC”模式。作为以实验研究成果为核心技术的初创公司，我们不具有Bigpharma模式所属的重资产体系，也没有Biotech企业需要的首席科学家坐镇，因此，我们选择了第三种模式——“VIC模式”。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" “VIC模式”，即“VC（风险投资）+IP（知识产权）+CRO（研发外包）”模式，我们在其中充当的角色为IP的所有者（核心技术），与VC、CRO公司进行相关合作，共同打造一款安全有效的抗帕金森病药物。详细合作情况将在“商业合作”中提到。 \")]),_c('img',{staticClass:\"tu\",attrs:{\"src\":require(\"../assets/en2-1.png\"),\"alt\":\"no pic\"}}),_c('div',{staticClass:\"ding\"}),_c('h1',{staticClass:\"title\"},[_vm._v(\"产业链\")]),_vm._m(2),_c('img',{staticClass:\"tu\",attrs:{\"src\":require(\"../assets/en2-2.png\"),\"alt\":\"no pic\"}}),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 作为一个初创型企业，我们充分评估了企业对于上游原材料购买，中游包装制造等方面的可能性，最终决定在公司初期阶段交由CRO公司进行这方面任务的承担。请点击此处查看ZJU-TheraParkin与CRO公司负责的不同业务清单。 \")]),_c('div',{staticClass:\"ding\"}),_c('h1',{staticClass:\"title\"},[_vm._v(\"竞争分析\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 创新药行业是一个核心技术高度集中的行业，相比于其他行业，竞争具有一定的特殊性。对此，我们考虑到以下的行业竞争因素。 \")]),_vm._m(3),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 我们考虑到初创公司可能所面临的竞争情况，运用波特五力模型进行市场上现有的帕金森疗法及药物疗法的竞争分析，这将在我们的拓展部分进行讨论。 \")]),_c('div',{staticClass:\"ding\"}),_c('h1',{staticClass:\"title\"},[_vm._v(\"SWOT分析\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" Strengths \")]),_vm._m(4),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" Weakness \")]),_vm._m(5),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" Opportunities \")]),_vm._m(6),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" Threats \")]),_vm._m(7),_c('div',{staticClass:\"ding\",attrs:{\"id\":\"des1\"}}),_c('h1',{staticClass:\"topic\"},[_vm._v(\"商业模式\")]),_c('img',{staticClass:\"tu\",attrs:{\"src\":require(\"../assets/en3-1.png\"),\"alt\":\"no pic\"}}),_c('div',{staticClass:\"ding\"}),_c('h1',{staticClass:\"title\"},[_vm._v(\"定价策略\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 由于TheraParkin创新药的特殊性，我们采用“需求驱动定价法”来主导我们的定价策略。目前市场上对有效性帕金森药物的需求极大，我们预计这款药物会有很大的利润空间。然而，我们需要将价格定在一个合理的区间，既能尽快回收前期研发成本，又能保证一定的销量（销量是比较重要的部分，让多数人疾病治愈也是我们的目标）。我们和VC公司方分析师沟通了相关事宜，并预计在将来制定出我们具体的定价策略。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 在涉及收入来源与利润分配问题时，我们考虑到一些比较重要的环节。 \")]),_c('div',{staticClass:\"ding\"}),_c('h1',{staticClass:\"title\"},[_vm._v(\"医保谈判 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 我们渴望与政府建立医保谈判关系，以此保证合适的价格与足够的销量。目前的形势下，医保控费是大趋势，未来医保对于同质化创新的支付会趋紧，而对首创性的药物会更加开放。 \")]),_c('img',{staticClass:\"tu\",attrs:{\"src\":require(\"../assets/en3-2.png\"),\"alt\":\"no pic\"}}),_c('div',{staticClass:\"ding\"}),_c('h1',{staticClass:\"title\"},[_vm._v(\"三方权益分配问题\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 这将在我们的拓展部分进行展示 \")]),_c('div',{staticClass:\"ding\",attrs:{\"id\":\"des2\"}}),_c('h1',{staticClass:\"topic\"},[_vm._v(\"资本财务\")]),_c('div',{staticClass:\"ding\"}),_c('h1',{staticClass:\"title\"},[_vm._v(\"现状、预测、分析\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 这将在我们的拓展部分进行展示。 \")]),_c('div',{staticClass:\"ding\"}),_c('h1',{staticClass:\"title\"},[_vm._v(\"风险退出\")]),_c('img',{staticClass:\"tu\",attrs:{\"src\":require(\"../assets/en3-3.png\"),\"alt\":\"no pic\"}}),_c('div',{staticClass:\"ding\",attrs:{\"id\":\"des3\"}}),_c('h1',{staticClass:\"topic\"},[_vm._v(\"推广运营\")]),_c('div',{staticClass:\"ding\"}),_c('h1',{staticClass:\"title\"},[_vm._v(\"发展路线图\")]),_c('img',{staticClass:\"tu\",attrs:{\"src\":require(\"../assets/en4-4.png\"),\"alt\":\"no pic\"}}),_c('div',{staticClass:\"ding\"}),_c('h1',{staticClass:\"title\"},[_vm._v(\"长期影响\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 我们以长远的目光注视我们的项目。 在ZJU-TheraParkin的业务中，我们不仅仅关注财务增长，而且更多地关注这款药物对社会医疗保健产生的长期影响。我们的团队相信通过不断地实践和验证，最终能为帕金森患者提供一套科学的解决方案。公司在长期发展中，也将拓展更多业务服务于帕金森患者，构建完整的帕金森服务体系链。我们将不只关注医药领域，同时在更多方面完善我们的服务工作（如：适合的家居设施；教育培训； \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 在这一方向，我们考虑到医患教育是很重要的一部分，因此我们也同样关心患者的关于这款新型药物的了解情况，我们对此进行了一系列人类实践，详情可见我们的综合人类实践模块和教育模块。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 请查看关于TheraParkin的商业计划书。 \")]),_c('div',{staticClass:\"ding\",attrs:{\"id\":\"des4\"}}),_c('h1',{staticClass:\"topic\"},[_vm._v(\"专利策略\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" TheraParkin是一款创新型药物，药品的科研创新是一条高成本赛道，企业要及时申请专利。在医药领域拥有好的专利布局，有利于制药企业的整体发展。 \")]),_c('div',{staticClass:\"ding\"}),_c('h1',{staticClass:\"title\"},[_vm._v(\"开端：新专利法解读\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 我们关注到2021年6月1日的新法规——修改后的《中华人民共和国专利法》正式实施。其中对于药品专利有两个倾向：一是规定了药品专利期限的补偿制度，二是新增药品专利早期纠纷解决机制，也就是药品专利链接制度。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 那么新专利法对创新药研发将带来怎样的影响？作为创新药企业应该如何应对？对此，我们在“2021大健康产业高质量发展大会暨第六届中国医药研发·创新峰会（PDI）”现场得到了百诺知识管理中心经理张蕙前瞻性的解答。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 她提到：“对原研药企业要做好严密高效的专利保护网，建立预警与防控机制，及时对仿制药企业的登记信息进行清盘与否作出判断。” \")]),_c('img',{staticClass:\"tu\",attrs:{\"src\":require(\"../assets/en4-5.png\"),\"alt\":\"no pic\"}}),_c('img',{staticClass:\"tu\",attrs:{\"src\":require(\"../assets/en4-6.png\"),\"alt\":\"no pic\"}}),_c('div',{staticClass:\"ding\"}),_c('h1',{staticClass:\"title\"},[_vm._v(\"发展：药物专利的PLM策略 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 然而，与此相对应的是“专利悬崖”的出现，如果没有专利的保护，制药企业就是化工企业，所以专利是制药企业获得利润的关键。为了减少部分专利到期的冲击，我们利用管理学中的常用PLM（产品生命周期管理）方法来指定药物专利策略。 \")]),_vm._m(8),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 采用各种专利的组合是制药企业的通用做法，但仅仅这些策略， 制药行业作为资本和知识密集型行业，维护市场需要强大的知识产权资源，产品差异化和产品认同。因此我们去访问了X公司医药组负责法务的X先生，他给我们分享了一些案例与可参考的医药法务知识，以便我们更好地开展我们的专利策略，具体可以在拓展模块查看。 \")]),_c('div',{staticClass:\"ding\",attrs:{\"id\":\"des5\"}}),_c('h1',{staticClass:\"topic\"},[_vm._v(\"商业合作\")]),_c('div',{staticClass:\"ding\"}),_c('h1',{staticClass:\"title\"},[_vm._v(\"产品合作>\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 我们的TheraParkin产品是一款针对于帕金森中、晚期的生物制剂，用于患者疾病治疗。同时，我们设计了一款硬件，针对于帕金森早期的疾病监测。作为一个负责任且人性化的团队，我们打算在公司原有产品的基础上，引进其他产品，或者与其他产品进行合作，以期提供覆盖帕金森全疗程联合疗法，更好地服务于帕金森患者。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 联合：早期康复训练 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 联合：中晚期物理疗法 \")]),_c('div',{staticClass:\"ding\"}),_c('h1',{staticClass:\"title\"},[_vm._v(\"VC公司合作\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 在之前的介绍中我们提到了“VIC”模式，这里主要就VC公司与ZJU-TheraParkin的合作情况做出介绍。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 与我们合作的VC公司是X。我们和与我们对接的负责人进行了一系列交谈，明确了投资者在评判项目好坏的基本准则。并且更加明确了TheraParkin的优势与市场定位。具体情况请看我们整理的文件。 \")]),_c('div',{staticClass:\"ding\"}),_c('h1',{staticClass:\"title\"},[_vm._v(\"CRO公司合作\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" CRO公司十分乐意参与我们的创业工作，并且向我们说明了他们所负责的领域与任务。X先生告诉我们他们公司的主要情况，并就具体合作事项达成了协议。附件。 \")]),_c('div',{staticClass:\"ding\"}),_c('h1',{staticClass:\"title\"},[_vm._v(\"并购与路演\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 在我们的项目实施期间，不断有其他公司的相关人员来询问我们项目的具体情况。考虑到有大公司联系我们的可能性，我们针对并购情况预先做好了准备。这里，我们进行了预先路演，并撰写了相关文件。 \")]),_c('img',{staticClass:\"tu\",attrs:{\"src\":require(\"../assets/en4-7.png\"),\"alt\":\"no pic\"}}),_c('div',{staticClass:\"ding\",attrs:{\"id\":\"des6\"}}),_c('h1',{staticClass:\"topic\"},[_vm._v(\"创业学习资源——ZJU一贯的团队精神\")]),_c('div',{staticClass:\"ding\"}),_c('h1',{staticClass:\"title\"},[_vm._v(\"躬身实践\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 我们希望ZJU-TheraParkin能够成为一家优秀的企业，因此，我们不断学习创业知识，寻找创新创业的机遇。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 我们参加了2022年6月举办的“合成生物学创业大赛”，与评委进行了交流展示。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 我们与X iGEM团队进行了创业交谈，并从对话中了解到合作、共同创业的可能性。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 我们参加了在上海举办的第十一届绿色医药创新企业大会，在现场与众多企业家们进行想法展示与项目交流。 \")]),_c('div',{staticClass:\"ding\"}),_c('h1',{staticClass:\"title\"},[_vm._v(\"创业活动的Campaign\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 在浙江省杭州市未来科技城举办创业宣讲会。介绍帕金森，介绍TheraParkin，介绍浙江大学团队。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 得到外界与ZJU-iGEM团队的合作资源。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 学校内，我们和历届iGEMer共享喜悦，并建立了一个共享平台与联系方式。（公众号） \")]),_c('div',{staticClass:\"ding\"}),_c('div',{staticClass:\"ding\"}),_c('div',{staticClass:\"ding\"}),_c('div',{staticClass:\"ding\"})])]),_vm._m(9)])}\nvar staticRenderFns = [function () {var _vm=this;var _h=_vm.$createElement;var _c=_vm._self._c||_h;return _c('div',{staticClass:\"bg\"},[_c('div',{staticClass:\"im\",attrs:{\"id\":\"bg\"}})])},function () {var _vm=this;var _h=_vm.$createElement;var _c=_vm._self._c||_h;return _c('div',{staticClass:\"box\"},[_c('div',{staticClass:\"p\",attrs:{\"id\":\"p1\"}},[_c('p',{staticClass:\"pagraph\"},[_vm._v(\" TheraParkin疗法具有首创性（First in class）。近年来国家大力支持创新药发展，出台了一系列相关政策。以2022年1月30日出台的《“十四五”医药工业发展规划》为例，规划提出“十四五”期间推动医药工业创新转型，实现高质量发展的目标，并对药企创新转型与国际化，创新药投资领域给予支持。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 为了更好地了解当下帕金森创新药发展的政策机遇，我们参加了“第五届中国资本市场IRM高峰论坛“，得到了星石资本的执行董事方先生的启示，他提到：“近几年应该是创新药政策最好的时候，无论是未来的宏观环境，还是医药的科技和消费属性，都非常适合医药企业的成长。” \")])]),_c('div',{staticClass:\"p\",attrs:{\"id\":\"p2\"}},[_c('p',{staticClass:\"pagraph\"},[_vm._v(\" TheraParkin所属领域增长高，潜力大。根据Frost&Sullivan的报告数据显示，全球范围内创新药在医药领域占比逐渐增大，增速不断上涨；创新药研发投入不断上升，行业具有较大的潜力。 \")]),_c('img',{staticClass:\"tu\",attrs:{\"src\":require(\"../assets/en1-1.png\"),\"alt\":\"no pic\"}}),_c('img',{staticClass:\"tu\",attrs:{\"src\":require(\"../assets/en1-2.png\"),\"alt\":\"no pic\"}})]),_c('div',{staticClass:\"p\",attrs:{\"id\":\"p3\"}},[_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 社会：TheraParkin用于治疗帕金森疾病，帕金森群体中大多为老年群体。随着人口老龄化程度加剧，现有条件下帕金森患者数量不断增多，与此相对应的帕金森用药需求需求也不断增大。中国作为世界范围内帕金森人数最多的国家，亟需解决帕金森病症难题。 \")]),_c('img',{staticClass:\"tu\",attrs:{\"src\":require(\"../assets/en1-3.png\"),\"alt\":\"no pic\"}})]),_c('div',{staticClass:\"p\",attrs:{\"id\":\"p4\"}},[_c('p',{staticClass:\"pagraph\"},[_vm._v(\" TheraParkin使用基因疗法进行帕金森疾病治疗。在帕金森创新药领域，合适的靶点及治愈手段是药物的关键，行业具有极高的技术壁垒。基因治疗作为一种独特的疗法，结合了当下前沿研究进展，为治愈帕金森疾病提供了良好的技术背景。 \")])])])},function () {var _vm=this;var _h=_vm.$createElement;var _c=_vm._self._c||_h;return _c('p',{staticClass:\"pagraph\"},[_c('ul',[_c('li',[_vm._v(\"上游：基因原料\")]),_c('li',[_vm._v(\"中游：生物创新药\")]),_c('li',[_vm._v(\"下游：医药流通\")])])])},function () {var _vm=this;var _h=_vm.$createElement;var _c=_vm._self._c||_h;return _c('p',{staticClass:\"pagraph\"},[_c('ul',[_c('li',[_vm._v(\"从市场方面来看，开发新药需要有成熟的销售通道。\")]),_c('li',[_vm._v(\"从技术方面来看，新药研发上市后，同行进行仿制的技术难度评估。\")]),_c('li',[_vm._v(\"从竞争格局来看，开发的新药需要看是否有已上市同类产品竞争，是否有同类在研产品进行研发及研发进程。\")]),_c('li',[_vm._v(\"从创新角度来看，需要观察开发的新药是否属于全新靶点的FIC药品。 \")]),_c('li',[_vm._v(\"从临床价值方面来看，需要看新药的临床疗效直接影响患者治疗意愿，也影响医生的处方习惯。\")]),_c('li',[_vm._v(\"从生命周期来看，新药生命周期从引入到撤市的过程是否严密，是否有严密的专利保护体系。\")]),_c('li',[_vm._v(\"从财务效率来看，需要注意新药研发过程的投资金额，投资周期及研发成功的风险大小等。\")])])])},function () {var _vm=this;var _h=_vm.$createElement;var _c=_vm._self._c||_h;return _c('p',{staticClass:\"pagraph\"},[_c('ul',[_c('li',[_vm._v(\"创新：治疗帕金森疾病的新方法\")]),_c('li',[_vm._v(\"多元：跨学科团队思维碰撞\")]),_c('li',[_vm._v(\"友好：满足需求，医患交流\")]),_c('li',[_vm._v(\"完整：早中晚期配套体系\")])])])},function () {var _vm=this;var _h=_vm.$createElement;var _c=_vm._self._c||_h;return _c('p',{staticClass:\"pagraph\"},[_c('ul',[_c('li',[_vm._v(\"年轻团队：商业和创业经验不足\")]),_c('li',[_vm._v(\"初创公司：尚未在市场上建立声誉\")]),_c('li',[_vm._v(\"资源受限：初期投资，管理体系劣势\")])])])},function () {var _vm=this;var _h=_vm.$createElement;var _c=_vm._self._c||_h;return _c('p',{staticClass:\"pagraph\"},[_c('ul',[_c('li',[_vm._v(\"标准化：与iGEM基金会的兼容性生物砖标准\")]),_c('li',[_vm._v(\"创新技术：新型治愈手段，较大推广潜力 \")]),_c('li',[_vm._v(\"市场优势：需求广阔、政策支持\")])])])},function () {var _vm=this;var _h=_vm.$createElement;var _c=_vm._self._c||_h;return _c('p',{staticClass:\"pagraph\"},[_c('ul',[_c('li',[_vm._v(\"竞争：拥有更多专业知识和资金的公司\")]),_c('li',[_vm._v(\"资源：资金链、原料受限 \")]),_c('li',[_vm._v(\"监管：监管法律的变化\")])])])},function () {var _vm=this;var _h=_vm.$createElement;var _c=_vm._self._c||_h;return _c('p',{staticClass:\"pagraph\"},[_c('ul',[_c('li',[_vm._v(\"缩短开发时间，加速药物的上市速度\")]),_c('li',[_vm._v(\"在药物销售的独占期注册商标，树立品牌形象\")]),_c('li',[_vm._v(\"销售独占期间积极拓展市场\")]),_c('li',[_vm._v(\"当仿制药进入市场时，采取积极的市场策略\")])])])},function () {var _vm=this;var _h=_vm.$createElement;var _c=_vm._self._c||_h;return _c('div',{staticClass:\"leftP\",attrs:{\"id\":\"lef\"}},[_c('ul',{staticClass:\"Shell\"},[_c('li',[_c('a',{attrs:{\"href\":\"#top\"}},[_vm._v(\"概述\")])]),_c('li',[_c('a',{attrs:{\"href\":\"#des1\"}},[_vm._v(\"商业模式\")])]),_c('li',[_c('a',{attrs:{\"href\":\"#des2\"}},[_vm._v(\"资本财务\")])]),_c('li',[_c('a',{attrs:{\"href\":\"#des3\"}},[_vm._v(\"推广运营\")])]),_c('li',[_c('a',{attrs:{\"href\":\"#des4\"}},[_vm._v(\"专利策略\")])]),_c('li',[_c('a',{attrs:{\"href\":\"#des5\"}},[_vm._v(\"商业合作\")])]),_c('li',[_c('a',{attrs:{\"href\":\"#des6\"}},[_vm._v(\"创业学习资源\")])])])])}]\n\nexport { render, staticRenderFns }","<template>\r\n  <div>\r\n    <div class=\"bg\"><div class=\"im\" id=\"bg\"></div></div>\r\n    <div class=\"back\">\r\n      <div class=\"content\">\r\n        <div class=\"ding\" id=\"top\"></div>\r\n        <h1 class=\"topic\">概述</h1>\r\n        <p class=\"pagraph\">\r\n          今年，ZJU-China团队开发了对抗帕金森疾病的一款药物——TheraParkin，在整个研究周期中，我们充分关注了项目的安全性和可行性，并做出了出色的实验设计和验证。然而，如何让这些实验成果走向现实社会，是我们需要重视的问题。为此，我们站在企业家的角度进行了全方位的创业考虑，并对未来发展作出了规划。\r\n        </p>\r\n        <p class=\"pagraph\">\r\n          作为一家由大学生创办的未来创业型医药企业，我们在实践过程中不断向各类主体吸收意见。我们遵循负责任、人性化的原则，制定了药物产品的商业计划和专利策略，期望达到推广产品，保障健康的目标。另外，我们与各大行业机构建立了广泛的商业合作，并积极参与创新创业类活动。根据可持续性原则，我们建立了专项的创业学习资源分享平台，希望这些资源能够为之后团队所用。\r\n        </p>\r\n        <div class=\"ding\"></div>\r\n        <h1 class=\"title\">帕金森创新药市场环境</h1>\r\n        <p class=\"pagraph\">\r\n          TheraParkin是一款抗帕金森病的药物，隶属于医药行业中的创新药领域。我们注意到这款由我们自主研发的药物在创新药市场中具有极大的推广潜力。下面我们将借助PEST模型来对帕金森创新药市场环境进行评估。\r\n        </p>\r\n        <div class=\"showBox\">\r\n          <div class=\"head\">\r\n            <div id=\"c1\" class=\"c\" @click=\"ch1()\">政策</div>\r\n            <div id=\"c2\" class=\"c\" @click=\"ch2()\">经济</div>\r\n            <div id=\"c3\" class=\"c\" @click=\"ch3()\">社会</div>\r\n            <div id=\"c4\" class=\"c\" @click=\"ch4()\">技术</div>\r\n          </div>\r\n          <div class=\"box\">\r\n            <div id=\"p1\" class=\"p\">\r\n              <p class=\"pagraph\">\r\n                TheraParkin疗法具有首创性（First in\r\n                class）。近年来国家大力支持创新药发展，出台了一系列相关政策。以2022年1月30日出台的《“十四五”医药工业发展规划》为例，规划提出“十四五”期间推动医药工业创新转型，实现高质量发展的目标，并对药企创新转型与国际化，创新药投资领域给予支持。\r\n              </p>\r\n              <p class=\"pagraph\">\r\n                为了更好地了解当下帕金森创新药发展的政策机遇，我们参加了“第五届中国资本市场IRM高峰论坛“，得到了星石资本的执行董事方先生的启示，他提到：“近几年应该是创新药政策最好的时候，无论是未来的宏观环境，还是医药的科技和消费属性，都非常适合医药企业的成长。”\r\n              </p>\r\n            </div>\r\n            <div id=\"p2\" class=\"p\">\r\n              <p class=\"pagraph\">\r\n                TheraParkin所属领域增长高，潜力大。根据Frost&Sullivan的报告数据显示，全球范围内创新药在医药领域占比逐渐增大，增速不断上涨；创新药研发投入不断上升，行业具有较大的潜力。\r\n              </p>\r\n              <img class=\"tu\" src=\"../assets/en1-1.png\" alt=\"no pic\" />\r\n              <img class=\"tu\" src=\"../assets/en1-2.png\" alt=\"no pic\" />\r\n            </div>\r\n            <div id=\"p3\" class=\"p\">\r\n              <p class=\"pagraph\">\r\n                社会：TheraParkin用于治疗帕金森疾病，帕金森群体中大多为老年群体。随着人口老龄化程度加剧，现有条件下帕金森患者数量不断增多，与此相对应的帕金森用药需求需求也不断增大。中国作为世界范围内帕金森人数最多的国家，亟需解决帕金森病症难题。\r\n              </p>\r\n              <img class=\"tu\" src=\"../assets/en1-3.png\" alt=\"no pic\" />\r\n            </div>\r\n            <div id=\"p4\" class=\"p\">\r\n              <p class=\"pagraph\">\r\n                TheraParkin使用基因疗法进行帕金森疾病治疗。在帕金森创新药领域，合适的靶点及治愈手段是药物的关键，行业具有极高的技术壁垒。基因治疗作为一种独特的疗法，结合了当下前沿研究进展，为治愈帕金森疾病提供了良好的技术背景。\r\n              </p>\r\n            </div>\r\n          </div>\r\n        </div>\r\n\r\n        <div class=\"ding\"></div>\r\n    <h1 class=\"title\">ZJU-TheraParkin公司在市场中的定位</h1>\r\n    <p class=\"pagraph\">\r\nZJU-TheraParkin公司致力于帕金森中期、晚期的药物研发工作，并在早期提供检测服务（详情可见硬件部分）。我们根据实际情况选择了“VIC“的研发模式，并明确了公司在产业链中的定位。\r\n    </p>\r\n\r\n    <div class=\"ding\"></div>\r\n    <h1 class=\"title\">研发模式：“VIC”</h1>\r\n    <p class=\"pagraph\">\r\n目前现有的制药公司研制创新药的研发模式主要有三种形式：大而强的Bigpharma模式、小而美的Biotech模式和新颖的“VIC”模式。作为以实验研究成果为核心技术的初创公司，我们不具有Bigpharma模式所属的重资产体系，也没有Biotech企业需要的首席科学家坐镇，因此，我们选择了第三种模式——“VIC模式”。\r\n    </p>\r\n     <p class=\"pagraph\">\r\n“VIC模式”，即“VC（风险投资）+IP（知识产权）+CRO（研发外包）”模式，我们在其中充当的角色为IP的所有者（核心技术），与VC、CRO公司进行相关合作，共同打造一款安全有效的抗帕金森病药物。详细合作情况将在“商业合作”中提到。\r\n    </p>\r\n    <img class=\"tu\" src=\"../assets/en2-1.png\" alt=\"no pic\" />\r\n<div class=\"ding\"></div>\r\n    <h1 class=\"title\">产业链</h1>\r\n    <p class=\"pagraph\">\r\n<ul>\r\n    <li>上游：基因原料</li>\r\n    <li>中游：生物创新药</li>\r\n    <li>下游：医药流通</li>\r\n</ul>\r\n    </p>\r\n    <img class=\"tu\" src=\"../assets/en2-2.png\" alt=\"no pic\" />\r\n\r\n    <p class=\"pagraph\">\r\n作为一个初创型企业，我们充分评估了企业对于上游原材料购买，中游包装制造等方面的可能性，最终决定在公司初期阶段交由CRO公司进行这方面任务的承担。请点击此处查看ZJU-TheraParkin与CRO公司负责的不同业务清单。\r\n    </p>\r\n\r\n<div class=\"ding\"></div>\r\n    <h1 class=\"title\">竞争分析</h1>\r\n    <p class=\"pagraph\">\r\n创新药行业是一个核心技术高度集中的行业，相比于其他行业，竞争具有一定的特殊性。对此，我们考虑到以下的行业竞争因素。\r\n    </p>\r\n    <p class=\"pagraph\">\r\n<ul>\r\n    <li>从市场方面来看，开发新药需要有成熟的销售通道。</li>\r\n    <li>从技术方面来看，新药研发上市后，同行进行仿制的技术难度评估。</li>\r\n    <li>从竞争格局来看，开发的新药需要看是否有已上市同类产品竞争，是否有同类在研产品进行研发及研发进程。</li>\r\n    <li>从创新角度来看，需要观察开发的新药是否属于全新靶点的FIC药品。 </li>\r\n    <li>从临床价值方面来看，需要看新药的临床疗效直接影响患者治疗意愿，也影响医生的处方习惯。</li>\r\n    <li>从生命周期来看，新药生命周期从引入到撤市的过程是否严密，是否有严密的专利保护体系。</li>\r\n    <li>从财务效率来看，需要注意新药研发过程的投资金额，投资周期及研发成功的风险大小等。</li>\r\n</ul>\r\n    </p>\r\n <p class=\"pagraph\">\r\n我们考虑到初创公司可能所面临的竞争情况，运用波特五力模型进行市场上现有的帕金森疗法及药物疗法的竞争分析，这将在我们的拓展部分进行讨论。\r\n    </p>\r\n\r\n    <div class=\"ding\"></div>\r\n    <h1 class=\"title\">SWOT分析</h1>\r\n    <p class=\"pagraph\">\r\nStrengths\r\n    </p>\r\n    <p class=\"pagraph\">\r\n<ul>\r\n    <li>创新：治疗帕金森疾病的新方法</li>\r\n    <li>多元：跨学科团队思维碰撞</li>\r\n    <li>友好：满足需求，医患交流</li>\r\n    <li>完整：早中晚期配套体系</li>\r\n</ul>\r\n    </p>\r\n    <p class=\"pagraph\">\r\nWeakness\r\n    </p>\r\n    <p class=\"pagraph\">\r\n<ul>\r\n    <li>年轻团队：商业和创业经验不足</li>\r\n    <li>初创公司：尚未在市场上建立声誉</li>\r\n    <li>资源受限：初期投资，管理体系劣势</li>\r\n</ul>\r\n    </p>\r\n    <p class=\"pagraph\">\r\nOpportunities\r\n    </p>\r\n    <p class=\"pagraph\">\r\n<ul>\r\n    <li>标准化：与iGEM基金会的兼容性生物砖标准</li>\r\n<li>创新技术：新型治愈手段，较大推广潜力 </li>\r\n<li>市场优势：需求广阔、政策支持</li></ul>\r\n    </p>\r\n    <p class=\"pagraph\">\r\nThreats\r\n    </p>\r\n    <p class=\"pagraph\">\r\n<ul>\r\n    <li>竞争：拥有更多专业知识和资金的公司</li>\r\n    <li>资源：资金链、原料受限 </li>\r\n    <li>监管：监管法律的变化</li>\r\n</ul>\r\n    </p>\r\n<div class=\"ding\" id=\"des1\"></div>\r\n    <h1 class=\"topic\">商业模式</h1>\r\n<img class=\"tu\" src=\"../assets/en3-1.png\" alt=\"no pic\" />\r\n\r\n <div class=\"ding\"></div>\r\n    <h1 class=\"title\">定价策略</h1>\r\n    <p class=\"pagraph\">\r\n由于TheraParkin创新药的特殊性，我们采用“需求驱动定价法”来主导我们的定价策略。目前市场上对有效性帕金森药物的需求极大，我们预计这款药物会有很大的利润空间。然而，我们需要将价格定在一个合理的区间，既能尽快回收前期研发成本，又能保证一定的销量（销量是比较重要的部分，让多数人疾病治愈也是我们的目标）。我们和VC公司方分析师沟通了相关事宜，并预计在将来制定出我们具体的定价策略。\r\n    </p>\r\n     <p class=\"pagraph\">\r\n在涉及收入来源与利润分配问题时，我们考虑到一些比较重要的环节。\r\n    </p>\r\n\r\n <div class=\"ding\"></div>\r\n    <h1 class=\"title\">医保谈判\t</h1>\r\n    <p class=\"pagraph\">\r\n我们渴望与政府建立医保谈判关系，以此保证合适的价格与足够的销量。目前的形势下，医保控费是大趋势，未来医保对于同质化创新的支付会趋紧，而对首创性的药物会更加开放。\r\n    </p>\r\n<img class=\"tu\" src=\"../assets/en3-2.png\" alt=\"no pic\" />\r\n<div class=\"ding\"></div>\r\n    <h1 class=\"title\">三方权益分配问题</h1>\r\n    <p class=\"pagraph\">\r\n这将在我们的拓展部分进行展示\r\n    </p>\r\n<div class=\"ding\" id=\"des2\"></div>\r\n    <h1 class=\"topic\">资本财务</h1>\r\n<div class=\"ding\"></div>\r\n    <h1 class=\"title\">现状、预测、分析</h1>\r\n    <p class=\"pagraph\">\r\n这将在我们的拓展部分进行展示。\r\n    </p>\r\n    <div class=\"ding\"></div>\r\n    <h1 class=\"title\">风险退出</h1>\r\n   <img class=\"tu\" src=\"../assets/en3-3.png\" alt=\"no pic\" />\r\n\r\n<div class=\"ding\" id=\"des3\"></div>\r\n    <h1 class=\"topic\">推广运营</h1>\r\n<div class=\"ding\"></div>\r\n    <h1 class=\"title\">发展路线图</h1>\r\n    <img class=\"tu\" src=\"../assets/en4-4.png\" alt=\"no pic\" />\r\n    <div class=\"ding\"></div>\r\n    <h1 class=\"title\">长期影响</h1>\r\n    <p class=\"pagraph\">\r\n我们以长远的目光注视我们的项目。 在ZJU-TheraParkin的业务中，我们不仅仅关注财务增长，而且更多地关注这款药物对社会医疗保健产生的长期影响。我们的团队相信通过不断地实践和验证，最终能为帕金森患者提供一套科学的解决方案。公司在长期发展中，也将拓展更多业务服务于帕金森患者，构建完整的帕金森服务体系链。我们将不只关注医药领域，同时在更多方面完善我们的服务工作（如：适合的家居设施；教育培训；\r\n    </p>\r\n<p class=\"pagraph\">\r\n在这一方向，我们考虑到医患教育是很重要的一部分，因此我们也同样关心患者的关于这款新型药物的了解情况，我们对此进行了一系列人类实践，详情可见我们的综合人类实践模块和教育模块。\r\n    </p>\r\n<p class=\"pagraph\">\r\n请查看关于TheraParkin的商业计划书。\r\n    </p>\r\n\r\n    <div class=\"ding\" id=\"des4\"></div>\r\n    <h1 class=\"topic\">专利策略</h1>\r\n     <p class=\"pagraph\">\r\nTheraParkin是一款创新型药物，药品的科研创新是一条高成本赛道，企业要及时申请专利。在医药领域拥有好的专利布局，有利于制药企业的整体发展。\r\n    </p>\r\n    <div class=\"ding\"></div>\r\n    <h1 class=\"title\">开端：新专利法解读</h1>\r\n    <p class=\"pagraph\">\r\n我们关注到2021年6月1日的新法规——修改后的《中华人民共和国专利法》正式实施。其中对于药品专利有两个倾向：一是规定了药品专利期限的补偿制度，二是新增药品专利早期纠纷解决机制，也就是药品专利链接制度。\r\n    </p>\r\n    <p class=\"pagraph\">\r\n那么新专利法对创新药研发将带来怎样的影响？作为创新药企业应该如何应对？对此，我们在“2021大健康产业高质量发展大会暨第六届中国医药研发·创新峰会（PDI）”现场得到了百诺知识管理中心经理张蕙前瞻性的解答。\r\n    </p>\r\n    <p class=\"pagraph\">\r\n她提到：“对原研药企业要做好严密高效的专利保护网，建立预警与防控机制，及时对仿制药企业的登记信息进行清盘与否作出判断。”\r\n    </p>\r\n<img class=\"tu\" src=\"../assets/en4-5.png\" alt=\"no pic\" />\r\n<img class=\"tu\" src=\"../assets/en4-6.png\" alt=\"no pic\" />\r\n\r\n    <div class=\"ding\"></div>\r\n    <h1 class=\"title\">发展：药物专利的PLM策略 </h1>\r\n    <p class=\"pagraph\">\r\n然而，与此相对应的是“专利悬崖”的出现，如果没有专利的保护，制药企业就是化工企业，所以专利是制药企业获得利润的关键。为了减少部分专利到期的冲击，我们利用管理学中的常用PLM（产品生命周期管理）方法来指定药物专利策略。\r\n    </p>\r\n    <p class=\"pagraph\">\r\n<ul>\r\n    <li>缩短开发时间，加速药物的上市速度</li>\r\n    <li>在药物销售的独占期注册商标，树立品牌形象</li>\r\n    <li>销售独占期间积极拓展市场</li>\r\n    <li>当仿制药进入市场时，采取积极的市场策略</li>\r\n</ul>\r\n    </p>\r\n    <p class=\"pagraph\">\r\n采用各种专利的组合是制药企业的通用做法，但仅仅这些策略， 制药行业作为资本和知识密集型行业，维护市场需要强大的知识产权资源，产品差异化和产品认同。因此我们去访问了X公司医药组负责法务的X先生，他给我们分享了一些案例与可参考的医药法务知识，以便我们更好地开展我们的专利策略，具体可以在拓展模块查看。\r\n    </p>\r\n\r\n    <div class=\"ding\" id=\"des5\"></div>\r\n    <h1 class=\"topic\">商业合作</h1>\r\n    <div class=\"ding\"></div>\r\n    <h1 class=\"title\">产品合作></h1>\r\n    <p class=\"pagraph\">\r\n我们的TheraParkin产品是一款针对于帕金森中、晚期的生物制剂，用于患者疾病治疗。同时，我们设计了一款硬件，针对于帕金森早期的疾病监测。作为一个负责任且人性化的团队，我们打算在公司原有产品的基础上，引进其他产品，或者与其他产品进行合作，以期提供覆盖帕金森全疗程联合疗法，更好地服务于帕金森患者。\r\n    </p>\r\n    <p class=\"pagraph\">\r\n联合：早期康复训练\r\n    </p>\r\n    <p class=\"pagraph\">\r\n\t联合：中晚期物理疗法\r\n    </p>\r\n    <div class=\"ding\"></div>\r\n    <h1 class=\"title\">VC公司合作</h1>\r\n    <p class=\"pagraph\">\r\n\t在之前的介绍中我们提到了“VIC”模式，这里主要就VC公司与ZJU-TheraParkin的合作情况做出介绍。\r\n    </p>\r\n    <p class=\"pagraph\">\r\n与我们合作的VC公司是X。我们和与我们对接的负责人进行了一系列交谈，明确了投资者在评判项目好坏的基本准则。并且更加明确了TheraParkin的优势与市场定位。具体情况请看我们整理的文件。\r\n    </p>\r\n    <div class=\"ding\"></div>\r\n    <h1 class=\"title\">CRO公司合作</h1>\r\n    <p class=\"pagraph\">\r\nCRO公司十分乐意参与我们的创业工作，并且向我们说明了他们所负责的领域与任务。X先生告诉我们他们公司的主要情况，并就具体合作事项达成了协议。附件。\r\n    </p>\r\n    <div class=\"ding\"></div>\r\n    <h1 class=\"title\">并购与路演</h1>\r\n    <p class=\"pagraph\">\r\n在我们的项目实施期间，不断有其他公司的相关人员来询问我们项目的具体情况。考虑到有大公司联系我们的可能性，我们针对并购情况预先做好了准备。这里，我们进行了预先路演，并撰写了相关文件。\r\n    </p>\r\n<img class=\"tu\" src=\"../assets/en4-7.png\" alt=\"no pic\" />\r\n\r\n<div class=\"ding\" id=\"des6\"></div>\r\n    <h1 class=\"topic\">创业学习资源——ZJU一贯的团队精神</h1>\r\n    <div class=\"ding\"></div>\r\n    <h1 class=\"title\">躬身实践</h1>\r\n    <p class=\"pagraph\">\r\n我们希望ZJU-TheraParkin能够成为一家优秀的企业，因此，我们不断学习创业知识，寻找创新创业的机遇。\r\n    </p>\r\n    <p class=\"pagraph\">\r\n我们参加了2022年6月举办的“合成生物学创业大赛”，与评委进行了交流展示。\r\n    </p>\r\n    <p class=\"pagraph\">\r\n我们与X iGEM团队进行了创业交谈，并从对话中了解到合作、共同创业的可能性。\r\n    </p>\r\n    <p class=\"pagraph\">\r\n我们参加了在上海举办的第十一届绿色医药创新企业大会，在现场与众多企业家们进行想法展示与项目交流。\r\n    </p>\r\n    \r\n    <div class=\"ding\"></div>\r\n    <h1 class=\"title\">创业活动的Campaign</h1>\r\n    <p class=\"pagraph\">\r\n在浙江省杭州市未来科技城举办创业宣讲会。介绍帕金森，介绍TheraParkin，介绍浙江大学团队。\r\n    </p>\r\n    <p class=\"pagraph\">\r\n得到外界与ZJU-iGEM团队的合作资源。\r\n    </p>\r\n    <p class=\"pagraph\">\r\n学校内，我们和历届iGEMer共享喜悦，并建立了一个共享平台与联系方式。（公众号）\r\n\r\n    </p>\r\n\r\n        <div class=\"ding\"></div>\r\n        <div class=\"ding\"></div>\r\n        <div class=\"ding\"></div>\r\n        <div class=\"ding\"></div>\r\n      </div>\r\n    </div>\r\n\r\n    \r\n\r\n    <div id=\"lef\" class=\"leftP\">\r\n      <ul class=\"Shell\">\r\n        <li><a href=\"#top\">概述</a></li>\r\n        <li><a href=\"#des1\">商业模式</a></li>\r\n        <li><a href=\"#des2\">资本财务</a></li>\r\n        <li><a href=\"#des3\">推广运营</a></li>\r\n        <li><a href=\"#des4\">专利策略</a></li>\r\n        <li><a href=\"#des5\">商业合作</a></li>\r\n        <li><a href=\"#des6\">创业学习资源</a></li>\r\n        \r\n      </ul>\r\n    </div>\r\n  </div>\r\n</template>\r\n<script>\r\nexport default {\r\n  return() {},\r\n  methods: {\r\n    ch1() {\r\n      let p1 = document.getElementById(\"p1\");\r\n      let p2 = document.getElementById(\"p2\");\r\n      let p3 = document.getElementById(\"p3\");\r\n      let p4 = document.getElementById(\"p4\");\r\n      p1.classList.add(\"showup\");\r\n      p2.classList.remove(\"showup\");\r\n      p3.classList.remove(\"showup\");\r\n      p4.classList.remove(\"showup\");\r\n    },\r\n    ch2() {\r\n      let p1 = document.getElementById(\"p1\");\r\n      let p2 = document.getElementById(\"p2\");\r\n      let p3 = document.getElementById(\"p3\");\r\n      let p4 = document.getElementById(\"p4\");\r\n      p2.classList.add(\"showup\");\r\n      p1.classList.remove(\"showup\");\r\n      p3.classList.remove(\"showup\");\r\n      p4.classList.remove(\"showup\");\r\n    },\r\n    ch3() {\r\n      let p1 = document.getElementById(\"p1\");\r\n      let p2 = document.getElementById(\"p2\");\r\n      let p3 = document.getElementById(\"p3\");\r\n      let p4 = document.getElementById(\"p4\");\r\n      p3.classList.add(\"showup\");\r\n      p2.classList.remove(\"showup\");\r\n      p1.classList.remove(\"showup\");\r\n      p4.classList.remove(\"showup\");\r\n    },\r\n    ch4() {\r\n      let p1 = document.getElementById(\"p1\");\r\n      let p2 = document.getElementById(\"p2\");\r\n      let p3 = document.getElementById(\"p3\");\r\n      let p4 = document.getElementById(\"p4\");\r\n      p4.classList.add(\"showup\");\r\n      p2.classList.remove(\"showup\");\r\n      p1.classList.remove(\"showup\");\r\n      p3.classList.remove(\"showup\");\r\n    },\r\n  },\r\n  mounted() {\r\n    let lef = document.getElementById(\"lef\");\r\n\r\n    function addEvent(obj, type, fn) {\r\n      undefined;\r\n      if (obj.attachEvent) {\r\n        obj.attachEvent(\"on\" + type, function () {\r\n          undefined;\r\n          fn.call(obj);\r\n        });\r\n      } else {\r\n        undefined;\r\n        obj.addEventListener(type, fn, false);\r\n      }\r\n    }\r\n\r\n    addEvent(window, \"scroll\", function () {\r\n      undefined;\r\n      if (window.pageYOffset >= 455) {\r\n        lef.classList.add(\"stick\");\r\n      } else {\r\n        lef.classList.remove(\"stick\");\r\n      }\r\n    });\r\n  },\r\n};\r\n</script>\r\n<style scoped>\r\n.p ul li{\r\n    text-indent: 0;\r\n}\r\n.title3 {\r\n  color: #3485a5;\r\n  font-family: Comic Sans MS;\r\n  margin: 10px;\r\n  font-size: 25px;\r\n  border-bottom: solid 2px #7fa2ab;\r\n  padding-bottom: 0.6em;\r\n}\r\n.showBox {\r\n  width: 100%;\r\n}\r\n.showBox .head .c {\r\n  width: 200px;\r\n  height: 40px;\r\n  line-height: 40px;\r\n  text-align: center;\r\n  display: inline-block;\r\n  margin: auto;\r\n  border-radius: 30px;\r\n  color: rgb(169, 207, 199);\r\n}\r\n.showBox .head .c:hover {\r\n  transform: scale(1.1);\r\n  transition: 0.6s;\r\n  background-color: #fff;\r\n  color: rgb(23, 97, 85);\r\n}\r\n.showBox .head #c1 {\r\n  background-color: #6ab480;\r\n}\r\n.showBox .head #c2 {\r\n  background-color: #6aafb4;\r\n}\r\n.showBox .head #c3 {\r\n  background-color: #2851aa;\r\n}\r\n.showBox .head #c4 {\r\n  background-color: #5636ad;\r\n}\r\n.showBox .box {\r\n  margin-top: 10px;\r\n  padding-left: 15px;\r\n  padding-right: 15px;\r\n  background-color: #d2e8eb;\r\n  width: 880px;\r\n  margin: auto;\r\n  border-radius: 30px;\r\n}\r\n.showBox .box .p {\r\n  display: none;\r\n}\r\n.showBox .box #p1.showup {\r\n  display: block;\r\n  transition: 1s;\r\n}\r\n.showBox .box #p2.showup {\r\n  display: block;\r\n  transition: 1s;\r\n}\r\n.showBox .box #p3.showup {\r\n  display: block;\r\n  transition: 1s;\r\n}\r\n.showBox .box #p4.showup {\r\n  display: block;\r\n  transition: 1s;\r\n}\r\n.ref {\r\n  font-style: italic;\r\n  font-family: Times New Roman, Times, serif !important;\r\n  padding-left: 2em;\r\n  text-align: left;\r\n  font-size: 0.8em;\r\n  color: #7d7d7d;\r\n  letter-spacing: 0.018em;\r\n}\r\n.showBox .box .p {\r\n  display: none;\r\n  margin-bottom:20px;\r\n  margin-top:20px;\r\n}\r\n.tu {\r\n  margin-right: auto;\r\n  margin-left: auto;\r\n  display: block;\r\n  margin-top: 20px;\r\n  width: 600px;\r\n  height: auto;\r\n  border-radius: 10px;\r\n  border: #1d5a56;\r\n  background-size: 5px;\r\n}\r\n.topic {\r\n  color: #1d3f5a;\r\n  font-size: 60px;\r\n  text-align: center;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  font-family: \"Arial\";\r\n  letter-spacing: 15px;\r\n}\r\n#lef.stick {\r\n  opacity: 0.7;\r\n  transition: all 1s;\r\n}\r\n.Shell li a {\r\n  display: block;\r\n  width: 260px;\r\n}\r\n.leftP {\r\n  position: fixed;\r\n  left: 10px;\r\n  top: 30%;\r\n  opacity: 0;\r\n  height: 64vh;\r\n  width: 200px;\r\n  background-color: #3c6b6d;\r\n  border-radius: 20px;\r\n}\r\n.Shell {\r\n  margin: 0;\r\n  padding: 0;\r\n  color: inherit;\r\n  background-color: inherit;\r\n}\r\n.Shell:first-child {\r\n  margin-top: 4vh;\r\n}\r\n.Shell li {\r\n  list-style: none;\r\n  height: 8vh;\r\n  line-height: 8vh;\r\n  padding-left: 20px;\r\n  color: inherit;\r\n  background-color: inherit;\r\n}\r\n.Shell li:hover {\r\n  /* transform:scale(1,1.2); */\r\n  background-color: #89cfd1;\r\n  border-radius: 10px;\r\n  color: #253f17;\r\n  transition: all 0.6s;\r\n}\r\n.Shell li:hover a {\r\n  color: white;\r\n}\r\n.Shell li a {\r\n  text-decoration: none;\r\n  color: #8ad6bd;\r\n}\r\n.ding {\r\n  height: 96px;\r\n}\r\n.top img {\r\n  float: right;\r\n  line-height: 60px;\r\n}\r\n.top img:hover {\r\n  transform: scale(1.3);\r\n  transition: all 0.4s;\r\n}\r\n.back {\r\n  width: 100%;\r\n  background-color: #c5ddd9;\r\n}\r\n.bg .im {\r\n  background-attachment: fixed;\r\n  width: 100%;\r\n  height: 100vh;\r\n  background-size: cover;\r\n  background-image: url(../assets/homeBanner.gif);\r\n}\r\n.content {\r\n  background-color: inherit;\r\n  width: 900px;\r\n  margin: 0 auto;\r\n  align-content: center;\r\n  padding: 20px;\r\n}\r\n.title {\r\n  color: #1d5a56;\r\n  font-family: Comic Sans MS;\r\n  margin: 10px;\r\n  border-bottom: solid 2px #7faba0;\r\n  padding-bottom: 0.6em;\r\n}\r\n.title2 {\r\n  color: #1d5a56;\r\n  font-family: Comic Sans MS;\r\n  margin: 10px;\r\n  margin-top: 50px;\r\n  border-bottom: solid 2px #a9ccc3;\r\n  padding-bottom: 0.6em;\r\n}\r\n.title:first-letter {\r\n  font-size: 50px;\r\n  text-shadow: 2px 2px 5px #444;\r\n}\r\n.title2:first-letter {\r\n  font-size: 50px;\r\n  text-shadow: 2px 2px 5px #444;\r\n}\r\n.pagraph {\r\n  font-family: \"Century Gothic\";\r\n  letter-spacing: 0.05em !important;\r\n  text-indent: 2em;\r\n  display: block;\r\n  transition: all 2s;\r\n  margin-left: 40px;\r\n  letter-spacing: 1.3px;\r\n  line-height: 1.8;\r\n  word-spacing: 3px;\r\n  color: #386f6c;\r\n}\r\n</style>\r\n","import mod from \"-!../../node_modules/cache-loader/dist/cjs.js??ref--13-0!../../node_modules/thread-loader/dist/cjs.js!../../node_modules/babel-loader/lib/index.js!../../node_modules/cache-loader/dist/cjs.js??ref--1-0!../../node_modules/vue-loader/lib/index.js??vue-loader-options!./entre.vue?vue&type=script&lang=js&\"; export default mod; export * from \"-!../../node_modules/cache-loader/dist/cjs.js??ref--13-0!../../node_modules/thread-loader/dist/cjs.js!../../node_modules/babel-loader/lib/index.js!../../node_modules/cache-loader/dist/cjs.js??ref--1-0!../../node_modules/vue-loader/lib/index.js??vue-loader-options!./entre.vue?vue&type=script&lang=js&\"","import { render, staticRenderFns } from \"./entre.vue?vue&type=template&id=7ba500f8&scoped=true&\"\nimport script from \"./entre.vue?vue&type=script&lang=js&\"\nexport * from \"./entre.vue?vue&type=script&lang=js&\"\nimport style0 from \"./entre.vue?vue&type=style&index=0&id=7ba500f8&scoped=true&lang=css&\"\n\n\n/* normalize component */\nimport normalizer from \"!../../node_modules/vue-loader/lib/runtime/componentNormalizer.js\"\nvar component = normalizer(\n  script,\n  render,\n  staticRenderFns,\n  false,\n  null,\n  \"7ba500f8\",\n  null\n  \n)\n\nexport default component.exports","var render = function () {var _vm=this;var _h=_vm.$createElement;var _c=_vm._self._c||_h;return _vm._m(0)}\nvar staticRenderFns = [function () {var _vm=this;var _h=_vm.$createElement;var _c=_vm._self._c||_h;return _c('div',[_c('div',{staticClass:\"bg\"},[_c('div',{staticClass:\"im\",attrs:{\"id\":\"bg\"}})]),_c('div',{staticClass:\"back\"},[_c('div',{staticClass:\"content\"},[_c('div',{staticClass:\"ding\",attrs:{\"id\":\"top\"}}),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 我们考虑项目对世界可持续发展的贡献，这十分重要。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 项目相关的可持续发展目标 \")]),_c('img',{staticClass:\"tu\",attrs:{\"src\":require(\"../assets/sus1.png\"),\"alt\":\"no pic\"}}),_c('div',{staticClass:\"ding\"}),_c('h1',{staticClass:\"title\"},[_vm._v(\" 简介\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 可持续发展目标（SDGs）是联合国到2030年要实现的17项目标。这些普遍目标涉及世界上紧迫的环境、政治和经济挑战，以实现所有人的更美好的未来。其中一些目标包括改善健康和教育，减少不平等和贫困，刺激经济增长以及应对气候变化。所有可持续发展目标和子目标的完整列表（https://sdgs.un.org/goals）。联合国呼吁所有国家在全球伙伴关系中帮助实现这些目标。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 我们项目相关的可持续发展目标有： \")]),_c('img',{staticClass:\"tu\",attrs:{\"src\":require(\"../assets/sus2.png\"),\"alt\":\"no pic\"}}),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 3. 良好健康与福祉 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 4. 优质教育 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 5. 促进目标实现的伙伴关系 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 在可持续发展目标3：良好健康与福祉方面，我们决定关注子目标3.4，该目标旨在降低“非传染性疾病和促进心理健康”的死亡率。和没有痴呆的老年人相比，患有帕金森氏症的病人的死亡风险增加了2-5倍。我们的项目旨在设计帕金森氏症多靶点治疗产品，帮助患者减轻症状，甚至痊愈，能够有效降低非传染性疾病的死亡率。同时我们关注神经疾病病人的社会关怀与心理健康状态，减少抑郁及自杀的风险。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 我们的项目还涉及子目标3.b，旨在开发相关药品，保护公众健康，同时保证药品价格，为更多的人提供使用药品的机会。我们和政府部门、企业合作，和医保谈判人员、药企人员交流，了解药品定价过程，为未来药品降价提供可能的思路。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 对于目标4，我们的项目主要针对子目标4.5，旨在消除教育中的歧视。我们的科普教育软件（和网站）中包括对神经退行性疾病的介绍、相关教育视频以及故事分享等等。通过网站和教育软件，我们希望能让更多的人们了解相关内容，让不同地区的人们都能接触到相关科普教育。我们的网站及软件具有包容性；网站及软件均具有中英文版本，并且具有语音条目，能为视障人士提供平等的教育机会。我们的网站和软件能够帮助减少教育中的歧视，因为访问网站和使用软件的权限人人平等，新冠疫情期间不论身在何处，均可访问我们的网站和软件，实现科普性教育。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 我们针对目标17，和其他iGEM团队开展了系列合作。我们组织了与可持续性目标相关的会议，在会议中交流了各团队项目与可持续性目标的关联性，并发布系列微博/推文在社交媒体上进行介绍，并相互合作，帮助大家完成任务。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 我们还开展了针对部分可持续性目标的队际辩论（或是和学院/学校）辩论赛事主办方联系，设定生物学伦理/道德/法律/政策/可持续性目标/人类重大健康问题等内容相关的辩题，有助于进一步了解相关内容/可持续性目标，为未来重大问题的解决提供思路。 \")]),_c('div',{staticClass:\"ding\"}),_c('div',{staticClass:\"ding\"}),_c('div',{staticClass:\"ding\"}),_c('div',{staticClass:\"ding\"})])]),_c('div',{staticClass:\"leftP\",attrs:{\"id\":\"lef\"}},[_c('a',{attrs:{\"href\":\"#top\"}},[_c('img',{attrs:{\"src\":require(\"../assets/homeTop.png\"),\"alt\":\"\"}})])])])}]\n\nexport { render, staticRenderFns }","<template>\r\n  <div>\r\n    <div class=\"bg\"><div class=\"im\" id=\"bg\"></div></div>\r\n    <div class=\"back\">\r\n      <div class=\"content\">\r\n          <div id=\"top\" class=\"ding\"></div>\r\n<p class=\"pagraph\">\r\n我们考虑项目对世界可持续发展的贡献，这十分重要。\r\n    </p>\r\n     <p class=\"pagraph\">\r\n项目相关的可持续发展目标\r\n    </p>\r\n     <img class=\"tu\" src=\"../assets/sus1.png\" alt=\"no pic\"> \r\n <div class=\"ding\"></div>\r\n<h1 class=\"title\">\r\n简介</h1>\r\n    <p class=\"pagraph\">\r\n可持续发展目标（SDGs）是联合国到2030年要实现的17项目标。这些普遍目标涉及世界上紧迫的环境、政治和经济挑战，以实现所有人的更美好的未来。其中一些目标包括改善健康和教育，减少不平等和贫困，刺激经济增长以及应对气候变化。所有可持续发展目标和子目标的完整列表（https://sdgs.un.org/goals）。联合国呼吁所有国家在全球伙伴关系中帮助实现这些目标。\r\n    </p>\r\n\r\n    \r\n   \r\n\r\n<p class=\"pagraph\">\r\n我们项目相关的可持续发展目标有：\r\n    </p>\r\n     <img class=\"tu\" src=\"../assets/sus2.png\" alt=\"no pic\"> \r\n\r\n<p class=\"pagraph\">\r\n3. 良好健康与福祉\r\n    </p>\r\n\r\n<p class=\"pagraph\">\r\n4. 优质教育\r\n    </p>\r\n\r\n<p class=\"pagraph\">\r\n5. 促进目标实现的伙伴关系\r\n    </p>\r\n\r\n<p class=\"pagraph\">\r\n在可持续发展目标3：良好健康与福祉方面，我们决定关注子目标3.4，该目标旨在降低“非传染性疾病和促进心理健康”的死亡率。和没有痴呆的老年人相比，患有帕金森氏症的病人的死亡风险增加了2-5倍。我们的项目旨在设计帕金森氏症多靶点治疗产品，帮助患者减轻症状，甚至痊愈，能够有效降低非传染性疾病的死亡率。同时我们关注神经疾病病人的社会关怀与心理健康状态，减少抑郁及自杀的风险。\r\n    </p>\r\n\r\n<p class=\"pagraph\">\r\n我们的项目还涉及子目标3.b，旨在开发相关药品，保护公众健康，同时保证药品价格，为更多的人提供使用药品的机会。我们和政府部门、企业合作，和医保谈判人员、药企人员交流，了解药品定价过程，为未来药品降价提供可能的思路。\r\n    </p>\r\n\r\n<p class=\"pagraph\">\r\n对于目标4，我们的项目主要针对子目标4.5，旨在消除教育中的歧视。我们的科普教育软件（和网站）中包括对神经退行性疾病的介绍、相关教育视频以及故事分享等等。通过网站和教育软件，我们希望能让更多的人们了解相关内容，让不同地区的人们都能接触到相关科普教育。我们的网站及软件具有包容性；网站及软件均具有中英文版本，并且具有语音条目，能为视障人士提供平等的教育机会。我们的网站和软件能够帮助减少教育中的歧视，因为访问网站和使用软件的权限人人平等，新冠疫情期间不论身在何处，均可访问我们的网站和软件，实现科普性教育。\r\n    </p>\r\n <p class=\"pagraph\">\r\n我们针对目标17，和其他iGEM团队开展了系列合作。我们组织了与可持续性目标相关的会议，在会议中交流了各团队项目与可持续性目标的关联性，并发布系列微博/推文在社交媒体上进行介绍，并相互合作，帮助大家完成任务。\r\n    </p>\r\n     <p class=\"pagraph\">\r\n我们还开展了针对部分可持续性目标的队际辩论（或是和学院/学校）辩论赛事主办方联系，设定生物学伦理/道德/法律/政策/可持续性目标/人类重大健康问题等内容相关的辩题，有助于进一步了解相关内容/可持续性目标，为未来重大问题的解决提供思路。\r\n    </p>\r\n\r\n\r\n\r\n        <div class=\"ding\"></div>\r\n        <div class=\"ding\"></div>\r\n        <div class=\"ding\"></div>\r\n        <div class=\"ding\"></div>\r\n      </div>\r\n    </div>\r\n\r\n    <div id=\"lef\" class=\"leftP\">\r\n      <a href=\"#top\"><img src=\"../assets/homeTop.png\" alt=\"\" /></a>\r\n    </div>\r\n  </div>\r\n</template>\r\n<script>\r\nexport default {\r\n  return() {},\r\n  methods: {\r\n    ch1() {\r\n      let p1 = document.getElementById(\"p1\");\r\n      let p2 = document.getElementById(\"p2\");\r\n      let p3 = document.getElementById(\"p3\");\r\n      let p4 = document.getElementById(\"p4\");\r\n      p1.classList.add(\"showup\");\r\n      p2.classList.remove(\"showup\");\r\n      p3.classList.remove(\"showup\");\r\n      p4.classList.remove(\"showup\");\r\n    },\r\n    ch2() {\r\n      let p1 = document.getElementById(\"p1\");\r\n      let p2 = document.getElementById(\"p2\");\r\n      let p3 = document.getElementById(\"p3\");\r\n      let p4 = document.getElementById(\"p4\");\r\n      p2.classList.add(\"showup\");\r\n      p1.classList.remove(\"showup\");\r\n      p3.classList.remove(\"showup\");\r\n      p4.classList.remove(\"showup\");\r\n    },\r\n    ch3() {\r\n      let p1 = document.getElementById(\"p1\");\r\n      let p2 = document.getElementById(\"p2\");\r\n      let p3 = document.getElementById(\"p3\");\r\n      let p4 = document.getElementById(\"p4\");\r\n      p3.classList.add(\"showup\");\r\n      p2.classList.remove(\"showup\");\r\n      p1.classList.remove(\"showup\");\r\n      p4.classList.remove(\"showup\");\r\n    },\r\n    ch4() {\r\n      let p1 = document.getElementById(\"p1\");\r\n      let p2 = document.getElementById(\"p2\");\r\n      let p3 = document.getElementById(\"p3\");\r\n      let p4 = document.getElementById(\"p4\");\r\n      p4.classList.add(\"showup\");\r\n      p2.classList.remove(\"showup\");\r\n      p1.classList.remove(\"showup\");\r\n      p3.classList.remove(\"showup\");\r\n    },\r\n  },\r\n  mounted() {\r\n    let lef = document.getElementById(\"lef\");\r\n\r\n    function addEvent(obj, type, fn) {\r\n      undefined;\r\n      if (obj.attachEvent) {\r\n        obj.attachEvent(\"on\" + type, function () {\r\n          undefined;\r\n          fn.call(obj);\r\n        });\r\n      } else {\r\n        undefined;\r\n        obj.addEventListener(type, fn, false);\r\n      }\r\n    }\r\n\r\n    addEvent(window, \"scroll\", function () {\r\n      undefined;\r\n      if (window.pageYOffset >= 455) {\r\n        lef.classList.add(\"stick\");\r\n      } else {\r\n        lef.classList.remove(\"stick\");\r\n      }\r\n    });\r\n  },\r\n};\r\n</script>\r\n<style scoped>\r\n.p ul li {\r\n  text-indent: 0;\r\n}\r\n.title3 {\r\n  color: #3485a5;\r\n  font-family: Comic Sans MS;\r\n  margin: 10px;\r\n  font-size: 25px;\r\n  border-bottom: solid 2px #7fa2ab;\r\n  padding-bottom: 0.6em;\r\n}\r\n.showBox {\r\n  width: 100%;\r\n}\r\n.showBox .head .c {\r\n  width: 200px;\r\n  height: 40px;\r\n  line-height: 40px;\r\n  text-align: center;\r\n  display: inline-block;\r\n  margin: auto;\r\n  border-radius: 30px;\r\n  color: rgb(169, 207, 199);\r\n}\r\n.showBox .head .c:hover {\r\n  transform: scale(1.1);\r\n  transition: 0.6s;\r\n  background-color: #fff;\r\n  color: rgb(23, 97, 85);\r\n}\r\n.showBox .head #c1 {\r\n  background-color: #6ab480;\r\n}\r\n.showBox .head #c2 {\r\n  background-color: #6aafb4;\r\n}\r\n.showBox .head #c3 {\r\n  background-color: #2851aa;\r\n}\r\n.showBox .head #c4 {\r\n  background-color: #5636ad;\r\n}\r\n.showBox .box {\r\n  margin-top: 10px;\r\n  padding-left: 15px;\r\n  padding-right: 15px;\r\n  background-color: #d2e8eb;\r\n  width: 880px;\r\n  margin: auto;\r\n  border-radius: 30px;\r\n}\r\n.showBox .box .p {\r\n  display: none;\r\n}\r\n.showBox .box #p1.showup {\r\n  display: block;\r\n  transition: 1s;\r\n}\r\n.showBox .box #p2.showup {\r\n  display: block;\r\n  transition: 1s;\r\n}\r\n.showBox .box #p3.showup {\r\n  display: block;\r\n  transition: 1s;\r\n}\r\n.showBox .box #p4.showup {\r\n  display: block;\r\n  transition: 1s;\r\n}\r\n.ref {\r\n  font-style: italic;\r\n  font-family: Times New Roman, Times, serif !important;\r\n  padding-left: 2em;\r\n  text-align: left;\r\n  font-size: 0.8em;\r\n  color: #7d7d7d;\r\n  letter-spacing: 0.018em;\r\n}\r\n.tu {\r\n  margin-right: auto;\r\n  margin-left: auto;\r\n  display: block;\r\n  margin-top: 20px;\r\n  width: 600px;\r\n  height: auto;\r\n  border-radius: 30px;\r\n  border: #1d5a56;\r\n  background-size: 5px;\r\n}\r\n.topic {\r\n  color: #1d3f5a;\r\n  font-size: 60px;\r\n  text-align: center;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  font-family: \"Arial\";\r\n  letter-spacing: 15px;\r\n}\r\n.Shell li a {\r\n  display: block;\r\n  width: 260px;\r\n}\r\n#lef.stick {\r\n  opacity: 1;\r\n  transition: all 1s;\r\n}\r\n#lef.stick:hover {\r\n  transform: scale(1.2);\r\n  transition: all 0.6s;\r\n}\r\n.leftP {\r\n  position: fixed;\r\n  left: 10px;\r\n  top: 30%;\r\n  opacity: 0;\r\n  height: 100px;\r\n  width: 100px;\r\n}\r\n.Shell {\r\n  margin: 0;\r\n  padding: 0;\r\n  color: inherit;\r\n  background-color: inherit;\r\n}\r\n.Shell:first-child {\r\n  margin-top: 4vh;\r\n}\r\n.Shell li {\r\n  list-style: none;\r\n  height: 8vh;\r\n  line-height: 8vh;\r\n  padding-left: 20px;\r\n  color: inherit;\r\n  background-color: inherit;\r\n}\r\n.Shell li:hover {\r\n  /* transform:scale(1,1.2); */\r\n  background-color: #89cfd1;\r\n  border-radius: 10px;\r\n  color: #253f17;\r\n  transition: all 0.6s;\r\n}\r\n.Shell li:hover a {\r\n  color: white;\r\n}\r\n.Shell li a {\r\n  text-decoration: none;\r\n  color: #8ad6bd;\r\n}\r\n.ding {\r\n  height: 96px;\r\n}\r\n.top img {\r\n  float: right;\r\n  line-height: 60px;\r\n}\r\n.top img:hover {\r\n  transform: scale(1.3);\r\n  transition: all 0.4s;\r\n}\r\n.back {\r\n  width: 100%;\r\n  background-color: #c5ddd9;\r\n}\r\n.bg .im {\r\n  background-attachment: fixed;\r\n  width: 100%;\r\n  height: 100vh;\r\n  background-size: cover;\r\n  background-image: url(../assets/homeBanner.gif);\r\n}\r\n.content {\r\n  background-color: inherit;\r\n  width: 900px;\r\n  margin: 0 auto;\r\n  align-content: center;\r\n  padding: 20px;\r\n}\r\n.title {\r\n  color: #1d5a56;\r\n  font-family: Comic Sans MS;\r\n  margin: 10px;\r\n  border-bottom: solid 2px #7faba0;\r\n  padding-bottom: 0.6em;\r\n}\r\n.title2 {\r\n  color: #1d5a56;\r\n  font-family: Comic Sans MS;\r\n  margin: 10px;\r\n  margin-top: 50px;\r\n  border-bottom: solid 2px #a9ccc3;\r\n  padding-bottom: 0.6em;\r\n}\r\n.title:first-letter {\r\n  font-size: 50px;\r\n  text-shadow: 2px 2px 5px #444;\r\n}\r\n.title2:first-letter {\r\n  font-size: 50px;\r\n  text-shadow: 2px 2px 5px #444;\r\n}\r\n.pagraph {\r\n  font-family: \"Century Gothic\";\r\n  letter-spacing: 0.05em !important;\r\n  text-indent: 2em;\r\n  display: block;\r\n  transition: all 2s;\r\n  margin-left: 40px;\r\n  letter-spacing: 1.3px;\r\n  line-height: 1.8;\r\n  word-spacing: 3px;\r\n  color: #386f6c;\r\n}\r\n</style>\r\n","import mod from \"-!../../node_modules/cache-loader/dist/cjs.js??ref--13-0!../../node_modules/thread-loader/dist/cjs.js!../../node_modules/babel-loader/lib/index.js!../../node_modules/cache-loader/dist/cjs.js??ref--1-0!../../node_modules/vue-loader/lib/index.js??vue-loader-options!./sustain.vue?vue&type=script&lang=js&\"; export default mod; export * from \"-!../../node_modules/cache-loader/dist/cjs.js??ref--13-0!../../node_modules/thread-loader/dist/cjs.js!../../node_modules/babel-loader/lib/index.js!../../node_modules/cache-loader/dist/cjs.js??ref--1-0!../../node_modules/vue-loader/lib/index.js??vue-loader-options!./sustain.vue?vue&type=script&lang=js&\"","import { render, staticRenderFns } from \"./sustain.vue?vue&type=template&id=0845c54b&scoped=true&\"\nimport script from \"./sustain.vue?vue&type=script&lang=js&\"\nexport * from \"./sustain.vue?vue&type=script&lang=js&\"\nimport style0 from \"./sustain.vue?vue&type=style&index=0&id=0845c54b&scoped=true&lang=css&\"\n\n\n/* normalize component */\nimport normalizer from \"!../../node_modules/vue-loader/lib/runtime/componentNormalizer.js\"\nvar component = normalizer(\n  script,\n  render,\n  staticRenderFns,\n  false,\n  null,\n  \"0845c54b\",\n  null\n  \n)\n\nexport default component.exports","var render = function () {var _vm=this;var _h=_vm.$createElement;var _c=_vm._self._c||_h;return _vm._m(0)}\nvar staticRenderFns = [function () {var _vm=this;var _h=_vm.$createElement;var _c=_vm._self._c||_h;return _c('div',[_c('div',{staticClass:\"bg\"},[_c('div',{staticClass:\"im\",attrs:{\"id\":\"bg\"}})]),_c('div',{staticClass:\"back\"},[_c('div',{staticClass:\"content\"},[_c('div',{staticClass:\"ding\",attrs:{\"id\":\"top\"}}),_c('h1',{staticClass:\"topic\"},[_vm._v(\"HSP70介导的α-syn(α-synuclein)降解模型\")]),_c('div',{staticClass:\"ding\"}),_c('h1',{staticClass:\"title\"},[_vm._v(\"原理简述\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" HSP70有两条路径可以使α-syn降解。一条路径是在底物（即α-syn）结合HSP70以后，让E3泛素连接酶CHIP（carboxyl terminus of Hsc70-interacting protein）识别α-syn并将其泛素化，进而使α-syn被蛋白酶体降解；另一条路径是在α-syn结合HSP70之后，将α-syn传入溶酶体并降解。 \")]),_c('div',{staticClass:\"ding\"}),_c('h1',{staticClass:\"title\"},[_vm._v(\"生物化学模型\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 先描述共有的过程，即α-syn结合HSP70的过程。根据查找得到的动力学参数形式，将该过程描述为以下形式： \")]),_c('img',{staticClass:\"gong\",attrs:{\"src\":require(\"../assets/m1-1.png\"),\"alt\":\"no pic\"}}),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 其中，S代表底物α-syn，C代表HSP70，S·C·X（X=ADP/ATP）代表三者连接形成的复合物。上述三个反应依次记为反应1，2，3. \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 另外还有两个过程：蛋白质HSP70和α-syn的翻译生成过程，和HSP70的降解过程（忽略α-syn的降解，一是因为没有准确的数据难以估计，二是因为HSP70通路本身就是为了降低α-syn的含量，考虑其降解只会让α-syn减少得更快，不可能影响最终结论）。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 对于生成过程，用一个常数来描述这一过程的速率。将翻译看作氨基酸作为底物、肽酰转移酶催化的酶促反应并将细胞内的氨基酸浓度视为常量，用肽酰转移酶的酶动力学参数借由米氏方程估计出速率。这里略去化学方程式，直接给出速率表达式： \")]),_c('img',{staticClass:\"gong\",attrs:{\"src\":require(\"../assets/m1-2.png\"),\"alt\":\"no pic\"}}),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 其中，v_{m,pep}=K_{cat,pep}[pep]，K_{cat,pep}为肽酰转移酶的转换数，[pep]为肽酰转移酶的浓度。作为一种较粗略的估计，HSP70和α-syn的产生速度都由这个值来表述。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 对于降解过程，直接用半衰期来刻画。这里也直接给出降解的数学方程： \")]),_c('img',{staticClass:\"gong\",attrs:{\"src\":require(\"../assets/m1-3.png\"),\"alt\":\"no pic\"}}),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 其中，t_{1/2,HSP70}为HSP70的半衰期。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 接下来，假设进入泛素化路径的α-syn比例为α，进入自噬途径的α-syn比例为β。进入泛素化过程的α-syn发生的反应： \")]),_c('img',{staticClass:\"gong\",attrs:{\"src\":require(\"../assets/m1-4.png\"),\"alt\":\"no pic\"}}),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 其中，S_{ubi}代表泛素化的α-syn，animoacids代表降解产生的氨基酸。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 进入自噬过程的α-syn发生的反应： \")]),_c('img',{staticClass:\"gong\",attrs:{\"src\":require(\"../assets/m1-5.png\"),\"alt\":\"no pic\"}}),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 上述方程均省略了相应的酶。上述三个反应依次记为反应4，5，6. \")]),_c('div',{staticClass:\"ding\"}),_c('h1',{staticClass:\"title\"},[_vm._v(\"数学模型\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 根据获得的动力学参数的形式，前三个反应用结合速率常数与解离速率常数描述，后三个反应用米氏方程描述。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 由此获得关于变量[S],[C·ATP],[S·C·ATP],[C·ADP],[S·C·ADP],[S_{ubi}·C·ADP]的微分方程组： \")]),_c('img',{staticClass:\"tu\",attrs:{\"src\":require(\"../assets/m1-6.png\"),\"alt\":\"no pic\"}}),_c('div',{staticClass:\"ding\"}),_c('h1',{staticClass:\"title\"},[_vm._v(\"参数选取\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 反应1，2，3的结合速率常数和解离速率常数摘自一篇Nature的ScientificReport（Table 1）[1]。反应4，5，6的酶动力学参数摘自酶数据库BRENDA[2]。其中，反应4由CHIP（EC2.3.2.27）催化，但由于没有找到CHIP的直接数据，其动力学参数由同属EC2.3.2的E3连接酶HECT-type E3 ubiquitin transferase（wild type，EC2.3.2.26）代替[3]。出于同样的原因和方式，反应5对应的酶用HsIU-HsIV peptidase（EC3.4.25.2）代替具有泛素依赖性的蛋白酶体26S（EC3.4.25.1）[4]。反应6的动力学参数用cathepsin H（EC3.4.22.16）估计[5]。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" [amino]的值被视为一个常量，因为细胞内的氨基酸浓度不太可能发生剧烈的变化。根据[6]以及氨基酸的平均相对分子质量，可以计算出其值。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" t\"),_c('sub',[_vm._v(\"1/2,HSP70\")]),_vm._v(\"从[7]估计。详细的参数取值见参数表。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 详细的参数取值见参数表。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 根据[8]，取\\\\alpha=0.7,\\\\beta=0.3.这一参数并不准确，所以在后续将对这两个参数进行灵敏度分析。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 根据[1]中的实验条件，取初值[C·ATP]=1x10\"),_c('sup',[_vm._v(\"-6\")]),_vm._v(\"M,[S·C·ATP]=[C·ADP]=[S\"),_c('sub',[_vm._v(\"ubi\")]),_vm._v(\"·C·ADP]=[S·C·ADP]=0.而[S]的初值将以动画的形式在[0,2x10\"),_c('sup',[_vm._v(\"-5\")]),_vm._v(\"](M)之间变化，在讨论其他变量时维持初值3x10\"),_c('sup',[_vm._v(\"-6\")]),_vm._v(\"(M)。[C·ATP]的值实际上在灵敏度分析中也在一定范围内变化，但在讨论其他变量的情况下维持上述初值。 \")]),_c('div',{staticClass:\"ding\"}),_c('h1',{staticClass:\"title\"},[_vm._v(\"模型结果\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 如下是[S]变化时，α-syn的浓度随时间的变化。 \")]),_c('img',{staticClass:\"tu\",attrs:{\"src\":require(\"../assets/m1-7.gif\"),\"alt\":\"no pic\"}}),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 从图可知，α-syn的浓度在最开始时稍有下降，之后上升到峰值，随后持续下降，600～1000s（约合17min）后接近于零。这足以说明HSP70对α-syn的抑制作用。最开始的短暂下降是由[C·ATP]的初值造成的，这将在灵敏度分析中提到。 \")]),_c('div',{staticClass:\"ding\"}),_c('h1',{staticClass:\"title\"},[_vm._v(\"Sensitive analysis\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 灵敏度分析的第一部分讨论(α,β)的取值带来的影响。令这两个值分别从0.1向0.9变化，得到图像如下。 \")]),_c('img',{staticClass:\"tu\",attrs:{\"src\":require(\"../assets/m1-8.gif\"),\"alt\":\"no pic\"}}),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 可以看到，在变化范围内，(α,β)的取值对曲线仅产生了很小幅度的影响，说明(α,β)取值不准确性的影响很小。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 第二部分讨论[C·ATP]的初值变化带来的影响。令其在[0,1x10\"),_c('sup',[_vm._v(\"-5\")]),_vm._v(\"](M)之间变化。 \")]),_c('img',{staticClass:\"tu\",attrs:{\"src\":require(\"../assets/m1-9.gif\"),\"alt\":\"no pic\"}}),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 可以发现，[C·ATP]的初值主要影响最开始的下降阶段，因而影响峰值的大小和曲线的陡峭程度，但对于曲线的走势和最终的稳定值没有影响。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 第三部分讨论酶浓度变化带来的影响。令所有酶的浓度在[1x10\"),_c('sup',[_vm._v(\"-10\")]),_vm._v(\",1x10\"),_c('sup',[_vm._v(\"-6\")]),_vm._v(\"](M)之间变化。 \")]),_c('img',{staticClass:\"tu\",attrs:{\"src\":require(\"../assets/m1-10.gif\"),\"alt\":\"no pic\"}}),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 可以发现，即使酶的浓度变化达到四个数量级，对曲线也没有产生可见的影响。所以，酶浓度估计不准确不会产生有效的影响。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 参数表： \")]),_c('img',{staticClass:\"tu\",attrs:{\"src\":require(\"../assets/m1-11.png\"),\"alt\":\"no pic\"}}),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 源代码在文档末尾，参考文献之前。 \")]),_c('div',{staticClass:\"ding\",attrs:{\"id\":\"des1\"}}),_c('h1',{staticClass:\"topic\"},[_vm._v(\"shRNA介导的SNCA基因沉默模型\")]),_c('div',{staticClass:\"ding\"}),_c('h1',{staticClass:\"title\"},[_vm._v(\"原理简述\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 表达shRNA的载体进入细胞核，并在细胞核中不断产生shRNA。shRNA被运输到细胞质中，经过Dicer酶处理转化为siRNA。siRNA与Argonaute（Ago）结合，形成RISC；在此过程中，siRNA的一条链被舍弃，一条链被保留。被保留的单链引导RISC结合至SNCA基因转录产生的mRNA，RISC随后将mRNA降解。 \")]),_c('div',{staticClass:\"ding\"}),_c('h1',{staticClass:\"title\"},[_vm._v(\"生物化学模型\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 参考查找得到的动力学参数的形式，将上述过程描述为以下五个小过程： \")]),_c('img',{staticClass:\"gong\",attrs:{\"src\":require(\"../assets/m1-12.png\"),\"alt\":\"no pic\"}}),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 按排列顺序，将上述五个反应记为反应1～5. \")]),_c('div',{staticClass:\"ding\"}),_c('h1',{staticClass:\"title\"},[_vm._v(\"数学模型\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 反应1类似第一个模型中的做法，用RNA聚合酶的动力学参数和米氏方程估计出一个常数，用这个常速率来描述转录过程。RNA聚合酶的动力学参数来自[11]。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 反应2用半衰期来描述。反应3用米氏方程来描述。Dicer的动力学参数来自[12]。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 反应4中，参考已有的模型[9]，可以假设含RISC的物质总量一定，并将这些物质划分成三种状态：游离的（RISCs\"),_c('sub',[_vm._v(\"free\")]),_vm._v(\"），结合了siRNA的（RISC\"),_c('sub',[_vm._v(\"act\")]),_vm._v(\"），结合了siRNA和mRNA的（RISC\"),_c('sub',[_vm._v(\"bound\")]),_vm._v(\"）。但是，从获得的参考数据上看，从RISC\"),_c('sub',[_vm._v(\"act\")]),_vm._v(\"向RISC\"),_c('sub',[_vm._v(\"bound\")]),_vm._v(\"的转化非常快速彻底（正反应速率常数比逆反应速率常数大14个数量级以上）。因此，近似认为RISC\"),_c('sub',[_vm._v(\"act\")]),_vm._v(\"一旦生成就立刻与mRNA结合，这两种形态不再区分，统一称为RISC\"),_c('sub',[_vm._v(\"act\")]),_vm._v(\"。在这样的假设下，可以验证 下式恒成立，即总量一定的假设没有被破坏。 \")]),_c('img',{staticClass:\"gong\",attrs:{\"src\":require(\"../assets/m1-13.png\"),\"alt\":\"no pic\"}}),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 反应5用米氏方程来描述。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 综上，得到关于[shRNA],[siRNA],[RISC\"),_c('sub',[_vm._v(\"free\")]),_vm._v(\"],[RISC\"),_c('sub',[_vm._v(\"act\")]),_vm._v(\"],[mRNA]的微分方程组： \")]),_c('img',{staticClass:\"tu\",attrs:{\"src\":require(\"../assets/m2-1.png\"),\"alt\":\"no pic\"}}),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 其中，v\"),_c('sub',[_vm._v(\"{m,X}\")]),_vm._v(\"的值与第一个模型一样，都是由转换数和酶浓度得到的。具体参数含义见参数表。 \")]),_c('div',{staticClass:\"ding\"}),_c('h1',{staticClass:\"title\"},[_vm._v(\"参数选取\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 方程1，2中的酶动力学参数均由酶数据库BRENDA[2]查得。其中方程1所用的酶的数据来自RNA polymerase II（EC2.7.7.6），方程2所用酶的数据来自ribonuclease III（EC3.1.26.3）。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 三种RNA的降解速率以及方程2，3，4涉及的两个速率常数来自[9]。其中，shRNA的降解速率数据不准确，因为结构与siRNA相似，假定其值与siRNA相同。后续进行灵敏度分析。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" RISC作为酶的动力学参数来自[10]。关于该过程规律可视作与酶促反应相同的结论也来自这篇文章。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 除了[RISC\"),_c('sub',[_vm._v(\"free\")]),_vm._v(\"]与[mRNA]，其他变量的初值均设定为0.[RISC\"),_c('sub',[_vm._v(\"free\")]),_vm._v(\"]的初值根据文献[9]确定。[mRNA]的初值将以动画的形式遍历，以直观证明shRNA介入的功能特性。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" [poly],[Dicer],[DNA]即RNA聚合酶II、Dicer、DNA的浓度均估计为1x10\"),_c('sup',[_vm._v(\"-9\")]),_vm._v(\"M.后续将对这些估计值作灵敏度分析。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 详细的参数值见参数表。 \")]),_c('div',{staticClass:\"ding\"}),_c('h1',{staticClass:\"title\"},[_vm._v(\"模型结果>\")]),_c('img',{staticClass:\"tu\",attrs:{\"src\":require(\"../assets/m2-2.gif\"),\"alt\":\"no pic\"}}),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 上图为SNCA的mRNA初始浓度在一定范围内变化时，mRNA浓度随时间的变化曲线。可以看见，在这一范围内，无论mRNA的初始浓度为多少，在经过6000～10000s（约合3h）之后，mRNA水平都会被控制到一个不随mRNA浓度初值变化而变化的常量。这说明shRNA通路对mRNA水平有较好的控制能力。并且，从灵敏度分析（见下）的第一部分可以知道，通过调控转录的速率可以做到控制这一常量的大小。这说明通过线路元件的合理设计，将SNCA控制在希望的某一水平是可行的。 \")]),_c('div',{staticClass:\"ding\"}),_c('h1',{staticClass:\"title\"},[_vm._v(\"Sensitive analysis\")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 灵敏度分析的第一部分将阐明转录速度如何影响模型结果。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 如上所述，转录的速率是自行计算得出的，这一速率的值是4.59x10\"),_c('sup',[_vm._v(\"-11\")]),_vm._v(\"M/s.现在改变这一数值，使其在[0,1x10\"),_c('sup',[_vm._v(\"-10\")]),_vm._v(\"](M/s)之间变化，得到的效果如下。（此时mRNA浓度初值设为0） \")]),_c('img',{staticClass:\"tu\",attrs:{\"src\":require(\"../assets/m2-3.gif\"),\"alt\":\"no pic\"}}),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 可以看到，随着转录速度的增长，曲线的大致形状没有改变，但是最后到达的稳定水平改变了。这就说明了调控转录速度能够控制最终的mRNA水平。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 第二部分证明在参数中，准确度比较低的三个值[poly],[Dicer],k\"),_c('sub',[_vm._v(\"shRNA\")]),_vm._v(\"对模型的影响极小，因而参数的不准确不会有影响。（[DNA]之所以不讨论，是因为其被估计出来是为了估算转录速度，而转录速度的影响已经在上一部分讨论过。参数本身并没有太大意义） \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 先讨论[poly],[Dicer]。同时改变[poly],[Dicer]的值，使其在[1x10\"),_c('sup',[_vm._v(\"-10\")]),_vm._v(\",1x10\"),_c('sup',[_vm._v(\"-8\")]),_vm._v(\"](M)之间变化。结果如下。 \")]),_c('img',{staticClass:\"tu\",attrs:{\"src\":require(\"../assets/m2-4.gif\"),\"alt\":\"no pic\"}}),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 从结果中可以看到，这两个值在变化的时，曲线并没有发生肉眼可见的变化。换言之，这两个参数的不准确性不会对结果造成很大影响。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 再讨论k\"),_c('sub',[_vm._v(\"shRNA\")]),_vm._v(\"}。令其在[1x10\"),_c('sup',[_vm._v(\"-6\")]),_vm._v(\",1x10\"),_c('sup',[_vm._v(\"-2\")]),_vm._v(\"](1/s)内变化，得到图像。同理，可以看出该参数的不准确性不会带来可见的影响。 \")]),_c('img',{staticClass:\"tu\",attrs:{\"src\":require(\"../assets/m2-5.gif\"),\"alt\":\"no pic\"}}),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 参数表： \")]),_c('img',{staticClass:\"tu\",attrs:{\"src\":require(\"../assets/m2-6.png\"),\"alt\":\"no pic\"}}),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 源代码： \")]),_c('p',{staticClass:\"pagraph\"},[_c('a',{attrs:{\"href\":\"https://pan.baidu.com/s/1W371FymQCYUlTvH_pONzlg?pwd=845q\"}},[_vm._v(\"链接\")]),_vm._v(\" ： 提取码: 845q \")]),_c('p',{staticClass:\"ref\"},[_vm._v(\" 参考文献： \")]),_c('p',{staticClass:\"ref\"},[_vm._v(\" [1]Huafeng Xu.Cochaperones enable Hsp70 to use ATP energy to stabilize native proteins out of the folding equilibrium[J/OL].Scientific Reports,2018-09-04:5. \")]),_c('a',{attrs:{\"href\":\"\"}}),_c('p',{staticClass:\"ref\"},[_vm._v(\" [2]BRENDA Enzyme Database[DB/OL].\"),_c('a',{attrs:{\"href\":\"https://www.brenda-enzymes.org,2022-02-07\"}},[_vm._v(\"https://www.brenda-enzymes.org,2022-02-07\")]),_vm._v(\". \")]),_c('p',{staticClass:\"ref\"},[_vm._v(\" [3]BRENDA Enzyme Database[DB/OL].\"),_c('a',{attrs:{\"href\":\"https://www.brenda-enzymes.org/enzyme.php?ecno=2.3.2.26,2022-02-07\"}},[_vm._v(\"https://www.brenda-enzymes.org/enzyme.php?ecno=2.3.2.26,2022-02-07\")]),_vm._v(\". \")]),_c('p',{staticClass:\"ref\"},[_vm._v(\" [4]BRENDA Enzyme Database[DB/OL].\"),_c('a',{attrs:{\"href\":\"https://www.brenda-enzymes.org/enzyme.php?ecno=3.4.25.1,2022-02-07\"}},[_vm._v(\"https://www.brenda-enzymes.org/enzyme.php?ecno=3.4.25.1,2022-02-07\")]),_vm._v(\". \")]),_c('p',{staticClass:\"ref\"},[_vm._v(\" [5]BRENDA Enzyme Database[DB/OL].\"),_c('a',{attrs:{\"href\":\"https://www.brenda-enzymes.org/enzyme.php?ecno=3.4.22.16,2022-02-07\"}},[_vm._v(\"https://www.brenda-enzymes.org/enzyme.php?ecno=3.4.22.16,2022-02-07\")]),_vm._v(\". \")]),_c('p',{staticClass:\"ref\"},[_vm._v(\" [6]百度百科.氨基酸[EB/OL].\"),_c('a',{attrs:{\"href\":\"https://baike.baidu.com/item/%E6%B0%A8%E5%9F%BA%E9%85%B8/303574?fr=aladdin,2022-02-07\"}},[_vm._v(\"https://baike.baidu.com/item/%E6%B0%A8%E5%9F%BA%E9%85%B8/303574?fr=aladdin,2022-02-07\")]),_vm._v(\". \")]),_c('p',{staticClass:\"ref\"},[_vm._v(\" [7]Shu-Bing,Qian,McDonough et al.CHIP-mediated stress recovery by sequential ubiquitination of substrates and Hsp70[J/OL].Nature,2006-03-23:551. \")]),_c('p',{staticClass:\"ref\"},[_vm._v(\" [8]Stephan N.Witt.Hsp70 molecular charperones and Parkinson's disease[J/OL].Biopolymers,2009-08-27:222 \")]),_c('p',{staticClass:\"ref\"},[_vm._v(\" [9]Derek W. Bartlett,Mark E. Davis.Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging[J/OL].Nucleic Acids Research,2006-01-12:325 \")]),_c('p',{staticClass:\"ref\"},[_vm._v(\" [10]Benjamin Haley,Phillip D Zamore.Kinetic analysis of the RNAi enzyme complex[J/OL].nature structural & molecular biology,2004-05-30:603. \")]),_c('p',{staticClass:\"ref\"},[_vm._v(\" [11]BRENDA Enzyme Database[DB/OL].\"),_c('a',{attrs:{\"href\":\"https://www.brenda-enzymes.org/enzyme.php?ecno=2.7.7.6,2022-02-07\"}},[_vm._v(\"https://www.brenda-enzymes.org/enzyme.php?ecno=2.7.7.6,2022-02-07\")]),_vm._v(\". \")]),_c('p',{staticClass:\"ref\"},[_vm._v(\" [12]BRENDA Enzyme Database[DB/OL].\"),_c('a',{attrs:{\"href\":\"https://www.brenda-enzymes.org/enzyme.php?ecno=3.1.26.3,2022-02-07\"}},[_vm._v(\"https://www.brenda-enzymes.org/enzyme.php?ecno=3.1.26.3,2022-02-07\")]),_vm._v(\". \")]),_c('div',{staticClass:\"ding\"}),_c('div',{staticClass:\"ding\"}),_c('div',{staticClass:\"ding\"}),_c('div',{staticClass:\"ding\"})])]),_c('div',{staticClass:\"leftP\",attrs:{\"id\":\"lef\"}},[_c('ul',{staticClass:\"Shell\"},[_c('li',[_c('a',{attrs:{\"href\":\"#top\"}},[_vm._v(\"α-syn降解模型\")])]),_c('li',[_c('a',{attrs:{\"href\":\"#des1\"}},[_vm._v(\"SNCA基因沉默模型\")])])])])])}]\n\nexport { render, staticRenderFns }","<template>\r\n  <div>\r\n    <div class=\"bg\"><div class=\"im\" id=\"bg\"></div></div>\r\n    <div class=\"back\">\r\n      <div class=\"content\">\r\n        <div class=\"ding\" id=\"top\"></div>\r\n    <h1 class=\"topic\">HSP70介导的α-syn(α-synuclein)降解模型</h1>\r\n\r\n<div class=\"ding\"></div>\r\n    <h1 class=\"title\">原理简述</h1>\r\n    <p class=\"pagraph\">\r\nHSP70有两条路径可以使α-syn降解。一条路径是在底物（即α-syn）结合HSP70以后，让E3泛素连接酶CHIP（carboxyl terminus of Hsc70-interacting protein）识别α-syn并将其泛素化，进而使α-syn被蛋白酶体降解；另一条路径是在α-syn结合HSP70之后，将α-syn传入溶酶体并降解。\r\n    </p>\r\n<div class=\"ding\"></div>\r\n    <h1 class=\"title\">生物化学模型</h1>\r\n    <p class=\"pagraph\">\r\n先描述共有的过程，即α-syn结合HSP70的过程。根据查找得到的动力学参数形式，将该过程描述为以下形式：\r\n    </p>\r\n     <img class=\"gong\" src=\"../assets/m1-1.png\" alt=\"no pic\">\r\n    <p class=\"pagraph\">\r\n其中，S代表底物α-syn，C代表HSP70，S·C·X（X=ADP/ATP）代表三者连接形成的复合物。上述三个反应依次记为反应1，2，3.\r\n    </p>\r\n    <p class=\"pagraph\">\r\n另外还有两个过程：蛋白质HSP70和α-syn的翻译生成过程，和HSP70的降解过程（忽略α-syn的降解，一是因为没有准确的数据难以估计，二是因为HSP70通路本身就是为了降低α-syn的含量，考虑其降解只会让α-syn减少得更快，不可能影响最终结论）。\r\n    </p>\r\n    <p class=\"pagraph\">\r\n对于生成过程，用一个常数来描述这一过程的速率。将翻译看作氨基酸作为底物、肽酰转移酶催化的酶促反应并将细胞内的氨基酸浓度视为常量，用肽酰转移酶的酶动力学参数借由米氏方程估计出速率。这里略去化学方程式，直接给出速率表达式：\r\n    </p>\r\n    <img class=\"gong\" src=\"../assets/m1-2.png\" alt=\"no pic\">\r\n    <p class=\"pagraph\">\r\n其中，v_{m,pep}=K_{cat,pep}[pep]，K_{cat,pep}为肽酰转移酶的转换数，[pep]为肽酰转移酶的浓度。作为一种较粗略的估计，HSP70和α-syn的产生速度都由这个值来表述。\r\n    </p>\r\n    <p class=\"pagraph\">\r\n对于降解过程，直接用半衰期来刻画。这里也直接给出降解的数学方程：\r\n    </p>\r\n    <img class=\"gong\" src=\"../assets/m1-3.png\" alt=\"no pic\">\r\n    <p class=\"pagraph\">\r\n其中，t_{1/2,HSP70}为HSP70的半衰期。\r\n    </p>\r\n    <p class=\"pagraph\">\r\n接下来，假设进入泛素化路径的α-syn比例为α，进入自噬途径的α-syn比例为β。进入泛素化过程的α-syn发生的反应：\r\n    </p>\r\n    <img class=\"gong\" src=\"../assets/m1-4.png\" alt=\"no pic\">\r\n    <p class=\"pagraph\">\r\n其中，S_{ubi}代表泛素化的α-syn，animoacids代表降解产生的氨基酸。\r\n    </p>\r\n    <p class=\"pagraph\">\r\n进入自噬过程的α-syn发生的反应：\r\n    </p>\r\n    <img class=\"gong\" src=\"../assets/m1-5.png\" alt=\"no pic\">\r\n    <p class=\"pagraph\">\r\n上述方程均省略了相应的酶。上述三个反应依次记为反应4，5，6.\r\n    </p>\r\n      <div class=\"ding\"></div>\r\n    <h1 class=\"title\">数学模型</h1>\r\n    <p class=\"pagraph\">\r\n根据获得的动力学参数的形式，前三个反应用结合速率常数与解离速率常数描述，后三个反应用米氏方程描述。\r\n    </p>\r\n    <p class=\"pagraph\">\r\n由此获得关于变量[S],[C·ATP],[S·C·ATP],[C·ADP],[S·C·ADP],[S_{ubi}·C·ADP]的微分方程组：\r\n    </p>\r\n    <img class=\"tu\" src=\"../assets/m1-6.png\" alt=\"no pic\">\r\n<div class=\"ding\"></div>\r\n    <h1 class=\"title\">参数选取</h1>\r\n    <p class=\"pagraph\">\r\n反应1，2，3的结合速率常数和解离速率常数摘自一篇Nature的ScientificReport（Table 1）[1]。反应4，5，6的酶动力学参数摘自酶数据库BRENDA[2]。其中，反应4由CHIP（EC2.3.2.27）催化，但由于没有找到CHIP的直接数据，其动力学参数由同属EC2.3.2的E3连接酶HECT-type E3 ubiquitin transferase（wild type，EC2.3.2.26）代替[3]。出于同样的原因和方式，反应5对应的酶用HsIU-HsIV peptidase（EC3.4.25.2）代替具有泛素依赖性的蛋白酶体26S（EC3.4.25.1）[4]。反应6的动力学参数用cathepsin H（EC3.4.22.16）估计[5]。\r\n    </p>\r\n    <p class=\"pagraph\">\r\n[amino]的值被视为一个常量，因为细胞内的氨基酸浓度不太可能发生剧烈的变化。根据[6]以及氨基酸的平均相对分子质量，可以计算出其值。\r\n    </p>\r\n    <p class=\"pagraph\">\r\nt<sub>1/2,HSP70</sub>从[7]估计。详细的参数取值见参数表。\r\n    </p>\r\n    <p class=\"pagraph\">\r\n详细的参数取值见参数表。\r\n    </p>\r\n    <p class=\"pagraph\">\r\n根据[8]，取\\alpha=0.7,\\beta=0.3.这一参数并不准确，所以在后续将对这两个参数进行灵敏度分析。\r\n    </p>\r\n    <p class=\"pagraph\">\r\n根据[1]中的实验条件，取初值[C·ATP]=1x10<sup>-6</sup>M,[S·C·ATP]=[C·ADP]=[S<sub>ubi</sub>·C·ADP]=[S·C·ADP]=0.而[S]的初值将以动画的形式在[0,2x10<sup>-5</sup>](M)之间变化，在讨论其他变量时维持初值3x10<sup>-6</sup>(M)。[C·ATP]的值实际上在灵敏度分析中也在一定范围内变化，但在讨论其他变量的情况下维持上述初值。\r\n    </p>\r\n    <div class=\"ding\"></div>\r\n    <h1 class=\"title\">模型结果</h1>\r\n    <p class=\"pagraph\">\r\n如下是[S]变化时，α-syn的浓度随时间的变化。\r\n    </p>\r\n     <img class=\"tu\" src=\"../assets/m1-7.gif\" alt=\"no pic\"> \r\n    <p class=\"pagraph\">\r\n从图可知，α-syn的浓度在最开始时稍有下降，之后上升到峰值，随后持续下降，600～1000s（约合17min）后接近于零。这足以说明HSP70对α-syn的抑制作用。最开始的短暂下降是由[C·ATP]的初值造成的，这将在灵敏度分析中提到。\r\n    </p>\r\n  <div class=\"ding\"></div>\r\n    <h1 class=\"title\">Sensitive analysis</h1>\r\n    <p class=\"pagraph\">\r\n灵敏度分析的第一部分讨论(α,β)的取值带来的影响。令这两个值分别从0.1向0.9变化，得到图像如下。\r\n    </p> \r\n    <img class=\"tu\" src=\"../assets/m1-8.gif\" alt=\"no pic\"> \r\n     <p class=\"pagraph\">\r\n可以看到，在变化范围内，(α,β)的取值对曲线仅产生了很小幅度的影响，说明(α,β)取值不准确性的影响很小。\r\n    </p>\r\n     <p class=\"pagraph\">\r\n第二部分讨论[C·ATP]的初值变化带来的影响。令其在[0,1x10<sup>-5</sup>](M)之间变化。\r\n    </p>    \r\n    <img class=\"tu\" src=\"../assets/m1-9.gif\" alt=\"no pic\"> \r\n          <p class=\"pagraph\">\r\n可以发现，[C·ATP]的初值主要影响最开始的下降阶段，因而影响峰值的大小和曲线的陡峭程度，但对于曲线的走势和最终的稳定值没有影响。\r\n    </p>\r\n      <p class=\"pagraph\">\r\n第三部分讨论酶浓度变化带来的影响。令所有酶的浓度在[1x10<sup>-10</sup>,1x10<sup>-6</sup>](M)之间变化。\r\n    </p>\r\n     <img class=\"tu\" src=\"../assets/m1-10.gif\" alt=\"no pic\"> \r\n        <p class=\"pagraph\">\r\n可以发现，即使酶的浓度变化达到四个数量级，对曲线也没有产生可见的影响。所以，酶浓度估计不准确不会产生有效的影响。\r\n    </p>\r\n\r\n\r\n    <p class=\"pagraph\">\r\n参数表：\r\n    </p>\r\n    <img class=\"tu\" src=\"../assets/m1-11.png\" alt=\"no pic\"> \r\n <p class=\"pagraph\">\r\n源代码在文档末尾，参考文献之前。\r\n    </p>\r\n\r\n    <div class=\"ding\" id=\"des1\"></div>\r\n    <h1 class=\"topic\">shRNA介导的SNCA基因沉默模型</h1>\r\n     <div class=\"ding\"></div>\r\n    <h1 class=\"title\">原理简述</h1>\r\n    <p class=\"pagraph\">\r\n表达shRNA的载体进入细胞核，并在细胞核中不断产生shRNA。shRNA被运输到细胞质中，经过Dicer酶处理转化为siRNA。siRNA与Argonaute（Ago）结合，形成RISC；在此过程中，siRNA的一条链被舍弃，一条链被保留。被保留的单链引导RISC结合至SNCA基因转录产生的mRNA，RISC随后将mRNA降解。\r\n    </p>\r\n     <div class=\"ding\"></div>\r\n    <h1 class=\"title\">生物化学模型</h1>\r\n    <p class=\"pagraph\">\r\n参考查找得到的动力学参数的形式，将上述过程描述为以下五个小过程：\r\n    </p>\r\n     <img class=\"gong\" src=\"../assets/m1-12.png\" alt=\"no pic\"> \r\n<p class=\"pagraph\">\r\n按排列顺序，将上述五个反应记为反应1～5.\r\n    </p>\r\n    <div class=\"ding\"></div>\r\n    <h1 class=\"title\">数学模型</h1>\r\n    <p class=\"pagraph\">\r\n反应1类似第一个模型中的做法，用RNA聚合酶的动力学参数和米氏方程估计出一个常数，用这个常速率来描述转录过程。RNA聚合酶的动力学参数来自[11]。\r\n    </p>\r\n    <p class=\"pagraph\">\r\n反应2用半衰期来描述。反应3用米氏方程来描述。Dicer的动力学参数来自[12]。\r\n    </p>\r\n    <p class=\"pagraph\">\r\n反应4中，参考已有的模型[9]，可以假设含RISC的物质总量一定，并将这些物质划分成三种状态：游离的（RISCs<sub>free</sub>），结合了siRNA的（RISC<sub>act</sub>），结合了siRNA和mRNA的（RISC<sub>bound</sub>）。但是，从获得的参考数据上看，从RISC<sub>act</sub>向RISC<sub>bound</sub>的转化非常快速彻底（正反应速率常数比逆反应速率常数大14个数量级以上）。因此，近似认为RISC<sub>act</sub>一旦生成就立刻与mRNA结合，这两种形态不再区分，统一称为RISC<sub>act</sub>。在这样的假设下，可以验证\r\n下式恒成立，即总量一定的假设没有被破坏。\r\n    </p>\r\n    <img class=\"gong\" src=\"../assets/m1-13.png\" alt=\"no pic\"> \r\n    <p class=\"pagraph\">\r\n反应5用米氏方程来描述。\r\n    </p>\r\n    <p class=\"pagraph\">\r\n综上，得到关于[shRNA],[siRNA],[RISC<sub>free</sub>],[RISC<sub>act</sub>],[mRNA]的微分方程组：\r\n    </p>\r\n<img class=\"tu\" src=\"../assets/m2-1.png\" alt=\"no pic\"> \r\n <p class=\"pagraph\">\r\n其中，v<sub>{m,X}</sub>的值与第一个模型一样，都是由转换数和酶浓度得到的。具体参数含义见参数表。\r\n    </p>\r\n\r\n    <div class=\"ding\"></div>\r\n    <h1 class=\"title\">参数选取</h1>\r\n    <p class=\"pagraph\">\r\n方程1，2中的酶动力学参数均由酶数据库BRENDA[2]查得。其中方程1所用的酶的数据来自RNA polymerase II（EC2.7.7.6），方程2所用酶的数据来自ribonuclease III（EC3.1.26.3）。\r\n    </p>\r\n     <p class=\"pagraph\">\r\n三种RNA的降解速率以及方程2，3，4涉及的两个速率常数来自[9]。其中，shRNA的降解速率数据不准确，因为结构与siRNA相似，假定其值与siRNA相同。后续进行灵敏度分析。\r\n    </p>\r\n     <p class=\"pagraph\">\r\nRISC作为酶的动力学参数来自[10]。关于该过程规律可视作与酶促反应相同的结论也来自这篇文章。\r\n    </p>\r\n     <p class=\"pagraph\">\r\n除了[RISC<sub>free</sub>]与[mRNA]，其他变量的初值均设定为0.[RISC<sub>free</sub>]的初值根据文献[9]确定。[mRNA]的初值将以动画的形式遍历，以直观证明shRNA介入的功能特性。\r\n    </p>\r\n     <p class=\"pagraph\">\r\n[poly],[Dicer],[DNA]即RNA聚合酶II、Dicer、DNA的浓度均估计为1x10<sup>-9</sup>M.后续将对这些估计值作灵敏度分析。\r\n    </p>\r\n     <p class=\"pagraph\">\r\n详细的参数值见参数表。\r\n    </p>\r\n     <div class=\"ding\"></div>\r\n    <h1 class=\"title\">模型结果></h1>\r\n<img class=\"tu\" src=\"../assets/m2-2.gif\" alt=\"no pic\"> \r\n    <p class=\"pagraph\">\r\n上图为SNCA的mRNA初始浓度在一定范围内变化时，mRNA浓度随时间的变化曲线。可以看见，在这一范围内，无论mRNA的初始浓度为多少，在经过6000～10000s（约合3h）之后，mRNA水平都会被控制到一个不随mRNA浓度初值变化而变化的常量。这说明shRNA通路对mRNA水平有较好的控制能力。并且，从灵敏度分析（见下）的第一部分可以知道，通过调控转录的速率可以做到控制这一常量的大小。这说明通过线路元件的合理设计，将SNCA控制在希望的某一水平是可行的。\r\n    </p>\r\n     <div class=\"ding\"></div>\r\n    <h1 class=\"title\">Sensitive analysis</h1>\r\n    <p class=\"pagraph\">\r\n灵敏度分析的第一部分将阐明转录速度如何影响模型结果。\r\n    </p>\r\n     <p class=\"pagraph\">\r\n如上所述，转录的速率是自行计算得出的，这一速率的值是4.59x10<sup>-11</sup>M/s.现在改变这一数值，使其在[0,1x10<sup>-10</sup>](M/s)之间变化，得到的效果如下。（此时mRNA浓度初值设为0）\r\n    </p>\r\n    <img class=\"tu\" src=\"../assets/m2-3.gif\" alt=\"no pic\"> \r\n     <p class=\"pagraph\">\r\n可以看到，随着转录速度的增长，曲线的大致形状没有改变，但是最后到达的稳定水平改变了。这就说明了调控转录速度能够控制最终的mRNA水平。\r\n    </p>\r\n     <p class=\"pagraph\">\r\n第二部分证明在参数中，准确度比较低的三个值[poly],[Dicer],k<sub>shRNA</sub>对模型的影响极小，因而参数的不准确不会有影响。（[DNA]之所以不讨论，是因为其被估计出来是为了估算转录速度，而转录速度的影响已经在上一部分讨论过。参数本身并没有太大意义）\r\n    </p>\r\n     <p class=\"pagraph\">\r\n先讨论[poly],[Dicer]。同时改变[poly],[Dicer]的值，使其在[1x10<sup>-10</sup>,1x10<sup>-8</sup>](M)之间变化。结果如下。\r\n    </p>\r\n     <img class=\"tu\" src=\"../assets/m2-4.gif\" alt=\"no pic\"> \r\n     <p class=\"pagraph\">\r\n从结果中可以看到，这两个值在变化的时，曲线并没有发生肉眼可见的变化。换言之，这两个参数的不准确性不会对结果造成很大影响。\r\n    </p>\r\n     <p class=\"pagraph\">\r\n再讨论k<sub>shRNA</sub>}。令其在[1x10<sup>-6</sup>,1x10<sup>-2</sup>](1/s)内变化，得到图像。同理，可以看出该参数的不准确性不会带来可见的影响。\r\n    </p>\r\n    <img class=\"tu\" src=\"../assets/m2-5.gif\" alt=\"no pic\"> \r\n     <p class=\"pagraph\">\r\n参数表：\r\n    </p>\r\n    <img class=\"tu\" src=\"../assets/m2-6.png\" alt=\"no pic\"> \r\n     <p class=\"pagraph\">\r\n源代码：\r\n    </p>\r\n     <p class=\"pagraph\">\r\n <a href=\"https://pan.baidu.com/s/1W371FymQCYUlTvH_pONzlg?pwd=845q\">链接</a> ： 提取码: 845q \r\n    </p>\r\n     <p class=\"ref\">\r\n参考文献：\r\n    </p>\r\n    <p class=\"ref\">\r\n[1]Huafeng Xu.Cochaperones enable Hsp70 to use ATP energy to stabilize native proteins out of the folding equilibrium[J/OL].Scientific Reports,2018-09-04:5.\r\n    </p>\r\n    <a href=\"\"></a>\r\n    <p class=\"ref\">\r\n[2]BRENDA Enzyme Database[DB/OL].<a href=\"https://www.brenda-enzymes.org,2022-02-07\">https://www.brenda-enzymes.org,2022-02-07</a>.\r\n    </p>\r\n    <p class=\"ref\">\r\n[3]BRENDA Enzyme Database[DB/OL].<a href=\"https://www.brenda-enzymes.org/enzyme.php?ecno=2.3.2.26,2022-02-07\">https://www.brenda-enzymes.org/enzyme.php?ecno=2.3.2.26,2022-02-07</a>.\r\n    </p>\r\n    <p class=\"ref\">\r\n[4]BRENDA Enzyme Database[DB/OL].<a href=\"https://www.brenda-enzymes.org/enzyme.php?ecno=3.4.25.1,2022-02-07\">https://www.brenda-enzymes.org/enzyme.php?ecno=3.4.25.1,2022-02-07</a>.\r\n    </p>\r\n    <p class=\"ref\">\r\n[5]BRENDA Enzyme Database[DB/OL].<a href=\"https://www.brenda-enzymes.org/enzyme.php?ecno=3.4.22.16,2022-02-07\">https://www.brenda-enzymes.org/enzyme.php?ecno=3.4.22.16,2022-02-07</a>.\r\n    </p>\r\n    <p class=\"ref\">\r\n[6]百度百科.氨基酸[EB/OL].<a href=\"https://baike.baidu.com/item/%E6%B0%A8%E5%9F%BA%E9%85%B8/303574?fr=aladdin,2022-02-07\">https://baike.baidu.com/item/%E6%B0%A8%E5%9F%BA%E9%85%B8/303574?fr=aladdin,2022-02-07</a>.\r\n    </p>\r\n    <p class=\"ref\">\r\n[7]Shu-Bing,Qian,McDonough et al.CHIP-mediated stress recovery by sequential ubiquitination of substrates and Hsp70[J/OL].Nature,2006-03-23:551.\r\n    </p>\r\n    <p class=\"ref\">\r\n[8]Stephan N.Witt.Hsp70 molecular charperones and Parkinson's disease[J/OL].Biopolymers,2009-08-27:222\r\n    </p>\r\n    <p class=\"ref\">\r\n[9]Derek W. Bartlett,Mark E. Davis.Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging[J/OL].Nucleic Acids Research,2006-01-12:325\r\n    </p>\r\n    <p class=\"ref\">\r\n[10]Benjamin Haley,Phillip D Zamore.Kinetic analysis of the RNAi enzyme complex[J/OL].nature structural & molecular biology,2004-05-30:603.\r\n    </p>\r\n    <p class=\"ref\">\r\n[11]BRENDA Enzyme Database[DB/OL].<a href=\"https://www.brenda-enzymes.org/enzyme.php?ecno=2.7.7.6,2022-02-07\">https://www.brenda-enzymes.org/enzyme.php?ecno=2.7.7.6,2022-02-07</a>.\r\n    </p>\r\n    <p class=\"ref\">\r\n[12]BRENDA Enzyme Database[DB/OL].<a href=\"https://www.brenda-enzymes.org/enzyme.php?ecno=3.1.26.3,2022-02-07\">https://www.brenda-enzymes.org/enzyme.php?ecno=3.1.26.3,2022-02-07</a>.\r\n    </p>\r\n\r\n    \r\n\r\n\r\n\r\n        <div class=\"ding\"></div>\r\n        <div class=\"ding\"></div>\r\n        <div class=\"ding\"></div>\r\n        <div class=\"ding\"></div>\r\n      </div>\r\n    </div>\r\n\r\n    <div id=\"lef\" class=\"leftP\">\r\n      <ul class=\"Shell\">\r\n        <li><a href=\"#top\">α-syn降解模型</a></li>\r\n        <li><a href=\"#des1\">SNCA基因沉默模型</a></li>\r\n\r\n      </ul>\r\n    </div>\r\n  </div>\r\n</template>\r\n<script>\r\nexport default {\r\n  return() {},\r\n  methods: {\r\n    ch1() {\r\n      let p1 = document.getElementById(\"p1\");\r\n      let p2 = document.getElementById(\"p2\");\r\n      let p3 = document.getElementById(\"p3\");\r\n      let p4 = document.getElementById(\"p4\");\r\n      p1.classList.add(\"showup\");\r\n      p2.classList.remove(\"showup\");\r\n      p3.classList.remove(\"showup\");\r\n      p4.classList.remove(\"showup\");\r\n    },\r\n    ch2() {\r\n      let p1 = document.getElementById(\"p1\");\r\n      let p2 = document.getElementById(\"p2\");\r\n      let p3 = document.getElementById(\"p3\");\r\n      let p4 = document.getElementById(\"p4\");\r\n      p2.classList.add(\"showup\");\r\n      p1.classList.remove(\"showup\");\r\n      p3.classList.remove(\"showup\");\r\n      p4.classList.remove(\"showup\");\r\n    },\r\n    ch3() {\r\n      let p1 = document.getElementById(\"p1\");\r\n      let p2 = document.getElementById(\"p2\");\r\n      let p3 = document.getElementById(\"p3\");\r\n      let p4 = document.getElementById(\"p4\");\r\n      p3.classList.add(\"showup\");\r\n      p2.classList.remove(\"showup\");\r\n      p1.classList.remove(\"showup\");\r\n      p4.classList.remove(\"showup\");\r\n    },\r\n    ch4() {\r\n      let p1 = document.getElementById(\"p1\");\r\n      let p2 = document.getElementById(\"p2\");\r\n      let p3 = document.getElementById(\"p3\");\r\n      let p4 = document.getElementById(\"p4\");\r\n      p4.classList.add(\"showup\");\r\n      p2.classList.remove(\"showup\");\r\n      p1.classList.remove(\"showup\");\r\n      p3.classList.remove(\"showup\");\r\n    },\r\n  },\r\n  mounted() {\r\n    let lef = document.getElementById(\"lef\");\r\n\r\n    function addEvent(obj, type, fn) {\r\n      undefined;\r\n      if (obj.attachEvent) {\r\n        obj.attachEvent(\"on\" + type, function () {\r\n          undefined;\r\n          fn.call(obj);\r\n        });\r\n      } else {\r\n        undefined;\r\n        obj.addEventListener(type, fn, false);\r\n      }\r\n    }\r\n\r\n    addEvent(window, \"scroll\", function () {\r\n      undefined;\r\n      if (window.pageYOffset >= 455) {\r\n        lef.classList.add(\"stick\");\r\n      } else {\r\n        lef.classList.remove(\"stick\");\r\n      }\r\n    });\r\n  },\r\n};\r\n</script>\r\n<style scoped>\r\n.ref a{\r\n   font-style: italic;\r\n  font-family: Times New Roman, Times, serif !important;\r\n  font-size: 1em;\r\n  color: #6a8691;\r\n  letter-spacing: 0.025em;\r\n}\r\n.pagraph a{\r\n   font-style: italic;\r\n  font-family: Times New Roman, Times, serif !important;\r\n  font-size: 1em;\r\n  color: #6a8691;\r\n  letter-spacing: 0.025em;\r\n}\r\n.title4{\r\n  color: #1d445a;\r\n  font-family: Comic Sans MS;\r\n  margin: 10px;\r\n  font-size: 20px;\r\n}\r\n.p ul li {\r\n  text-indent: 0;\r\n}\r\n.title3 {\r\n  color: #3485a5;\r\n  font-family: Comic Sans MS;\r\n  margin: 10px;\r\n  font-size: 35px;\r\n  border-bottom: solid 2px #7fa2ab;\r\n  padding-bottom: 0.6em;\r\n}\r\n.showBox {\r\n  width: 100%;\r\n}\r\n.showBox .head .c {\r\n  width: 200px;\r\n  height: 40px;\r\n  line-height: 40px;\r\n  text-align: center;\r\n  display: inline-block;\r\n  margin: auto;\r\n  border-radius: 30px;\r\n  color: rgb(169, 207, 199);\r\n}\r\n.showBox .head .c:hover {\r\n  transform: scale(1.1);\r\n  transition: 0.6s;\r\n  background-color: #fff;\r\n  color: rgb(23, 97, 85);\r\n}\r\n.showBox .box .p {\r\n  display: none;\r\n  margin-bottom:20px;\r\n  margin-top:20px;\r\n}\r\n.showBox .head #c1 {\r\n  background-color: #6ab480;\r\n}\r\n.showBox .head #c2 {\r\n  background-color: #6aafb4;\r\n}\r\n.showBox .head #c3 {\r\n  background-color: #2851aa;\r\n}\r\n.showBox .head #c4 {\r\n  background-color: #5636ad;\r\n}\r\n.showBox .box {\r\n  margin-top: 10px;\r\n  padding-left: 15px;\r\n  padding-right: 15px;\r\n  background-color: #d2e8eb;\r\n  width: 880px;\r\n  margin: auto;\r\n  border-radius: 30px;\r\n}\r\n.showBox .box .p {\r\n  display: none;\r\n}\r\n.showBox .box #p1.showup {\r\n  display: block;\r\n  transition: 1s;\r\n}\r\n.showBox .box #p2.showup {\r\n  display: block;\r\n  transition: 1s;\r\n}\r\n.showBox .box #p3.showup {\r\n  display: block;\r\n  transition: 1s;\r\n}\r\n.showBox .box #p4.showup {\r\n  display: block;\r\n  transition: 1s;\r\n}\r\n.ref {\r\n  font-style: italic;\r\n  font-family: Times New Roman, Times, serif !important;\r\n  padding-left: 2em;\r\n  text-align: left;\r\n  font-size: 0.8em;\r\n  color: #7d7d7d;\r\n  letter-spacing: 0.018em;\r\n}\r\n.tu {\r\n  margin-right: auto;\r\n  margin-left: auto;\r\n  display: block;\r\n  margin-top: 20px;\r\n  width: 600px;\r\n  height: auto;\r\n  border-radius: 10px;\r\n  border: #1d5a56;\r\n  background-size: 5px;\r\n}\r\n.gong {\r\n  margin-right: auto;\r\n  margin-left: auto;\r\n  display: block;\r\n  margin-top: 20px;\r\n  width: 300px;\r\n  height: auto;\r\n  border-radius: 10px;\r\n  border: #1d5a56;\r\n  background-size: 5px;\r\n}\r\n.topic {\r\n  color: #1d3f5a;\r\n  font-size: 60px;\r\n  text-align: center;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  font-family: \"Arial\";\r\n  letter-spacing: 15px;\r\n}\r\n#lef.stick {\r\n  opacity: 0.7;\r\n  transition: all 1s;\r\n}\r\n.Shell li a {\r\n  display: block;\r\n  width: 260px;\r\n}\r\n.leftP {\r\n  position: fixed;\r\n  left: 10px;\r\n  top: 30%;\r\n  opacity: 0;\r\n  height: 24vh;\r\n  width: 260px;\r\n  background-color: #3c6b6d;\r\n  border-radius: 20px;\r\n}\r\n.Shell {\r\n  margin: 0;\r\n  padding: 0;\r\n  color: inherit;\r\n  background-color: inherit;\r\n}\r\n.Shell:first-child {\r\n  margin-top: 4vh;\r\n}\r\n.Shell li {\r\n  list-style: none;\r\n  height: 8vh;\r\n  line-height: 8vh;\r\n  padding-left: 20px;\r\n  color: inherit;\r\n  background-color: inherit;\r\n}\r\n.Shell li:hover {\r\n  /* transform:scale(1,1.2); */\r\n  background-color: #89cfd1;\r\n  border-radius: 10px;\r\n  color: #253f17;\r\n  transition: all 0.6s;\r\n}\r\n.Shell li:hover a {\r\n  color: white;\r\n}\r\n.Shell li a {\r\n  text-decoration: none;\r\n  color: #8ad6bd;\r\n}\r\n.ding {\r\n  height: 96px;\r\n}\r\n.top img {\r\n  float: right;\r\n  line-height: 60px;\r\n}\r\n.top img:hover {\r\n  transform: scale(1.3);\r\n  transition: all 0.4s;\r\n}\r\n.back {\r\n  width: 100%;\r\n  background-color: #c5ddd9;\r\n}\r\n.bg .im {\r\n  background-attachment: fixed;\r\n  width: 100%;\r\n  height: 100vh;\r\n  background-size: cover;\r\n  background-image: url(../assets/homeBanner.gif);\r\n}\r\n.content {\r\n  background-color: inherit;\r\n  width: 900px;\r\n  margin: 0 auto;\r\n  align-content: center;\r\n  padding: 20px;\r\n}\r\n.title {\r\n  color: #1d5a56;\r\n  font-family: Comic Sans MS;\r\n  margin: 10px;\r\n  border-bottom: solid 2px #7faba0;\r\n  padding-bottom: 0.6em;\r\n}\r\n.title2 {\r\n  color: #1d5a56;\r\n  font-family: Comic Sans MS;\r\n  margin: 10px;\r\n  margin-top: 50px;\r\n  border-bottom: solid 2px #a9ccc3;\r\n  padding-bottom: 0.6em;\r\n}\r\n.title:first-letter {\r\n  font-size: 50px;\r\n  text-shadow: 2px 2px 5px #444;\r\n}\r\n.title2:first-letter {\r\n  font-size: 50px;\r\n  text-shadow: 2px 2px 5px #444;\r\n}\r\n.pagraph {\r\n  font-family: \"Century Gothic\";\r\n  letter-spacing: 0.05em !important;\r\n  text-indent: 2em;\r\n  display: block;\r\n  transition: all 2s;\r\n  margin-left: 40px;\r\n  letter-spacing: 1.3px;\r\n  line-height: 1.8;\r\n  word-spacing: 3px;\r\n  color: #386f6c;\r\n}\r\n</style>\r\n","import mod from \"-!../../node_modules/cache-loader/dist/cjs.js??ref--13-0!../../node_modules/thread-loader/dist/cjs.js!../../node_modules/babel-loader/lib/index.js!../../node_modules/cache-loader/dist/cjs.js??ref--1-0!../../node_modules/vue-loader/lib/index.js??vue-loader-options!./model.vue?vue&type=script&lang=js&\"; export default mod; export * from \"-!../../node_modules/cache-loader/dist/cjs.js??ref--13-0!../../node_modules/thread-loader/dist/cjs.js!../../node_modules/babel-loader/lib/index.js!../../node_modules/cache-loader/dist/cjs.js??ref--1-0!../../node_modules/vue-loader/lib/index.js??vue-loader-options!./model.vue?vue&type=script&lang=js&\"","import { render, staticRenderFns } from \"./model.vue?vue&type=template&id=57a29492&scoped=true&\"\nimport script from \"./model.vue?vue&type=script&lang=js&\"\nexport * from \"./model.vue?vue&type=script&lang=js&\"\nimport style0 from \"./model.vue?vue&type=style&index=0&id=57a29492&scoped=true&lang=css&\"\n\n\n/* normalize component */\nimport normalizer from \"!../../node_modules/vue-loader/lib/runtime/componentNormalizer.js\"\nvar component = normalizer(\n  script,\n  render,\n  staticRenderFns,\n  false,\n  null,\n  \"57a29492\",\n  null\n  \n)\n\nexport default component.exports","var render = function () {var _vm=this;var _h=_vm.$createElement;var _c=_vm._self._c||_h;return _c('div',[_vm._m(0),_c('div',{staticClass:\"back\"},[_c('div',{staticClass:\"content\"},[_c('div',{staticClass:\"ding\"}),_vm._m(1),_vm._m(2),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 我们设计的硬件基于超常光透射（extraordinary optical transmission，EOT）原理进行检测。检测仪器由光源、滤光片、透镜组、一次性检测试盒以及感光元件组成。其中关键部分是我们的试盒。这是一个内置包被有抗体的纳米金孔阵列的微流控芯片。 \")]),_c('div',{staticClass:\"ding\"}),_c('div',{staticClass:\"showBox\"},[_c('div',{staticClass:\"head\"},[_c('div',{staticClass:\"c\",attrs:{\"id\":\"c1\"},on:{\"click\":function($event){return _vm.ch1()}}},[_vm._v(\"检测仪器\")]),_c('div',{staticClass:\"c\",attrs:{\"id\":\"c2\"},on:{\"click\":function($event){return _vm.ch2()}}},[_vm._v(\"检测试盒\")]),_c('div',{staticClass:\"c\",attrs:{\"id\":\"c3\"},on:{\"click\":function($event){return _vm.ch3()}}},[_vm._v(\"检测原理\")]),_c('div',{staticClass:\"c\",attrs:{\"id\":\"c4\"},on:{\"click\":function($event){return _vm.ch4()}}},[_vm._v(\"检测过程\")])]),_vm._m(3)]),_c('div',{staticClass:\"ding\"}),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 依此，我们设计了两种检测方式分别对不同形式的α-syn蛋白进行检测。检测寡聚体α-syn蛋白时，我们在金孔阵列和胶体金颗粒表面包被的是识别同一抗原表位的单抗，这样，即使金孔阵列表面的抗体捕捉到单体形式的α-syn蛋白，纳米金胶体颗粒上的抗体由于表位的限制也无法与单体α-syn蛋白结合（下图右上），而寡聚体α-syn由于具有多个暴露的表位，因此可以与纳米金胶体颗粒上的抗体结合，进而发生EOT。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 同理，当检测α-syn总蛋白浓度时，将会使用包被有另外一种识别不同抗原表位的单抗的金纳米颗粒，这样，无论何种形式的蛋白都能与金纳米颗粒上的抗体结合，发生EOT。 当两种检测完成后，我们就可以依据信号强度对两种形式的蛋白浓度进行定量，从而得出其比值，判断患者的患病风险。 \")]),_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 最终的数据可以通过装置上的蓝牙通信模块传输至手机和云端以供患者和医生进行诊断。同时，只要更换金孔阵列以及胶体金表面包被的抗体，即可实现对其他疾病的诊断。 \")]),_c('p',{staticClass:\"ref\"},[_vm._v(\" 参考文献 \")]),_c('p',{staticClass:\"ref\"},[_vm._v(\" [1] ROCHET J, HAY B A, GUO M. chapter 5 - Molecular Insights into Parkinson's Disease[M]//Teplow D B. Molecular Biology of Neurodegenerative Diseases. Academic Press, 2012:125-188. \")]),_c('p',{staticClass:\"ref\"},[_vm._v(\" [2] BLOEM B R, OKUN M S, KLEIN C. Parkinson's disease[J]. LANCET, 2021,397(10291): 2284-2303. \")]),_c('p',{staticClass:\"ref\"},[_vm._v(\" [3] HONG Z, TIAN C, STEWART T, et al. Development of a Sensitive Diagnostic Assay for Parkinson Disease Quantifying alpha-Synuclein-Containing Extracellular Vesicles[J]. NEUROLOGY, 2021,96(18): E2332-E2345. \")]),_c('p',{staticClass:\"ref\"},[_vm._v(\" [4] HERRMANN Y, BUJNICKI T, ZAFIU C, et al. Nanoparticle standards for immuno-based quantitation of alpha-synuclein oligomers in diagnostics of Parkinson's disease and other synucleinopathies[J]. CLINICA CHIMICA ACTA, 2017,466: 152-159. \")]),_c('div',{staticClass:\"ding\"}),_c('div',{staticClass:\"ding\"}),_c('div',{staticClass:\"ding\"}),_c('div',{staticClass:\"ding\"})])]),_vm._m(4)])}\nvar staticRenderFns = [function () {var _vm=this;var _h=_vm.$createElement;var _c=_vm._self._c||_h;return _c('div',{staticClass:\"bg\"},[_c('div',{staticClass:\"im\",attrs:{\"id\":\"bg\"}})])},function () {var _vm=this;var _h=_vm.$createElement;var _c=_vm._self._c||_h;return _c('p',{staticClass:\"pagraph\"},[_vm._v(\" 作为一种严重且多见的神经退行性疾病，帕金森症一旦发病，对于其的治疗就显得极为有限\"),_c('sup',[_vm._v(\"[1]\")]),_vm._v(\"。因此，对于帕金森症患者的早期诊断与筛查，是控制帕金森症的一个关键环节，能给予我们更长的时间去治疗疾病或者缓解病症的发生与发展\"),_c('sup',[_vm._v(\"[2]\")]),_vm._v(\"。 \")])},function () {var _vm=this;var _h=_vm.$createElement;var _c=_vm._self._c||_h;return _c('p',{staticClass:\"pagraph\"},[_vm._v(\" 目前已经有文献指出，人类血液与脑脊液中α-syn蛋白的含量与存在形式（单体与寡聚体），可以作为帕金森症的分子标志\"),_c('sup',[_vm._v(\"[3]\")]),_vm._v(\"。但是，其在血液中的总浓度非常低，在10-12-10-15M级别\"),_c('sup',[_vm._v(\"[4]\")]),_vm._v(\"，因此，使用常规的手段难以准确、快速地测量出血液中不同形式α-syn蛋白的浓度。并且，由于人的个体差异以及仪器的检出限等问题，在这种情况下检测单体与寡聚体浓度的比值，将会减少错误诊断的一个有力手段。我们开发的硬件就是基于对不同形式α-syn蛋白的浓度的分别检测以及对其比例的计算，来诊断该患者患上帕金森病的风险。 \")])},function () {var _vm=this;var _h=_vm.$createElement;var _c=_vm._self._c||_h;return _c('div',{staticClass:\"box\"},[_c('div',{staticClass:\"p\",attrs:{\"id\":\"p1\"}},[_c('img',{staticClass:\"tu\",attrs:{\"src\":require(\"../assets/ha1.png\"),\"alt\":\"no pic\"}})]),_c('div',{staticClass:\"p\",attrs:{\"id\":\"p2\"}},[_c('p',{staticClass:\"pagraph\"},[_vm._v(\" 当特定波长的光穿透规律排列的纳米金孔阵列时，由于超常光透射现象，较大部分光线将会透过该阵列，但是若是阵列表面存在有例如胶体金颗粒的物质时，将会破坏这一区域的超常光透射现象，进而该区域的透光能力就会下降。 \")]),_c('img',{staticClass:\"tu\",attrs:{\"src\":require(\"../assets/ha2.png\"),\"alt\":\"no pic\"}})]),_c('div',{staticClass:\"p\",attrs:{\"id\":\"p3\"}},[_c('img',{staticClass:\"tu\",attrs:{\"src\":require(\"../assets/ha3.png\"),\"alt\":\"no pic\"}})]),_c('div',{staticClass:\"p\",attrs:{\"id\":\"p4\"}},[_c('img',{staticClass:\"tu\",attrs:{\"src\":require(\"../assets/ha4.png\"),\"alt\":\"no pic\"}})])])},function () {var _vm=this;var _h=_vm.$createElement;var _c=_vm._self._c||_h;return _c('div',{staticClass:\"leftP\",attrs:{\"id\":\"lef\"}},[_c('a',{attrs:{\"href\":\"#top\"}},[_c('img',{attrs:{\"src\":require(\"../assets/homeTop.png\"),\"alt\":\"\"}})])])}]\n\nexport { render, staticRenderFns }","<template>\r\n  <div>\r\n    <div class=\"bg\"><div class=\"im\" id=\"bg\"></div></div>\r\n    <div class=\"back\">\r\n      <div class=\"content\">\r\n        <div class=\"ding\"></div>\r\n\r\n    <p class=\"pagraph\">\r\n作为一种严重且多见的神经退行性疾病，帕金森症一旦发病，对于其的治疗就显得极为有限<sup>[1]</sup>。因此，对于帕金森症患者的早期诊断与筛查，是控制帕金森症的一个关键环节，能给予我们更长的时间去治疗疾病或者缓解病症的发生与发展<sup>[2]</sup>。\r\n    </p>\r\n    <p class=\"pagraph\">\r\n目前已经有文献指出，人类血液与脑脊液中α-syn蛋白的含量与存在形式（单体与寡聚体），可以作为帕金森症的分子标志<sup>[3]</sup>。但是，其在血液中的总浓度非常低，在10-12-10-15M级别<sup>[4]</sup>，因此，使用常规的手段难以准确、快速地测量出血液中不同形式α-syn蛋白的浓度。并且，由于人的个体差异以及仪器的检出限等问题，在这种情况下检测单体与寡聚体浓度的比值，将会减少错误诊断的一个有力手段。我们开发的硬件就是基于对不同形式α-syn蛋白的浓度的分别检测以及对其比例的计算，来诊断该患者患上帕金森病的风险。\r\n    </p>\r\n    <p class=\"pagraph\">\r\n我们设计的硬件基于超常光透射（extraordinary optical transmission，EOT）原理进行检测。检测仪器由光源、滤光片、透镜组、一次性检测试盒以及感光元件组成。其中关键部分是我们的试盒。这是一个内置包被有抗体的纳米金孔阵列的微流控芯片。\r\n    </p>\r\n    <div class=\"ding\"></div>\r\n<div class=\"showBox\">\r\n          <div class=\"head\">\r\n            <div id=\"c1\" class=\"c\" @click=\"ch1()\">检测仪器</div>\r\n            <div id=\"c2\" class=\"c\" @click=\"ch2()\">检测试盒</div>\r\n            <div id=\"c3\" class=\"c\" @click=\"ch3()\">检测原理</div>\r\n            <div id=\"c4\" class=\"c\" @click=\"ch4()\">检测过程</div>\r\n          </div>\r\n          <div class=\"box\">\r\n            <div id=\"p1\" class=\"p\">\r\n             <img class=\"tu\" src=\"../assets/ha1.png\" alt=\"no pic\"> \r\n\r\n            </div>\r\n            <div id=\"p2\" class=\"p\">\r\n              <p class=\"pagraph\">\r\n当特定波长的光穿透规律排列的纳米金孔阵列时，由于超常光透射现象，较大部分光线将会透过该阵列，但是若是阵列表面存在有例如胶体金颗粒的物质时，将会破坏这一区域的超常光透射现象，进而该区域的透光能力就会下降。\r\n    </p>\r\n    <img class=\"tu\" src=\"../assets/ha2.png\" alt=\"no pic\"> \r\n            </div>\r\n            <div id=\"p3\" class=\"p\">\r\n              <img class=\"tu\" src=\"../assets/ha3.png\" alt=\"no pic\"> \r\n            </div>\r\n            <div id=\"p4\" class=\"p\">\r\n                <img class=\"tu\" src=\"../assets/ha4.png\" alt=\"no pic\"> \r\n              \r\n            </div>\r\n          </div>\r\n  \r\n    </div>\r\n\r\n\r\n    <div class=\"ding\"></div>\r\n    \r\n    <p class=\"pagraph\">\r\n依此，我们设计了两种检测方式分别对不同形式的α-syn蛋白进行检测。检测寡聚体α-syn蛋白时，我们在金孔阵列和胶体金颗粒表面包被的是识别同一抗原表位的单抗，这样，即使金孔阵列表面的抗体捕捉到单体形式的α-syn蛋白，纳米金胶体颗粒上的抗体由于表位的限制也无法与单体α-syn蛋白结合（下图右上），而寡聚体α-syn由于具有多个暴露的表位，因此可以与纳米金胶体颗粒上的抗体结合，进而发生EOT。\r\n    </p>\r\n    <p class=\"pagraph\">\r\n同理，当检测α-syn总蛋白浓度时，将会使用包被有另外一种识别不同抗原表位的单抗的金纳米颗粒，这样，无论何种形式的蛋白都能与金纳米颗粒上的抗体结合，发生EOT。\r\n当两种检测完成后，我们就可以依据信号强度对两种形式的蛋白浓度进行定量，从而得出其比值，判断患者的患病风险。\r\n    </p>\r\n    <p class=\"pagraph\">\r\n最终的数据可以通过装置上的蓝牙通信模块传输至手机和云端以供患者和医生进行诊断。同时，只要更换金孔阵列以及胶体金表面包被的抗体，即可实现对其他疾病的诊断。\r\n    </p>\r\n    <p class=\"ref\">\r\n参考文献\r\n    </p>\r\n    <p class=\"ref\">\r\n    [1]    ROCHET J, HAY B A, GUO M. chapter 5 - Molecular Insights into Parkinson's Disease[M]//Teplow D B. Molecular Biology of Neurodegenerative Diseases. Academic Press, 2012:125-188.\r\n    </p>\r\n    <p class=\"ref\">\r\n     [2]   \tBLOEM B R, OKUN M S, KLEIN C. Parkinson's disease[J]. LANCET, 2021,397(10291): 2284-2303.\r\n    </p>\r\n    <p class=\"ref\">\r\n        [3]\tHONG Z, TIAN C, STEWART T, et al. Development of a Sensitive Diagnostic Assay for Parkinson Disease Quantifying alpha-Synuclein-Containing Extracellular Vesicles[J]. NEUROLOGY, 2021,96(18): E2332-E2345.\r\n    </p>\r\n    <p class=\"ref\">\r\n      [4]  HERRMANN Y, BUJNICKI T, ZAFIU C, et al. Nanoparticle standards for immuno-based quantitation of alpha-synuclein oligomers in diagnostics of Parkinson's disease and other synucleinopathies[J]. CLINICA CHIMICA ACTA, 2017,466: 152-159.\r\n    </p>\r\n\r\n\r\n\r\n        <div class=\"ding\"></div>\r\n        <div class=\"ding\"></div>\r\n        <div class=\"ding\"></div>\r\n        <div class=\"ding\"></div>\r\n      </div>\r\n    </div>\r\n\r\n    <div id=\"lef\" class=\"leftP\">\r\n      <a href=\"#top\"><img src=\"../assets/homeTop.png\" alt=\"\" /></a>\r\n    </div>\r\n  </div>\r\n</template>\r\n<script>\r\nexport default {\r\n  return() {},\r\n   methods: {\r\n    ch1() {\r\n      let p1 = document.getElementById(\"p1\");\r\n      let p2 = document.getElementById(\"p2\");\r\n      let p3 = document.getElementById(\"p3\");\r\n      let p4 = document.getElementById(\"p4\");\r\n      p1.classList.add(\"showup\");\r\n      p2.classList.remove(\"showup\");\r\n      p3.classList.remove(\"showup\");\r\n      p4.classList.remove(\"showup\");\r\n    },\r\n    ch2() {\r\n      let p1 = document.getElementById(\"p1\");\r\n      let p2 = document.getElementById(\"p2\");\r\n      let p3 = document.getElementById(\"p3\");\r\n      let p4 = document.getElementById(\"p4\");\r\n      p2.classList.add(\"showup\");\r\n      p1.classList.remove(\"showup\");\r\n      p3.classList.remove(\"showup\");\r\n      p4.classList.remove(\"showup\");\r\n    },\r\n    ch3() {\r\n      let p1 = document.getElementById(\"p1\");\r\n      let p2 = document.getElementById(\"p2\");\r\n      let p3 = document.getElementById(\"p3\");\r\n      let p4 = document.getElementById(\"p4\");\r\n      p3.classList.add(\"showup\");\r\n      p2.classList.remove(\"showup\");\r\n      p1.classList.remove(\"showup\");\r\n      p4.classList.remove(\"showup\");\r\n    },\r\n    ch4() {\r\n      let p1 = document.getElementById(\"p1\");\r\n      let p2 = document.getElementById(\"p2\");\r\n      let p3 = document.getElementById(\"p3\");\r\n      let p4 = document.getElementById(\"p4\");\r\n      p4.classList.add(\"showup\");\r\n      p2.classList.remove(\"showup\");\r\n      p1.classList.remove(\"showup\");\r\n      p3.classList.remove(\"showup\");\r\n    },\r\n  },\r\n  mounted() {\r\n    let lef = document.getElementById(\"lef\");\r\n\r\n    function addEvent(obj, type, fn) {\r\n      undefined;\r\n      if (obj.attachEvent) {\r\n        obj.attachEvent(\"on\" + type, function () {\r\n          undefined;\r\n          fn.call(obj);\r\n        });\r\n      } else {\r\n        undefined;\r\n        obj.addEventListener(type, fn, false);\r\n      }\r\n    }\r\n\r\n    addEvent(window, \"scroll\", function () {\r\n      undefined;\r\n      if (window.pageYOffset >= 455) {\r\n        lef.classList.add(\"stick\");\r\n      } else {\r\n        lef.classList.remove(\"stick\");\r\n      }\r\n    });\r\n  },\r\n};\r\n</script>\r\n<style scoped>\r\n.ref a{\r\n   font-style: italic;\r\n  font-family: Times New Roman, Times, serif !important;\r\n  font-size: 1em;\r\n  color: #6a8691;\r\n  letter-spacing: 0.025em;\r\n}\r\n.pagraph a{\r\n   font-style: italic;\r\n  font-family: Times New Roman, Times, serif !important;\r\n  font-size: 1em;\r\n  color: #6a8691;\r\n  letter-spacing: 0.025em;\r\n}\r\n.showBox .box .p {\r\n  display: none;\r\n  margin-bottom:20px;\r\n  margin-top:20px;\r\n}\r\n.title4{\r\n  color: #1d445a;\r\n  font-family: Comic Sans MS;\r\n  margin: 10px;\r\n  font-size: 20px;\r\n}\r\n.p ul li {\r\n  text-indent: 0;\r\n}\r\n.title3 {\r\n  color: #3485a5;\r\n  font-family: Comic Sans MS;\r\n  margin: 10px;\r\n  font-size: 35px;\r\n  border-bottom: solid 2px #7fa2ab;\r\n  padding-bottom: 0.6em;\r\n}\r\n.showBox {\r\n  width: 100%;\r\n}\r\n.showBox .head .c {\r\n  width: 200px;\r\n  height: 40px;\r\n  line-height: 40px;\r\n  text-align: center;\r\n  display: inline-block;\r\n  margin: auto;\r\n  border-radius: 30px;\r\n  color: rgb(169, 207, 199);\r\n}\r\n.showBox .head .c:hover {\r\n  transform: scale(1.1);\r\n  transition: 0.6s;\r\n  background-color: #fff;\r\n  color: rgb(23, 97, 85);\r\n}\r\n.showBox .head #c1 {\r\n  background-color: #6ab480;\r\n}\r\n.showBox .head #c2 {\r\n  background-color: #6aafb4;\r\n}\r\n.showBox .head #c3 {\r\n  background-color: #2851aa;\r\n}\r\n.showBox .head #c4 {\r\n  background-color: #5636ad;\r\n}\r\n.showBox .box {\r\n  margin-top: 10px;\r\n  padding-left: 15px;\r\n  padding-right: 15px;\r\n  background-color: #d2e8eb;\r\n  width: 880px;\r\n  margin: auto;\r\n  border-radius: 30px;\r\n}\r\n.showBox .box .p {\r\n  display: none;\r\n}\r\n.showBox .box #p1.showup {\r\n  display: block;\r\n  transition: 1s;\r\n}\r\n.showBox .box #p2.showup {\r\n  display: block;\r\n  transition: 1s;\r\n}\r\n.showBox .box #p3.showup {\r\n  display: block;\r\n  transition: 1s;\r\n}\r\n.showBox .box #p4.showup {\r\n  display: block;\r\n  transition: 1s;\r\n}\r\n.ref {\r\n  font-style: italic;\r\n  font-family: Times New Roman, Times, serif !important;\r\n  padding-left: 2em;\r\n  text-align: left;\r\n  font-size: 0.8em;\r\n  color: #7d7d7d;\r\n  letter-spacing: 0.018em;\r\n}\r\n.tu {\r\n  margin-right: auto;\r\n  margin-left: auto;\r\n  display: block;\r\n  margin-top: 20px;\r\n  width: 600px;\r\n  height: auto;\r\n  border-radius: 10px;\r\n  border: #1d5a56;\r\n  background-size: 5px;\r\n}\r\n.gong {\r\n  margin-right: auto;\r\n  margin-left: auto;\r\n  display: block;\r\n  margin-top: 20px;\r\n  width: 300px;\r\n  height: auto;\r\n  border-radius: 10px;\r\n  border: #1d5a56;\r\n  background-size: 5px;\r\n}\r\n.topic {\r\n  color: #1d3f5a;\r\n  font-size: 60px;\r\n  text-align: center;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  font-family: \"Arial\";\r\n  letter-spacing: 15px;\r\n}\r\n.Shell li a {\r\n  display: block;\r\n  width: 260px;\r\n}\r\n#lef.stick {\r\n  opacity: 1;\r\n  transition: all 1s;\r\n}\r\n#lef.stick:hover {\r\n  transform: scale(1.2);\r\n  transition: all 0.6s;\r\n}\r\n.leftP {\r\n  position: fixed;\r\n  left: 10px;\r\n  top: 30%;\r\n  opacity: 0;\r\n  height: 100px;\r\n  width: 100px;\r\n}\r\n.Shell {\r\n  margin: 0;\r\n  padding: 0;\r\n  color: inherit;\r\n  background-color: inherit;\r\n}\r\n.Shell:first-child {\r\n  margin-top: 4vh;\r\n}\r\n.Shell li {\r\n  list-style: none;\r\n  height: 8vh;\r\n  line-height: 8vh;\r\n  padding-left: 20px;\r\n  color: inherit;\r\n  background-color: inherit;\r\n}\r\n.Shell li:hover {\r\n  /* transform:scale(1,1.2); */\r\n  background-color: #89cfd1;\r\n  border-radius: 10px;\r\n  color: #253f17;\r\n  transition: all 0.6s;\r\n}\r\n.Shell li:hover a {\r\n  color: white;\r\n}\r\n.Shell li a {\r\n  text-decoration: none;\r\n  color: #8ad6bd;\r\n}\r\n.ding {\r\n  height: 96px;\r\n}\r\n.top img {\r\n  float: right;\r\n  line-height: 60px;\r\n}\r\n.top img:hover {\r\n  transform: scale(1.3);\r\n  transition: all 0.4s;\r\n}\r\n.back {\r\n  width: 100%;\r\n  background-color: #c5ddd9;\r\n}\r\n.bg .im {\r\n  background-attachment: fixed;\r\n  width: 100%;\r\n  height: 100vh;\r\n  background-size: cover;\r\n  background-image: url(../assets/homeBanner.gif);\r\n}\r\n.content {\r\n  background-color: inherit;\r\n  width: 900px;\r\n  margin: 0 auto;\r\n  align-content: center;\r\n  padding: 20px;\r\n}\r\n.title {\r\n  color: #1d5a56;\r\n  font-family: Comic Sans MS;\r\n  margin: 10px;\r\n  border-bottom: solid 2px #7faba0;\r\n  padding-bottom: 0.6em;\r\n}\r\n.title2 {\r\n  color: #1d5a56;\r\n  font-family: Comic Sans MS;\r\n  margin: 10px;\r\n  margin-top: 50px;\r\n  border-bottom: solid 2px #a9ccc3;\r\n  padding-bottom: 0.6em;\r\n}\r\n.title:first-letter {\r\n  font-size: 50px;\r\n  text-shadow: 2px 2px 5px #444;\r\n}\r\n.title2:first-letter {\r\n  font-size: 50px;\r\n  text-shadow: 2px 2px 5px #444;\r\n}\r\n.pagraph {\r\n  font-family: \"Century Gothic\";\r\n  letter-spacing: 0.05em !important;\r\n  text-indent: 2em;\r\n  display: block;\r\n  transition: all 2s;\r\n  margin-left: 40px;\r\n  letter-spacing: 1.3px;\r\n  line-height: 1.8;\r\n  word-spacing: 3px;\r\n  color: #386f6c;\r\n}\r\n</style>\r\n","import mod from \"-!../../node_modules/cache-loader/dist/cjs.js??ref--13-0!../../node_modules/thread-loader/dist/cjs.js!../../node_modules/babel-loader/lib/index.js!../../node_modules/cache-loader/dist/cjs.js??ref--1-0!../../node_modules/vue-loader/lib/index.js??vue-loader-options!./hardware.vue?vue&type=script&lang=js&\"; export default mod; export * from \"-!../../node_modules/cache-loader/dist/cjs.js??ref--13-0!../../node_modules/thread-loader/dist/cjs.js!../../node_modules/babel-loader/lib/index.js!../../node_modules/cache-loader/dist/cjs.js??ref--1-0!../../node_modules/vue-loader/lib/index.js??vue-loader-options!./hardware.vue?vue&type=script&lang=js&\"","import { render, staticRenderFns } from \"./hardware.vue?vue&type=template&id=3f2776e7&scoped=true&\"\nimport script from \"./hardware.vue?vue&type=script&lang=js&\"\nexport * from \"./hardware.vue?vue&type=script&lang=js&\"\nimport style0 from \"./hardware.vue?vue&type=style&index=0&id=3f2776e7&scoped=true&lang=css&\"\n\n\n/* normalize component */\nimport normalizer from \"!../../node_modules/vue-loader/lib/runtime/componentNormalizer.js\"\nvar component = normalizer(\n  script,\n  render,\n  staticRenderFns,\n  false,\n  null,\n  \"3f2776e7\",\n  null\n  \n)\n\nexport default component.exports","var render = function () {var _vm=this;var _h=_vm.$createElement;var _c=_vm._self._c||_h;return _vm._m(0)}\nvar staticRenderFns = [function () {var _vm=this;var _h=_vm.$createElement;var _c=_vm._self._c||_h;return _c('div',[_c('div',{staticClass:\"bg\"},[_c('div',{staticClass:\"im\",attrs:{\"id\":\"bg\"}})]),_c('div',{staticClass:\"back\"},[_c('div',{staticClass:\"content\"},[_c('div',{staticClass:\"ding\"}),_c('h1',{staticClass:\"title\"},[_vm._v(\"Part\")]),_c('img',{staticClass:\"tu\",attrs:{\"src\":require(\"../assets/part.png\"),\"alt\":\"no pic\"}}),_c('div',{staticClass:\"ding\"}),_c('div',{staticClass:\"ding\"}),_c('div',{staticClass:\"ding\"}),_c('div',{staticClass:\"ding\"})])]),_c('div',{staticClass:\"leftP\",attrs:{\"id\":\"lef\"}},[_c('a',{attrs:{\"href\":\"#top\"}},[_c('img',{attrs:{\"src\":require(\"../assets/homeTop.png\"),\"alt\":\"\"}})])])])}]\n\nexport { render, staticRenderFns }","<template>\r\n  <div>\r\n    <div class=\"bg\"><div class=\"im\" id=\"bg\"></div></div>\r\n    <div class=\"back\">\r\n      <div class=\"content\">\r\n         <div class=\"ding\"></div>\r\n    <h1 class=\"title\">Part</h1>\r\n        <img class=\"tu\" src=\"../assets/part.png\" alt=\"no pic\"> \r\n\r\n        <div class=\"ding\"></div>\r\n        <div class=\"ding\"></div>\r\n        <div class=\"ding\"></div>\r\n        <div class=\"ding\"></div>\r\n      </div>\r\n    </div>\r\n\r\n    <div id=\"lef\" class=\"leftP\">\r\n      <a href=\"#top\"><img src=\"../assets/homeTop.png\" alt=\"\" /></a>\r\n    </div>\r\n  </div>\r\n</template>\r\n<script>\r\nexport default {\r\n  return() {},\r\n   methods: {\r\n    ch1() {\r\n      let p1 = document.getElementById(\"p1\");\r\n      let p2 = document.getElementById(\"p2\");\r\n      let p3 = document.getElementById(\"p3\");\r\n      let p4 = document.getElementById(\"p4\");\r\n      p1.classList.add(\"showup\");\r\n      p2.classList.remove(\"showup\");\r\n      p3.classList.remove(\"showup\");\r\n      p4.classList.remove(\"showup\");\r\n    },\r\n    ch2() {\r\n      let p1 = document.getElementById(\"p1\");\r\n      let p2 = document.getElementById(\"p2\");\r\n      let p3 = document.getElementById(\"p3\");\r\n      let p4 = document.getElementById(\"p4\");\r\n      p2.classList.add(\"showup\");\r\n      p1.classList.remove(\"showup\");\r\n      p3.classList.remove(\"showup\");\r\n      p4.classList.remove(\"showup\");\r\n    },\r\n    ch3() {\r\n      let p1 = document.getElementById(\"p1\");\r\n      let p2 = document.getElementById(\"p2\");\r\n      let p3 = document.getElementById(\"p3\");\r\n      let p4 = document.getElementById(\"p4\");\r\n      p3.classList.add(\"showup\");\r\n      p2.classList.remove(\"showup\");\r\n      p1.classList.remove(\"showup\");\r\n      p4.classList.remove(\"showup\");\r\n    },\r\n    ch4() {\r\n      let p1 = document.getElementById(\"p1\");\r\n      let p2 = document.getElementById(\"p2\");\r\n      let p3 = document.getElementById(\"p3\");\r\n      let p4 = document.getElementById(\"p4\");\r\n      p4.classList.add(\"showup\");\r\n      p2.classList.remove(\"showup\");\r\n      p1.classList.remove(\"showup\");\r\n      p3.classList.remove(\"showup\");\r\n    },\r\n  },\r\n  mounted() {\r\n    let lef = document.getElementById(\"lef\");\r\n\r\n    function addEvent(obj, type, fn) {\r\n      undefined;\r\n      if (obj.attachEvent) {\r\n        obj.attachEvent(\"on\" + type, function () {\r\n          undefined;\r\n          fn.call(obj);\r\n        });\r\n      } else {\r\n        undefined;\r\n        obj.addEventListener(type, fn, false);\r\n      }\r\n    }\r\n\r\n    addEvent(window, \"scroll\", function () {\r\n      undefined;\r\n      if (window.pageYOffset >= 455) {\r\n        lef.classList.add(\"stick\");\r\n      } else {\r\n        lef.classList.remove(\"stick\");\r\n      }\r\n    });\r\n  },\r\n};\r\n</script>\r\n<style scoped>\r\n.ref a{\r\n   font-style: italic;\r\n  font-family: Times New Roman, Times, serif !important;\r\n  font-size: 1em;\r\n  color: #6a8691;\r\n  letter-spacing: 0.025em;\r\n}\r\n.pagraph a{\r\n   font-style: italic;\r\n  font-family: Times New Roman, Times, serif !important;\r\n  font-size: 1em;\r\n  color: #6a8691;\r\n  letter-spacing: 0.025em;\r\n}\r\n.title4{\r\n  color: #1d445a;\r\n  font-family: Comic Sans MS;\r\n  margin: 10px;\r\n  font-size: 20px;\r\n}\r\n.p ul li {\r\n  text-indent: 0;\r\n}\r\n.title3 {\r\n  color: #3485a5;\r\n  font-family: Comic Sans MS;\r\n  margin: 10px;\r\n  font-size: 35px;\r\n  border-bottom: solid 2px #7fa2ab;\r\n  padding-bottom: 0.6em;\r\n}\r\n.showBox {\r\n  width: 100%;\r\n}\r\n.showBox .head .c {\r\n  width: 200px;\r\n  height: 40px;\r\n  line-height: 40px;\r\n  text-align: center;\r\n  display: inline-block;\r\n  margin: auto;\r\n  border-radius: 30px;\r\n  color: rgb(169, 207, 199);\r\n}\r\n.showBox .head .c:hover {\r\n  transform: scale(1.1);\r\n  transition: 0.6s;\r\n  background-color: #fff;\r\n  color: rgb(23, 97, 85);\r\n}\r\n.showBox .head #c1 {\r\n  background-color: #6ab480;\r\n}\r\n.showBox .head #c2 {\r\n  background-color: #6aafb4;\r\n}\r\n.showBox .head #c3 {\r\n  background-color: #2851aa;\r\n}\r\n.showBox .head #c4 {\r\n  background-color: #5636ad;\r\n}\r\n.showBox .box {\r\n  margin-top: 10px;\r\n  padding-left: 15px;\r\n  padding-right: 15px;\r\n  background-color: #d2e8eb;\r\n  width: 880px;\r\n  margin: auto;\r\n  border-radius: 30px;\r\n}\r\n.showBox .box .p {\r\n  display: none;\r\n}\r\n.showBox .box #p1.showup {\r\n  display: block;\r\n  transition: 1s;\r\n}\r\n.showBox .box #p2.showup {\r\n  display: block;\r\n  transition: 1s;\r\n}\r\n.showBox .box #p3.showup {\r\n  display: block;\r\n  transition: 1s;\r\n}\r\n.showBox .box #p4.showup {\r\n  display: block;\r\n  transition: 1s;\r\n}\r\n.ref {\r\n  font-style: italic;\r\n  font-family: Times New Roman, Times, serif !important;\r\n  padding-left: 2em;\r\n  text-align: left;\r\n  font-size: 0.8em;\r\n  color: #7d7d7d;\r\n  letter-spacing: 0.018em;\r\n}\r\n.tu {\r\n  margin-right: auto;\r\n  margin-left: auto;\r\n  display: block;\r\n  margin-top: 20px;\r\n  width: 600px;\r\n  height: auto;\r\n  border-radius: 5px;\r\n  border: #1d5a56;\r\n  background-size: 5px;\r\n}\r\n.gong {\r\n  margin-right: auto;\r\n  margin-left: auto;\r\n  display: block;\r\n  margin-top: 20px;\r\n  width: 300px;\r\n  height: auto;\r\n  border-radius: 10px;\r\n  border: #1d5a56;\r\n  background-size: 5px;\r\n}\r\n.topic {\r\n  color: #1d3f5a;\r\n  font-size: 60px;\r\n  text-align: center;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  font-family: \"Arial\";\r\n  letter-spacing: 15px;\r\n}\r\n.Shell li a {\r\n  display: block;\r\n  width: 260px;\r\n}\r\n#lef.stick {\r\n  opacity: 1;\r\n  transition: all 1s;\r\n}\r\n#lef.stick:hover {\r\n  transform: scale(1.2);\r\n  transition: all 0.6s;\r\n}\r\n.leftP {\r\n  position: fixed;\r\n  left: 10px;\r\n  top: 30%;\r\n  opacity: 0;\r\n  height: 100px;\r\n  width: 100px;\r\n}\r\n.Shell {\r\n  margin: 0;\r\n  padding: 0;\r\n  color: inherit;\r\n  background-color: inherit;\r\n}\r\n.Shell:first-child {\r\n  margin-top: 4vh;\r\n}\r\n.Shell li {\r\n  list-style: none;\r\n  height: 8vh;\r\n  line-height: 8vh;\r\n  padding-left: 20px;\r\n  color: inherit;\r\n  background-color: inherit;\r\n}\r\n.Shell li:hover {\r\n  /* transform:scale(1,1.2); */\r\n  background-color: #89cfd1;\r\n  border-radius: 10px;\r\n  color: #253f17;\r\n  transition: all 0.6s;\r\n}\r\n.Shell li:hover a {\r\n  color: white;\r\n}\r\n.Shell li a {\r\n  text-decoration: none;\r\n  color: #8ad6bd;\r\n}\r\n.ding {\r\n  height: 96px;\r\n}\r\n.top img {\r\n  float: right;\r\n  line-height: 60px;\r\n}\r\n.top img:hover {\r\n  transform: scale(1.3);\r\n  transition: all 0.4s;\r\n}\r\n.back {\r\n  width: 100%;\r\n  background-color: #c5ddd9;\r\n}\r\n.bg .im {\r\n  background-attachment: fixed;\r\n  width: 100%;\r\n  height: 100vh;\r\n  background-size: cover;\r\n  background-image: url(../assets/homeBanner.gif);\r\n}\r\n.content {\r\n  background-color: inherit;\r\n  width: 900px;\r\n  margin: 0 auto;\r\n  align-content: center;\r\n  padding: 20px;\r\n}\r\n.title {\r\n  color: #1d5a56;\r\n  font-family: Comic Sans MS;\r\n  margin: 10px;\r\n  border-bottom: solid 2px #7faba0;\r\n  padding-bottom: 0.6em;\r\n}\r\n.title2 {\r\n  color: #1d5a56;\r\n  font-family: Comic Sans MS;\r\n  margin: 10px;\r\n  margin-top: 50px;\r\n  border-bottom: solid 2px #a9ccc3;\r\n  padding-bottom: 0.6em;\r\n}\r\n.title:first-letter {\r\n  font-size: 50px;\r\n  text-shadow: 2px 2px 5px #444;\r\n}\r\n.title2:first-letter {\r\n  font-size: 50px;\r\n  text-shadow: 2px 2px 5px #444;\r\n}\r\n.pagraph {\r\n  font-family: \"Century Gothic\";\r\n  letter-spacing: 0.05em !important;\r\n  text-indent: 2em;\r\n  display: block;\r\n  transition: all 2s;\r\n  margin-left: 40px;\r\n  letter-spacing: 1.3px;\r\n  line-height: 1.8;\r\n  word-spacing: 3px;\r\n  color: #386f6c;\r\n}\r\n</style>\r\n","import mod from \"-!../../node_modules/cache-loader/dist/cjs.js??ref--13-0!../../node_modules/thread-loader/dist/cjs.js!../../node_modules/babel-loader/lib/index.js!../../node_modules/cache-loader/dist/cjs.js??ref--1-0!../../node_modules/vue-loader/lib/index.js??vue-loader-options!./part.vue?vue&type=script&lang=js&\"; export default mod; export * from \"-!../../node_modules/cache-loader/dist/cjs.js??ref--13-0!../../node_modules/thread-loader/dist/cjs.js!../../node_modules/babel-loader/lib/index.js!../../node_modules/cache-loader/dist/cjs.js??ref--1-0!../../node_modules/vue-loader/lib/index.js??vue-loader-options!./part.vue?vue&type=script&lang=js&\"","import { render, staticRenderFns } from \"./part.vue?vue&type=template&id=4cd64650&scoped=true&\"\nimport script from \"./part.vue?vue&type=script&lang=js&\"\nexport * from \"./part.vue?vue&type=script&lang=js&\"\nimport style0 from \"./part.vue?vue&type=style&index=0&id=4cd64650&scoped=true&lang=css&\"\n\n\n/* normalize component */\nimport normalizer from \"!../../node_modules/vue-loader/lib/runtime/componentNormalizer.js\"\nvar component = normalizer(\n  script,\n  render,\n  staticRenderFns,\n  false,\n  null,\n  \"4cd64650\",\n  null\n  \n)\n\nexport default component.exports","import Vue from 'vue'\r\nimport VueRouter from 'vue-router'\r\n\r\nimport myHome from '@/components/myHome.vue'\r\n\r\nimport description from '@/components/description.vue'\r\nimport design from '@/components/design.vue'\r\nimport proof from '@/components/proof.vue'\r\nimport experiment from '@/components/experiment.vue'\r\nimport safety from '@/components/safety.vue'\r\nimport imple from '@/components/imple.vue'\r\n\r\nimport Integrated from '@/components/Integrated.vue'\r\nimport communication from '@/components/communication.vue'\r\nimport education from '@/components/education.vue'\r\nimport inclusivity from '@/components/inclusivity.vue'\r\nimport entre from '@/components/entre.vue'\r\nimport sustain from '@/components/sustain.vue'\r\n\r\nimport model from '@/components/model.vue'\r\nimport software from '@/components/software.vue'\r\nimport hardware from '@/components/hardware.vue'\r\n\r\nimport part from '@/components/part.vue'\r\n\r\nVue.use(VueRouter)\r\nconst router = new VueRouter({\r\n    routes:[\r\n        {path:\"/\",component:myHome},\r\n        {path:\"/myHome\",component:myHome},\r\n        {path:\"/description\",component:description},\r\n        {path:\"/design\",component:design},\r\n        {path:\"/proof\",component:proof},\r\n        {path:\"/experiment\",component:experiment},\r\n        {path:\"/safety\",component:safety},\r\n        {path:\"/imple\",component:imple},\r\n\r\n        {path:\"/Integrated\",component:Integrated},\r\n        {path:\"/communication\",component:communication},\r\n        {path:\"/education\",component:education},\r\n        {path:\"/inclusivity\",component:inclusivity},\r\n        {path:\"/entre\",component:entre},\r\n        {path:\"/sustain\",component:sustain},\r\n\r\n        {path:\"/model\",component:model},\r\n        {path:\"/software\",component:software},\r\n        {path:\"/hardware\",component:hardware},\r\n\r\n        {path:\"/part\",component:part},\r\n\r\n\r\n    ]\r\n    \r\n})\r\nexport default router","import Vue from 'vue'\r\nimport App from './App.vue'\r\nimport router from '@/router/index.js'\r\n\r\nVue.config.productionTip = false\r\n\r\nnew Vue({\r\n  render: h => h(App),\r\n  router\r\n}).$mount('#app')\r\n\r\nVue.directive('color',function(el,binding){\r\n  el.style.color = binding.value\r\n})","module.exports = __webpack_public_path__ + \"img/m2-4.e17282da.gif\";","export * from \"-!../../node_modules/mini-css-extract-plugin/dist/loader.js??ref--7-oneOf-1-0!../../node_modules/css-loader/dist/cjs.js??ref--7-oneOf-1-1!../../node_modules/vue-loader/lib/loaders/stylePostLoader.js!../../node_modules/postcss-loader/src/index.js??ref--7-oneOf-1-2!../../node_modules/cache-loader/dist/cjs.js??ref--1-0!../../node_modules/vue-loader/lib/index.js??vue-loader-options!./hardware.vue?vue&type=style&index=0&id=3f2776e7&scoped=true&lang=css&\"","module.exports = __webpack_public_path__ + \"img/ha4.1a06d35c.png\";","module.exports = __webpack_public_path__ + \"img/ha1.d5abf366.png\";","module.exports = __webpack_public_path__ + \"img/m2-3.86db073f.gif\";","module.exports = \"data:image/png;base64,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\"","export * from \"-!../../node_modules/mini-css-extract-plugin/dist/loader.js??ref--7-oneOf-1-0!../../node_modules/css-loader/dist/cjs.js??ref--7-oneOf-1-1!../../node_modules/vue-loader/lib/loaders/stylePostLoader.js!../../node_modules/postcss-loader/src/index.js??ref--7-oneOf-1-2!../../node_modules/cache-loader/dist/cjs.js??ref--1-0!../../node_modules/vue-loader/lib/index.js??vue-loader-options!./Integrated.vue?vue&type=style&index=0&id=3695d588&scoped=true&lang=css&\"","module.exports = __webpack_public_path__ + \"img/en4-5.5aea8878.png\";","export * from \"-!../node_modules/mini-css-extract-plugin/dist/loader.js??ref--7-oneOf-1-0!../node_modules/css-loader/dist/cjs.js??ref--7-oneOf-1-1!../node_modules/vue-loader/lib/loaders/stylePostLoader.js!../node_modules/postcss-loader/src/index.js??ref--7-oneOf-1-2!../node_modules/cache-loader/dist/cjs.js??ref--1-0!../node_modules/vue-loader/lib/index.js??vue-loader-options!./App.vue?vue&type=style&index=0&id=33069531&scoped=true&lang=css&\"","module.exports = __webpack_public_path__ + \"img/en4-6.1fe844f1.png\";","module.exports = \"data:image/png;base64,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\"","module.exports = __webpack_public_path__ + \"img/edu2-1.a3fb1483.png\";","module.exports = __webpack_public_path__ + \"img/en4-4.80198215.png\";","module.exports = __webpack_public_path__ + \"img/in1-4-1.bc404f88.png\";","module.exports = __webpack_public_path__ + \"img/m1-6.5c8e5cb6.png\";","module.exports = __webpack_public_path__ + \"img/com2-3.afad8bbd.png\";","module.exports = __webpack_public_path__ + \"img/des1-2-2.4d31ebdc.png\";","module.exports = __webpack_public_path__ + \"img/in1-2.cff6b581.png\";","module.exports = __webpack_public_path__ + \"img/sus1.869008da.png\";","module.exports = __webpack_public_path__ + \"img/ha3.526f7fef.png\";","module.exports = __webpack_public_path__ + \"img/en3-1.0e06b1bd.png\";","module.exports = __webpack_public_path__ + \"img/des2-1.d6548c18.jpg\";","module.exports = __webpack_public_path__ + \"img/in1-3-1.a9781910.png\";","module.exports = __webpack_public_path__ + \"img/sa2-3.f0e346f2.png\";","module.exports = __webpack_public_path__ + \"img/sa2-1.82ad30f4.png\";","module.exports = __webpack_public_path__ + \"img/m2-5.b16b0e46.gif\";","module.exports = __webpack_public_path__ + \"img/en1-3.88b8babd.png\";","module.exports = __webpack_public_path__ + \"img/com2-4.bd177f3e.png\";","module.exports = __webpack_public_path__ + \"img/des1-1.e6c57b51.png\";","module.exports = __webpack_public_path__ + \"img/in1-2-1.58801c30.png\";","module.exports = __webpack_public_path__ + \"img/sa2-2.a7c3314e.png\";","module.exports = __webpack_public_path__ + \"img/1.dbe6568b.gif\";","module.exports = __webpack_public_path__ + \"img/m1-10.461492ba.gif\";","module.exports = __webpack_public_path__ + \"img/m1-12.ab335922.png\";","module.exports = __webpack_public_path__ + \"img/m2-2.b4448f43.gif\";","module.exports = __webpack_public_path__ + \"img/com1-3.c7745c21.png\";","module.exports = __webpack_public_path__ + \"img/com1-2.26efe838.png\";","export * from \"-!../../node_modules/mini-css-extract-plugin/dist/loader.js??ref--7-oneOf-1-0!../../node_modules/css-loader/dist/cjs.js??ref--7-oneOf-1-1!../../node_modules/vue-loader/lib/loaders/stylePostLoader.js!../../node_modules/postcss-loader/src/index.js??ref--7-oneOf-1-2!../../node_modules/cache-loader/dist/cjs.js??ref--1-0!../../node_modules/vue-loader/lib/index.js??vue-loader-options!./myHome.vue?vue&type=style&index=0&id=77e52305&scoped=true&lang=css&\"","module.exports = __webpack_public_path__ + \"img/in1-4-2.e6e7a173.png\";","export * from \"-!../../node_modules/mini-css-extract-plugin/dist/loader.js??ref--7-oneOf-1-0!../../node_modules/css-loader/dist/cjs.js??ref--7-oneOf-1-1!../../node_modules/vue-loader/lib/loaders/stylePostLoader.js!../../node_modules/postcss-loader/src/index.js??ref--7-oneOf-1-2!../../node_modules/cache-loader/dist/cjs.js??ref--1-0!../../node_modules/vue-loader/lib/index.js??vue-loader-options!./education.vue?vue&type=style&index=0&id=3318ef58&scoped=true&lang=css&\"","export * from \"-!../../node_modules/mini-css-extract-plugin/dist/loader.js??ref--7-oneOf-1-0!../../node_modules/css-loader/dist/cjs.js??ref--7-oneOf-1-1!../../node_modules/vue-loader/lib/loaders/stylePostLoader.js!../../node_modules/postcss-loader/src/index.js??ref--7-oneOf-1-2!../../node_modules/cache-loader/dist/cjs.js??ref--1-0!../../node_modules/vue-loader/lib/index.js??vue-loader-options!./part.vue?vue&type=style&index=0&id=4cd64650&scoped=true&lang=css&\"","module.exports = __webpack_public_path__ + \"img/en4-7.da42bcc8.png\";","module.exports = __webpack_public_path__ + \"img/en2-1.53dbc45e.png\";","module.exports = __webpack_public_path__ + \"img/com1-1.d21bc771.png\";","module.exports = __webpack_public_path__ + \"img/logo.9db63978.png\";","module.exports = __webpack_public_path__ + \"img/m1-9.8f96cbd1.gif\";","module.exports = __webpack_public_path__ + \"img/des2-3-1.c445ede1.png\";","module.exports = __webpack_public_path__ + \"img/m2-1.a7400b29.png\";","module.exports = __webpack_public_path__ + \"img/en1-1.cfe94ad3.png\";","module.exports = __webpack_public_path__ + \"img/des1-3.44bdd495.png\";","export * from \"-!../../node_modules/mini-css-extract-plugin/dist/loader.js??ref--7-oneOf-1-0!../../node_modules/css-loader/dist/cjs.js??ref--7-oneOf-1-1!../../node_modules/vue-loader/lib/loaders/stylePostLoader.js!../../node_modules/postcss-loader/src/index.js??ref--7-oneOf-1-2!../../node_modules/cache-loader/dist/cjs.js??ref--1-0!../../node_modules/vue-loader/lib/index.js??vue-loader-options!./experiment.vue?vue&type=style&index=0&id=375954a2&scoped=true&lang=css&\"","module.exports = __webpack_public_path__ + \"img/des2-3-2.38a301ae.png\";","module.exports = __webpack_public_path__ + \"img/edu3-1.aba142c6.png\";","module.exports = __webpack_public_path__ + \"img/part.869aea0a.png\";","module.exports = __webpack_public_path__ + \"img/m1-7.8ca8fcb4.gif\";","module.exports = \"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAO0AAAA2CAIAAACk1ok0AAAACXBIWXMAABJ0AAASdAHeZh94AAAJC0lEQVR4nO1dzZGcOhDuefXOLt99GG0EDgHIw1WAEwFF4SMiBgeAyMAZIA4OwL67eIevpl+vYLyzuwx/o+80CAENfLS6W62e0zAMFBCwc/yztgABATMg8DjgCAg8DjgC/l1bgMdC27ZEdD6flVJry3IVzrm+74koiqK1ZbkVQR8virIsd+FYD8NQluXaUrwCgceLQikVx/H9lLExJkkS59x7TgIh5xFoKQQeHwp1XRPRlo2WOyHYx4dC0zRri7AOgj4OOAIeQh875+q6ds4VRYExN8/zKIqyLFtZMiJjTNu2Sqk0Ta21bD3nee6cq6pKKYXfRMSbRIRD2ISw1tZ1LW+KW+I4xhMgovFd88NxzsVxXBTFQnc+L4YHQBzHXdfFcRzH8TAMXdcRUZZly0viXRQidV3XdR0YifayLKuqyrIMLlfXdeislMqyrGkanIrP1nVdlmW4L+wdhkEphZY4jsuy7LoOVgfOBqClqqrh8ljwG5e711O4A47P46qqONrFL16SYEnIiyKwxawCTfk3t3AH6FGmaVmW3B8kBinRoSxLcFfetcdUbOLh8HWZvoHH2wJ4UFWVJE1VVfw6l4RHKckVSSnI6ZEMupk3Je/RH/pbtuBT4UO8LwcfhhRPKeV9S3vB8f08jNeYSGNrsm3bdUOksHdZBi/iq5TyWth+5U1rLVu66G+MkS1EZK2VMTjnHJiKTdmfO+wucgwcn8eAfOsAv2mtNViitdZaE5HWml0rCecc2q21xhjugGP5EGMM9hpjrLWTsxL4rnjiF05YURTcn1tY/nH/NE0huezPLd5dS6Kz8JLlxhic84VHuUk8Co+lHtJa89tq2/Z8PmMOLE3TsizzPC+KIooihAUk6rpO0zRJEiLKsgwdrLU4pCgKfBJ937dtm+d5lmUcKPBwPp9J0IgVZ13Xk6q073s5zYa9SimttdefW8YanYiiKLLW8tlkH6017OMbH+mm8BBxNyJK01RrHUURiMtvK4qiuq6zLOMWVoHjWTEcjs7QytDQWZaBwVCQRVGcTid4XX3fW2vHwSwcUtf1+Xxm7hpjJLNlhgNCcrzpkVi2jHW8vC6+K8iGZ2KM6fseqnqvQTd6jLgb0HXdpG+nlIKPD18QjVmWTXaO4xid4ah5oS6+EHtLiBvwLi9I0jRNVVVwvPCbd8mjIJuMl6FFXrfrurIsvRZPMO8Sw+WZILIxvtNhP3ggHl8DcxchW25k3jdNw6+ZLv4+B7aYsjgDdjEJ6Hm8dpVg39uwLx4/il1xDdJnb9sWgzL8ejaj8zyP47iqKliTcLmstRidYSGcz+e2bdnshlOFEfwBs3ZWwNof0sqQyvLa7+EyykMHS/XMneUITkTjPkDQx3fCo/P4FsD0HIZBKeWZrZOdpaXhAVGCVaZgbkdVVfAp1xbkFTgNe1iesC4QK0BEgog42WgSHK2D1xiwEOb6IJqmwUwpu/NKqY0rnoDDYDY/T2vdNM3T0xNP+TrnEG0d93xx4U2apjsNyAesgnl4rLVGCN05xzNVZVnit4dbZj6vDdy/f/9+l6ABi+DDhw9LX3JG3e7lT3Gm7Iz4/v370g8o4JX48uXLvC/9Fszp5z09PcEZ501Md3m4ZTVv0Me7xvL6eM55EEwf8O9rq4awiubvp7oWE1hhwAp4H37+/Pnp06e7X2ZG3Y71M/i9o4B/wP3w9etXIvr27du9LzSnPkb+FBFNZngFvApYf0ovhatXB6JP1xbt/vnzh4hOp9O9xZh5HsRbtrAAvER1TtJFXqXXuCMgZ+OuxYdmAd54XdfX5n36vp8MW82LmfPol2dM27ZIWtdao7oeA2s0JtPYdwGZ+38PJEmC8fM9eFHIBUhMB1gPwsMu0sDlCjYsNsZE43oC+uBRYl1Ajy5DsgVwnLxNWeQ0SRIkvK8ozySstasvcQW4usUxcAQeo5IDm8WYXNwCVwIWw+55LNf9WmuTJNmaITEX4E4h+Q5FtBAiwJJvIkKmP1fNwibW8KnnRbTQRwYZuAWZfWgcZ7lwbgyWEWzIB713YO/ewGJMZLjjjracZNc0zYsZzIC32E7WCuJ1KNiFdGe6cBeNRBTHsezDu5AvIMsR4emB0+pSwQjLaaVIstoQSIyeqMr1qucwO3bv5wHGmCiK8IL3G6D4C7AqG9oRWhD+ALQydCSKfZEYozgW5i5/lcCBUeluuksFR6Td4vzqeS2YJEl4KRfv3YjPSrR/fUxEnPQ8DAPeweSaolUA8jHAlfg5JqWV+tir7ObV+BpGBa+k8h4uS7u9pdQ0VYZLqlWIypveXsjABQ5X18f7to9Z8bAZl2VZWZZ1XW9kQtGbHUC84rWyuedFtLwaX4CM46ID98cAJS1dr7QFq16ZHuOcY1Nt+6WG9m1XjN8QxseyLL1UJLiAcFMwP0JExpg8z/GSJOAtmQt49MQqaD4Ev92loNYteXxvg5d0xR4eS45KA7KDZLkxBnvZgWN3gs/AhbbkJup0of4QPf9yUDtmCwWkgX3zGPD+HgvvzLOSsSgf/EYRNFicKGblnRDqHJ4+6l/BFuRD+r5ni5PraL1/buwapKmKefgoijgBY6xKvbJuMIidqEZHRFEU8S3wVfgk/CWg5gH4zWfQWltrt7UAcV2z5s1g/5oudarRjort3M4mI9Y8S/+d68mObTu487ImC7wfXAgzLDhc1iL6yzJp78w33qA0cHFpSIVABN+dLIM0XIxjaT3D4fNsX3mDw/NcxUGY9RzlwI2j+JB0SIZt2Md75XE3AtrBMMBbjSLfCt1Q/wrvFS7RMKoMJHcNo/pX1/DmuBuKG3GcS5bJmqx/Nb6ut+nd9eQh3v3iqHHPwONFwUSUygmKmetfSaLLwu7D87okaJE6eMzySYw5dw0ej7eMLfB43/GK2wGTUV1qerNJrZSSNVvhUSHHqG1beDPw68fZ1TAuYSzeOLl17xS2x8W6n9HWwPWvJhWMp3FhJt4pVh308atwhHjFXGB/HHWIx3E0qUoRN7iffkVd5HEt8a0Bmd+r/6N6qIv1P8DLHz9+/Pr1i4g+f/788ePHa50R86JR1C9gFQQeBxwBwa4IOAICjwOOgP8ANlL9oGNZOHAAAAAASUVORK5CYII=\"","export * from \"-!../../node_modules/mini-css-extract-plugin/dist/loader.js??ref--7-oneOf-1-0!../../node_modules/css-loader/dist/cjs.js??ref--7-oneOf-1-1!../../node_modules/vue-loader/lib/loaders/stylePostLoader.js!../../node_modules/postcss-loader/src/index.js??ref--7-oneOf-1-2!../../node_modules/cache-loader/dist/cjs.js??ref--1-0!../../node_modules/vue-loader/lib/index.js??vue-loader-options!./communication.vue?vue&type=style&index=0&id=43689d2d&scoped=true&lang=css&\"","module.exports = __webpack_public_path__ + \"img/m2-6.48904ff0.png\";","module.exports = __webpack_public_path__ + \"img/m1-4.ad413519.png\";","module.exports = __webpack_public_path__ + \"img/m1-8.78fd40b4.gif\";","export * from \"-!../../node_modules/mini-css-extract-plugin/dist/loader.js??ref--7-oneOf-1-0!../../node_modules/css-loader/dist/cjs.js??ref--7-oneOf-1-1!../../node_modules/vue-loader/lib/loaders/stylePostLoader.js!../../node_modules/postcss-loader/src/index.js??ref--7-oneOf-1-2!../../node_modules/cache-loader/dist/cjs.js??ref--1-0!../../node_modules/vue-loader/lib/index.js??vue-loader-options!./safety.vue?vue&type=style&index=0&id=6cf105e4&scoped=true&lang=css&\"","module.exports = __webpack_public_path__ + \"img/sa3-1.fdca9880.png\";","module.exports = \"data:image/png;base64,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\"","module.exports = __webpack_public_path__ + \"img/en3-3.74179c38.png\";"],"sourceRoot":""}